Perioperative Chemotherapy versus Surgery Alone for R Cancer

New England Journal of Medicine

355, 11-20

DOI: 10.1056/nejmoa055531

Citation Report

#	Article	IF	Citations
1	Epidemiology and Clinical Presentation in Esophageal Cancer. , 2007, , 1-13.		6
2	Preoperative Serum Tumor Marker Levels in Gastric Cancer. Pakistan Journal of Medical Sciences, 1969, 30, 145-9.	0.3	16
3	Proctolin: A peptide transmitter candidate in insects. Life Sciences, 1975, 17, 1241-1252.	2.0	200
5	Prediction of doxorubicin sensitivity in gastric cancers based on a set of novel markers. Oncology Reports, 1994, 20, 963.	1.2	3
6	New horizons for gastric cancer: commentary. European Journal of Cancer, Supplement, 2006, 4, 1-3.	2.2	1
7	The role of chemotherapy in patients with established gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2006, 20, 789-799.	1.0	7
8	Cancer of the Gastroesophageal Junction: Combined Modality Therapy. Surgical Oncology Clinics of North America, 2006, 15, 803-824.	0.6	18
9	What's new in the other general journals. BMJ: British Medical Journal, 2006, 333, 141-142.	2.4	0
10	Preoperative chemotherapy for resectable thoracic esophageal cancer. , 2006, , CD001556.		32
11	Modern Surgery for Gastric Cancer â€" Japanese Perspective. Scandinavian Journal of Surgery, 2006, 95, 232-235.	1.3	24
12	What's new in the other general journals. BMJ: British Medical Journal, 2006, 332, 289-290.	2.4	1
13	The Essentials of Locoregional Control in the Treatment of Gastric Cancer. Scandinavian Journal of Surgery, 2006, 95, 236-242.	1.3	7
14	In vitro chemosensitivity test to predict chemosensitivity for paclitaxel, using human gastric carcinoma tissues. International Journal of Clinical Oncology, 2006, 11, 449-453.	1.0	18
15	Neoadjuvant chemotherapy for bladder cancer. World Journal of Urology, 2006, 24, 531-542.	1.2	30
16	Re: Survival after Neoadjuvant Therapy Compared with Surgery Alone for Resectable Esophageal Cancer in a Population Based Study. World Journal of Surgery, 2006, 30, 2191-2192.	0.8	4
20	Docetaxel in the treatment of gastric cancer. Future Oncology, 2006, 2, 603-620.	1.1	12
22	Treatment of Gastric Cancer. New England Journal of Medicine, 2006, 355, 1386-1388.	13.9	5
23	Molecular Markers for Gastric Adenocarcinoma. Molecular Diagnosis and Therapy, 2006, 10, 345-352.	1.6	25

#	Article	IF	Citations
24	Gastric Cancer â€" New Therapeutic Options. New England Journal of Medicine, 2006, 355, 76-77.	13.9	85
27	Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine. New England Journal of Medicine, 2007, 357, 1810-1820.	13.9	2,238
28	Radiotherapy in gastric cancer: a systematic review of literature and new perspectives. Expert Review of Anticancer Therapy, 2007, 7, 1379-1393.	1.1	24
29	[18F]2-Fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil. British Journal of Cancer, 2007, 97, 902-909.	2.9	14
30	Advances in the treatment of patients with gastric adenocarcinoma. Acta OncolÃ³gica, 2007, 46, 277-285.	0.8	47
32	Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. Journal of Clinical Oncology, 2007, 25, 2580-2585.	0.8	68
33	Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2007, 18, ii17-ii18.	0.6	3
34	Response: Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1346-1347.	3.0	1
35	Re: Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients with 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 1345-1346.	3.0	4
36	Short and long-term survival from gastric cancer. A population-based study from a county hospital during 25 years. Acta OncolÃ³gica, 2007, 46, 308-315.	0.8	41
37	East Meets West in the Treatment of Gastric Cancer. New England Journal of Medicine, 2007, 357, 1863-1865.	13.9	70
39	Docetaxel, Cisplatin, and Fluorouracil; Docetaxel and Cisplatin; and Epirubicin, Cisplatin, and Fluorouracil As Systemic Treatment for Advanced Gastric Carcinoma: A Randomized Phase II Trial of the Swiss Group for Clinical Cancer Research. Journal of Clinical Oncology, 2007, 25, 3217-3223.	0.8	247
40	Neo-adjuvant and adjuvant chemotherapy of gastric cancer. Annals of Oncology, 2007, 18, vi120-vi123.	0.6	50
41	Epigenetic Silencing of Cyclooxygenase-2 Affects Clinical Outcome in Gastric Cancer. Journal of Clinical Oncology, 2007, 25, 4887-4894.	0.8	65
42	Management of Gastroesophageal Tumors. Oncologist, 2007, 12, 175-185.	1.9	37
43	Adjuvant Treatment of High-Risk, Radically Resected Gastric Cancer Patients With 5-Fluorouracil, Leucovorin, Cisplatin, and Epidoxorubicin in a Randomized Controlled Trial. Journal of the National Cancer Institute, 2007, 99, 601-607.	3.0	96
44	Systemic chemotherapy does not increase the risk of gastrointestinal perforation. Annals of Oncology, 2007, 18, 2006-2008.	0.6	8
45	Pharmacogenetics and stomach cancer: an update. Pharmacogenomics, 2007, 8, 497-505.	0.6	15

#	Article	IF	Citations
46	Fluorouracil-Based Chemotherapy in Patients with Gastrointestinal Malignancies: Influence of Nutritional Folate Status on Toxicity. Journal of Chemotherapy, 2007, 19, 744-749.	0.7	11
47	Adjuvant Therapy for Gastric Cancer: How Negative Results Can Help Patients. Journal of the National Cancer Institute, 2007, 99, 580-582.	3.0	3
48	Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM) Tj ETQq0 0 0 rgBT /Overlock 10	0.6	98
49	Methylation of Tumor-Related Genes in Neoadjuvant-Treated Gastric Cancer: Relation to Therapy Response and Clinicopathologic and Molecular Features. Clinical Cancer Research, 2007, 13, 5095-5102.	3.2	35
50	ADDITIONAL ARTICLES ABSTRACTED IN ACP JOURNAL CLUB. Evidence-Based Medicine, 2007, 12, 30-30.	0.6	1
51	Best practice in macroscopic examination of gastric resections. Journal of Clinical Pathology, 2007, 61, 172-178.	1.0	5
52	Pathogenesis, diagnosis and therapeutic possibilities of esophageal cancer. Current Opinion in Gastroenterology, 2007, 23, 456-461.	1.0	10
54	Adjuvant and Neoadjuvant Approaches in Gastric Cancer. Cancer Journal (Sudbury, Mass), 2007, 13, 168-174.	1.0	31
55	Induction Chemotherapy in Barrett Cancer. Annals of Surgery, 2007, 246, 624-631.	2.1	50
56	Neoadjuvant treatment in upper gastrointestinal adenocarcinomas: new paradigms from old concepts?. Current Opinion in Oncology, 2007, 19, 384-389.	1.1	7
57	Esophageal Cancer: Adjuvant Therapy. Cancer Journal (Sudbury, Mass), 2007, 13, 162-167.	1.0	10
58	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. Yearbook of Medicine, 2007, 2007, 406-407.	0.1	3
59	Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer. Yearbook of Gastroenterology, 2007, 2007, 82-84.	0.1	0
60	A Phase I Study of Docetaxel, Oxaliplatin, and Capecitabine in Patients With Metastatic Gastroesophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 346-349.	0.6	16
61	Positron Emission Tomographic Scanning Predicts Survival After Induction Chemotherapy for Esophageal Carcinoma. Annals of Thoracic Surgery, 2007, 84, 393-400.	0.7	64
62	Adjuvant chemotherapy with 5-fluorouracil, doxorubicin and mitomycin-C (FAM) for 6 months after curative resection of gastric carcinoma. European Journal of Surgical Oncology, 2007, 33, 843-848.	0.5	6
63	Gene expression of 5-fluorouracil metabolic enzymes in primary gastric cancer: Correlation with drug sensitivity against 5-fluorouracil. Cancer Letters, 2007, 252, 307-313.	3.2	29
64	Is it time to consider neoadjuvant treatment as the standard of care in oesophageal cancer?. Lancet Oncology, The, 2007, 8, 189-190.	5.1	21

#	Article	IF	Citations
65	Lancet Asia Medical Forum 2007. Lancet Oncology, The, 2007, 8, 190-191.	5.1	0
66	PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial. Lancet Oncology, The, 2007, 8, 797-805.	5.1	757
67	134 INVITED Specific requirements for molecular targeted agents in radiotherapy, including specific pre-clinical research designs. European Journal of Cancer, Supplement, 2007, 5, 36-37.	2.2	0
70	137 INVITED Treatment of localized gastric cancer: pre-operative versus post-operative adjuvant treatment. European Journal of Cancer, Supplement, 2007, 5, 37.	2.2	0
71	138 INVITED Gastric cancer: multimodal treatment. European Journal of Cancer, Supplement, 2007, 5, 37-38.	2.2	0
72	Systemic therapy for gastric cancer and adenocarcinoma of the gastroesophageal junction: present status and future directions. Expert Opinion on Investigational Drugs, 2007, 16, 1059-1068.	1.9	2
74	Long-Term Results of RTOG Trial 8911 (USA Intergroup 113): A Random Assignment Trial Comparison of Chemotherapy Followed by Surgery Compared With Surgery Alone for Esophageal Cancer. Journal of Clinical Oncology, 2007, 25, 3719-3725.	0.8	489
75	Preoperative Staging and Postoperative Surveillance for Gastric Cancer. Surgical Oncology Clinics of North America, 2007, 16, 329-342.	0.6	25
76	The Current Management of Esophageal Cancer. Advances in Surgery, 2007, 41, 93-119.	0.6	26
77	Systemic therapy for advanced gastric cancer: a review. Hematology/Oncology Clinics of North America, 2007, 21, 18-25.	0.9	1
78	Gastric carcinoma: review of the results of treatment in a community teaching hospital. World Journal of Surgical Oncology, 2007, 5, 81.	0.8	10
79	Pharmacotherapy for Oesophagogastric Cancer. Drugs, 2007, 67, 2539-2556.	4.9	4
80	Neoadjuvante und palliative Therapie des Ã–sophagus- und Magenkarzinoms. Oncology Research and Treatment, 2007, 30, 23-26.	0.8	1
81	Hospital volume does not influence long-term survival of patients undergoing surgery for oesophageal or gastric cancer. British Journal of Surgery, 2007, 94, 578-584.	0.1	76
83	Tailoring treatments for curable gastric cancer. British Journal of Surgery, 2007, 94, 263-264.	0.1	55
84	The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma. Cancer, 2007, 109, 1448-1449.	2.0	2
86	Clinical stage after preoperative chemoradiation is a better predictor of patient outcome than the baseline stage for localized gastric cancer. Cancer, 2007, 110, 989-995.	2.0	24
87	Molecular gene expression signature patterns for gastric cancer diagnosis. Computational Biology and Chemistry, 2007, 31, 275-287.	1.1	20

#	Article	IF	Citations
88	Adjuvant Chemoradiation for Gastric Cancer: Experience in the Chinese Population. Clinical Oncology, 2007, 19, 333-340.	0.6	10
89	Prospective study on late renal toxicity following postoperative chemoradiotherapy in gastric cancer. International Journal of Radiation Oncology Biology Physics, 2007, 67, 781-785.	0.4	97
90	Three-Dimensional Nonâ€“Coplanar Conformal Radiotherapy Yields Better Results Than Traditional Beam Arrangements for Adjuvant Treatment of Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 364-369.	0.4	24
91	A Phase Iâ€“II Study of Postoperative Capecitabine-Based Chemoradiotherapy in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2007, 69, 1424-1428.	0.4	44
92	A Four-Dimensional CT-Based Evaluation of Techniques for Gastric Irradiation. International Journal of Radiation Oncology Biology Physics, 2007, 69, 903-909.	0.4	37
93	Postoperative chemoradiotherapy in gastric cancer â€“ a phase I/II dose-finding study of radiotherapy with dose escalation of cisplatin and capecitabine chemotherapy. British Journal of Cancer, 2007, 97, 712-716.	2.9	34
95	A PILOT STUDY OF PREOPERATIVE AND POSTOPERATIVE CHEMOTHERAPY IN PATIENTS WITH OPERABLE GASTRIC CANCER: AUSTRALASIAN GASTROINTESTINAL TRIALS GROUP STUDY 9601. ANZ Journal of Surgery, 2007, 77, 247-252.	0.3	3
96	Immediate versus delayed chemotherapy in patients with asymptomatic incurable metastatic cancer. Asia-Pacific Journal of Clinical Oncology, 2007, 3, 187-198.	0.7	3
97	Endoscopic Ultrasound Predicts Outcomes for Patients with Adenocarcinoma of the Gastroesophageal Junction. Journal of the American College of Surgeons, 2007, 205, 593-601.	0.2	59
100	The effect of neoadjuvant chemotherapy on lymph node micrometastases in squamous cell carcinomas of the thoracic esophagus. Surgery, 2007, 141, 570-580.	1.0	55
101	Palliative management of gastric cancer. Surgical Oncology, 2007, 16, 267-275.	0.8	33
102	Gastric tumours. Medicine, 2007, 35, 216-219.	0.2	2
103	Clinical Correlation of Endoscopic Ultrasonography with Pathologic Stage and Outcome in Patients Undergoing Curative Resection for Gastric Cancer. Annals of Surgical Oncology, 2007, 14, 1853-1859.	0.7	116
104	Treatment of the Adenocarcinoma of the Esophagogastric Junction at a Single Institution in Mexico. Annals of Surgical Oncology, 2007, 14, 1439-1448.	0.7	8
105	Level I Evidence in Support of Perioperative Chemotherapy for Operable Gastric Cancer: Sufficient for Wide Clinical Use?. Annals of Surgical Oncology, 2007, 14, 2691-2695.	0.7	76
106	The UK NCRI MAGIC Trial of Perioperative Chemotherapy in Resectable Gastric Cancer: Implications for Clinical Practice. Annals of Surgical Oncology, 2007, 14, 2687-2690.	0.7	56
107	A Phase-II Clinical Trial of Laparoscopy-Assisted Distal Gastrectomy with D2 Lymph Node Dissection for Gastric Cancer Patients. Annals of Surgical Oncology, 2007, 14, 3148-3153.	0.7	72
108	A Systematic Review and Meta-analysis of the Randomized Controlled Trials on Adjuvant Intraperitoneal Chemotherapy for Resectable Gastric Cancer. Annals of Surgical Oncology, 2007, 14, 2702-2713.	0.7	321

#	Article	IF	Citations
109	Does Graded Histologic Response After Neoadjuvant Chemotherapy Predict Survival for Completely Resected Gastric Cancer?. Annals of Surgical Oncology, 2007, 14, 3412-3418.	0.7	95
110	Can We Understand the Clinical Biology of Gastric Cancer and Exploit it? May be, but It is a Challenge!. Annals of Surgical Oncology, 2007, 14, 3290-3292.	0.7	3
113	Significance of Radiation Therapy for Adenocarcinomas of the Esophagus, Gastroesophageal Junction and Gastric Cancer with Special Reference to the MAGIC Trial. Strahlentherapie Und Onkologie, 2007, 183, 163-169.	1.0	20
117	Staging Laparoscopy for Advanced Gastric Cancer: Is It Also Useful for the Group Which has an Aggressive Surgical Strategy?. World Journal of Surgery, 2007, 31, 1230-1235.	0.8	32
118	The beginning of a new era: East meets West more comfortably regarding lymphadenectomy for gastric cancer â€" Japan will finally drop the surgery-alone arm in its pursuit of a multimodal treatment strategy. Gastric Cancer, 2007, 10, 69-74.	2.7	8
119	Surgeons' knowledge of quality indicators for gastric cancer surgery. Gastric Cancer, 2007, 10, 205-214.	2.7	20
121	Combined-modality therapy for esophageal and gastroesophageal junction cancers. Current Oncology Reports, 2007, 9, 184-192.	1.8	10
122	Pathological complete response following docetaxel-based neoadjuvant chemotherapy for locally advanced gastric adenocarcinoma. Clinical and Translational Oncology, 2007, 9, 335-338.	1.2	1
123	Management of gastric adenocarcinoma. Clinical and Translational Oncology, 2007, 9, 438-442.	1.2	18
124	Perioperative and adjuvant treatments for gastric cancer. Definitive new standards of care or are we still on the way?. Clinical and Translational Oncology, 2007, 9, 747-748.	1.2	1
126	Multimodal treatment of gastric cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 965-981.	1.0	35
127	Multimodal treatment of oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2007, 21, 947-963.	1.0	17
129	Echoendoscopie et cancer de lâ€™Å“sophage et de lâ€™estomac. Acta Endoscopica, 2008, 38, 1-5.	0.0	0
131	To the Editor: The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery, 2008, 32, 1219-1220.	0.8	1
132	Prognostic Biomarkers and Targeted Therapy in Gastric Cancer: Reply. World Journal of Surgery, 2008, 32, 1227-1229.	0.8	6
133	EGFR as a Prognostic Marker for Gastric Cancer. World Journal of Surgery, 2008, 32, 1225-1226.	0.8	11
134	Continuing Debate on D2ÂLymphadenectomy for Gastric Cancer. World Journal of Surgery, 2008, 32, 2127-2128.	0.8	1
137	The role of biologics in stomach cancer. Targeted Oncology, 2008, 3, 71-79.	1.7	3

#	Article	IF	Citations
138	Positive VEGF Immunostaining Independently Predicts Poor Prognosis in Curatively Resected Gastric Cancer Patients: Results of a Study Assessing a Panel of Angiogenic Markers. Journal of Gastrointestinal Surgery, 2008, 12, 1005-1014.	0.9	41
139	The Effect of Perineural Invasion on Overall Survival in Patients with Gastric Carcinoma. Journal of Gastrointestinal Surgery, 2008, 12, 1263-1267.	0.9	38
140	Developments in Treatment of Esophageal/Gastric Cancer. Current Treatment Options in Oncology, 2008, 9, 375-387.	1.3	11
141	Adjuvant and neoadjuvant therapy of gastric cancer: A comparison of three pivotal studies. Current Oncology Reports, 2008, 10, 191-198.	1.8	14
142	Perioperative therapy in gastric cancer. Memo - Magazine of European Medical Oncology, 2008, 1, 71-73.	0.3	4
145	Stage-Specific Survival Differences Associated with Postoperative Radiotherapy for Gastrointestinal Cancers. Journal of Gastrointestinal Cancer, 2008, 39, 86-99.	0.6	4
146	Choice of Radiotherapy Planning Modality Influences Toxicity in the Treatment of Locally Advanced Esophageal Cancer. Journal of Gastrointestinal Cancer, 2008, 39, 130-137.	0.6	7
150	The new credo: induction chemotherapy in locally advanced gastric cancer: consequences for surgical strategies. Gastric Cancer, 2008, 11, 1-9.	2.7	51
151	Minichromosome maintenance 2 (MCM2) immunoreactivity in stage III human gastric carcinoma: clinicopathological significance. Gastric Cancer, 2008, 11, 37-46.	2.7	24
152	Locoregional control remains a critical issue in gastric cancer. Gastric Cancer, 2008, 11, 64-65.	2.7	0
153	Current status of chemoradiotherapy for gastric cancer in Japan. International Journal of Clinical Oncology, 2008, 13, 117-120.	1.0	10
154	Surgery and adjuvant chemotherapy. International Journal of Clinical Oncology, 2008, 13, 193-195.	1.0	10
155	Recent advances in chemotherapy and chemoradiotherapy for gastrointestinal tract cancers: adjuvant chemoradiotherapy for gastric cancer. International Journal of Clinical Oncology, 2008, 13, 479-482.	1.0	10
157	Glutathione-S-transferase P1, T1 and M1 genetic polymorphisms in neoadjuvant-treated locally advanced gastric cancer: GSTM1-present genotype is associated with better prognosis in completely resected patients. International Journal of Colorectal Disease, 2008, 23, 773-782.	1.0	40
158	Determinants of complications and adequacy of surgical resection in laparoscopic versus open total gastrectomy for adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 980-984.	1.3	91
159	Robot-assisted laparoscopic total and partial gastric resection with D2 lymph node dissection for adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 2753-2760.	1.3	105
160	Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer?. Surgical Endoscopy and Other Interventional Techniques, 2008, 22, 1402-1404.	1.3	44
161	Benefit of mediastinal and paraâ€aortic lymphâ€node dissection for advanced gastric cancer with esophageal invasion. Journal of Surgical Oncology, 2008, 97, 392-395.	0.8	28

#	Article	IF	Citations
162	Dihydropyrimidine dehydrogenases and cytidineâ€deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. Journal of Surgical Oncology, 2008, 98, 130-134.	0.8	16
163	Selection of best candidates for multiorgan resection among patients with T4 gastric carcinoma. Journal of Surgical Oncology, 2008, 98, 336-342.	0.8	27
164	Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Cancer, 2008, 112, 2368-2376.	2.0	91
165	miRâ€15b and miRâ€16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. International Journal of Cancer, 2008, 123, 372-379.	2.3	647
166	Population-based study of surgical factors in relation to health-related quality of life after oesophageal cancer resection. British Journal of Surgery, 2008, 95, 592-601.	0.1	57
167	Caveats in the interpretation of the surgical literature. British Journal of Surgery, 2008, 95, 541-546.	0.1	23
168	Gastric cancer in Europe. British Journal of Surgery, 2008, 95, 406-408.	0.1	10
169	Gastric cancer in Europe (Br J Surg 2008; 95: 406â€“408). British Journal of Surgery, 2008, 95, 1189-1189.	0.1	3
170	Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer. British Journal of Surgery, 2008, 96, 26-33.	0.1	91
171	Long-Term Results After Intraoperative Radiation Therapy for Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 70, 715-721.	0.4	23
172	Adjuvant Therapy for Resected Gastric Cancerâ€”Rapid, Yet Incomplete Adoption Following Results of Intergroup 0116 Trial. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1073-1080.	0.4	45
173	Adenocarcinoma of the Esophagogastric Junction: The Pattern of Metastatic Lymph Node Dissemination as a Rationale for Elective Lymphatic Target Volume Definition. International Journal of Radiation Oncology Biology Physics, 2008, 70, 1408-1417.	0.4	51
174	Chemoradiation Therapy for Potentially Resectable Gastric Cancer: Clinical Outcomes Among Patients Who Do Not Undergo Planned Surgery. International Journal of Radiation Oncology Biology Physics, 2008, 71, 167-172.	0.4	13
175	Incidence, Natural History, and Patterns of Locoregional Recurrence in Gastric Cancer Patients Treated With Preoperative Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2008, 71, 741-747.	0.4	22
176	The Survival Impact of the Intergroup 0116 Trial on Patients With Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2008, 72, 517-521.	0.4	43
177	Intraoperative Radiotherapy Combined With Adjuvant Chemoradiotherapy for Locally Advanced Gastric Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1488-1494.	0.4	23
178	Expression of Vascular Endothelial Growth Factor (VEGF) and Epidermal Growth Factor Receptor (EGFR) is an Independent Prognostic Indicator of Worse Outcome in Gastric Cancer Patients. Annals of Surgical Oncology, 2008, 15, 69-79.	0.7	220
179	Stage-Specific Effect of Adjuvant Therapy Following Gastric Cancer Resection: a Population-based Analysis of 4,041 Patients. Annals of Surgical Oncology, 2008, 15, 500-507.	0.7	48

#	Article	IF	Citations
180	Breast Conservation Therapy: Multiple Reexcisions or Subcutaneous and Nipple-Sparing Mastectomy?. Annals of Surgical Oncology, 2008, 15, 943-944.	0.7	2
181	Laparoscopic Gastrectomy: Feasibility, Safety and Efficacy. Annals of Surgical Oncology, 2008, 15, 1249-1250.	0.7	0
182	Prophylactic Surgery in the Complex Decision-Making Management of BRCA Mutation Carriers. Annals of Surgical Oncology, 2008, 15, 1788-1790.	0.7	4
183	Controversy in the Treatment of Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 1795-1797.	0.7	3
184	More Controversy than Ever â€“ Challenges and Promises Towards Personalized Treatment of Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 956-960.	0.7	81
185	Minimal Residual Disease in Breast Cancer: Can It Be Used as a Prognostic Marker?. Annals of Surgical Oncology, 2008, 15, 1793-1794.	0.7	0
186	Adjuvant Therapy for Adenocarcinoma of the Pancreas: Analysis of Reported Trials and Recommendations for Future Progress. Annals of Surgical Oncology, 2008, 15, 2773-2786.	0.7	60
187	Metastatic Dormancy Imposed by the Primary Tumor: Does it Exist in Humans?. Annals of Surgical Oncology, 2008, 15, 3308-3315.	0.7	48
188	Refining Esophageal Cancer Staging After Neoadjuvant Therapy: Importance of Treatment Response. Annals of Surgical Oncology, 2008, 15, 2894-2902.	0.7	68
189	Integrated Therapy in Localized Gastric Cancer: Targeted and Tailored Approach. Annals of Surgical Oncology, 2008, 15, 2983-2985.	0.7	1
190	Benefits and Harms in Avoiding Axilla Lymphadenectomy in Breast Cancer. Annals of Surgical Oncology, 2008, 15, 2978-2979.	0.7	0
191	Nodal Micrometastases Statusâ€"Will It Influence Decisions on Surgical and Adjuvant Treatment for Breast Cancer?. Annals of Surgical Oncology, 2008, 15, 1256-1257.	0.7	1
192	Appropriate Treatment for Patients with Gastric Adenocarcinoma. Annals of Surgical Oncology, 2008, 15, 1798-1799.	0.7	1
193	Targeting VEGF, EGFR, and Other Interacting Pathways for Gastric Cancerâ€"Promises and Reality. Annals of Surgical Oncology, 2008, 15, 2981-2982.	0.7	7
194	Stage-Specific Guided Adjuvant Treatment for Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 2622-2623.	0.7	2
195	7-Year Survival Results of Perioperative Chemotherapy with Epidoxorubicin, Etoposide, and Cisplatin (EEP) in Locally Advanced Resectable Gastric Cancer: Up-to-date Analysis of a Phase-II Study. Annals of Surgical Oncology, 2008, 15, 2146-2152.	0.7	11
196	Angiopoietin-1 protects mesenchymal stem cells against serum deprivation and hypoxia-induced apoptosis through the PI3KAkt pathway¹. Acta Pharmacologica Sinica, 2008, 29, 815-822.	2.8	59
197	Met expression is an independent prognostic risk factor in patients with oesophageal adenocarcinoma. British Journal of Cancer, 2008, 98, 1102-1108.	2.9	50

#	Article	IF	Citations
198	Survival from cancer of the stomach in England and Wales up to 2001. British Journal of Cancer, 2008, 99, S19-S20.	2.9	1
199	PANCREATICODUODENECTOMY FOR LOCALLY ADVANCED STOMACH CANCER: PRELIMINARY RESULTS. ANZ Journal of Surgery, 2008, 78, 767-770.	0.3	15
201	Tumeurs digestives et bÃ©vacizumab. Journal De Chirurgie, 2008, 145, 16-20.	0.1	0
202	Are Patients with Esophageal Cancer Who Become PET Negative after Neoadjuvant Chemoradiation Free of Cancer?. Journal of the American College of Surgeons, 2008, 206, 879-886.	0.2	49
203	Use of 18F-fluorodeoxyglucose-positron emission tomography to evaluate responses to neo-adjuvant chemotherapy for primary tumor and lymph node metastasis in esophageal squamous cell carcinoma. Surgery, 2008, 144, 793-802.	1.0	49
204	Oesophageal cancer. Surgery, 2008, 26, 458-462.	0.1	0
205	Locally Advanced and Metastatic Gastric Cancer. Drugs, 2008, 68, 299-317.	4.9	37
206	Perioperative Chemotherapy for Gastric Cancer. Annals of Surgical Oncology, 2008, 15, 1253-1253.	0.7	1
207	Transhiatal esophagectomy in a high volume institution. World Journal of Surgical Oncology, 2008, 6, 88.	0.8	21
209	Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings, 2008, 83, 712-722.	1.4	29
210	Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer. New England Journal of Medicine, 2008, 358, 36-46.	13.9	2,052
211	Sensitization of Cancer Cells for Chemo/Immuno/Radio-therapy. , 2008, , .		3
212	Chronic advanced gastric cancer: clinicopathologic analysis of survival data. Human Pathology, 2008, 39, 641-649.	1.1	7
213	Primary gastric tumors of infancy and childhood: 54-year experience at a single institution. Journal of Pediatric Surgery, 2008, 43, 1487-1493.	0.8	43
214	Immunogenicity of anthracyclines: moving towards more personalized medicine. Trends in Molecular Medicine, 2008, 14, 141-151.	3.5	108
215	Is Cardiopulmonary Exercise Testing a Useful Test Before Esophagectomy?. Annals of Thoracic Surgery, 2008, 85, 294-299.	0.7	96
216	Outcomes After Transhiatal and Transthoracic Esophagectomy for Cancer. Annals of Thoracic Surgery, 2008, 85, 424-429.	0.7	253
217	Resection for Esophageal Cancer: Strategies for Optimal Management. Annals of Thoracic Surgery, 2008, 85, S751-S756.	0.7	115

#	Article	IF	Citations
218	Long-Term Results of a Phase II Trial of Neoadjuvant Chemotherapy Followed by Esophagectomy for Locally Advanced Esophageal Neoplasm. Annals of Thoracic Surgery, 2008, 85, 1930-1937.	0.7	60
223	Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group. European Journal of Cancer, 2008, 44, 182-194.	1.3	93
225	Treatment results for gastric cancer surgery: 12 yearsâ€™ experience at a single institute in Korea. European Journal of Surgical Oncology, 2008, 34, 36-41.	0.5	82
226	A feasibility, pharmacokinetic and frequency-escalation trial of intraperitoneal chemotherapy in high risk gastrointestinal tract cancer. European Journal of Surgical Oncology, 2008, 34, 403-409.	0.5	4
227	Advanced gastric cancer with or without peritoneal carcinomatosis treated with hyperthermic intraperitoneal chemotherapy: A single western center experience. European Journal of Surgical Oncology, 2008, 34, 1246-1252.	0.5	102
228	The role of 18F-FDG PET/CT in the evaluation of oesophageal carcinoma. Clinical Radiology, 2008, 63, 1297-1309.	0.5	42
229	Advances in neoadjuvant therapy for colorectal cancer with liver metastases. Cancer Treatment Reviews, 2008, 34, 293-301.	3.4	26
230	Updates in the management of esophageal and gastric cancers. Community Oncology, 2008, 5, 617-624.	0.2	0
231	Innovative genomic-based model for personalized treatment of gastric cancer: integrating current standards and new technologies. Expert Review of Molecular Diagnostics, 2008, 8, 29-39.	1.5	82
232	Adenocarcinomas of the esophagus: Response to chemoradiotherapy is associated with decrease of metabolic tumor volume as measured on PETâ€“CT. Radiotherapy and Oncology, 2008, 89, 278-286.	0.3	110
233	Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet, The, 2008, 371, 1007-1016.	6.3	1,759
234	Peptides and Peptidomimetics as Cancer Therapy Sensitizing Agents. , 2008, , 279-303.		1
235	Survival Trends in Patients With Gastric and Esophageal Adenocarcinomas: A Population-Based Study. Mayo Clinic Proceedings, 2008, 83, 1087-1094.	1.4	51
236	Neoadjuvant Therapy for Gastric Cancer. Advances in Surgery, 2008, 42, 151-168.	0.6	9
237	The Role of Postoperative Adjuvant Chemotherapy Following Curative Resection for Gastric Cancer: A Meta-Analysis. Cancer Investigation, 2008, 26, 317-325.	0.6	39
238	Multimodality therapy for the curative treatment of cancer of the esophagus and gastroesophageal junction. Expert Review of Anticancer Therapy, 2008, 8, 1953-1964.	1.1	4
239	HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Annals of Oncology, 2008, 19, 1523-1529.	0.6	931
240	Adjuvant Chemotherapy for Gastric Cancer or Not: A Dilemma?. Journal of the National Cancer Institute, 2008, 100, 376-377.	3.0	9

#	Article	IF	Citations
241	The role of UFT in advanced gastric cancer. Annals of Oncology, 2008, 19, 1045-1052.	0.6	10
242	Protein Expression Profiling in Esophageal Adenocarcinoma Patients Indicates Association of Heat-Shock Protein 27 Expression and Chemotherapy Response. Clinical Cancer Research, 2008, 14, 8279-8287.	3.2	54
243	Phase II Trial of Neoadjuvant Cisplatin, 5-Fluorouracil and Interferon-Alpha in Operable Squamous Cell Carcinoma of the Esophagus. Chemotherapy, 2008, 54, 315-322.	0.8	6
244	Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii23-ii24.	0.6	14
245	The Potential Role of Pemetrexed in Gastrointestinal Cancer. Chemotherapy, 2008, 54, 1-8.	0.8	9
246	Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil: Is it time to move forward?. Cancer Biology and Therapy, 2008, 7, 986-994.	1.5	77
247	Postoperative Chemotherapy in Resected Gastric Cancer: Results of a Single Center Experience. Journal of Chemotherapy, 2008, 20, 497-502.	0.7	1
248	Paclitaxel in the Neoadjuvant Treatment for Adeno carcinoma of the Distal Esophagus (AEG I). A Comparison of Two Phase II Trials with Long-Term Follow-Up. Onkologie, 2008, 31, 366-372.	1.1	29
249	Stomach and Duodenum. , 2008, , 841-874.		0
250	Malignant Tumors of the Esophagus. , 2008, , 827-839.		0
251	Emerging drugs in the treatment of advanced gastric cancer. Expert Opinion on Emerging Drugs, 2008, 13, 135-144.	1.0	11
252	Phase III Trial of Trimodality Therapy With Cisplatin, Fluorouracil, Radiotherapy, and Surgery Compared With Surgery Alone for Esophageal Cancer: CALGB 9781. Journal of Clinical Oncology, 2008, 26, 1086-1092.	0.8	1,245
253	The decision to operate: role of integrated computed tomography positron emission tomography in staging oesophageal and oesophagogastric junction cancer by the multidisciplinary teamâ˜†. European Journal of Cardio-thoracic Surgery, 2008, 33, 1112-1116.	0.6	15
254	S-1 adjuvant chemotherapy for advanced gastric cancer. Nature Clinical Practice Oncology, 2008, 5, 370-371.	4.3	0
255	Progress in the multidisciplinary treatment of gastrointestinal cancers, impact on clinical practice: peri-operative management of gastro-esophageal cancer. Annals of Oncology, 2008, 19, vii259-vii265.	0.6	1
256	Perioperative or postoperative therapy for resectable gastric cancer?. Annals of Oncology, 2008, 19, v99-v102.	0.6	4
257	Early Metabolic Response Evaluation by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Allows In vivo Testing of Chemosensitivity in Gastric Cancer: Long-term Results of a Prospective Study. Clinical Cancer Research, 2008, 14, 2012-2018.	3.2	140
258	Serum Interleukin-6 Level but not Genotype Predicts Survival after Resection in Stages II and III Gastric Carcinoma. Clinical Cancer Research, 2008, 14, 428-434.	3.2	76

#	Article	IF	Citations
259	Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2008, 19, ii21-ii22.	0.6	13
260	The evolving role of catumaxomab in gastric cancer. Expert Opinion on Biological Therapy, 2008, 8, 1407-1415.	1.4	14
262	Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy, 2008, 8, 975-991.	1.1	6
263	Nodal Dissection for Gastric Cancer. New England Journal of Medicine, 2008, 359, 2392-2393.	13.9	5
267	Locally advanced esophageal adenocarcinoma: current standards and molecular predictors of outcome. Future Oncology, 2008, 4, 413-425.	1.1	4
268	Capecitabine in the treatment of advanced gastric cancer. Future Oncology, 2008, 4, 179-198.	1.1	11
269	Treatment options for esophageal cancer. Expert Opinion on Pharmacotherapy, 2008, 9, 3197-3210.	0.9	8
270	Cancer of the Esophagus and Stomach. Mayo Clinic Proceedings, 2008, 83, 712-722.	1.4	57
271	Barrett Esophagus and Esophageal Adenocarcinoma. , 0, , 826-848.		2
272	Gastric Cancer Surgery â€“ A Balance of Risk and Radicality. Annals of the Royal College of Surgeons of England, 2008, 90, 235-242.	0.3	31
273	Combined Modality Therapy of Esophageal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 851-861.	2.3	15
274	Endoskopische und endosonographische Diagnostik. Chirurgische Gastroenterologie Interdisziplinar, 2008, 24, 16-21.	0.0	0
275	Outcomes of Adjuvant Chemoradiotherapy After a Radical Gastrectomy and a D2 Node Dissection for Gastric Adenocarcinoma. Cancer Journal (Sudbury, Mass), 2008, 14, 269-275.	1.0	22
278	Gastroesophageal Cancers: Progress and Problems. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 813-814.	2.3	27
279	Review of docetaxel in the treatment of gastric cancer. Therapeutics and Clinical Risk Management, 2008, Volume 4, 999-1007.	0.9	24
280	Long-Term Survivorship of Esophageal Cancer Patients Treated with Radical Intent. Canadian Journal of Gastroenterology & Hepatology, 2008, 22, 393-398.	1.8	5
282	Systemic therapy for gastric cancer. , 0, , 98-119.		0
284	Carcinogenesis and Treatment of Gastric Cancer. Frontiers of Gastrointestinal Research, 2009, , 199-210.	0.1	0

#	Article	IF	Citations
285	Fatores prognÃ³sticos nas gastrectomias com linfadenectomia D2 por adenocarcinoma gÃ¡strico. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2009, 22, 158-164.	0.5	1
286	Newly emerging standard chemotherapies for gastric cancer and clinical potential in elderly patients. World Journal of Gastrointestinal Oncology, 2009, 1, 47.	0.8	5
287	Divide and Conquer: Progress in the Molecular Stratification of Cancer. Yonsei Medical Journal, 2009, 50, 464.	0.9	4
288	Surgical management of gastric cancer. , 0, , 83-97.		0
289	Adenocarcinomas on the Rise â€" Does it Influence Survival from Oesophageal Cancer?. Scandinavian Journal of Surgery, 2009, 98, 214-220.	1.3	12
291	Apoptosis in Carcinogenesis and Chemotherapy. , 2009, , .		10
292	A review ofin vitroandin vivomodels of oesophageal and gastric cancer. Expert Opinion on Drug Discovery, 2009, 4, 1267-1279.	2.5	0
293	Identification of GAS1 as an Epirubicin Resistance-related Gene in Human Gastric Cancer Cells with a Partially Randomized Small Interfering RNA Library. Journal of Biological Chemistry, 2009, 284, 26273-26285.	1.6	41
294	Trastuzumab for gastric cancer. Expert Opinion on Biological Therapy, 2009, 9, 1543-1551.	1.4	38
295	Biomarkers of response to therapy in oesophago-gastric cancer. Gut, 2009, 58, 127-143.	6.1	74
296	Clinical Staging of Adenocarcinoma of the Esophagogastric Junction. Recent Results in Cancer Research, 2009, 182, 73-83.	1.8	17
297	Total Gastrectomyâ€"Reply. Archives of Surgery, 2009, 144, 289.	2.3	0
298	Is Laparoscopic Colectomy a Good Operation for Colon Cancer?. Archives of Surgery, 2009, 144, 289.	2.3	1
299	Trends in Presentation and Survival for Gallbladder Cancer During a Period of More Than 4 Decadesâ€"Invited Critique. Archives of Surgery, 2009, 144, 447.	2.3	0
300	Total Gastrectomy. Archives of Surgery, 2009, 144, 289.	2.3	1
301	Role of intensity-modulated radiation therapy in gastrointestinal cancer. Expert Review of Anticancer Therapy, 2009, 9, 637-647.	1.1	22
302	The degree of circumferential tumour involvement as a prognostic factor in oesophageal cancerâ˜†â˜†â˜†. European Journal of Cardio-thoracic Surgery, 2009, 36, 368-373.	0.6	17
303	Gastric cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv34-iv36.	0.6	94

#	Article	IF	Citations
305	Perspectives in Adjuvant Therapy of Gastric Cancer. Oncology, 2009, 77, 38-42.	0.9	17
306	Trends in Presentation and Survival for Gallbladder Cancer During a Period of More Than 4 Decades. Archives of Surgery, 2009, 144, 441.	2.3	85
307	Optimal surgery for advanced gastric cancer. Expert Review of Anticancer Therapy, 2009, 9, 1849-1858.	1.1	6
308	Importance and Limitations of Chemotherapy Among the Available Treatments for Gastrointestinal Tumours. Anti-Cancer Agents in Medicinal Chemistry, 2009, 9, 162-184.	0.9	38
309	Clopidogrel plus Aspirin in Atrial Fibrillation. New England Journal of Medicine, 2009, 361, 1312-1315.	13.9	1
310	Case 19-2009: Carcinoma of the Gastroesophageal Junction. New England Journal of Medicine, 2009, 361, 1315-1316.	13.9	0
311	Case 19-2009. New England Journal of Medicine, 2009, 360, 2656-2664.	13.9	4
314	Treatment of resectable gastric cancer: current standards of care. Expert Review of Anticancer Therapy, 2009, 9, 135-142.	1.1	14
316	Follow up your unexpected clinical observations!. Acta OncolÃ³gica, 2009, 48, 325-327.	0.8	1
317	Esophageal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology, 2009, 20, iv32-iv33.	0.6	26
318	Surgery for gastric cancer: An evidence-based perspective. Journal of Cancer Research and Therapeutics, 2009, 5, 225.	0.3	11
319	ML17032 trial: capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in advanced gastric cancer. Expert Review of Anticancer Therapy, 2009, 9, 1745-1751.	1.1	14
320	¹⁸F-FDG PET and ¹⁸F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer. Journal of Nuclear Medicine, 2009, 50, 89S-96S.	2.8	87
321	Chemotherapy induced carcinoma-adenoma regression in the caecum. Journal of Clinical Pathology, 2009, 62, 282-283.	1.0	0
322	Histological type of esophageal cancer might affect response to neo-adjuvant radiochemotherapy and subsequent prognosis. Annals of Oncology, 2009, 20, 231-238.	0.6	90
323	Lymphadenectomy for Gastric Adenocarcinoma: Should West Meet East?. Oncologist, 2009, 14, 871-882.	1.9	51
324	Review: Integration of targeted agents in the neo-adjuvant treatment of gastro-esophageal cancers. Therapeutic Advances in Medical Oncology, 2009, 1, 145-165.	1.4	6
325	Gastrectomy for adenocarcinoma. Continuing Education in Anaesthesia, Critical Care & Pain, 2009, 9, 65-69.	0.6	0

#	Article	IF	Citations
326	Transition in Biology and Philosophy in the Treatment of Gastroesophageal Junction Adenocarcinoma. Journal of Clinical Oncology, 2009, 27, 836-837.	0.8	11
328	Is Laparoscopic Colectomy a Good Operation for Colon Cancer?â€"Reply. Archives of Surgery, 2009, 144, 289.	2.3	0
329	Trends and variation in the management of oesophagogastric cancer patients: a population-based survey. BMC Health Services Research, 2009, 9, 231.	0.9	11
330	Emerging Role of Capecitabine in Gastric Cancer. Pharmacotherapy, 2009, 29, 318-330.	1.2	16
334	CD4+CD25+CD127low/â^' regulatory T cells express Foxp3 and suppress effector T cell proliferation and contribute to gastric cancers progression. Clinical Immunology, 2009, 131, 109-118.	1.4	123
335	Treatment and outcomes of gastric cancer among United Statesâ€born and foreignâ€born Asians and Pacific Islanders. Cancer, 2009, 115, 4595-4605.	2.0	23
336	Lymph nodes and gastric cancer. Journal of Surgical Oncology, 2009, 99, 199-206.	0.8	80
337	Survivin expression in gastric cancer: Association with histomorphological response to neoadjuvant therapy and prognosis. Journal of Surgical Oncology, 2009, 99, 409-413.	0.8	21
338	Value of multidetectorâ€row computed tomography in the preoperative T and N staging of gastric carcinoma: A largeâ€scale Chinese study. Journal of Surgical Oncology, 2009, 100, 205-214.	0.8	89
339	Evidenceâ€based medicine in the treatment of peritoneal carcinomatosis: Past, present, and future. Journal of Surgical Oncology, 2009, 100, 335-344.	0.8	33
340	Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. British Journal of Surgery, 2009, 96, 1015-1022.	0.1	198
341	High preoperative serum vascular endothelial growth factor levels predict poor clinical outcome after curative resection of gastric cancer. British Journal of Surgery, 2009, 96, 1443-1451.	0.1	47
342	Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. Journal of Cancer Research and Clinical Oncology, 2009, 135, 29-38.	1.2	40
343	Adjuvant chemotherapy with 5-FU or regimens including oral fluoropyrimidine for curable gastric cancer. Gastric Cancer, 2009, 12, 10-15.	2.7	4
345	Improving outcome for scirrhous gastric cancer. Gastric Cancer, 2009, 12, 3-5.	2.7	9
347	An orthotopic nude mouse model for preclinical research of gastric cardia cancer. International Journal of Colorectal Disease, 2009, 24, 31-39.	1.0	22
348	Combined Adjuvant Radiochemotherapy With IMRT/XELOX Improves Outcome With Low Renal Toxicity in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1187-1195.	0.4	35
349	Metabolic Tumor Width Parameters as Determined on PET/CT Predict Disease-free Survival and Treatment Response in Squamous Cell Carcinoma of the Esophagus. Molecular Imaging and Biology, 2009, 11, 54-60.	1.3	50

#	Article	IF	Citations
350	Recommendations on current approach to gastric cancer. Clinical and Translational Oncology, 2009, 11, 518-525.	1.2	3
351	Long-term results of neoadjuvant chemotherapy and combined chemoradiotherapy before surgery in the management of locally advanced oesophageal cancer: a single-centre experience. Clinical and Translational Oncology, 2009, 11, 835-841.	1.2	7
353	Diagnostic performance of 64-MDCT and 1.5-T MRI with highresolution sequences in the T staging of gastric cancer: a comparative analysis with histopathology. Radiologia Medica, 2009, 114, 1065-1079.	4.7	42
354	Multimodale Therapie bei Karzinomen des gastroÃ¶sophagealen Ãœbergangs (GÃ–Ãœ). Onkopipeline, 2009, 2, 92-100.	0.0	0
355	Gastric cancer â€“ ASCO 2009. Memo - Magazine of European Medical Oncology, 2009, 2, 206-207.	0.3	0
356	Advances in the management of gastric cancer. Indian Journal of Surgery, 2009, 71, 342-349.	0.2	2
363	Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 735-744.	3.3	54
364	Usefulness of CT volumetry for primary gastric lesions in predicting pathologic response to neoadjuvant chemotherapy in advanced gastric cancer. Abdominal Imaging, 2009, 34, 430-440.	2.0	53
365	Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma. Cancer Immunology, Immunotherapy, 2009, 58, 1819-1830.	2.0	29
366	A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3Âmonths of platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2009, 64, 455-462.	1.1	29
367	Management of synchronous adenocarcinoma of the esophago-gastric junction and ampulla of Vater: case report of a surgically challenging condition. Patient Safety in Surgery, 2009, 3, 23.	1.1	5
368	Tumour regression grade (TRG) analyses in patients with resectable gastroâ€oesophageal adenocarcinomas treated with platinumâ€based neoadjuvant chemotherapy. Histopathology, 2009, 55, 399-406.	1.6	39
369	Prognostic significance of histopathological tumor regression after neoadjuvant chemotherapy in esophageal adenocarcinomas. Modern Pathology, 2009, 22, 1555-1563.	2.9	101
370	A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. British Journal of Cancer, 2009, 100, 1725-1730.	2.9	20
371	Effects of neoadjuvant chemotherapy on primary tumor and lymph node metastasis in esophageal squamous cell carcinoma: additive association with prognosis. Ecological Management and Restoration, 2009, 22, 291-297.	0.2	19
372	Intraluminal brachytherapy in the management of squamous carcinoma of the esophagus. Ecological Management and Restoration, 2009, 22, 513-518.	0.2	9
373	Oesophagectomy for tumours and dysplasia of the oesophagus and gastroâ€oesophageal junction. ANZ Journal of Surgery, 2009, 79, 251-257.	0.3	9
374	Oxaliplatin and Capecitabine-Based Chemoradiotherapy for Gastric Cancerâ€"An Extended Phase I MARGIT and AIO Trial. International Journal of Radiation Oncology Biology Physics, 2009, 73, 142-147.	0.4	21

#	Article	IF	Citations
375	Study to Determine Adequate Margins in Radiotherapy Planning for Esophageal Carcinoma by Detailing Patterns of Recurrence After Definitive Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2009, 73, 818-823.	0.4	77
376	Chemoradiotherapy in Gastrointestinal Malignancies. Clinical Oncology, 2009, 21, 543-556.	0.6	22
377	Systemic treatment of gastric cancer. Critical Reviews in Oncology/Hematology, 2009, 70, 216-234.	2.0	25
378	Gastric cancer. Critical Reviews in Oncology/Hematology, 2009, 71, 127-164.	2.0	347
379	Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy for Peritoneal Surface Malignancy: Non-Colorectal Indications. Current Problems in Cancer, 2009, 33, 168-193.	1.0	16
380	Limited Advantages of Intensity-Modulated Radiotherapy Over 3D Conformal Radiation Therapy in the Adjuvant Management of Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 74, 562-566.	0.4	35
381	Phase II Trial of Preoperative Irinotecanâ€“Cisplatin Followed by Concurrent Irinotecanâ€“Cisplatin and Radiotherapy for Resectable Locally Advanced Gastric and Esophagogastric Junction Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2009, 75, 1430-1436.	0.4	34
382	Helicobacter pylori and Clinical Aspects of Gastric Cancer. Helicobacter, 2009, 14, 41-45.	1.6	16
383	Is There a Role for Surgery in Recurrent Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1074-1075.	0.7	4
384	Predicting Prognosis of Gastric Cancer: Limitations of Metastatic Lymph Nodes Number and Promise of Genomics. Annals of Surgical Oncology, 2009, 16, 1432-1433.	0.7	1
385	Perioperative Chemotherapy for Gastric Cancer: How Should We Measure the Efficacy?. Annals of Surgical Oncology, 2009, 16, 1077-1079.	0.7	2
386	Genome-Wide Association Studies and Aggressive Surgery Toward Individualized Prevention, and Improved Local Control and Overall Survival for Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 795-798.	0.7	88
387	Surgical Factors Influence the Outcome After Ivor-Lewis Esophagectomy with Intrathoracic Anastomosis for Adenocarcinoma of the Esophagogastric Junction: A Consecutive Series of 240 Patients at an Experienced Center. Annals of Surgical Oncology, 2009, 16, 1017-1025.	0.7	79
388	Assessing Potential Synergistic Effects of S-1 Plus Paclitaxel Chemotherapy in Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1442-1443.	0.7	0
389	Neoadjuvant and Postoperative Adjuvant Anticancer Chemotherapy in Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1444-1445.	0.7	0
390	Laparoscopic Versus Open Subtotal Gastrectomy for Adenocarcinoma: A Caseâ€“Control Study. Annals of Surgical Oncology, 2009, 16, 1507-1513.	0.7	170
391	Prognostic Significance of Tumor Size in T3 Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 1875-1882.	0.7	39
392	Centralization of Esophageal Cancer Surgery: Does It Improve Clinical Outcome?. Annals of Surgical Oncology, 2009, 16, 1789-1798.	0.7	142

#	Article	IF	Citations
393	Allelic Imbalance at p53 and Microsatellite Instability Are Predictive Markers for Resistance to Chemotherapy in Gastric Carcinoma. Annals of Surgical Oncology, 2009, 16, 2926-2935.	0.7	16
394	Better 5-Year Survival Rate Following Curative Gastrectomy in Overweight Patients. Annals of Surgical Oncology, 2009, 16, 3245-3251.	0.7	86
395	Induction Chemotherapy with S-1 Plus Cisplatin Followed by Surgery for Treatment of Gastric Cancer with Peritoneal Dissemination. Annals of Surgical Oncology, 2009, 16, 3227-3236.	0.7	105
396	Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Advanced Drug Delivery Reviews, 2009, 61, 402-407.	6.6	29
397	Phase III Comparison of Preoperative Chemotherapy Compared With Chemoradiotherapy in Patients With Locally Advanced Adenocarcinoma of the Esophagogastric Junction. Journal of Clinical Oncology, 2009, 27, 851-856.	0.8	880
398	Toward molecularly selected chemotherapy for advanced gastric cancer: State of the art and future perspectives. Cancer Treatment Reviews, 2009, 35, 451-462.	3.4	24
399	CyclinD1 and interleukin-1 receptor antagonist polymorphisms are associated with prognosis in neoadjuvant-treated gastric carcinoma. European Journal of Cancer, 2009, 45, 3326-3335.	1.3	21
400	Short and long-term advantages of transhiatal and transthoracic oesophageal cancer resection. European Journal of Surgical Oncology, 2009, 35, 793-797.	0.5	19
401	FDG-PET has no definite role in preoperative imaging in gastric cancer. European Journal of Surgical Oncology, 2009, 35, 449-455.	0.5	122
402	Tumors of the Esophagus, Gastroesophageal Junction, and Stomach. Seminars in Oncology Nursing, 2009, 25, 61-75.	0.7	15
405	Routine positron emission tomography does not alter nodal staging in patients undergoing EUS-guided FNA for esophageal cancer. Gastrointestinal Endoscopy, 2009, 69, 1210-1217.	0.5	44
406	Analysis of postoperative morbidity in patients with gastric adenocarcinoma treated using a protocol of preoperative chemoradiotherapy and surgery. CirugÃa EspaÃ±ola (English Edition), 2009, 86, 351-357.	0.1	1
407	Perioperative Chemotherapy for Gastric Cancer. Annals of Surgical Oncology, 2009, 16, 226-227.	0.7	2
408	Upper Gastrointestinal Malignancies: A New Era in Clinical Colorectal Cancer. Clinical Colorectal Cancer, 2009, 8, 185-189.	1.0	1
410	Advances in the Pharmacological Treatment of Gastro-Oesophageal Cancer. Drugs and Aging, 2009, 26, 627-646.	1.3	16
411	Multidisciplinary Approach to Esophageal and Gastric Cancer. Surgical Clinics of North America, 2009, 89, 79-96.	0.5	30
412	Evidence-based radiation oncology: Oesophagus. Radiotherapy and Oncology, 2009, 92, 276-290.	0.3	59
413	Survival after radiotherapy in gastric cancer: Systematic review and meta-analysis. Radiotherapy and Oncology, 2009, 92, 176-183.	0.3	84

#	Article	IF	Citations
414	Monitoring Response to Therapeutic Interventions in Patients With Cancer. Seminars in Nuclear Medicine, 2009, 39, 210-232.	2.5	35
415	Preoperative treatment and surgery in gastric cancer: friends or foes?. Lancet Oncology, The, 2009, 10, 191-195.	5.1	48
416	Is there a role for second-line chemotherapy in advanced gastric cancer?. Lancet Oncology, The, 2009, 10, 903-912.	5.1	98
417	Gastric cancer. Lancet, The, 2009, 374, 477-490.	6.3	871
418	Mortality in patients with schizophrenia â€“ Author's reply. Lancet, The, 2009, 374, 1592-1593.	6.3	4
419	Gastric cancer. Lancet, The, 2009, 374, 1593-1594.	6.3	12
420	CÃ¡ncer de esÃ³fago. Medicine, 2009, 10, 1715-1722.	0.0	0
421	CÃ¡ncer de estÃ³mago. Medicine, 2009, 10, 1723-1729.	0.0	0
422	Predictors of Long-Term Survival After Resection of Esophageal Carcinoma With Nonregional Nodal Metastases. Annals of Thoracic Surgery, 2009, 88, 186-193.	0.7	46
423	Role of Neoadjuvant Therapy for Esophageal Adenocarcinoma. Surgical Oncology Clinics of North America, 2009, 18, 533-546.	0.6	11
424	Preoperative Therapy for Esophageal Cancer. Gastroenterology Clinics of North America, 2009, 38, 135-152.	1.0	13
425	Stomach cancer mortality in two large cohorts of migrants from the Former Soviet Union to Israel and Germany: are there implications for prevention?. European Journal of Gastroenterology and Hepatology, 2009, 21, 409-416.	0.8	23
426	The Perioperative Period is an Underutilized Window of Therapeutic Opportunity in Patients With Colorectal Cancer. Annals of Surgery, 2009, 249, 727-734.	2.1	175
427	Signet Ring Cell Histology is an Independent Predictor of Poor Prognosis in Gastric Adenocarcinoma Regardless of Tumoral Clinical Presentation. Annals of Surgery, 2009, 250, 878-887.	2.1	249
428	Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenetics and Genomics, 2009, 19, 955-964.	0.7	6
429	Early Gastric Cancer. Annals of Surgery, 2009, 250, 791-797.	2.1	141
430	Radical Surgery for Gastric Carcinoma: It is Not an Issue of Whether to Perform D1 or D2. Dissect as Many Lymph Nodes as Possible and You Will Be Rewarded. Acta Chirurgica Belgica, 2009, 109, 27-35.	0.2	8
431	Perineural Invasion After Preoperative Chemotherapy Predicts Poor Survival in Patients With Locally Advanced Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2009, 32, 356-362.	0.6	18

#	Article	IF	Citations
432	Mature Results from a Phase II Trial of Postoperative Concurrent Chemoradiotherapy for Poor Prognosis Cancer of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology, 2009, 4, 1264-1269.	0.5	46
433	Secondary Malignancies. , 2009, , 72-81.		0
434	Pre- and postoperative management of patients with oesophageal cancer. Gastrointestinal Nursing, 2009, 7, 26-32.	0.0	0
436	Comparison of Gastric Cancer Survival Following R0 Resection in the United States and Korea Using an Internationally Validated Nomogram. Annals of Surgery, 2010, 251, 640-646.	2.1	314
437	Recent Patents of DNA Methylation Biomarkers in Gastrointestinal Oncology. Recent Patents on DNA & Gene Sequences, 2010, 4, 202-209.	0.7	12
438	Revisional Surgery After Gastrectomy for Gastric Cancer. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2010, 20, 332-337.	0.4	12
439	Laparoscopy-assisted Total Gastrectomy for Advanced Gastric Cancer With Carcinomatous Ascites After S1 Plus Cisplatin Chemotherapy. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2010, 20, e206-e210.	0.4	0
440	Thoracoscopic-Assisted Esophagectomy for Esophageal Cancer. Annals of Surgery, 2010, 252, 281-291.	2.1	42
441	Prognostic Value of Preoperative Clinical Staging Assessed by Computed Tomography in Resectable Gastric Cancer Patients. Annals of Surgery, 2010, 251, 428-435.	2.1	72
442	Gastric carcinoma in China: Current status and future perspectives (Review). Oncology Letters, 2010, 1, 407-412.	0.8	44
443	Advancements in Radiation Techniques for Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 428-436.	2.3	3
444	Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology Letters, 2010, 1, 327-333.	0.8	5
445	Phase II Randomized Study of Two Regimens of Sequentially Administered Mitomycin C and Irinotecan in Patients with Unresectable Esophageal and Gastroesophageal Adenocarcinoma. Journal of Thoracic Oncology, 2010, 5, 713-718.	0.5	14
447	A Phase II Study of Perioperative Concurrent Chemotherapy, Gefitinib, and Hyperfractionated Radiation Followed by Maintenance Gefitinib in Locoregionally Advanced Esophagus and Gastroesophageal Junction Cancer. Journal of Thoracic Oncology, 2010, 5, 229-235.	0.5	52
448	Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2010, 8, 378-409.	2.3	140
449	Reply to â€œLymphadenectomy in Gastric Cancer: The Controversy Refuses to Dieâ€• Annals of Surgical Oncology, 2010, 17, 336-337.	0.7	0
450	Does Chemoradiotherapy Improve Outcomes for Surgically Resected Adenocarcinoma of the Stomach or Esophagus?. Annals of Surgical Oncology, 2010, 17, 98-108.	0.7	10
451	Temporary Placement of Self-Expanding Oesophageal Stents as Bridging for Neo-Adjuvant Therapy. Annals of Surgical Oncology, 2010, 17, 470-475.	0.7	61

#	Article	IF	Citations
452	KAP1 Is Associated With Peritoneal Carcinomatosis in Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 821-828.	0.7	99
453	Neoadjuvant Docetaxel, Capecitabine and Cisplatin (DXP) in Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 1024-1032.	0.7	53
454	Pathologic Response after Neoadjuvant Therapy is the Major Determinant of Survival in Patients with Esophageal Cancer. Annals of Surgical Oncology, 2010, 17, 1159-1167.	0.7	205
455	Stage and Microscopic Positive Margins in the Treatment of Patients with Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 943-945.	0.7	2
456	Advanced Gastric Cancer with Early Cancer Macroscopic Appearance: Is It Worthy of D2 Lymphadenectomy?. Annals of Surgical Oncology, 2010, 17, 1278-1290.	0.7	16
457	Can Superextended Lymph Node Dissection be Justified for Gastric Cancer with Pathologically Positive Para-aortic Lymph Nodes?. Annals of Surgical Oncology, 2010, 17, 2031-2036.	0.7	39
458	Prognostic Significance of Perineural Invasion in Patients with Gastric Cancer Who Underwent Curative Resection. Annals of Surgical Oncology, 2010, 17, 2037-2044.	0.7	84
459	Peritoneal Carcinomatosis from Gastric Cancer: A Multi-Institutional Study of 159 Patients Treated by Cytoreductive Surgery Combined with Perioperative Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2010, 17, 2370-2377.	0.7	408
460	Prognostic Significance of Free Peritoneal Tumor Cells in the Peritoneal Cavity Before and After Neoadjuvant Chemotherapy in Patients with Gastric Carcinoma Undergoing Potentially Curative Resection. Annals of Surgical Oncology, 2010, 17, 2733-2739.	0.7	89
461	Histone Deacetylase (HDAC) 1 and 2 Expression and Chemotherapy in Gastric Cancer. Annals of Surgical Oncology, 2010, 17, 3336-3343.	0.7	64
462	Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients. Annals of Surgical Oncology, 2010, 17, 3173-3180.	0.7	166
463	Significance of Lavage Cytology in Advanced Gastric Cancer Patients. World Journal of Surgery, 2010, 34, 563-568.	0.8	41
464	Differential Pathologic Variables and Outcomes across the Spectrum of Adenocarcinoma of the Esophagogastric Junction. World Journal of Surgery, 2010, 34, 2821-2829.	0.8	28
465	Intravenous paclitaxel against metastasis of human gastric tumors of diffuse type. Cancer Chemotherapy and Pharmacology, 2010, 66, 773-783.	1.1	6
466	A randomized phase III study of adjuvant platinum/docetaxel chemotherapy with or without radiation therapy in patients with gastric cancer. Cancer Chemotherapy and Pharmacology, 2010, 65, 1009-1021.	1.1	85
467	Determining the role of radiotherapy in the adjuvant management of gastric cancer: an ocean apart. Cancer Chemotherapy and Pharmacology, 2010, 65, 1005-1007.	1.1	1
469	Expression of thymidylate synthase determines the response of gastric cancer patients undergoing gastrectomy to 5-fluorouracil-based adjuvant chemotherapy. Langenbeck's Archives of Surgery, 2010, 395, 217-225.	0.8	11
470	Immunohistochemically detectable dickkopf-3 expression in tumor vessels predicts survival in gastric cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2010, 456, 635-646.	1.4	16

#	Article	IF	Citations
471	Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. Journal of Cancer Research and Clinical Oncology, 2010, 136, 883-889.	1.2	80
472	Adenocarcinoma of the esophagogastric junction: incidence, characteristics, and treatment strategies. Gastric Cancer, 2010, 13, 63-73.	2.7	118
473	Geminin, Ki67, and minichromosome maintenance 2 in gastric hyperplastic polyps, adenomas, and intestinal-type carcinomas: pathobiological significance. Gastric Cancer, 2010, 13, 177-185.	2.7	21
474	A feasibility study of postoperative chemotherapy with S-1 and cisplatin (CDDP) for gastric carcinoma (CCOG0703). Gastric Cancer, 2010, 13, 197-203.	2.7	39
475	Lymph node dissection in the resection of gastric cancer: Review of existing evidence. Gastric Cancer, 2010, 13, 137-148.	2.7	49
476	Multimodality treatment of esophagus cancer: current status and future perspectives in the United States. Esophagus, 2010, 7, 1-6.	1.0	3
480	Minimally invasive surgery and cancer: controversies part 1. Surgical Endoscopy and Other Interventional Techniques, 2010, 24, 304-334.	1.3	39
481	Gastric cancer â€“ ASCO 2010. Memo - Magazine of European Medical Oncology, 2010, 3, 168-170.	0.3	1
483	Risk stratification for recurrence in patients with esophageal and junctional carcinoma treated with neoadjuvant chemotherapy and surgery. Medical Oncology, 2010, 27, 242-248.	1.2	6
484	Updating controversies on the multidisciplinary management of gastric cancer. Clinical and Translational Oncology, 2010, 12, 677-685.	1.2	5
485	Treatment Options for Surgically Resectable Gastric Cancer. Current Treatment Options in Oncology, 2010, 11, 14-23.	1.3	28
486	Novel Perspectives for the Treatment of Gastric Cancer: From a Global Approach to a Personalized Strategy. Current Oncology Reports, 2010, 12, 175-185.	1.8	13
488	Esophageal Adenocarcinoma: Treatment Modalities in the Era of Targeted Therapy. Digestive Diseases and Sciences, 2010, 55, 3304-3314.	1.1	8
489	Management of Esophageal Cancer. Current Problems in Surgery, 2010, 47, 845-946.	0.6	25
490	Survival of patients with distal esophageal and gastric cardia tumors: A population-based analysis of gastroesophageal junction carcinomas. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 43-48.	0.4	31
491	Predictors of survival in patients with persistent nodal metastases after preoperative chemotherapy for esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2010, 139, 387-394.	0.4	23
492	Utility of response evaluation to neo-adjuvant chemotherapy by 18F-fluorodeoxyglucose-positron emission tomography in locally advanced esophageal squamous cell carcinoma. Surgery, 2010, 148, 908-918.	1.0	38
493	The combination of docetaxel and cisplatin plus fluorouracil as neoadjuvant chemotherapy in the treatment of T4 stage gastric cancer. Surgical Oncology, 2010, 19, 1-3.	0.8	7

#	Article	IF	Citations
494	Radiation, chemotherapy and biological therapy in the curative treatment of locally advanced rectal cancer. Colorectal Disease, 2010, 12, 2-24.	0.7	11
495	High number of CD45RO+ tumor infiltrating lymphocytes is an independent prognostic factor in non-metastasized (stage I-IIA) esophageal adenocarcinoma. BMC Cancer, 2010, 10, 608.	1.1	51
496	Recurrence after Esophagectomy for Adenocarcinoma: Defining Optimal Follow-Up Intervals and Testing. Journal of the American College of Surgeons, 2010, 210, 428-435.	0.2	159
497	A Moderated Journal Club Is More Effective than an Internet Journal Club in Teaching Critical Appraisal Skills: Results of a Multicenter Randomized Controlled Trial. Journal of the American College of Surgeons, 2010, 211, 769-776.	0.2	54
498	Variations in gastric cancer care. Cancer, 2010, 116, 465-475.	2.0	50
499	Role of microRNA in anticancer drug resistance. International Journal of Cancer, 2010, 126, 2-10.	2.3	223
500	PTENâ€•and p53â€•mediated apoptosis and cell cycle arrest by FTY720 in gastric cancer cells and nude mice. Journal of Cellular Biochemistry, 2010, 111, 218-228.	1.2	74
501	Review of open and minimal access approaches to oesophagectomy for cancer. British Journal of Surgery, 2010, 97, 1845-1853.	0.1	105
502	The role of surgery in the treatment of gastric cancer. Journal of Surgical Oncology, 2010, 101, 687-692.	0.8	66
503	Neoadjuvant strategies for the treatment of locally advanced esophageal cancer. Journal of Surgical Oncology, 2010, 101, 299-304.	0.8	22
504	Neoadjuvant therapy of locally advanced gastric cancer. Journal of Surgical Oncology, 2010, 101, 305-314.	0.8	48
505	Management of gastric cancer in Ontario. Journal of Surgical Oncology, 2010, 102, 54-63.	0.8	45
506	[¹⁸F]â€fluorodeoxyglucoseâ€positron emission tomography for the assessment of histopathologic response and prognosis after completion of neoadjuvant chemotherapy in gastric cancer. Journal of Surgical Oncology, 2010, 102, 135-140.	0.8	37
507	Cytoreductive surgery and hyperthermic intraâ€peritoneal chemotherapy (HIPEC) for gastric adenocarcinoma: Why haven't we reached the promised land?. Journal of Surgical Oncology, 2010, 102, 359-360.	0.8	9
508	Extensive lymphatic spread of cancer cells in patients with thoracic esophageal squamous cell carcinoma: Detection of CEAâ€mRNA in the threeâ€field lymph nodes. Journal of Surgical Oncology, 2010, 102, 509-515.	0.8	10
509	Preoperative clinically inapparent leucopenia in patients undergoing neoadjuvant chemotherapy for locally advanced gastric cancer is not a risk factor for surgical or general postoperative complications. Journal of Surgical Oncology, 2010, 102, 321-324.	0.8	7
510	High pretherapeutic thymidylate synthetase and MRPâ€1 protein levels are associated with nonresponse to neoadjuvant chemotherapy in oesophageal adenocarcinoma patients. Journal of Surgical Oncology, 2010, 102, 503-508.	0.8	23
511	The extent of lymph node dissection for gastric cancer: A critical appraisal. Journal of Surgical Oncology, 2010, 102, 552-562.	0.8	18

#	Article	IF	Citations
512	Neoadjuvant therapy of colorectal liver metastases: Lessons learned from clinical trials. Journal of Surgical Oncology, 2010, 102, 932-936.	0.8	14
513	Predictive significance of preoperative serum VEGFâ€C and VEGFâ€D, independently and combined with Ca19â€9, for the presence of malignancy and lymph node metastasis in patients with gastric cancer. Journal of Surgical Oncology, 2010, 102, 699-703.	0.8	18
514	Neoadjuvant FOLFOX chemotherapy in 34 consecutive patients with mucinous peritoneal carcinomatosis of appendiceal origin. Journal of Surgical Oncology, 2010, 102, 576-581.	0.8	84
515	Adjuvant Radiotherapy for Gastric Cancer: A Dosimetric Comparison of 3-Dimensional Conformal Radiotherapy, TomotherapyÂ® and Conventional Intensity Modulated Radiotherapy Treatment Plans. Medical Dosimetry, 2010, 35, 115-121.	0.4	31
516	Use of Adjuvant 5-Fluorouracil and Radiation Therapy After Gastric Cancer Resection Among the Elderly and Impact on Survival. International Journal of Radiation Oncology Biology Physics, 2010, 76, 1404-1412.	0.4	19
517	Adjuvant chemo-radiation for gastric adenocarcinoma: an institutional experience. Radiation Oncology, 2010, 5, 50.	1.2	4
518	Barrett's oesophageal adenocarcinoma encompasses tumourâ€initiating cells that do not express common cancer stem cell markers. Journal of Pathology, 2010, 221, 379-389.	2.1	21
519	Impact of adjuvant chemoradiation for adenocarcinoma of stomach after curative gastrectomy in Chinese: A 7â€year audit. Surgical Practice, 2010, 14, 85-91.	0.1	0
520	Human apurinic/apyrimidinic endonuclease (APE1) is a prognostic factor in ovarian, gastro-oesophageal and pancreatico-biliary cancers. British Journal of Cancer, 2010, 102, 704-709.	2.9	85
521	Tumour regression and ERCC1 nuclear protein expression predict clinical outcome in patients with gastro-oesophageal cancer treated with neoadjuvant chemotherapy. British Journal of Cancer, 2010, 102, 1600-1607.	2.9	79
522	Role of Helicobacter pylori infection in gastric cancer pathogenesis: A chance for prevention. Journal of Digestive Diseases, 2010, 11, 2-11.	0.7	28
523	A Review of Docetaxel: Its Use in the Treatment of Gastric Cancer. Clinical Medicine Insights Therapeutics, 2010, 2, CMT.S5191.	0.4	0
525	CÃ¡ncer de la uniÃ³n gastroesofÃ¡gica: EvaluaciÃ³n de los resultados quirÃºrgicos, sobrevida alejada y factores pronÃ³sticos en enfermos con terapia resectiva. Revista Medica De Chile, 2010, 138, .	0.1	3
526	Management of esophageal and gastric cancer in older adults. , 0, , 135-147.		0
527	Circulating Tumor Cells in Gastrointestinal Malignancies: Current Techniques and Clinical Implications. Journal of Oncology, 2010, 2010, 1-9.	0.6	33
528	Endoscopic ultrasound in the pre-therapeutic staging of gastroesophageal adenocarcinoma: the diagnostic value in defining patients eligible for a neoadjuvant chemotherapy regimen. Wideochirurgia I Inne Techniki Maloinwazyjne, 2010, 1, 1-6.	0.3	0
529	Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. Experimental and Therapeutic Medicine, 2010, 1, 611-617.	0.8	2
530	In VitroAdenosine Triphosphate Based Chemotherapy Response Assay in Gastric Cancer. Journal of Gastric Cancer, 2010, 10, 155.	0.9	7

#	Article	IF	Citations
531	Race and ethnicity correlate with survival in patients with gastric adenocarcinoma. Annals of Oncology, 2010, 21, 152-160.	0.6	116
532	Reply to F. Sclafani et al. Journal of Clinical Oncology, 2010, 28, e617-e618.	0.8	1
533	Modulation of Lymphocyte Regulation for Cancer Therapy: A Phase II Trial of Tremelimumab in Advanced Gastric and Esophageal Adenocarcinoma. Clinical Cancer Research, 2010, 16, 1662-1672.	3.2	236
534	The role of peri-operative treatment in resectable liver metastases of colorectal cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 389-398.	1.4	2
535	Benefit of Adjuvant Chemotherapy for Resectable Gastric Cancer. JAMA - Journal of the American Medical Association, 2010, 303, 1729.	3.8	711
536	Adjuvant Chemotherapy with Etoposide, Adriamycin and Cisplatin Compared with Surgery Alone in the Treatment of Gastric Cancer: A Phase III Randomized, Multicenter, Clinical Trial. Oncology, 2010, 78, 54-61.	0.9	50
537	Multidisciplinary management of gastric cancer. Current Opinion in Gastroenterology, 2010, 26, 640-646.	1.0	43
538	Predicting Response to Treatment in Gastroesophageal Junction Adenocarcinomas: Combining Clinical, Imaging, and Molecular Biomarkers. Oncologist, 2010, 15, 270-284.	1.9	22
539	Postoperative Chemoradiotherapy or Surgery Alone for Gastric Cancer: The Plausibility of the Question and Pertinence of the Answer. Journal of Clinical Oncology, 2010, 28, e615-e616.	0.8	3
540	Effect of S-1 Adjuvant Chemotherapy on Survival following Recurrence and Efficacy of First-Line Treatment in Recurrent Gastric Cancer. Chemotherapy, 2010, 56, 436-443.	0.8	5
541	Gastric Cancer Working Group Report. Japanese Journal of Clinical Oncology, 2010, 40, i28-i37.	0.6	107
542	Postoperative chemoradiotherapy in gastric cancerâ€“â€“a phase Iâ€“II study of radiotherapy with dose escalation of weekly cisplatin and daily capecitabine chemotherapy. Annals of Oncology, 2010, 21, 530-534.	0.6	30
543	Gastric Cancer in Poland â€“ Clinical Characteristics and Results of Surgery. Digestive Surgery, 2010, 27, 409-416.	0.6	2
544	Predictors of Timing and Patterns of Recurrence after Curative Resection for Gastric Cancer. Digestive Surgery, 2010, 27, 481-486.	0.6	48
545	A Comparison of Multimodality Treatment: Two or Four Courses of Paclitaxel plus Cisplatin or S-1 plus Cisplatin Followed by Surgery for Locally Advanced Gastric Cancer, a Randomized Phase II Trial (COMPASS). Japanese Journal of Clinical Oncology, 2010, 40, 369-372.	0.6	22
546	Further Refinement of the Optimal Treatment Following Radical Gastric Resection for Gastric Adenocarcinoma. Archives of Surgery, 2010, 145, 239.	2.3	0
547	Gastric Cancerâ€"An Enigmatic and Heterogeneous Disease. JAMA - Journal of the American Medical Association, 2010, 303, 1753.	3.8	97
548	Safety and efficacy of weekly 5-fluorouracil/ folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer. Therapeutic Advances in Medical Oncology, 2010, 2, 161-174.	1.4	14

#	Article	IF	Citations
549	A Phase II Trial of Epirubicin, Oxaliplatin, and Capecitabine (EOX) as First-Line Chemotherapy in Advanced Gastric Cancer: A Chinese Single-Center Experience. Chemotherapy, 2010, 56, 171-177.	0.8	6
550	Resectable Esophageal Cancer: Surgery As Primary Therapy Is Not the Answer, but Then, What Is and Why?. Journal of Clinical Oncology, 2010, 28, e243-e244.	0.8	4
551	Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954. Journal of Clinical Oncology, 2010, 28, 5210-5218.	0.8	619
552	Gastric Cancer: Patterns of Disease Spread via the Perigastric Ligaments Shown by CT. American Journal of Roentgenology, 2010, 195, 398-404.	1.0	19
555	Expression of class I histone deacetylases (HDAC1 and HDAC2) in oesophageal adenocarcinomas: an immunohistochemical study. Journal of Clinical Pathology, 2010, 63, 994-998.	1.0	30
556	Multimodality treatment for localized gastro-oesophageal cancer. Annals of Oncology, 2010, 21, vii286-vii293.	0.6	12
557	Is Metastatic Lymph Node Ratio Superior to the Number of Metastatic Lymph Nodes to Assess Outcome and Survival of Gastric Cancer?. Oncology Research and Treatment, 2010, 33, 101-105.	0.8	19
558	Rechallenge with Platinum plus Fluoropyrimidine +/â€“ Epirubicin in Patients with Oesophagogastric Cancer. Oncology, 2010, 79, 150-158.	0.9	13
559	The Effect of Tumor Size on Overall Survival in Patients with pT3 Gastric Cancer: Experiences from 3 Centers. Onkologie, 2010, 33, 676-682.	1.1	17
560	Perioperative management of esophageal cancer. Nature Reviews Clinical Oncology, 2010, 7, 231-238.	12.5	23
562	Upper gastrointestinal tumors. Endoscopy, 2010, 42, 42-45.	1.0	1
563	Hsp90 as a therapeutic target in patients with oesophageal carcinoma. Expert Opinion on Therapeutic Targets, 2010, 14, 317-328.	1.5	13
565	Randomized Clinical Trials in Gastric Cancer. Surgical Oncology Clinics of North America, 2010, 19, 81-100.	0.6	4
566	Neoadjuvant chemotherapy for advanced gastric cancer: A meta-analysis. World Journal of Gastroenterology, 2010, 16, 5621.	1.4	98
567	Endosonographic radial tumor thickness after neoadjuvant chemoradiation therapy to predict response and survival in patients with locally advanced esophageal cancer: a prospective multicenter phase II study by the Swiss Group for Clinical Cancer Research (SAKK 75/02). Gastrointestinal Endoscopy, 2010, 71, 1114-1121.	0.5	35
568	The ERK MAP kinase-PEA3/ETV4-MMP-1 axis is operative in oesophageal adenocarcinoma. Molecular Cancer, 2010, 9, 313.	7.9	51
569	Recent advances in gastrointestinal oncology - updates and insights from the 2009 annual meeting of the American Society of Clinical Oncology. Journal of Hematology and Oncology, 2010, 3, 11.	6.9	32
570	Pathological complete response after neoadjuvant chemotherapy with trastuzumab-containing regimen in gastric cancer: a case report. Journal of Hematology and Oncology, 2010, 3, 31.	6.9	29

#	Article	IF	Citations
571	Role of Adjuvant Therapy After Resection of Colorectal Cancer Liver Metastases. Journal of Clinical Oncology, 2010, 28, 2300-2309.	0.8	69
572	Gene Expression Profiling of Metaplastic Lineages Identifies CDH17 as a Prognostic Marker in Early Stage Gastric Cancer. Gastroenterology, 2010, 139, 213-225.e3.	0.6	133
573	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
574	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v50-v54.	0.6	737
575	Chemotherapy for advanced gastric cancer. , 2010, , CD004064.		422
576	A retrospective comparison of concurrent 5-fluoro-uracil or oral UFT in postoperative chemoradiation for gastric adenocarsinoma. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2010, 14, 19-23.	0.6	1
577	Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews, 2010, 36, 235-248.	3.4	52
578	Localized adenocarcinoma of the esophagogastric junction â€“ Is there a standard of care?. Cancer Treatment Reviews, 2010, 36, 400-409.	3.4	9
579	Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: A population-based study in the Netherlands. European Journal of Cancer, 2010, 46, 1101-1110.	1.3	135
580	Trastuzumab in gastric cancer. European Journal of Cancer, 2010, 46, 1949-1959.	1.3	66
581	Health-related quality of life and survival in the 2years after surgery for gastric cancer. European Journal of Surgical Oncology, 2010, 36, 148-154.	0.5	62
582	A phase II study of preoperative chemotherapy with S-1 plus cisplatin followed by D2/D3 gastrectomy for clinically serosa-positive gastric cancer (JACCRO GC-01 study). European Journal of Surgical Oncology, 2010, 36, 546-551.	0.5	52
583	Introducing national guidelines on perioperative chemotherapy for gastric cancer in Norway: A retrospective audit. European Journal of Surgical Oncology, 2010, 36, 610-616.	0.5	12
584	Gastric cancer in the elderly: An overview. European Journal of Surgical Oncology, 2010, 36, 709-717.	0.5	133
585	Prospective randomized trial of short-term neoadjuvant chemotherapy for advanced gastric cancer. European Journal of Surgical Oncology, 2010, 36, 963-968.	0.5	16
586	A single-institution experience with 491 cases of small bowel adenocarcinoma. American Journal of Surgery, 2010, 199, 797-803.	0.9	185
587	Esophageal cancer: An update. International Journal of Surgery, 2010, 8, 417-422.	1.1	64
588	Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet, The, 2010, 376, 687-697.	6.3	5,899

#	Article	IF	Citations
590	Population-based differences in treatment outcome following anticancer drug therapies. Lancet Oncology, The, 2010, 11, 75-84.	5.1	121
591	Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncology, The, 2010, 11, 439-449.	5.1	1,493
592	Extended follow-up after extended lymphadenectomy for gastric cancer: was it worth the wait?. Lancet Oncology, The, 2010, 11, 404-405.	5.1	5
593	Randomized Clinical Trials in Esophageal Carcinoma. Surgical Oncology Clinics of North America, 2010, 19, 59-80.	0.6	15
594	Prise en charge du cancer de la jonction Å“so-gastrique non mÃ©tastatique. , 2010, , 139-150.		0
595	Adenocarcinoma of the Esophagogastric Junction. Recent Results in Cancer Research, 2010, , .	1.8	5
596	Esophageal cancer: Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2010, 21, v46-v49.	0.6	117
597	Impact of the Extent of Surgery and Postoperative Chemoradiotherapy on Recurrence Patterns in Gastric Cancer. Journal of Clinical Oncology, 2010, 28, 2430-2436.	0.8	186
598	Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer. Journal of Clinical Oncology, 2011, 29, 4387-4393.	0.8	1,186
600	Guidelines for the management of oesophageal and gastric cancer. Gut, 2011, 60, 1449-1472.	6.1	570
602	Enfoque terapÃ©utico del cÃ¡ncer gÃ¡strico. RevisiÃ³n de la literatura. Revista Colombiana De CancerologÃa, 2011, 15, 30-39.	0.0	1
604	The Roles of Surgical Oncologists in the New Era â€“ Minimally Invasive Surgery for Early Gastric Cancer and Adjuvant Surgery for Metastatic Gastric Cancer. Pathobiology, 2011, 78, 343-352.	1.9	41
605	Targeting the human EGFR family in esophagogastric cancer. Nature Reviews Clinical Oncology, 2011, 8, 492-503.	12.5	132
606	Gastric Adenocarcinoma Surgery and Adjuvant Therapy. Surgical Clinics of North America, 2011, 91, 1039-1077.	0.5	25
607	Management of esophageal adenocarcinoma. Journal of Visceral Surgery, 2011, 148, e161-e170.	0.4	11
608	Optimal Therapeutic Strategies for Resectable Oesophageal or Oesophagogastric Junction Cancer. Drugs, 2011, 71, 541-555.	4.9	16
609	Targeted Therapies for Gastric Cancer. Drugs, 2011, 71, 1367-1384.	4.9	37
610	Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics Journal, 2011, 11, 81-92.	0.9	78

#	Article	IF	Citations
611	DNA Repair Gene and MTHFR Gene Polymorphisms as Prognostic Markers in Locally Advanced Adenocarcinoma of the Esophagus or Stomach Treated with Cisplatin and 5-Fluorouracil-Based Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2011, 18, 2688-2698.	0.7	49
613	Clinical efficacy of cytoreductive surgery and hyperthermic chemotherapy in peritoneal carcinomatosis from gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 1505-1508.	1.1	11
614	Cancer de lâ€™estomac. , 2011, , 341-358.		0
615	Evolving standards of care in advanced gastric cancer. Future Oncology, 2011, 7, 1441-1450.	1.1	3
616	Principles of Anticancer Drug Development. , 2011, , .		0
617	Progress, challenges and new genome-based concepts in the multidisciplinary treatment of gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 503-506.	1.1	7
619	84-Year-Old Man With Respiratory Distress and Abdominal Distention. Mayo Clinic Proceedings, 2011, 86, e10-e13.	1.4	0
620	Double contrastâ€“enhanced ultrasonography for the preoperative evaluation of gastric cancer: A comparison to endoscopic ultrasonography with respect to histopathology. American Journal of Surgery, 2011, 202, 605-611.	0.9	34
621	DNA methyltransferase 1 as a predictive biomarker and potential therapeutic target for chemotherapy in gastric cancer. European Journal of Cancer, 2011, 47, 1817-1825.	1.3	114
622	Hospital volume and survival in oesophagectomy and gastrectomy for cancer. European Journal of Cancer, 2011, 47, 2408-2414.	1.3	71
623	The interaction between N-category and N-ratio as a new tool to improve lymph node metastasis staging in gastric cancer: Results of a single cancer center in Brazil. European Journal of Surgical Oncology, 2011, 37, 47-54.	0.5	18
624	Venous thromboembolism in oesophago-gastric carcinoma: Incidence of symptomatic and asymptomatic events following chemotherapy and surgery. European Journal of Surgical Oncology, 2011, 37, 1072-1077.	0.5	42
625	Traitement des adÃ©nocarcinomes de lâ€™Å“sophage. Journal De Chirurgie ViscÃ©rale, 2011, 148, 184-195.	0.0	0
626	Metastatic Lymph Node Targeted Chemosensitivity Test for Gastric Cancer. Journal of Surgical Research, 2011, 171, 657-662.	0.8	2
627	Oesophagogastric junction adenocarcinoma: which therapeutic approach?. Lancet Oncology, The, 2011, 12, 296-305.	5.1	164
628	Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncology, The, 2011, 12, 681-692.	5.1	1,467
629	Dissection of lymph node metastases in esophageal cancer. Expert Review of Anticancer Therapy, 2011, 11, 571-578.	1.1	20
630	Prognosis of Esophageal Cancer Patients With Pathologic Complete Response After Preoperative Concurrent Chemoradiotherapy. International Journal of Radiation Oncology Biology Physics, 2011, 81, 691-697.	0.4	16

#	Article	IF	Citations
631	Vascular invasion is not a risk factor in oesophageal cancer recurrence. International Journal of Surgery, 2011, 9, 237-240.	1.1	11
632	Gastric Cancer Metastasis. , 0, , 325-332.		0
633	MR Imaging of Gastric Carcinoma. , 0, , .		0
634	Total adventitial resection of the cardia: â€˜optimal local resectionâ€™ for tumours of the oesophagogastric junction. Annals of the Royal College of Surgeons of England, 2011, 93, 608-614.	0.3	6
636	Evaluation of the 7th UICC TNM Staging System of Gastric Cancer. Journal of Gastric Cancer, 2011, 11, 78.	0.9	66
637	Latest developments and emerging treatment options in the management of stomach cancer. Cancer Management and Research, 0, , 257.	0.9	19
638	New developments in the treatment of metastatic gastric cancer: focus on trastuzumab. OncoTargets and Therapy, 2011, 4, 21.	1.0	17
639	Gastric Cancer in the Setting of Persistently Elevated Human Chorionic Gonadotropin: A Case Report. Case Reports in Obstetrics and Gynecology, 2011, 2011, 1-4.	0.2	6
640	Lymph Node Dissection in Curative Gastrectomy for Advanced Gastric Cancer. International Journal of Surgical Oncology, 2011, 2011, 1-8.	0.3	37
641	Registro de evaluaciÃ³n de tratamiento de cÃ¡ncer gÃ¡strico en Chile (REGATE): CaracterÃsticas clÃnicas bÃ¡sales de 523 pacientes. Revista Chilena De Cirugia, 2011, 63, 147-153.	0.1	8
642	Discovery of New Molecular Subtypes in Oesophageal Adenocarcinoma. PLoS ONE, 2011, 6, e23985.	1.1	24
643	Capecitabine in Combination with Oxaliplatin as First-Line Therapy for Advanced Gastric Cancer: A Case Report. Tumori, 2011, 97, 115-118.	0.6	1
644	How to Classify Adenocarcinomas of the Esophagogastric Junction. American Journal of Surgical Pathology, 2011, 35, 1512-1522.	2.1	56
645	Optimal Extent of Lymph Node Dissection for Siewert Type II Esophagogastric Junction Carcinoma. Annals of Surgery, 2011, 254, 274-280.	2.1	110
646	Multidisciplinary Management of Early and Locally Advanced Esophageal Cancer. Journal of Clinical Gastroenterology, 2011, 45, 391-399.	1.1	18
647	Long-term Outcome of 2920 Patients With Cancers of the Esophagus and Esophagogastric Junction. Annals of Surgery, 2011, 253, 689-698.	2.1	132
648	Editorial [Hot Topic: Molecular Targeted Therapy of Gastrointestinal Cancer (Guest Editor: Marcus W.) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	1
649	No Survival Benefit From Postoperative Adjuvant Chemotherapy After D2 Radical Resection for the Patients With Stage II Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 309-313.	0.6	4

#	Article	IF	Citations
650	Significance of Histopathological Tumor Regression After Neoadjuvant Chemotherapy in Gastric Adenocarcinomas. Annals of Surgery, 2011, 253, 934-939.	2.1	266
652	Aurora-A as an independent molecular prognostic marker in gastric cancer. Oncology Reports, 2011, 26, 23-32.	1.2	25
653	The role of neoadjuvant and adjuvant treatment for adenocarcinoma of the upper gastrointestinal tract. European Journal of Medical Research, 2011, 16, 265.	0.9	19
655	Endoscopic Therapy of Esophageal Premalignancy and Early Malignancy. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 890-899.	2.3	11
656	Esophageal and Esophagogastric Junction Cancers. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 830-887.	2.3	190
658	Modern Approaches to Localized Cancer of the Esophagus. Journal of the National Comprehensive Cancer Network: JNCCN, 2011, 9, 902-911.	2.3	9
659	Left thoracoabdominal esophagectomy: results from a single specialist center. Ecological Management and Restoration, 2011, 24, 138-144.	0.2	13
660	Human leukocyte antigenâ€€ is closely associated with tumor immune escape in gastric cancer by increasing local regulatory T cells. Cancer Science, 2011, 102, 1272-1280.	1.7	71
661	Perioperative therapy for resectable gastric cancer: What does the future hold?. Asia-Pacific Journal of Clinical Oncology, 2011, 7, 93-95.	0.7	3
662	Recurrence and survival after pathologic complete response to preoperative therapy followed by surgery for gastric or gastrooesophageal adenocarcinoma. British Journal of Cancer, 2011, 104, 1840-1847.	2.9	92
663	Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models. Journal of Cellular and Molecular Medicine, 2011, 15, 316-326.	1.6	5
664	Systemic chemotherapy and its implications for resection of colorectal liver metastasis. Surgical Oncology, 2011, 20, 57-72.	0.8	27
665	Barrettâ€™s oesophagus and oesophageal adenocarcinoma. Medicine, 2011, 39, 142-148.	0.2	1
666	Gastric tumours. Medicine, 2011, 39, 169-172.	0.2	0
667	Oesophageal cancer. Surgery, 2011, 29, 557-562.	0.1	1
668	Neoadjuvant Chemotherapy Alone for Early-Stage Rectal Cancer: An Evolving Paradigm?. Seminars in Radiation Oncology, 2011, 21, 196-202.	1.0	8
669	Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): The Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial. BMC Cancer, 2011, 11, 266.	1.1	21
670	Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS). BMC Cancer, 2011, 11, 329.	1.1	175

#	Article	IF	Citations
671	A Prospective Phase II Evaluation of Esophageal Stenting for Neoadjuvant Therapy for Esophageal Cancer: Optimal Performance and Surgical Safety. Journal of the American College of Surgeons, 2011, 212, 582-588.	0.2	46
672	Neoadjuvant Chemoradiotherapy for Resectable Oesophageal and Gastro-oesophageal Junction Cancerâ€"Do We Need Another Randomised Trial?. Clinical Oncology, 2011, 23, 696-705.	0.6	23
673	Advanced gastric cancer (GC) and cancer of the gastro-oesophageal junction (GEJ): focus on targeted therapies. Critical Reviews in Oncology/Hematology, 2011, 81, 38-48.	2.0	30
674	Clinical Significance of the Costimulatory Molecule B7-H1 in Barrett Carcinoma. Annals of Thoracic Surgery, 2011, 91, 1025-1031.	0.7	45
675	Clinical T2-T3N0M0 Esophageal Cancer: The Risk of Node Positive Disease. Annals of Thoracic Surgery, 2011, 92, 491-498.	0.7	83
676	Surgical resection following combination chemotherapy with oral s-1 and biweekly docetaxel in a patient with advanced gastric cancer and a prior coronary artery bypass graft with the right gastroepiploic artery: Report of a case. Surgery Today, 2011, 41, 1531-1537.	0.7	6
677	Chemotherapy for Operable Gastric Cancer: Current Perspectives. Indian Journal of Surgical Oncology, 2011, 2, 334-342.	0.3	7
678	Guideline Recommended Gastric Cancer Care in the Elderly: Insights into the Applicability of Cancer Trials to Real World. Annals of Surgical Oncology, 2011, 18, 26-33.	0.7	41
679	Preoperative Chemotherapy with Cisplatin and Docetaxel Followed by Surgery and Clip-Oriented Postoperative Chemoradiation in Patients with Localized Gastric or Gastroesophageal Junction Adenocarcinoma: Results from a Phase II Feasibility Study. Annals of Surgical Oncology, 2011, 18, 677-683.	0.7	10
680	How Closely Should We Follow Gastric Cancer Patients Following Surgical Resection?. Annals of Surgical Oncology, 2011, 18, 311-313.	0.7	2
681	Using Gene Expression Profiling to Predict Response and Prognosis in Gastrointestinal Cancersâ€"The Promise and the Perils. Annals of Surgical Oncology, 2011, 18, 1484-1491.	0.7	28
682	Aggressive Surgical Approach for Patients with T4 Gastric Carcinoma: Promise or Myth?. Annals of Surgical Oncology, 2011, 18, 1606-1614.	0.7	51
683	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial. Annals of Surgical Oncology, 2011, 18, 1575-1581.	0.7	534
684	Hyperthermic Intraperitoneal Chemotherapy in Advanced Gastric Cancer: The End of Skepticism?. Annals of Surgical Oncology, 2011, 18, 1524-1526.	0.7	11
685	FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review. Annals of Surgical Oncology, 2011, 18, 3338-3352.	0.7	72
686	Molecular Imaging of Proliferation and Glucose Utilization: Utility for Monitoring Response and Prognosis after Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Annals of Surgical Oncology, 2011, 18, 3316-3323.	0.7	58
687	Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients with Peritoneal Dissemination. Annals of Surgical Oncology, 2011, 18, 3726-3731.	0.7	54
688	Cytostatic activity of the duplex drug linking 2â€²-deoxy-5-fluorouridine (5FdU) with 3â€²-C-ethynylcytidine (ECyd) against gastric adenocarcinoma cell lines. Investigational New Drugs, 2011, 29, 1294-1302.	1.2	9

#	Article	IF	Citations
689	Integrated PET/CT Fusion Imaging and Endoscopic Ultrasound in the Pre-operative Staging and Evaluation of Esophageal Cancer. Molecular Imaging and Biology, 2011, 13, 166-171.	1.3	65
690	Two-phase laparoscopic-assisted oesophago-gastrectomy: a single-unit experience of 111 consecutive cases and outcomes. Surgical Endoscopy and Other Interventional Techniques, 2011, 25, 3658-3667.	1.3	4
691	Gastric cancer: surgery in 2011. Langenbeck's Archives of Surgery, 2011, 396, 743-758.	0.8	42
692	18F-FDG PET or PET-CT to evaluate prognosis for head and neck cancer: a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2011, 137, 1085-1093.	1.2	97
693	Surgical resection of locally advanced primary transverse colon cancerâ€"not a worse outcome in stage II tumor. International Journal of Colorectal Disease, 2011, 26, 859-865.	1.0	6
694	Management of adjuvant S-1 therapy after curative resection of gastric cancer: dose reduction and treatment schedule modification. Gastric Cancer, 2011, 14, 28-34.	2.7	17
695	Effectiveness and safety of oxaliplatin compared to cisplatin for advanced, unresectable gastric cancer: a systematic review and meta-analysis. Gastric Cancer, 2011, 14, 50-55.	2.7	106
696	Adjuvant chemoradiation for resected gastric cancer: a 10-year experience. Gastric Cancer, 2011, 14, 63-71.	2.7	18
697	Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus curative resection alone: final results of the Japan Clinical Oncology Group trial JCOG9206-2. Gastric Cancer, 2011, 14, 212-218.	2.7	63
698	Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer, 2011, 14, 113-123.	2.7	2,086
699	Extended lymph node dissection for gastric cancer from a European perspective. Gastric Cancer, 2011, 14, 396-398.	2.7	12
700	ERCC1 expression is a predictor of survival in gastric cancer patients treated with surgery and adjuvant chemotherapy. Chinese-German Journal of Clinical Oncology, 2011, 10, 92-95.	0.1	1
701	Her-2 in gastroesophageal cancer: pathobiology, diagnostic and therapeutic implications. European Surgery - Acta Chirurgica Austriaca, 2011, 43, 162-167.	0.3	4
702	Adenocarcinoma of the esophagogastric junction: Neoadjuvant radiochemotherapy and radical surgery. Strahlentherapie Und Onkologie, 2011, 187, 231-237.	1.0	16
704	177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 312-322.	3.3	31
705	Cancer of the Gastric Cardia is Rising in Incidence in an Asian Population and is Associated with Adverse Outcome. World Journal of Surgery, 2011, 35, 617-624.	0.8	118
706	Challenges in the Treatment of Gastroesophageal Cancer: Reply. World Journal of Surgery, 2011, 35, 1411.	0.8	0
707	Predictive Value of Baseline Neutrophil/Lymphocyte Ratio for T4 Disease in Wallâ€Penetrating Gastric Cancer. World Journal of Surgery, 2011, 35, 2717-2722.	0.8	42

#	Article	IF	Citations
708	Two phase I studies of concurrent radiation therapy with continuous-infusion 5-fluorouracil plus epirubicin, and either cisplatin or irinotecan for locally advanced upper gastrointestinal adenocarcinomas. Cancer Chemotherapy and Pharmacology, 2011, 67, 621-627.	1.1	5
709	Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial. Cancer Chemotherapy and Pharmacology, 2011, 68, 37-43.	1.1	15
710	Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemotherapy and Pharmacology, 2011, 68, 863-870.	1.1	8
711	Gastric Cancer. Current Problems in Cancer, 2011, 35, 97-127.	1.0	10
712	Postoperative chemoradiotherapy in gastric cancer: a phase I study of radiotherapy with dose escalation of oxaliplatin, 5-fluorouracil, and leucovorin (FOLFOX regimen). Medical Oncology, 2011, 28, 274-279.	1.2	10
713	SEOM clinical guidelines for the treatment of oesophageal cancer. Clinical and Translational Oncology, 2011, 13, 520-524.	1.2	2
714	Gastric cancer â€“ still many questions to be solved. Memo - Magazine of European Medical Oncology, 2011, 4, 71-74.	0.3	4
715	Positive Peritoneal Cytology in Patients with Gastric Cancer: Natural History and Outcome of 291 Patients. Indian Journal of Surgical Oncology, 2011, 2, 16-23.	0.3	17
716	The Role of Peri-operative Chemotherapy for Resectable Colorectal Liver Metastasis: What Does the Evidence Support?. Journal of Gastrointestinal Surgery, 2011, 15, 410-415.	0.9	11
717	Alternating Treatment with S-1 Plus Low-Dose Cisplatin and S-1 Alone for Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2011, 15, 791-796.	0.9	2
718	An Evidence-Based Review of the Surgical Treatment of Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2011, 15, 730-741.	0.9	10
719	The Amount of Neoadjuvant Chemotherapy for Barrettâ€™s Carcinoma Does Not Correlate with Long-Term Survival. Journal of Gastrointestinal Surgery, 2011, 15, 1750-1755.	0.9	1
720	Gastric Cancer Surgery: An American Perspective on the Current Options and Standards. Current Treatment Options in Oncology, 2011, 12, 72-84.	1.3	22
721	Targeted Therapies for Metastatic Esophagogastric Cancer. Current Treatment Options in Oncology, 2011, 12, 46-60.	1.3	16
722	The Role of Radiation in the Perioperative Treatment of Esophagogastric Cancer. Current Treatment Options in Oncology, 2011, 12, 61-71.	1.3	2
723	Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group. BMC Cancer, 2011, 11, 176.	1.1	22
724	Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study). BMC Cancer, 2011, 11, 346.	1.1	93
725	Clinical management of gastric cancer: results of a multicentre survey. BMC Cancer, 2011, 11, 369.	1.1	4

#	Article	IF	Citations
726	Complications after radical gastrectomy following FOLFOX7 neoadjuvant chemotherapy for gastric cancer. World Journal of Surgical Oncology, 2011, 9, 110.	0.8	39
727	Is there any advantage to combined trastuzumab and chemotherapy in perioperative setting her 2neu positive localized gastric adenocarcinoma?. World Journal of Surgical Oncology, 2011, 9, 112.	0.8	16
728	Postoperative chemoradiation for resected gastric cancer - is the Macdonald Regimen Tolerable? a retrospective multi-institutional study. Radiation Oncology, 2011, 6, 127.	1.2	12
729	The role of radiation therapy in the control of locoregional and metastatic cancer. Journal of Surgical Oncology, 2011, 103, 627-638.	0.8	7
730	Morbidity, mortality, and pathological response in patients with gastric cancer preoperatively treated with chemotherapy or chemoradiotherapy. Journal of Surgical Oncology, 2011, 104, 124-129.	0.8	36
731	Surgical outcomes for gastric cancer patients with intraperitoneal free cancer cell, but no macroscopic peritoneal metastasis. Journal of Surgical Oncology, 2011, 104, 534-537.	0.8	19
732	Prospective evaluation of the reliability, validity, and minimally important difference of the functional assessment of cancer therapyâ€gastric (FACTâ€Ga) qualityâ€ofâ€life instrument. Cancer, 2011, 117, 1302-1312.	2.0	56
733	Improved survival in patients with lymph nodeâ€positive gastric cancer who received preoperative radiation. Cancer, 2011, 117, 3908-3916.	2.0	21
734	Changing clinical and pathological features of gastric cancer over time. British Journal of Surgery, 2011, 98, 1273-1283.	0.1	74
735	Systematic review of intraperitoneal chemotherapy for gastric cancer. British Journal of Surgery, 2011, 98, 1225-1235.	0.1	36
736	Adjuvant Chemoradiation for Gastric Cancer Using Epirubicin, Cisplatin, and 5-Fluorouracil Before and After Three-Dimensional Conformal Radiotherapy With Concurrent Infusional 5-Fluorouracil: A Multicenter Study of the Trans-Tasman Radiation Oncology Group. International Journal of Radiation Oncology Biology Physics, 2011, 79, 690-695.	0.4	49
737	Patterns of Response After Preoperative Treatment in Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2011, 80, 698-704.	0.4	16
738	Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncology, 2011, 7, 409-426.	1.1	7
739	Reexamining a proposal. Cancer Biology and Therapy, 2011, 12, 750-755.	1.5	11
740	Perioperative therapy improves gastroesophageal cancer survival. Nature Reviews Clinical Oncology, 2011, 8, 450-452.	12.5	2
743	Gastroesophageal junction carcinoma multimodal treatment: standards, debate and new therapeutic options. Expert Review of Gastroenterology and Hepatology, 2011, 5, 1-4.	1.4	1
745	An expert opinion on esophageal cancer therapy. Expert Opinion on Pharmacotherapy, 2011, 12, 225-239.	0.9	15
746	Assessment of ErbB2 (Her2) in oesophageal adenocarcinomas: summary of a revised immunohistochemical evaluation system, bright field double in situ hybridisation and fluorescence in situ hybridisation. Modern Pathology, 2011, 24, 908-916.	2.9	44

#	Article	IF	Citations
748	Intratumor Heterogeneity Characterized by Textural Features on Baseline ¹⁸F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer. Journal of Nuclear Medicine, 2011, 52, 369-378.	2.8	626
749	Capecitabine in gastric cancer. Expert Review of Anticancer Therapy, 2011, 11, 1791-1806.	1.1	11
750	¹⁸F-FDG PETâ€“Guided Salvage Neoadjuvant Radiochemotherapy of Adenocarcinoma of the Esophagogastric Junction: The MUNICON II Trial. Journal of Nuclear Medicine, 2011, 52, 1189-1196.	2.8	167
751	Clinicopathological Characteristics and Computed Tomography Features of Mucinous Gastric Carcinoma. Journal of International Medical Research, 2011, 39, 291-301.	0.4	12
753	Targeting Angiogenesis in Esophagogastric Adenocarcinoma. Oncologist, 2011, 16, 844-858.	1.9	44
754	The role of S-1 in the treatment of gastric cancer. Gastrointestinal Cancer: Targets and Therapy, 2011, , 59.	5.5	0
755	T Cells and Adoptive Immunotherapy: Recent Developments and Future Prospects in Gastrointestinal Oncology. Clinical and Developmental Immunology, 2011, 2011, 1-17.	3.3	16
756	Inflammatory Lesions of the Peritoneum Mimic Carcinomatosis After Treatment With Intravenous Chemotherapy and Intraperitoneal Catumaxomab. Journal of Clinical Oncology, 2011, 29, e644-e646.	0.8	11
757	Signet Ring Cell Carcinoma of the Stomach Is Significantly Associated with Poor Prognosis and Diffuse Gastric Cancer (Laurenâ€™s): Single-Center Experience of 160 Cases. Onkologie, 2011, 34, 682-686.	1.1	52
758	The Impact of Perioperative Chemotherapy on Survival in Patients With Gastric Signet Ring Cell Adenocarcinoma. Annals of Surgery, 2011, 254, 684-693.	2.1	177
759	Present and Future Status of Gastric Cancer Surgery. Japanese Journal of Clinical Oncology, 2011, 41, 307-313.	0.6	87
760	EUS in the Evaluation of Gastric Tumors. , 2011, , 97-114.		0
761	Tumeurs solides. , 2011, , 542-798.		0
762	Systemic Therapy for Elderly Patients with Gastrointestinal Cancer. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6983.	0.6	2
763	Reduced Lymph Node Harvest after Neoadjuvant Chemotherapy in Gastric Cancer. Journal of International Medical Research, 2011, 39, 2086-2095.	0.4	30
765	Docetaxel plus Oxaliplatin in Combination with Capecitabine as First-Line Treatment for Advanced Gastric Cancer. Oncology, 2011, 80, 359-365.	0.9	18
767	Epidemiology, Surgical Management and Early Postoperative Outcome in a Cohort of Gastric Cancer Patients of a Tertiary Referral Center in Relation to Multi-Center Quality Assurance Studies. Polski Przeglad Chirurgiczny, 2011, 83, 123-34.	0.2	3
768	Gastric Cancer: Nagoya Is Not New York. Journal of Clinical Oncology, 2011, 29, 4348-4350.	0.8	34

#	Article	IF	Citations
769	Cohort Study Based on the Seventh Edition of the TNM Classification for Gastric Cancer: Proposal of a New Staging System. Journal of Clinical Oncology, 2011, 29, 2364-2371.	0.8	94
770	Durable Complete Response of Metastatic Gastric Cancer with Anti-Met Therapy Followed by Resistance at Recurrence. Cancer Discovery, 2011, 1, 573-579.	7.7	105
771	Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma. American Journal of Gastroenterology, 2011, 106, 1048-1054.	0.2	89
772	PEA3/ETV4-related transcription factors coupled with active ERK signalling are associated with poor prognosis in gastric adenocarcinoma. British Journal of Cancer, 2011, 105, 124-130.	2.9	47
773	Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial. Journal of Clinical Oncology, 2011, 29, 1715-1721.	0.8	1,696
774	Multimodal endoscopic therapy for multifocal intraepithelial neoplasia and superficial esophageal squamous cell carcinoma - a case series. Endoscopy, 2011, 43, 360-364.	1.0	16
775	Gastric cancer in India. Indian Journal of Medical and Paediatric Oncology, 2011, 32, 12-16.	0.1	44
776	Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-17.	3.0	33
777	Post-operative radiochemotherapy in patients with gastric cancer: one departmentâ€™s experience of 56 patients. British Journal of Radiology, 2011, 84, 457-463.	1.0	6
778	Postoperative chemoradiation in patients with localized gastric adenocarcinoma: Single center experience. Indian Journal of Cancer, 2011, 48, 24.	0.2	3
779	Increasing Nodal Ratio is a Poor Prognostic Factor for Survival in Stage III-IV (M0) Gastric Cancer Patients Who Received Curative Surgery Followed by Adjuvant Chemotherapy: A Retrospective Study. Japanese Journal of Clinical Oncology, 2011, 41, 245-252.	0.6	5
780	Targeting HER-2 in gastric cancer – incorporation of trastuzumab into the treatment of operable disease. Gastrointestinal Cancer: Targets and Therapy, 2011, , 41.	5.5	1
781	Oesophageal and Gastric Cancer. InnovAiT, 2011, 4, 609-616.	0.0	0
782	Upregulation of Leukotriene Receptors in Gastric Cancer. Cancers, 2011, 3, 3156-3168.	1.7	14
783	Challenges with Demographic Disparities in Gastric Cancer Care and Survival: Spectral Rather than Black and White. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 221-222.	1.1	0
784	What Is the Optimal Management of Dysphagia in Metastatic Esophageal Cancer?. Current Oncology, 2012, 19, 60-66.	0.9	36
785	The Royal College of Physicians Simms Lecture, 6 December 2011: Clinical research networks and the benefits of intensive healthcare systems. Clinical Medicine, 2012, 12, 446-452.	0.8	7
786	Gastric Cancer and Helicobacter pylori. , 2012, , 25-60.		0

#	Article	IF	Citations
787	Endoscopic ultrasound staging in gastric cancer: Does it help management decisions in the era of neoadjuvant treatment?. Endoscopy, 2012, 44, 572-576.	1.0	36
788	Perioperative chemotherapy with docetaxel, cisplatin and capecitabine (DCX) in gastro-oesophageal adenocarcinoma: a phase II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Annals of Oncology, 2012, 23, 2827-2834.	0.6	67
789	Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Annals of Oncology, 2012, 23, 664-670.	0.6	30
790	Esophageal self-expandable stent material and mesh grid density are the major determining factors of external beam radiation dose perturbation: results from a phantom model. Endoscopy, 2012, 45, 42-47.	1.0	15
791	Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 2012, 6, 199-209.	1.4	69
793	Surgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer. International Journal of Surgical Oncology, 2012, 2012, 1-4.	0.3	5
794	Treatment of squamous cell and adenocarcinoma of the esophagus. Gastrointestinal Cancer: Targets and Therapy, 2012, , 39.	5.5	0
795	Localized Gastric Cancer Treated with Chemoradation without Surgery: UTMD Anderson Cancer Center Experience. Oncology, 2012, 82, 347-351.	0.9	8
796	Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation?. Annals of Oncology, 2012, 23, 2517-2526.	0.6	50
797	A Comparison of Multimodality Treatment: Two and Four Courses of Neoadjuvant Chemotherapy Using S-1/CDDP or S-1/CDDP/Docetaxel Followed by Surgery and S-1 Adjuvant Chemotherapy for Macroscopically Resectable Serosa-positive Gastric Cancer: A Randomized Phase II Trial (COMPASS-D) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	16
798	Laparoscopic or Open Distal Gastrectomy After Neoadjuvant Chemotherapy for Operable Gastric Cancer, a Randomized Phase II Trial (LANDSCOPE Trial). Japanese Journal of Clinical Oncology, 2012, 42, 654-657.	0.6	11
799	Lanthanum, constipation, bafflying X-rays and a perforated colonic diverticulum. CKJ: Clinical Kidney Journal, 2012, 5, 331-333.	1.4	6
800	Genetic polymorphism of IGF-I predicts recurrence in patients with gastric cancer who have undergone curative gastrectomy. Annals of Oncology, 2012, 23, 659-664.	0.6	16
801	Gastrointestinal oncology â€“ what you need to know. Clinical Medicine, 2012, 12, 575-579.	0.8	0
802	Adjuvant Therapy for Gastric Cancer: Revisiting the Past to Clarify the Future. Journal of Clinical Oncology, 2012, 30, 2297-2299.	0.8	17
803	Treatment of resectable gastric cancer. Therapeutic Advances in Gastroenterology, 2012, 5, 49-69.	1.4	70
804	Perioperative docetaxel, cisplatin, and 5-fluorouracil (DCF) for locally advanced esophageal and gastric adenocarcinoma: a multicenter phase II trial. Annals of Oncology, 2012, 23, 1512-1517.	0.6	96
805	Evaluation of Three Definitions of Progression-free Survival in Preoperative Cancer Therapy (JCOG0801-A). Japanese Journal of Clinical Oncology, 2012, 42, 896-902.	0.6	7

#	Article	IF	Citations
807	Adjuvant chemotherapy after D2 gastrectomy for gastric cancer. Nature Reviews Clinical Oncology, 2012, 9, 192-194.	12.5	16
808	Prognostic significance of SUV on PET/CT in patients with localised oesophagogastric junction cancer receiving neoadjuvant chemotherapy/chemoradiation: a systematic review and meta-analysis. British Journal of Radiology, 2012, 85, e694-e701.	1.0	40
809	Phase III Trial Comparing Capecitabine Plus Cisplatin Versus Capecitabine Plus Cisplatin With Concurrent Capecitabine Radiotherapy in Completely Resected Gastric Cancer With D2 Lymph Node Dissection: The ARTIST Trial. Journal of Clinical Oncology, 2012, 30, 268-273.	0.8	667
810	Phase II multi-institutional prospective randomised trial comparing S-1+paclitaxel with S-1+cisplatin in patients with unresectable and/or recurrent advanced gastric cancer. British Journal of Cancer, 2012, 107, 31-36.	2.9	28
811	Long-Term Survivors of Gastric Cancer: A California Population-Based Study. Journal of Clinical Oncology, 2012, 30, 3507-3515.	0.8	116
812	Losses of Chromosome 5q and 14q Are Associated with Favorable Clinical Outcome of Patients with Gastric Cancer. Oncologist, 2012, 17, 653-662.	1.9	27
813	[18F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomographyâ€"Positive Gastric Adenocarcinoma in a 12-Year-Old Girl With Peutz-Jeghers Syndrome. Journal of Clinical Oncology, 2012, 30, e140-e143.	0.8	4
814	Locally Advanced Cancer of the Esophagus, Current Treatment Strategies, and Future Directions. Frontiers in Oncology, 2012, 2, 52.	1.3	4
815	Assessment of Histopathological Response in Gastric and Gastro-Oesophageal Junction Adenocarcinoma following Neoadjuvant Chemotherapy: Which Scoring System to Use?. ISRN Pathology, 2012, 2012, 1-8.	0.4	20
816	Relative Prognostic Value of Human Epidermal Growth Factor Receptor 2 (HER2) Expression in Operable Oesophagogastric Cancer. ISRN Surgery, 2012, 2012, 1-6.	1.4	6
817	Survival Benefit of Adjuvant Radiation Therapy for Gastric Cancer following Gastrectomy and Extended Lymphadenectomy. International Journal of Surgical Oncology, 2012, 2012, 1-7.	0.3	8
818	Bimonthly Regimen of High-Dose Leucovorin, Infusional 5-Fluorouracil, Epirubicin and Cisplatin (Modified ECF) as Adjuvant Chemotherapy in Resected Gastric Adenocarcinoma. Chemotherapy, 2012, 58, 233-240.	0.8	1
819	Current Management and Future Strategies of Gastric Cancer. Yonsei Medical Journal, 2012, 53, 248.	0.9	57
820	Survival after Adjuvant Chemoradiotherapy or Surgery Alone in Resectable Adenocarcinoma at the Gastro-Esophageal Junction. Scandinavian Journal of Surgery, 2012, 101, 26-31.	1.3	24
821	Esophageal carcinoma advances in treatment results for locally advanced disease: review. Annals of Oncology, 2012, 23, 1095-1103.	0.6	99
822	Phase II Trial of Preoperative Chemotherapy with Docetaxel, Cisplatin and S-1 for T4 Locally Advanced Gastric Cancer. Japanese Journal of Clinical Oncology, 2012, 42, 131-133.	0.6	13
823	Prevention is better than cure. Journal of Surgical Case Reports, 2012, 2012, 14-14.	0.2	1
824	Localized gastric cancerâ€"a CLASSIC shift in the paradigm?. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 194-195.	8.2	1

#	Article	IF	Citations
825	Proposal for a Multifactorial Prognostic Score That Accurately Classifies 3 Groups of Gastric Carcinoma Patients With Different Outcomes After Neoadjuvant Chemotherapy and Surgery. Annals of Surgery, 2012, 256, 1002-1007.	2.1	53
826	HER2 Expression in Gastric and Gastroesophageal Junction Adenocarcinoma in a US Population. Applied Immunohistochemistry and Molecular Morphology, 2012, 20, 13-24.	0.6	118
829	PWE-042â€...The relevance of the siewert classification in the era of multimodal therapy for adenocarcinoma of the gastro-oesophageal junction. Gut, 2012, 61, A313.2-A313.	6.1	0
831	Ent-11Î±-Hydroxy-15-Oxo-Kaur-16-en-19-Oic-Acid Induces Apoptosis of Human Malignant Cancer Cells. Current Drug Targets, 2012, 13, 1730-1737.	1.0	6
832	An update of adjuvant treatments for localized advanced gastric cancer. Clinical Investigation, 2012, 2, 1101-1108.	0.0	3
833	Prognostic Value of the 7th AJCC/UICC TNM Classification of Noncardia Gastric Cancer. Annals of Surgery, 2012, 255, 486-491.	2.1	124
834	Adjuvant combined systemic chemotherapy and intraperitoneal chemotherapy for locally advanced gastric cancer. Oncology Letters, 2012, 4, 1309-1314.	0.8	10
836	Current therapeutic approaches to localized carcinoma of the esophagus and gastroesophageal junction. Clinical Practice (London, England), 2012, 9, 463-471.	0.1	0
837	Results of postoperative radiochemotherapy of the patients with resectable gastroesophageal junction adenocarcinoma in Slovenia. Radiology and Oncology, 2012, 46, 337-45.	0.6	2
838	Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Oncology Reports, 2012, 27, 1639-45.	1.2	16
839	Changes in intracellular redox status influence multidrug resistance in gastric adenocarcinoma cells. Experimental and Therapeutic Medicine, 2012, 4, 291-296.	0.8	27
840	The CROSS trial: end of the debate on neoadjuvant therapy for esophageal cancer?. Clinical Practice (London, England), 2012, 9, 607-609.	0.1	0
841	Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet, The, 2012, 379, 315-321.	6.3	1,422
842	Management of Gastroesophageal Junction Tumors. Surgical Clinics of North America, 2012, 92, 1199-1212.	0.5	16
843	Improving Outcomes After Gastroesophageal Cancer Resection. Archives of Surgery, 2012, 147, 738.	2.3	32
845	Evaluation of serum highâ€density lipoprotein cholesterol levels as a prognostic factor in gastric cancer patients. Journal of Gastroenterology and Hepatology (Australia), 2012, 27, 1635-1640.	1.4	49
847	PG 9.03 Can adjuvant radiochemothrapy replace extended lymph node dissection?. European Journal of Cancer, 2012, 48, S9-S10.	1.3	0
848	PG 9.04 Oesophagogastric cancer: A case for perioperative chemotherapy. European Journal of Cancer, 2012, 48, S10.	1.3	4

#	Article	IF	Citations
849	PG 10.01 Predicting the response to neoadjuvant chemotherapy I (Who profits from neoadjuvant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.3	0
850	PG 10.02 Predicting the response to neoadjuvant chemotherapy II (Ability of pretherapeutic parameters) Tj ETQq1 1 0.784314 rgBT /O Journal of Cancer, 2012, 48, S10.	1.3	0
851	PG 10.03 Lessons from the GASTRIC metaanalysis of adjuvant treatment. European Journal of Cancer, 2012, 48, S10-S11.	1.3	0
852	Impact of postoperative morbidity on long-term survival after oesophagectomy. British Journal of Surgery, 2012, 100, 95-104.	0.1	60
853	Impact of targeted neoadjuvant therapies in the treatment of solid organ tumours. British Journal of Surgery, 2012, 100, 5-14.	0.1	5
854	Improving outcomes in gastrointestinal cancer. British Journal of Surgery, 2012, 100, 1-2.	0.1	5
856	Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer. Cancer Immunology, Immunotherapy, 2012, 61, 2251-2259.	2.0	115
857	Definitive Therapy for Isolated Esophageal Metastases Prolongs Survival. Annals of Thoracic Surgery, 2012, 94, 413-420.	0.7	10
858	Postoperative Chemotherapy Followed by Conformal Concomitant Chemoradiotherapy in High-Risk Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2012, 83, 574-580.	0.4	8
859	Intensity-Modulated Radiation Therapy With Concurrent Chemotherapy as Preoperative Treatment for Localized Gastric Adenocarcinoma. International Journal of Radiation Oncology Biology Physics, 2012, 83, 581-586.	0.4	37
860	Phase 3 Trial of Postoperative Chemotherapy Alone Versus Chemoradiation Therapy in Stage III-IV Gastric Cancer Treated With R0 Gastrectomy and D2 Lymph Node Dissection. International Journal of Radiation Oncology Biology Physics, 2012, 84, e585-e592.	0.4	94
861	Does Surgery Improve Outcomes for Esophageal Squamous Cell Carcinoma? An Analysis Using the Surveillance Epidemiology and End Results Registry from 1998 to 2008. Journal of the American College of Surgeons, 2012, 215, 643-651.	0.2	50
862	Does neoadjuvant chemotherapy improve outcomes for patients with gastric cancer?. Journal of Surgical Research, 2012, 178, 623-631.	0.8	7
863	Adjuvant chemoradiotherapy with or without intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma. Radiotherapy and Oncology, 2012, 102, 51-55.	0.3	21
864	Apoptosis index correlates with chemotherapy efficacy and predicts the survival of patients with gastric cancer. Tumor Biology, 2012, 33, 1151-1158.	0.8	19
865	Laparoscopic Resection for Gastric Carcinoma: Western Experience. Surgical Oncology Clinics of North America, 2012, 21, 141-158.	0.6	13
866	Surgery for Gastric Cancer: What the Trials Indicate. Surgical Oncology Clinics of North America, 2012, 21, 79-97.	0.6	4
867	Management of Cancer in the Older Adult. Clinics in Geriatric Medicine, 2012, 28, 33-49.	1.0	12

#	Article	IF	Citations
868	37. Surveillance of Barrett's oesophagus. European Journal of Surgical Oncology, 2012, 38, 742-743.	0.5	0
869	38. Neoadjuvant studies in upper gastro-intestinal cancers. European Journal of Surgical Oncology, 2012, 38, 743.	0.5	0
870	Evidence-Based Review of the Management of Cancers of the Gastroesophageal Junction. Thoracic Surgery Clinics, 2012, 22, 109-121.	0.4	5
871	Phase I and II Clinical Trials for Gastric Cancer. Surgical Oncology Clinics of North America, 2012, 21, 113-128.	0.6	3
872	39. Patient selection and results of surgical treatment. European Journal of Surgical Oncology, 2012, 38, 743.	0.5	0
873	Gastric Cancer Eastern Experience. Surgical Oncology Clinics of North America, 2012, 21, 71-77.	0.6	14
874	Preoperative and Postoperative Chemotherapy for Gastric Cancer. Surgical Oncology Clinics of North America, 2012, 21, 99-112.	0.6	20
875	Esophageal Carcinoma. , 2012, , 493-534.		1
876	Surgical Complications in Gastric Cancer Patients Preoperatively Treated with Chemotherapy: Their Risk Factors and Clinical Relevance. Annals of Surgical Oncology, 2012, 19, 2452-2458.	0.7	52
877	Staging Gastric Cancer Patients after Complete Surgical Resection: Which System Should We Use?. Annals of Surgical Oncology, 2012, 19, 2423-2425.	0.7	2
878	Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection. Journal of Clinical Oncology, 2012, 30, 2327-2333.	0.8	719
879	Comparison of the prognostic value of tumour and patient related factors in patients undergoing potentially curative resection of gastric cancer. American Journal of Surgery, 2012, 204, 294-299.	0.9	78
880	Human epithelial growth factor receptor 2 (HER2) status in primary and metastatic esophagogastric junction adenocarcinomas. Human Pathology, 2012, 43, 1206-1212.	1.1	34
881	Diagnostic et traitement des adÃ©nocarcinomes de la jonction Å“sogastrique non mÃ©tastatiquesÂ: quels standards actuelsÂ?. Journal De Chirurgie ViscÃ©rale, 2012, 149, 25-35.	0.0	0
882	Effect of hospital volume on postoperative mortality and survival after oesophageal and gastric cancer surgery in the Netherlands between 1989 and 2009. European Journal of Cancer, 2012, 48, 1004-1013.	1.3	134
883	Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer â€“ Differential treatment strategies for subtypes of early gastroesophageal cancer. European Journal of Cancer, 2012, 48, 2941-2953.	1.3	129
884	Phase II trial of preoperative S-1 plus cisplatin followed by surgery for initially unresectable locally advanced gastric cancer. European Journal of Surgical Oncology, 2012, 38, 143-149.	0.5	34
885	Preoperative chemotherapy does not influence the number of evaluable lymph nodes in resected gastric cancer. European Journal of Surgical Oncology, 2012, 38, 319-325.	0.5	14

#	Article	IF	Citations
886	Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction. British Journal of Surgery, 2012, 99, 1406-1414.	0.1	33
887	Staging and outcome depending on surgical treatment in adenocarcinomas of the oesophagogastric junction (Br J Surg 2012; 99: 1406â€“1414). British Journal of Surgery, 2012, 99, 1414-1414.	0.1	0
888	Survival in patients with stage IV noncardia gastric cancer - the influence of DNA ploidy and Helicobacter Pyloriinfection. BMC Cancer, 2012, 12, 264.	1.1	20
889	Peri-operative chemotherapy in the management of resectable colorectal cancer pulmonary metastases. BMC Cancer, 2012, 12, 326.	1.1	26
890	Benefits of hyperthermic intraperitoneal chemotherapy for patients with serosal invasion in gastric cancer: a meta-analysis of the randomized controlled trials. BMC Cancer, 2012, 12, 526.	1.1	88
891	Intrathoracic versus Cervical Anastomosis after Resection of Esophageal Cancer: A matched pair analysis of 72 patients in a single center study. World Journal of Surgical Oncology, 2012, 10, 159.	0.8	45
892	Comparison of efficacy of different route of administration of chemotherapy on unresectable, advanced gastric cancer. World Journal of Surgical Oncology, 2012, 10, 162.	0.8	11
893	Safety and preliminary results of perioperative chemotherapy and hyperthermic intraperitoneal chemotherapy (HIPEC) for high-risk gastric cancer patients. World Journal of Surgical Oncology, 2012, 10, 195.	0.8	20
894	Decreased expression of microRNA let-7i and its association with chemotherapeutic response in human gastric cancer. World Journal of Surgical Oncology, 2012, 10, 225.	0.8	44
895	Nimotuzumab promotes radiosensitivity of EGFR-overexpression esophageal squamous cell carcinoma cells by upregulating IGFBP-3. Journal of Translational Medicine, 2012, 10, 249.	1.8	33
898	Prognosis of Curatively Resected pT4b Gastric Cancer with Respect to Invaded Organ Type. Annals of Surgical Oncology, 2012, 19, 494-501.	0.7	15
899	Prognostic significance of vascular endothelial growth factor immunohistochemical expression in gastric cancer: a meta-analysis. Molecular Biology Reports, 2012, 39, 9473-9484.	1.0	46
900	Pan-Histone Deacetylase Inhibitor Panobinostat Sensitizes Gastric Cancer Cells to Anthracyclines via Induction of CITED2. Gastroenterology, 2012, 143, 99-109.e10.	0.6	36
901	The EORTC Gastrointestinal Tract Cancer Group: 50 years of research contributing to improved gastrointestinal cancer management. European Journal of Cancer, Supplement, 2012, 10, 51-57.	2.2	2
902	Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncology, The, 2012, 13, 1152-1160.	5.1	377
903	Imaging-guided curative surgical resection of pancreatic cancer in a xenograft mouse model. Cancer Letters, 2012, 324, 179-185.	3.2	35
904	Diagnosis and treatment of non-metastatic esophagogastric junction adenocarcinoma: What are the current options?. Journal of Visceral Surgery, 2012, 149, e23-e33.	0.4	26
906	Angiogenesis-related agents in esophageal cancer. Expert Opinion on Biological Therapy, 2012, 12, 1335-1345.	1.4	11

#	Article	IF	Citations
907	A Preoperative Nomogram to Predict the Risk of Perioperative Mortality Following Gastric Resections for Malignancy. Journal of Gastrointestinal Surgery, 2012, 16, 2026-2036.	0.9	13
908	Targeted Therapy for Gastric Cancer. Current Treatment Options in Oncology, 2012, 13, 377-389.	1.3	62
909	Multi-Modality Therapy for Cancer of the Esophagus and GE Junction. Current Treatment Options in Oncology, 2012, 13, 390-402.	1.3	8
910	Preoperative docetaxel/cisplatin/5-fluorouracil chemotherapy in patients with locally advanced gastro-esophageal adenocarcinoma. Medical Oncology, 2012, 29, 1707-1710.	1.2	10
911	Gastric Carcinoma. , 2012, , 231-246.		0
912	Pathological complete response of locally advanced gastric cancer after four courses of neoadjuvant chemotherapy with paclitaxel plus cisplatin: report of a case. Surgery Today, 2012, 42, 983-987.	0.7	7
916	Influence of Young Age on Outcome After Esophagectomy for Cancer. World Journal of Surgery, 2012, 36, 2612-2621.	0.8	8
917	A phase II study of docetaxel and oxaliplatin combination in recurrent gastric cancer patients after fluoropyrimidine and/or cisplatin adjuvant treatment: a Korean Cancer Study Group Protocol ST06-02. Cancer Chemotherapy and Pharmacology, 2012, 70, 665-672.	1.1	6
918	Safety and feasibility of adjuvant chemotherapy with S-1 for Korean patients with curatively resected advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2012, 70, 523-529.	1.1	10
920	Malignant Gastrocolic Fistula as a Late Complication of Radiation Therapy. Journal of Gastrointestinal Cancer, 2012, 43, 269-272.	0.6	0
921	Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer. New England Journal of Medicine, 2012, 366, 2074-2084.	13.9	4,296
923	Prediction of Response and Prognosis by a Score Including only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients. Recent Results in Cancer Research, 2012, 196, 269-289.	1.8	7
924	Optimal Surgery for Gastric Cancer: Is More Always Better?. Recent Results in Cancer Research, 2012, 196, 215-227.	1.8	9
925	Effects of neo-adjuvant chemotherapy for oesophago-gastric cancer on neuro-muscular gastric function. Molecular Biology Reports, 2012, 39, 9989-9994.	1.0	6
928	Innovation in Esophageal Surgery. , 2012, , .		1
929	Radiotherapy for tumors of the stomach and gastroesophageal junction â€“ a review of its role in multimodal therapy. Radiation Oncology, 2012, 7, 192.	1.2	18
930	FDG-PET Parameters as Prognostic Factor in Esophageal Cancer Patients: A Review. Indian Journal of Surgical Oncology, 2012, 3, 330-344.	0.3	1
931	Evidence of Prognostic Relevant Expression Profiles of Heat-Shock Proteins and Glucose-Regulated Proteins in Oesophageal Adenocarcinomas. PLoS ONE, 2012, 7, e41420.	1.1	25

#	Article	IF	Citations
932	Adenoviral Delivery of the EMX2 Gene Suppresses Growth in Human Gastric Cancer. PLoS ONE, 2012, 7, e45970.	1.1	19
933	Prognostic Role of Host Cyclooxygenase and Cytokine Genotypes in a Caucasian Cohort of Patients with Gastric Adenocarcinoma. PLoS ONE, 2012, 7, e46179.	1.1	9
934	Lymph node dissection for gastric cancer: a critical review. Oncology Reviews, 2012, 6, 12.	0.8	5
935	The role of perioperative radiotherapy in gastric cancer. Oncology Reviews, 2012, 6, 23.	0.8	2
936	The elderly cancer patient: the interplay between age and clinical decision-making. Journal of Solid Tumors, 2012, 2, .	0.1	0
937	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: A monocentric study. Tumori, 2012, 98, 451-457.	0.6	6
938	Current management of gastric cancer. Revista Espanola De Enfermedades Digestivas, 2012, 104, 134-141.	0.1	25
939	Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study. Oncology Letters, 2012, 3, 1154-1158.	0.8	4
940	Neoadjuvant Chemotherapy in Extra-Pulmonary Neuroendocrine Carcinoma. , 2012, , .		0
941	Cisplatin and solid tumors: Still working, after all these years. Journal of Solid Tumors, 2012, 2, .	0.1	4
942	Comparisons of Gastric Cancer Treatments: East vs. West. Journal of Gastric Cancer, 2012, 12, 55.	0.9	121
943	Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy. Oncology Letters, 2012, 3, 781-786.	0.8	6
944	ECF with Infusional Fluorouracil for 5 Days in Locally Advanced and Metastatic Gastric Cancer, Is It Better than the Standard?. Cancer and Clinical Oncology, 2012, 2, .	0.2	0
945	Comparative effectiveness research â€" a proposal for a new NHMRC funding stream. Medical Journal of Australia, 2012, 196, 22-23.	0.8	3
947	Neoplasms of the Esophagus and Stomach. , 2012, , 1272-1278.		0
948	Targeted therapy for esophagogastric cancers: a review. OncoTargets and Therapy, 2012, 5, 91.	1.0	0
949	FDG-PET/CT based response-adapted treatment. Cancer Imaging, 2012, 12, 324-335.	1.2	17
950	Clinical validation of the EORTC QLQâ€OG25 questionnaire for the evaluation of healthâ€related quality of life in Mexican patients with esophagogastric cancers. Psycho-Oncology, 2012, 21, 745-753.	1.0	10

#	Article	IF	Citations
951	The Impact of 18F-Fluorodeoxyglucose Positron Emission Tomography Positive Lymph Nodes on Postoperative Recurrence and Survival in Resectable Thoracic Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2012, 19, 652-660.	0.7	28
952	Use of Multimodality Neoadjuvant Therapy for Esophageal Cancer in the United States: Assessment of 987 Hospitals. Annals of Surgical Oncology, 2012, 19, 357-364.	0.7	50
953	Clinicopathological Features and Prognostic Factors of Adenocarcinoma of the Esophagogastric Junction According to Siewert Classification: Experiences at a Single Institution in Japan. Annals of Surgical Oncology, 2012, 19, 677-683.	0.7	101
954	Risk of Thromboembolic Events after Perioperative Chemotherapy Versus Surgery Alone for Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2012, 19, 684-692.	0.7	13
955	Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with nodeâ€negative gastric cancer. Journal of Surgical Oncology, 2012, 105, 400-404.	0.8	10
956	Efficacy of preâ€operative chemotherapy with docetaxel, cisplatin, and Sâ€1 (DCS therapy) and curative resection for gastric cancer with pathologically positive paraâ€aortic lymph nodes. Journal of Surgical Oncology, 2012, 105, 535-541.	0.8	42
957	The quality of life trajectory of resected gastric cancer. Journal of Surgical Oncology, 2012, 105, 337-341.	0.8	28
958	Clinical significance of zinc finger Eâ€box binding homeobox 1 (ZEB1) in human gastric cancer. Journal of Surgical Oncology, 2012, 106, 280-285.	0.8	47
959	Neoadjuvant chemotherapy with FOLFOX: Improved outcomes in Chinese patients with locally advanced gastric cancer. Journal of Surgical Oncology, 2012, 105, 793-799.	0.8	47
960	Does nonâ€curative gastrectomy improve survival in patients with metastatic gastric cancer?. Journal of Surgical Oncology, 2012, 106, 193-196.	0.8	37
961	Clinical relevance of induction triplet chemotherapy for esophageal cancer invading adjacent organs. Journal of Surgical Oncology, 2012, 106, 441-447.	0.8	42
962	Primary small cell carcinoma of the stomach: An experience of two decades (1990â€“2011) in a Chinese cancer institute. Journal of Surgical Oncology, 2012, 106, 994-998.	0.8	18
963	MAGIC in practice: Experience of periâ€operative ECF/X chemotherapy in gastroâ€esophageal adenocarcinomas. Journal of Surgical Oncology, 2012, 106, 748-752.	0.8	19
964	Influence of hospital type on outcomes after oesophageal and gastric cancer surgery. British Journal of Surgery, 2012, 99, 954-963.	0.1	33
965	Phase 2 trial of induction and concurrent chemoradiotherapy with weekly irinotecan and cisplatin followed by surgery for esophageal cancer. Cancer, 2012, 118, 2820-2827.	2.0	67
966	Cathepsin B cleavable novel prodrug Acâ€Pheâ€Lysâ€PABCâ€ADM enhances efficacy at reduced toxicity in treating gastric cancer peritoneal carcinomatosis. Cancer, 2012, 118, 2986-2996.	2.0	51
967	A prospective evaluation of the utility of 2â€deoxyâ€2â€[¹⁸F]fluoroâ€<scp>D</scp>â€glucose positron emission tomography and computed tomography in staging locally advanced gastric cancer. Cancer, 2012, 118, 5481-5488.	2.0	122
968	Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumor Biology, 2012, 33, 749-756.	0.8	101

#	Article	IF	Citations
969	Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Investigational New Drugs, 2012, 30, 1671-1675.	1.2	9
972	Cyclooxygenase Isoenzyme-2 and Vascular Endothelial Growth Factor are Associated with Poor Prognosis in Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2012, 16, 956-966.	0.9	38
974	Current Developments in the Management of Locally Advanced Esophageal Cancer. Current Oncology Reports, 2012, 14, 342-349.	1.8	18
975	SEOM clinical guidelines for the diagnosis and treatment of gastric adenocarcinoma. Clinical and Translational Oncology, 2012, 14, 528-535.	1.2	16
976	Recent advances and future challenges in the treatment of upper gastrointestinal malignancies. Memo - Magazine of European Medical Oncology, 2012, 5, 157-160.	0.3	0
977	Gastric cancer: Imaging and staging with MDCT based on the 7th AJCC guidelines. Abdominal Imaging, 2012, 37, 531-540.	2.0	47
978	Phase I study of neoadjuvant chemoradiotherapy with S-1 and oxaliplatin in patients with locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2012, 69, 1333-1338.	1.1	14
979	Laparoscopic gastrectomy for patients with advanced gastric cancer produces oncologic outcomes similar to those for open resection. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 1813-1821.	1.3	17
980	The use of biodegradable (SX-ELLA) oesophageal stents to treat dysphagia due to benign and malignant oesophageal disease. Surgical Endoscopy and Other Interventional Techniques, 2012, 26, 2367-2375.	1.3	46
981	Predicting the effects of chemoradiotherapy for squamous cell carcinoma of the esophagus by induction chemotherapy response assessed by positron emission tomography: toward PET-response-guided selection of chemoradiotherapy or esophagectomy. International Journal of Clinical Oncology, 2012, 17, 225-232.	1.0	18
982	Adjuvant postoperative radiochemotherapy for patients with gastric carcinoma: a single institution experience. Chinese-German Journal of Clinical Oncology, 2012, 11, 249-256.	0.1	0
983	Safety and efficacy of self-expanding removable metal esophageal stents during neoadjuvant chemotherapy for resectable esophageal cancer. Ecological Management and Restoration, 2012, 25, 48-53.	0.2	46
984	Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer. Clinical Nutrition, 2012, 31, 74-77.	2.3	213
985	Randomized study of clinical effect of enteral nutrition support during neoadjuvant chemotherapy on chemotherapy-related toxicity in patients with esophageal cancer. Clinical Nutrition, 2012, 31, 330-336.	2.3	80
986	Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment. Critical Reviews in Oncology/Hematology, 2012, 82, 310-322.	2.0	19
987	Capecitabine for the treatment for advanced gastric cancer: efficacy, safety and ethnicity. Journal of Clinical Pharmacy and Therapeutics, 2012, 37, 266-275.	0.7	17
988	Evolving progress in oncologic and operative outcomes for esophageal and junctional cancer: Lessons from the experience of a high-volume center. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1130-1137.e1.	0.4	36
989	Postoperative information needs and communication barriers of esophageal cancer patients. Patient Education and Counseling, 2012, 88, 138-146.	1.0	47

#	Article	IF	Citations
990	Cancerâ€testis antigen <scp>BORIS</scp> is a novel prognostic marker for patients with esophageal cancer. Cancer Science, 2012, 103, 1617-1624.	1.7	30
991	Pathologic Nonresponders after Neoadjuvant Chemoradiation for Esophageal Cancer Demonstrate no Survival Benefit Compared with Patients Treated with Primary Esophagectomy. Annals of Surgical Oncology, 2012, 19, 1678-1684.	0.7	59
992	Adenocarcinomas of the Esophagogastric Junction Are More Likely to Respond to Preoperative Chemotherapy than Distal Gastric Cancer. Annals of Surgical Oncology, 2012, 19, 2108-2118.	0.7	65
993	Posttherapy Nodal Status, Not Graded Histologic Response, Predicts Survival after Neoadjuvant Chemotherapy for Advanced Gastric Cancer. Annals of Surgical Oncology, 2012, 19, 1936-1943.	0.7	37
994	Prediction of Response and Prognosis by a Score Including Only Pretherapeutic Parameters in 410 Neoadjuvant Treated Gastric Cancer Patients. Annals of Surgical Oncology, 2012, 19, 2119-2127.	0.7	62
995	The Real Estate of Gastric Cancer Induction Therapy: Location Versus Intrinsic Molecular Architecture. Annals of Surgical Oncology, 2012, 19, 2081-2083.	0.7	0
996	Prospective impact of tumor grade assessment in biopsies on tumor stage and prognostic grouping in gastroesophageal adenocarcinoma. Cancer, 2012, 118, 349-357.	2.0	14
997	Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5â€fluorouracil, oxaliplatin and docetaxel. International Journal of Cancer, 2012, 130, 1706-1713.	2.3	88
998	Intraperitoneal docetaxel combined with Sâ€1 for advanced gastric cancer with peritoneal dissemination. Journal of Surgical Oncology, 2012, 105, 38-42.	0.8	60
999	Clinicopathologic variables predicting tumor response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Journal of Surgical Oncology, 2012, 105, 293-296.	0.8	34
1000	Role of positron emission tomographyâ€“computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma. British Journal of Surgery, 2012, 99, 239-245.	0.1	29
1001	Prognostic significance of peritoneal washing cytology in patients with gastric cancer. British Journal of Surgery, 2012, 99, 397-403.	0.1	68
1002	Intratumoral Heterogeneity Determines Discordant Results of Diagnostic Tests for Human Epidermal Growth Factor Receptor (HER) 2 in Gastric Cancer Specimens. Cell Biochemistry and Biophysics, 2012, 62, 221-228.	0.9	89
1003	Neoadjuvant Radiochemotherapy in Adenocarcinoma of the Esophagus: ERCC1 Gene Polymorphisms for Prediction of Response and Prognosis. Journal of Gastrointestinal Surgery, 2012, 16, 26-34.	0.9	48
1004	Is there a Role for Surgery with Adequate Nodal Evaluation Alone in Gastric Adenocarcinoma?. Journal of Gastrointestinal Surgery, 2012, 16, 238-247.	0.9	12
1008	Is Pretreatment Endoscopic Biopsy a Good Predictor of Signet Ring Cell Histology in Gastric Carcinoma?. World Journal of Surgery, 2012, 36, 346-354.	0.8	20
1009	Impact of Clinical and Pathohistological Characteristics on the Incidence of Recurrence and Survival in Elderly Patients with Gastric Cancer. World Journal of Surgery, 2012, 36, 338-345.	0.8	14
1011	A pilot study of S-1 plus cisplatin versus 5-fluorouracil plus cisplatin for postoperative chemotherapy in histological stage IIIB-IV (M0) gastric cancer. Investigational New Drugs, 2012, 30, 357-363.	1.2	7

#	Article	IF	Citations
1012	Impact of pretherapeutic routine clinical staging for the individualization of treatment in gastric cancer patients. Langenbeck's Archives of Surgery, 2012, 397, 45-55.	0.8	18
1013	Gastric linitis plastica: which role for surgical resection?. Gastric Cancer, 2012, 15, 56-60.	2.7	42
1014	Phase II trial of combined treatment consisting of preoperative S-1 plus cisplatin followed by gastrectomy and postoperative S-1 for stage IV gastric cancer. Gastric Cancer, 2012, 15, 61-69.	2.7	47
1015	The potential value of bursectomy in operations for trans-serosal gastric adenocarcinoma. Gastric Cancer, 2012, 15, 3-4.	2.7	31
1016	Adherence to national guidelines for gastric cancer in the Netherlands: A retrospective populationâ€based audit. International Journal of Cancer, 2013, 132, 1156-1161.	2.3	18
1017	Randomized trials and quality assurance in gastric cancer surgery. Journal of Surgical Oncology, 2013, 107, 298-305.	0.8	8
1018	Clinical trials in gastric cancer and the future. Journal of Surgical Oncology, 2013, 107, 289-297.	0.8	8
1019	Lapatinib, a dual inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2, potentiates the antitumor effects of cisplatin on esophageal carcinoma. Ecological Management and Restoration, 2013, 26, 487-495.	0.2	6
1020	Blood neutrophil-lymphocyte ratio predicts survival for stages III-IV gastric cancer treated with neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2013, 11, 112.	0.8	60
1021	D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2013, 11, 31.	0.8	26
1022	Evaluation of chemosensitivity prediction using quantitative doseâ€“response curve classification for highly advanced/relapsed gastric cancer. World Journal of Surgical Oncology, 2013, 11, 11.	0.8	9
1023	Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiation Oncology, 2013, 8, 6.	1.2	18
1024	High EpCAM expression is linked to proliferation and lauren classification in gastric cancer. BMC Research Notes, 2013, 6, 253.	0.6	26
1025	Outcomes among patients treated for gastric adenocarcinoma during the last decade. Journal of Surgical Oncology, 2013, 107, 752-757.	0.8	11
1026	Long-Term Survival After Gastrectomy for Cancer in Randomized, Controlled Oncological Trials: Comparison between West and East. Annals of Surgical Oncology, 2013, 20, 2328-2338.	0.7	81
1027	Gastric lymph node contouring atlas: A tool to aid in clinical target volume definition in 3-dimensional treatment planning for gastric cancer. Practical Radiation Oncology, 2013, 3, e11-e19.	1.1	23
1028	Tying the knot between cytokine and tollâ€like receptor signaling in gastrointestinal tract cancers. Cancer Science, 2013, 104, 1139-1145.	1.7	27
1029	New Advances on Disease Biomarkers and Molecular Targets in Biomedicine. , 2013, , .		0

#	Article	IF	Citations
1030	Lymph Node Dissection in Resectable Advanced Gastric Cancer. Digestive Surgery, 2013, 30, 96-103.	0.6	28
1031	Extended Lymphadenectomy in Gastric Cancer Is Crucial. World Journal of Surgery, 2013, 37, 1768-1772.	0.8	7
1032	Tissue inhibitor of metalloproteinase 1 (TIMP-1) as a biomarker in gastric cancer: a review. Scandinavian Journal of Gastroenterology, 2013, 48, 899-905.	0.6	55
1033	A reliable risk score for stage IV esophagogastric cancer. European Journal of Surgical Oncology, 2013, 39, 823-830.	0.5	42
1034	Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas â€“ PRODIGE 19 â€“ FFCD1103 â€“ ADCI002. BMC Cancer, 2013, 13, 281.	1.1	56
1035	Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer â€“ the RAPIDO trial. BMC Cancer, 2013, 13, 279.	1.1	237
1036	Who Benefits From Adjuvant Radiation Therapy for Gastric Cancer? A Meta-Analysis. International Journal of Radiation Oncology Biology Physics, 2013, 86, 330-335.	0.4	51
1037	Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas. Journal of Gastroenterology, 2013, 48, 1213-1221.	2.3	18
1038	CÃ¡ncer de estÃ³mago. Medicine, 2013, 11, 1512-1518.	0.0	0
1039	Updates on Surgical Management of Advanced Gastric Cancer: New Evidence and Trends. Insights from the First International Course on Upper Gastrointestinal Surgeryâ€”Varese (Italy), December 2, 2011. Annals of Surgical Oncology, 2013, 20, 3942-3947.	0.7	8
1041	Improved Long-Term Survival After Esophagectomy for Esophageal Cancer: Influence of Epidemiologic Shift and Neoadjuvant Therapy. Journal of Gastrointestinal Surgery, 2013, 17, 1193-1201.	0.9	33
1042	Preoperative Chemotherapy Does Not Adversely Affect Pancreatic Structure and Short-Term Outcome after Pancreatectomy. Journal of Gastrointestinal Surgery, 2013, 17, 488-493.	0.9	17
1043	Adjuvant Therapy in Gastric Cancer: What Is The Optimal Approach?. Current Oncology Reports, 2013, 15, 146-151.	1.8	6
1044	Sunitinib Reverse Multidrug Resistance in Gastric Cancer Cells by Modulating Stat3 and Inhibiting P-gp Function. Cell Biochemistry and Biophysics, 2013, 67, 575-581.	0.9	20
1045	Curative Treatment of Esophageal Cancer; An Evidenced Based Review. Journal of Gastrointestinal Cancer, 2013, 44, 375-384.	0.6	23
1046	Docetaxel-Based Preoperative Chemoradiation in Localized Gastric Cancer: Impact of Pathological Complete Response on Patient Outcome. Journal of Gastrointestinal Cancer, 2013, 44, 162-169.	0.6	5
1047	Systemic Treatment of Gastrointestinal Cancer in Elderly Patients. Journal of Gastrointestinal Cancer, 2013, 44, 22-32.	0.6	18
1048	The role of systemic inflammatory and nutritional blood-borne markers in predicting response to neoadjuvant chemotherapy and survival in oesophagogastric cancer. Medical Oncology, 2013, 30, 596.	1.2	38

#	Article	IF	Citations
1049	Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clinical and Translational Oncology, 2013, 15, 443-449.	1.2	18
1050	Prognostic impact of lymph node involvement and the extent of lymphadenectomy (LAD) in adenocarcinoma of the esophagogastric junction (AEG). Langenbeck's Archives of Surgery, 2013, 398, 973-981.	0.8	29
1051	Preoperative therapy of esophagogastric cancer: the problem of nonresponding patients. Langenbeck's Archives of Surgery, 2013, 398, 211-220.	0.8	20
1052	National outcomes and uptake of laparoscopic gastrectomy for cancer in England. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 3348-3358.	1.3	23
1053	Prognostic relevance of gastric cancer staging by endoscopic ultrasound. Surgical Endoscopy and Other Interventional Techniques, 2013, 27, 1124-1129.	1.3	23
1054	Adjuvant and Neoadjuvant Therapy for Gastric Cancer. Current Treatment Options in Oncology, 2013, 14, 311-320.	1.3	17
1055	Laparoscopy-assisted resection of proximal gastric cancer: is less than all more or less complete, or is all more, nonetheless?. Gastric Cancer, 2013, 16, 277-279.	2.7	0
1056	Defining the target volume for post-operative radiotherapy after D2 dissection in gastric cancer by CT-based vessel-guided delineation. Radiotherapy and Oncology, 2013, 108, 72-77.	0.3	18
1057	Multimodality imaging evaluation of esophageal cancer: staging, therapy assessment, and complications. Abdominal Imaging, 2013, 38, 974-993.	2.0	24
1058	Robotâ€assisted Gastrectomy for Gastric Cancer: Current Status and Technical Considerations. World Journal of Surgery, 2013, 37, 2771-2781.	0.8	64
1059	ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2013, 72, 159-165.	1.1	38
1060	Correlation between expressions of ERCC1/TS mRNA and effects of gastric cancer to chemotherapy in the short term. Cancer Chemotherapy and Pharmacology, 2013, 71, 921-928.	1.1	10
1061	A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker. Cancer Chemotherapy and Pharmacology, 2013, 71, 789-797.	1.1	57
1063	Accuracy of multidetector-row CT for restaging after neoadjuvant treatment in patients with oesophageal cancer. European Radiology, 2013, 23, 2492-2502.	2.3	30
1064	Apparent diffusion coefficient modifications in assessing gastro-oesophageal cancer response to neoadjuvant treatment: comparison with tumour regression grade at histology. European Radiology, 2013, 23, 2165-2174.	2.3	94
1066	Cure for peritoneal metastases? An evidenceâ€based review. ANZ Journal of Surgery, 2013, 83, 821-826.	0.3	6
1067	Feasibility of laparoscopic gastrectomy for advanced gastric cancer with positive peritoneal cytology. Surgery Today, 2013, 43, 859-864.	0.7	4
1068	Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlentherapie Und Onkologie, 2013, 189, 417-423.	1.0	20

#	Article	IF	Citations
1071	Surgical Considerations in the Treatment of Gastric Cancer. Gastroenterology Clinics of North America, 2013, 42, 337-357.	1.0	18
1072	Modern Oncological Approaches to Gastric Adenocarcinoma. Gastroenterology Clinics of North America, 2013, 42, 359-369.	1.0	41
1073	Commentary on: Prognostic significance of 18-FDG PET/CT and EUS-defined tumour characteristics in patientsÂwith oesophageal cancer. Clinical Radiology, 2013, 68, 338-339.	0.5	5
1074	Molecular Diagnostics in Esophageal and Gastric Neoplasms. Clinics in Laboratory Medicine, 2013, 33, 867-873.	0.7	7
1075	Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma. Redox Biology, 2013, 1, 285-291.	3.9	25
1076	Improved short term surgical outcomes in Scotland for oesophageal cancer. European Journal of Surgical Oncology, 2013, 39, 131-135.	0.5	5
1077	Neoadjuvant therapy reduces the incidence of nodal micrometastases in esophageal adenocarcinoma. American Journal of Surgery, 2013, 206, 732-738.	0.9	12
1078	Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. The Cochrane Library, 2013, , CD008415.	1.5	39
1079	Effect of adjuvant chemoradiotherapy on overall survival of gastric cancer patients submitted to D2 lymphadenectomy. Gastric Cancer, 2013, 16, 233-238.	2.7	20
1080	WD40 repeat-containing 62 overexpression as a novel indicator of poor prognosis for human gastric cancer. European Journal of Cancer, 2013, 49, 3752-3762.	1.3	20
1081	Priority of Lymph Node Dissection for Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction. Annals of Surgical Oncology, 2013, 20, 4252-4259.	0.7	49
1082	Surgical treatment results of intestinal and diffuse type gastric cancer. Implications for a differentiated therapeutic approach?. European Journal of Surgical Oncology, 2013, 39, 686-693.	0.5	40
1083	Management of gastroesophageal cancer: A perspective from Catalonia. Oncologie, 2013, 15, 181-188.	0.2	0
1084	Adjuvant (Postoperative) Therapy for Esophageal Cancer. Thoracic Surgery Clinics, 2013, 23, 525-533.	0.4	11
1085	Gastric Cancer: Current Status of Diagnosis and Treatment. Cancers, 2013, 5, 48-63.	1.7	159
1086	KRAS and BRAF mutations are rare and related to DNA mismatch repair deficiency in gastric cancer from the East and the West: Results from a large international multicentre study. British Journal of Cancer, 2013, 108, 1495-1501.	2.9	76
1087	Extranodal metastasis is a powerful prognostic factor in patients with adenocarcinoma of the esophagogastric junction. Journal of Surgical Oncology, 2013, 108, 542-549.	0.8	16
1088	Neoadjuvant Chemotherapy or Chemoradiotherapy for Locally Advanced Esophageal Cancer. Thoracic Surgery Clinics, 2013, 23, 509-523.	0.4	9

#	Article	IF	Citations
1089	Induction Therapy for Esophageal Cancer. Thoracic Surgery Clinics, 2013, 23, 499-507.	0.4	5
1090	Population-Based Outcome of Stage IA-IIA Resected Gastric Adenocarcinoma: Who Should Get Adjuvant Treatment?. Annals of Surgical Oncology, 2013, 20, 2304-2310.	0.7	6
1091	Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, The, 2013, 14, e535-e547.	5.1	418
1092	Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Overview and rationale. European Journal of Surgical Oncology, 2013, 39, 1309-1316.	0.5	61
1093	Geographic differences in approach to advanced gastric cancer: Is there a standard approach?. Critical Reviews in Oncology/Hematology, 2013, 88, 416-426.	2.0	39
1095	Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. Journal of Hematology and Oncology, 2013, 6, 66.	6.9	18
1096	A Prospective Validation Study to Diagnose Serosal Invasion and Nodal Metastases of Gastric Cancer by Multidetector-row CT. Annals of Surgical Oncology, 2013, 20, 2016-2022.	0.7	58
1097	Expression and role of grainyhead-like 2 in gastric cancer. Medical Oncology, 2013, 30, 714.	1.2	36
1098	Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer. Journal of Experimental and Clinical Cancer Research, 2013, 32, 87.	3.5	52
1100	Cost-effectiveness of adjuvant chemotherapy for curatively resected gastric cancer with S-1. BMC Cancer, 2013, 13, 443.	1.1	16
1101	Members of the EpCAM signalling pathway are expressed in gastric cancer tissue and are correlated with patient prognosis. British Journal of Cancer, 2013, 109, 2217-2227.	2.9	39
1102	Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials. European Journal of Cancer, 2013, 49, 2116-2125.	1.3	38
1103	Biomarkers in Oncology. , 2013, , .		1
1104	Gastric cancerâ€"molecular and clinical dimensions. Nature Reviews Clinical Oncology, 2013, 10, 643-655.	12.5	376
1105	A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Seminars in Cancer Biology, 2013, 23, 512-521.	4.3	104
1106	Internal hernia after gastrectomy for cancer with Roux-Y reconstruction. Surgery, 2013, 154, 305-311.	1.0	44
1107	Feasibility of perioperative chemotherapy with infusional 5-FU, leucovorin, and oxaliplatin with (FLOT) or without (FLO) docetaxel in elderly patients with locally advanced esophagogastric cancer. British Journal of Cancer, 2013, 108, 519-526.	2.9	93
1108	Quality of Care Indicators for the Surgical Treatment of Gastric Cancer: A Systematic Review. Annals of Surgical Oncology, 2013, 20, 381-398.	0.7	28

#	Article	IF	Citations
1109	Phase II study of preoperative chemotherapy with Sâ€1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). Journal of Surgical Oncology, 2013, 107, 741-745.	0.8	98
1110	The prognosis of gastric cancer patients with marginally elevated carcinoembryonic antigen (CEA) values after D2 radical gastrectomy. Journal of Surgical Oncology, 2013, 107, 641-645.	0.8	20
1111	New therapeutic strategies for squamous cell cancer and adenocarcinoma. Annals of the New York Academy of Sciences, 2013, 1300, 213-225.	1.8	2
1112	Gastric cancer: ESMOâ€"ESSOâ€"ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi57-vi63.	0.6	250
1114	Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology, 2013, 24, 1253-1261.	0.6	76
1115	The diagnosis and management of gastric cancer. BMJ, The, 2013, 347, f6367-f6367.	3.0	122
1116	WNT6 is a novel target gene of caveolin-1 promoting chemoresistance to epirubicin in human gastric cancer cells. Oncogene, 2013, 32, 375-387.	2.6	79
1117	Impact of Genetic Targets on Cancer Therapy in Esophagogastric Cancer. Advances in Experimental Medicine and Biology, 2013, 779, 55-65.	0.8	1
1119	Neoadjuvant or adjuvant therapy for resectable gastric cancer: a systematic review and practice guideline for North America. Gastric Cancer, 2013, 16, 28-40.	2.7	48
1120	Chemoradiation Therapy. Surgical Oncology Clinics of North America, 2013, 22, 511-524.	0.6	13
1121	Evaluation of response to induction chemotherapy in esophageal cancer: is barium esophagography or PET-CT useful?. Clinical Imaging, 2013, 37, 468-474.	0.8	11
1122	Pirosis en un varÃ³n de 47 aÃ±os. Medicine, 2013, 11, 1558.e1-1558.e4.	0.0	0
1123	Multidisciplinary Management ofÂGastric Cancer. Surgical Oncology Clinics of North America, 2013, 22, 247-264.	0.6	11
1124	Multidisciplinary Management of Esophageal Cancer. Surgical Oncology Clinics of North America, 2013, 22, 217-246.	0.6	12
1125	Disease-Free Survival as a Surrogate for Overall Survival in Adjuvant Trials of Gastric Cancer: A Meta-Analysis. Journal of the National Cancer Institute, 2013, 105, 1600-1607.	3.0	133
1126	miR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology, 2013, 306, 162-168.	2.0	185
1127	Risk factors of peritoneal recurrence in eso-gastric signet ring cell adenocarcinoma: Results of a multicentre retrospective study. European Journal of Surgical Oncology, 2013, 39, 235-241.	0.5	34
1128	Preoperative chemo(radio)therapy versus primary surgery for gastroesophageal adenocarcinoma: Systematic review with meta-analysis combining individual patient and aggregate data. European Journal of Cancer, 2013, 49, 3149-3158.	1.3	145

#	Article	IF	Citations
1129	CÃ¡ncer de esÃ³fago. Medicine, 2013, 11, 1505-1511.	0.0	1
1130	What provider volumes and characteristics are appropriate for gastric cancer resection? Results ofÂanÂinternational RAND/UCLA expertÂpanel. Surgery, 2013, 154, 1100-1109.	1.0	14
1131	Treatment Strategies for Esophageal Cancer. Gastroenterology Clinics of North America, 2013, 42, 187-197.	1.0	30
1132	Perioperative chemotherapy for resectable gastroesophageal cancer: A single-center experience. European Journal of Surgical Oncology, 2013, 39, 814-822.	0.5	11
1133	Targeted therapy and chemoradiotherapy in oesophageal cancer. Lancet Oncology, The, 2013, 14, 569-570.	5.1	3
1134	Clinicopathological Characteristics and Survival Difference Between Gastric Stump Carcinoma and Primary Upper Third Gastric Cancer. Journal of Gastrointestinal Surgery, 2013, 17, 313-318.	0.9	43
1135	Perioperative DCF chemotherapy protocol for patients with gastroesophageal adenocarcinoma: correlation between response to treatment and outcome. Medical Oncology, 2013, 30, 377.	1.2	6
1136	A role for p21â€activated kinaseÂ7 in the development of gastric cancer. FEBS Journal, 2013, 280, 46-55.	2.2	50
1137	Preoperative Assessment of Tumor Location and Stationâ€Specific Lymph Node Status in Patients with Adenocarcinoma of the Gastroesophageal Junction. World Journal of Surgery, 2013, 37, 147-155.	0.8	62
1138	Oesophageal cancerâ€”an overview. Nature Reviews Gastroenterology and Hepatology, 2013, 10, 230-244.	8.2	77
1139	Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. Journal of Pathology, 2013, 230, 410-419.	2.1	71
1140	Management of localized gastric cancer. Journal of Surgical Oncology, 2013, 107, 265-270.	0.8	25
1141	Neoadjuvant chemotherapy for gastric cancer: A metaâ€analysis of randomized, controlled trials. Journal of Gastroenterology and Hepatology (Australia), 2013, 28, 777-782.	1.4	26
1143	Treatment Trends and Predictors of Adjuvant and Neoadjuvant Therapy for Gastric Adenocarcinoma in the United States. Annals of Surgical Oncology, 2013, 20, 362-370.	0.7	37
1144	Role of Repeat Staging Laparoscopy in Locoregionally Advanced Gastric or Gastroesophageal Cancer after Neoadjuvant Therapy. Annals of Surgical Oncology, 2013, 20, 548-554.	0.7	26
1146	Survival and recurrence free benefits with different lymphadenectomy for resectable gastric cancer: A metaâ€analysis. Journal of Surgical Oncology, 2013, 107, 807-814.	0.8	71
1147	Survival after Definitive (Chemo)Radiotherapy in Esophageal Cancer Patients: A Population-Based Study in the North-East Netherlands. Annals of Surgical Oncology, 2013, 20, 1985-1992.	0.7	26
1148	Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: A systematic review and meta-analysis of randomised controlled trials. International Journal of Hyperthermia, 2013, 29, 156-167.	1.1	64

#	Article	IF	Citations
1149	Emerging tyrosine kinase inhibitors for esophageal cancer. Expert Opinion on Emerging Drugs, 2013, 18, 219-230.	1.0	9
1150	Quality Research in Radiation Oncology Analysis of Clinical Performance Measures in the Management of Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 355-362.	0.4	5
1151	Oesophageal carcinoma. Lancet, The, 2013, 381, 400-412.	6.3	2,082
1152	Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2013, 71, 1309-1314.	1.1	43
1153	Perioperative chemo(radio)therapy versus primary surgery for resectable adenocarcinoma of the stomach, gastroesophageal junction, and lower esophagus. The Cochrane Library, 2013, , CD008107.	1.5	110
1154	Treatment Decisions and Medical Treatment of Cancer in Elderly Patients. , 2013, , 229-247.		1
1155	Chemotherapeutic Options for Gastroesophageal Junction Tumors. Seminars in Radiation Oncology, 2013, 23, 24-30.	1.0	10
1156	The Impact of Multimodality Therapy of Distal Esophageal and Gastroesophageal Junction Adenocarcinomas on Treatment-Related Toxicity and Complications. Seminars in Radiation Oncology, 2013, 23, 60-73.	1.0	18
1157	Therapy for Locally Advanced Adenocarcinoma of the Gastroesophageal Junction: Optimizing Outcome. Seminars in Radiation Oncology, 2013, 23, 38-50.	1.0	13
1158	Bevacizumab with peri-operative epirubicin, cisplatin and capecitabine (ECX) in localised gastro-oesophageal adenocarcinoma: a safety report. Annals of Oncology, 2013, 24, 702-709.	0.6	64
1159	Abnormal expression of paxillin correlates with tumor progression and poor survival in patients with gastric cancer. Journal of Translational Medicine, 2013, 11, 277.	1.8	35
1160	Palliative Resection for Advanced Gastric and Junctional Adenocarcinoma: Which Patients will Benefit from Surgery?. Annals of Surgical Oncology, 2013, 20, 1240-1249.	0.7	38
1161	The Impact of Preoperative Lymph Node Size on Long-Term Outcome Following Curative Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1598-1603.	0.7	24
1162	Poor Survival Rate in Patients with Postoperative Intra-Abdominal Infectious Complications Following Curative Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2013, 20, 1575-1583.	0.7	278
1163	Influence of Treatment Modality in Outcomes for Different Stages of Resectable Esophageal Adenocarcinomas. Annals of Surgical Oncology, 2013, 20, 1660-1667.	0.7	4
1164	Factors predicting prognosis and recurrence in patients with esophago-gastric adenocarcinoma and histopathological response with less than 10Â% residual tumor. Langenbeck's Archives of Surgery, 2013, 398, 239-249.	0.8	36
1165	Pre-operative chemoradiation followed by post-operative adjuvant therapy with tetrathiomolybdate, a novel copper chelator, for patients with resectable esophageal cancer. Investigational New Drugs, 2013, 31, 435-442.	1.2	25
1166	Neoadjuvant Chemotherapy for Nonmetastatic Esophago-Gastric Adenocarcinomas: A Systematic Review and Meta-Analysis. Cancer Investigation, 2013, 31, 421-431.	0.6	11

#	Article	IF	Citations
1167	Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Annals of Oncology, 2013, 24, 1721-1730.	0.6	131
1168	Treatment Approaches to Esophagogastric Junction Tumors. Digestive Surgery, 2013, 30, 169-173.	0.6	17
1169	Chemoradiotherapy Before and After Surgery for Locally Advanced Esophageal Cancer: A SEER-Medicare Analysis. Annals of Surgical Oncology, 2013, 20, 3999-4007.	0.7	22
1170	Induction Chemoradiotherapy and Surgery forÂEsophageal Cancer: Survival Benefit WithÂDownstaging. Annals of Thoracic Surgery, 2013, 96, 225-231.	0.7	12
1172	Supraclavicular metastases from distant primaries: what is the role of the head and neck surgeon?. British Journal of Oral and Maxillofacial Surgery, 2013, 51, 288-293.	0.4	14
1173	Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2013, 24, vi51-vi56.	0.6	194
1174	A phase II study of neoadjuvant docetaxel, oxaliplatin, and S-1 (DOS) chemotherapy followed by surgery and adjuvant S-1 chemotherapy in potentially resectable gastric or gastroesophageal junction adenocarcinoma. Cancer Chemotherapy and Pharmacology, 2013, 72, 815-823.	1.1	48
1175	Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer. Journal of Radiation Research, 2013, 54, 890-898.	0.8	23
1176	Complex General Surgical Oncology: A Case-Based Approach - Volume 1. , 2013, , .		0
1178	Gastric cancer guidelines and genome differences between Japan and the west. Future Oncology, 2013, 9, 1053-1056.	1.1	7
1181	Predictive Factors of Postoperative Mortality After Junctional and Gastric Adenocarcinoma Resection. JAMA Surgery, 2013, 148, 624.	2.2	33
1182	The identification of predictive factors for perioperative chemotherapy in esophago-gastric cancer. Annals of Oncology, 2013, 24, 1135-1138.	0.6	5
1183	Impact of pathologic complete response on disease-free survival in patients with esophagogastric adenocarcinoma receiving preoperative docetaxel-based chemotherapy. Annals of Oncology, 2013, 24, 2068-2073.	0.6	96
1184	The Role of Radiotherapy in the Multimodal Management of Esophageal Cancer. Digestive Diseases, 2013, 31, 30-37.	0.8	18
1185	Oncologic specimen from laparoscopic assisted gastrectomy for gastric adenocarcinoma is comparable to D1-open surgery: the experience of a Canadian centre. Canadian Journal of Surgery, 2013, 56, 249-255.	0.5	6
1186	Planning comparison between standard and conformal 3D techniques in post-operative radiotherapy of gastric cancer: a systematic review. British Journal of Radiology, 2013, 86, 20130274.	1.0	7
1187	Phase II study of patients with peritoneal carcinomatosis from gastric cancer treated with preoperative systemic chemotherapy followed by peritonectomy and intraperitoneal chemotherapy. Acta OncolÃ³gica, 2013, 52, 824-830.	0.8	27
1188	Gastric cancer and trastuzumab: first biologic therapy in gastric cancer. Therapeutic Advances in Medical Oncology, 2013, 5, 143-151.	1.4	68

#	Article	IF	Citations
1189	The Postoperative Component of MAGIC Chemotherapy Is Associated with Improved Prognosis following Surgical Resection in Gastric and Gastrooesophageal Junction Adenocarcinomas. International Journal of Surgical Oncology, 2013, 2013, 1-6.	0.3	26
1190	Tumor Regression Grading of Gastrointestinal Carcinomas after Neoadjuvant Treatment. Frontiers in Oncology, 2013, 3, 262.	1.3	105
1191	Molecular Targeted Agents for Gastric Cancer: A Step Forward Towards Personalized Therapy. Cancers, 2013, 5, 64-91.	1.7	45
1192	Prognostic Scoring System Predictive of Survival after Surgical Resection of Esophageal Carcinoma. Thoracic and Cardiovascular Surgeon, 2013, 61, 470-478.	0.4	2
1193	Hypoxia-regulated gene expression and prognosis in loco-regional gastroesophageal cancer. Acta OncolÃ³gica, 2013, 52, 1327-1335.	0.8	14
1194	Targeted therapy for gastric cancerâ€"current status. Journal of Oncology Pharmacy Practice, 2013, 19, 75-81.	0.5	8
1195	Palliative Treatment and the Role of Surgical Resection in Gastric Cancer. Digestive Surgery, 2013, 30, 174-180.	0.6	17
1196	(Neo)-Adjuvant Chemo(-Radio) Therapy for Adenocarcinomas of the Gastroesophageal Junction and the Stomach in the West. Digestive Surgery, 2013, 30, 112-118.	0.6	14
1197	Classification of Pathologic Response to Neoadjuvant Therapy in Esophageal and Junctional Cancer. Annals of Surgery, 2013, 258, 784-792.	2.1	76
1198	Prognostic and Putative Predictive Biomarkers of Gastric Cancer for Personalized Medicine. Diagnostic Molecular Pathology, 2013, 22, 127-137.	2.1	51
1199	The trifunctional antibody catumaxomab amplifies and shapes tumor-specific immunity when applied to gastric cancer patients in the adjuvant setting. Human Vaccines and Immunotherapeutics, 2013, 9, 2533-2542.	1.4	21
1200	Combined HER2 analysis of biopsies and surgical specimens to optimize detection of trastuzumab-eligible patients in eso-gastric adenocarcinoma: a GERCOR study. Annals of Oncology, 2013, 24, 3035-3039.	0.6	36
1201	Prognostic Role of Lemur Tyrosine Kinase-3 Germline Polymorphisms in Adjuvant Gastric Cancer in Japan and the United States. Molecular Cancer Therapeutics, 2013, 12, 2261-2272.	1.9	19
1202	No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy. Annals of Oncology, 2013, 24, 3056-3060.	0.6	126
1203	miR-106a confers cisplatin resistance by regulating PTEN/Akt pathway in gastric cancer cells. Acta Biochimica Et Biophysica Sinica, 2013, 45, 963-972.	0.9	59
1204	Adjuvant Treatment for Gastric Cancer: Chemotherapy Versus Radiation. Oncologist, 2013, 18, 1013-1021.	1.9	38
1205	Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Annals of Oncology, 2013, 24, 1754-1761.	0.6	72
1206	Advanced gastric cancer: is chemotherapy needed after surgery?. Expert Review of Gastroenterology and Hepatology, 2013, 7, 673-675.	1.4	4

#	Article	IF	Citations
1207	DNA Damage-Inducible Gene, Reprimo Functions as a Tumor Suppressor and Is Suppressed by Promoter Methylation in Gastric Cancer. Molecular Cancer Research, 2013, 11, 1362-1374.	1.5	40
1208	The New Era of Gastric Cancer in the East and West: Have Our Approaches Harmonized?. Digestive Surgery, 2013, 30, 130-131.	0.6	0
1209	Is Surgery in the Elderly for Oesophageal Cancer Justifiable? Results from a Single Centre. ISRN Surgery, 2013, 2013, 1-7.	1.4	6
1210	A Pilot Study to Investigate the Role of Thymidylate Synthase as a Marker of Prognosis for Neoadjuvant Chemotherapy in Gastric and Gastro-Oesophageal Junction Adenocarcinoma. Gastroenterology Research and Practice, 2013, 2013, 1-7.	0.7	5
1211	Increased Myeloid-Derived Suppressor Cells in Gastric Cancer Correlate with Cancer Stage and Plasma S100A8/A9 Proinflammatory Proteins. Journal of Immunology, 2013, 190, 794-804.	0.4	216
1212	Prospective clinical trial of diagnostic peritoneal lavage to detect positive peritoneal cytology in patients with gastric cancer. Journal of Surgical Oncology, 2013, 107, 794-798.	0.8	21
1213	Capecitabine in the treatment of esophageal and gastric cancers. Expert Opinion on Investigational Drugs, 2013, 22, 1645-1657.	1.9	10
1214	The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients. Journal of Cellular and Molecular Medicine, 2013, 17, 1415-1421.	1.6	76
1215	Overview of Adjuvant and Neoadjuvant Therapy for Resectable Gastric Cancer in the East. Digestive Surgery, 2013, 30, 119-129.	0.6	49
1216	Changes in treatment patterns and their influence on long-term survival in patients with stages I-III gastric cancer in The Netherlands. International Journal of Cancer, 2013, 133, 1859-1866.	2.3	42
1217	Registry of gastric cancer treatment evaluation (<scp>REGATE</scp>): <scp>II</scp> treatment practice. Asia-Pacific Journal of Clinical Oncology, 2013, 9, 373-380.	0.7	10
1218	Differential expression and prognostic value of ERCC1 and thymidylate synthase in resected gastric adenocarcinoma. Cancer, 2013, 119, 3242-3250.	2.0	19
1219	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma. Journal of Surgical Oncology, 2013, 107, 728-734.	0.8	30
1220	Prognostic Implications of the Seventh Edition of the International Union Against Cancer Classification for Patients With Gastric Cancer: The Western Experience of Patients Treated in a Single-Center European Institution. Journal of Clinical Oncology, 2013, 31, 263-271.	0.8	102
1221	Locally advanced gastric cancer: a new definition to standardise. Journal of Clinical Pathology, 2013, 66, 164-165.	1.0	13
1222	Adjuvant chemotherapy for gastric cancer: a randomised phase 3 trial of mitomycin-C plus either short-term doxifluridine or long-term doxifluridine plus cisplatin after curative D2 gastrectomy (AMC0201). British Journal of Cancer, 2013, 108, 1245-1251.	2.9	50
1223	ActualizaciÃ³n del diagnÃ³stico y tratamiento del cÃ¡ncer gÃ¡strico. Revista MÃ©dica ClÃ¬nica Las Condes, 2013, 24, 627-636.	0.2	1
1224	An individual coding polymorphism and the haplotype of the SPARC gene predict gastric cancer recurrence. Pharmacogenomics Journal, 2013, 13, 342-348.	0.9	6

#	Article	IF	Citations
1225	Association of Smoking History with Cancer Recurrence and Survival in Stage IIIâ€“IV Male Gastric Cancer Patients. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1805-1812.	1.1	20
1226	Somatic Mutations and Deletions of the E-Cadherin Gene Predict Poor Survival of Patients With Gastric Cancer. Journal of Clinical Oncology, 2013, 31, 868-875.	0.8	145
1227	Second Cancer Incidence, Risk Factor, and Specific Mortality in Head and Neck Squamous Cell Carcinoma. Otolaryngology - Head and Neck Surgery, 2013, 149, 579-586.	1.1	76
1228	Adenovirus-mediated ING4 expression reduces multidrug resistance of human gastric carcinoma cells in vitro and in vivo. Oncology Reports, 2013, 30, 2187-2194.	1.2	9
1229	Gastric cancer: past accomplishments, present approaches and future aspirations. Clinical Practice (London, England), 2013, 10, 47-77.	0.1	0
1230	A Phase II Study of Preoperative Chemotherapy With Modified FOLFOX6 Followed by Surgery and Postoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma. Oncology Research, 2013, 20, 327-332.	0.6	9
1231	Immunotherapy for Gastrointestinal Malignancies. Cancer Control, 2013, 20, 32-42.	0.7	36
1232	Radiation Therapy and Esophageal Cancer. Cancer Control, 2013, 20, 97-110.	0.7	80
1233	Treatment of Early-Stage Esophageal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 640-644.	2.3	1
1234	Neoadjuvant or Adjuvant Therapy for Resectable Esophageal Cancer: Is There a Standard of Care?. Cancer Control, 2013, 20, 89-96.	0.7	34
1236	Gastric Cancer, Version 2.2013. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 531-546.	2.3	422
1238	Chemotherapeutic and Targeted Strategies for Locally Advanced and Metastatic Esophageal Cancer. Journal of Thoracic Oncology, 2013, 8, 673-684.	0.5	21
1239	Postoperative Nodal Status and Diffuse-type Histology Are Independent Prognostic Factors in Resectable Advanced Gastric Carcinomas After Preoperative Chemotherapy. American Journal of Surgical Pathology, 2013, 37, 1022-1029.	2.1	28
1240	Sensitivity of gastric adenocarcinoma and normal cell lines against combined or conjugated antimetabolites. Anti-Cancer Drugs, 2013, 24, 375-383.	0.7	1
1241	Gene expression of bone morphogenic protein 8B in the primary site, peripheral blood and bone marrow of patients with gastric cancer. Oncology Letters, 2013, 6, 387-392.	0.8	17
1243	Oncogenic and Anti-Oncogenic Effects of Transient Receptor Potential Channels. Current Topics in Medicinal Chemistry, 2013, 13, 344-366.	1.0	33
1244	Pathologic and Oncologic Outcomes in Locally Advanced Gastric Cancer with Neoadjuvant Chemotherapy or Chemoradiotherapy. Yonsei Medical Journal, 2013, 54, 888.	0.9	21
1245	Locally Advanced Esophageal Cancer. , 0, , .		0

#	Article	IF	Citations
1246	Neoadjuvant Treatment for Gastric Cancer. Journal of Gastric Cancer, 2013, 13, 73.	0.9	18
1247	Radioquimioterapia neoadyuvante en cÃ¡ncer de uniÃ³n gastroesofÃ¡gica. Revista Chilena De Cirugia, 2013, 65, 192-194.	0.1	0
1248	Recurrence of esophageal cancer after R0 surgery: risk factors and evolution. Revista Espanola De Enfermedades Digestivas, 2013, 105, 318-325.	0.1	5
1249	The influence of advanced age on the morbi-mortality of gastric cancer after curative surgery. Revista Espanola De Enfermedades Digestivas, 2013, 105, 194-200.	0.1	2
1250	PERIOPERATIVE CHEMOTHERAPY IN LOCALLY ADVANCED GASTRIC CANCER. Arquivos De Gastroenterologia, 2013, 50, 236-242.	0.3	7
1252	Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus. World Journal of Gastroenterology, 2013, 19, 9282.	1.4	44
1253	Laparoscopic Gastrectomy for Gastric Cancer with Peritoneal Dissemination after Induction Chemotherapy. Case Reports in Gastroenterology, 2013, 7, 516-521.	0.3	2
1254	Noninvasive Visualization of MicroRNA-16 in the Chemoresistance of Gastric Cancer Using a Dual Reporter Gene Imaging System. PLoS ONE, 2013, 8, e61792.	1.1	32
1255	High Expression of Heat Shock Protein 90 Is Associated with Tumor Aggressiveness and Poor Prognosis in Patients with Advanced Gastric Cancer. PLoS ONE, 2013, 8, e62876.	1.1	70
1256	Intratumor Hypoxia Promotes Immune Tolerance by Inducing Regulatory T Cells via TGF-Î²1 in Gastric Cancer. PLoS ONE, 2013, 8, e63777.	1.1	101
1257	Validation of the Memorial Sloan-Kettering Cancer Center Nomogram to Predict Disease-Specific Survival after R0 Resection in a Chinese Gastric Cancer Population. PLoS ONE, 2013, 8, e76041.	1.1	16
1258	Incidence, Predictive Factors, and Clinical Outcomes of Acute Kidney Injury after Gastric Surgery for Gastric Cancer. PLoS ONE, 2013, 8, e82289.	1.1	55
1259	Gastric carcinoma: imaging diagnosis, staging and assessment of treatment response. Cancer Imaging, 2013, 13, 212-227.	1.2	116
1260	Upregulated expression of LOX is a novel independent prognostic marker of worse outcome in gastric cancer patients after curative surgery. Oncology Letters, 2013, 5, 896-902.	0.8	25
1261	Profiling the Prognosis of Gastric Cancer Patients: Is It Worth Correlating the Survival with the Clinical/Pathological and Molecular Features of Gastric Cancers?. Scientific World Journal, The, 2013, 2013, 1-9.	0.8	3
1262	New and emerging combination therapies for esophageal cancer. Cancer Management and Research, 2013, 5, 133.	0.9	28
1263	Chemotherapy for Advanced Gastric Cancer: Review and Update of Current Practices. Gut and Liver, 2013, 7, 385-395.	1.4	57
1264	Gastric Carcinoma: A Review on Epidemiology, Current Surgical and Chemotherapeutic Options. , 2013, , .		1

#	Article	IF	Citations
1265	Gastric Carcinoma: Morphologic Classifications and Molecular Changes. , 0, , .		1
1266	Strategies to reduce pulmonary complications after esophagectomy. World Journal of Gastroenterology, 2013, 19, 6509.	1.4	49
1267	Unanswered Questions in the Management of Gastroesophageal Junction Adenocarcinoma: An Overview from the Medical Oncologist's Perspective. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, , e155-e159.	1.8	0
1268	Quadricuspid aortic valve with aortic regurgitation: a rare echocardiographic finding. BMJ Case Reports, 2013, 2013, bcr2012006639-bcr2012006639.	0.2	2
1269	New possibilities for the treatment of gastric cancer. Studia Medyczne, 2013, 4, 343-348.	0.0	2
1270	Clinical Practice Guidelines for Gastric Cancer in Korea: An Evidence-Based Approach. Journal of Gastric Cancer, 2014, 14, 87.	0.9	163
1272	Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Gastric Carcinoma: Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS ONE, 2014, 9, e86941.	1.1	68
1273	Computed Tomography (CT) Perfusion as an Early Predictive Marker for Treatment Response to Neoadjuvant Chemotherapy in Gastroesophageal Junction Cancer and Gastric Cancer - A Prospective Study. PLoS ONE, 2014, 9, e97605.	1.1	38
1274	Surgical Outcomes and Prognostic Factors of T4 Gastric Cancer Patients without Distant Metastasis. PLoS ONE, 2014, 9, e107061.	1.1	16
1275	Ask ACCC's Community Resource Centers: Gastric Cancer. Oncology Issues, 2014, 29, 58-59.	0.0	0
1276	Navigating the GE Junction. Oncology Issues, 2014, 29, 54-60.	0.0	0
1277	Usefulness of Combined PET/CT to Assess Regional Lymph Node Involvement in Gastric Cancer. Tumori, 2014, 100, 201-206.	0.6	27
1278	Neoadjuvant Chemotherapy with FOLFOX4 Regimen to Treat Advanced Gastric Cancer Improves Survival without Increasing Adverse Events: A Retrospective Cohort Study from a Chinese Center. Scientific World Journal, The, 2014, 2014, 1-10.	0.8	12
1279	Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma. World Journal of Gastroenterology, 2014, 20, 264.	1.4	3
1280	Inactivation of Akt by arsenic trioxide induces cell death via mitochondrial-mediated apoptotic signaling in SGC-7901 human gastric cancer cells. Oncology Reports, 2014, 31, 1645-1652.	1.2	19
1281	Adjuvant therapy for gastric cancer: Current and future directions. World Journal of Gastroenterology, 2014, 20, 13718.	1.4	38
1282	Treatment of gastric cancer. World Journal of Gastroenterology, 2014, 20, 1635.	1.4	508
1283	Annexin A2 is implicated in multi-drug-resistance in gastric cancer through p38MAPK and AKT pathway. Neoplasma, 2014, 61, 627-637.	0.7	30

#	Article	IF	Citations
1284	Impact of Annexin A3 expression in gastric cancer cells. Neoplasma, 2014, 61, 257-264.	0.7	20
1285	A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy. Oncology Letters, 2014, 8, 1844-1848.	0.8	3
1286	Can Perioperative Chemotherapy for Advanced Gastric Cancer Be Recommended on the Basis of Current Research? A Critical Analysis. Journal of Gastric Cancer, 2014, 14, 39.	0.9	12
1287	Esophageal Cancer: Treatmentâ˜†. , 2014, , .		1
1288	Neoadjuvant therapy for esophageal cancer. World Journal of Gastrointestinal Oncology, 2014, 6, 403.	0.8	22
1289	New Directions in Perioperative Management of Locally Advanced Esophagogastric Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2014, , e172-e178.	1.8	6
1290	BAX and CDKN1A polymorphisms correlated with clinical outcomes of gastric cancer patients treated with postoperative chemotherapy. Medical Oncology, 2014, 31, 249.	1.2	13
1291	Multimodality Management of Esophageal Cancer. Indian Journal of Surgery, 2014, 76, 494-503.	0.2	5
1292	How Prognostic and Predictive Biomarkers Are Transforming Our Understanding and Management of Advanced Gastric Cancer. Oncologist, 2014, 19, 1046-1055.	1.9	20
1293	Cost-effectiveness analysis of adjuvant chemotherapies in patients presenting with gastric cancer after D2 gastrectomy. BMC Cancer, 2014, 14, 984.	1.1	50
1294	Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study. Cancer Chemotherapy and Pharmacology, 2014, 74, 1139-1147.	1.1	10
1295	Downregulation of Runx3 is closely related to the decreased Th1-associated factors in patients with gastric carcinoma. Tumor Biology, 2014, 35, 12235-12244.	0.8	4
1297	Benchmarking of gastric cancer sensitivity to anti-cancer drugs ex vivo as a basis for drug selection in systemic and intraperitoneal therapy. Journal of Experimental and Clinical Cancer Research, 2014, 33, 110.	3.5	23
1298	ALDH1A1 overexpression is associated with the progression and prognosis in gastric cancer. BMC Cancer, 2014, 14, 705.	1.1	65
1300	A phase II study of catumaxomab administered intra- and postoperatively as part of a multimodal approach in primarily resectable gastric cancer. Gastric Cancer, 2015, 18, 833-42.	2.7	16
1302	SATB1 is an independent prognostic factor in radically resected upper gastrointestinal tract adenocarcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 465, 649-659.	1.4	26
1303	Prognostic value of histopathological regression in 850 neoadjuvantly treated oesophagogastric adenocarcinomas. British Journal of Cancer, 2014, 110, 1712-1720.	2.9	94
1304	Impact of neoadjuvant chemotherapy on lymphocytes and co-inhibitory B7-H4 molecule in gastric cancer: low B7-H4 expression associates with favorable prognosis. Tumor Biology, 2014, 35, 11837-11843.	0.8	27

#	Article	IF	Citations
1305	Tumour expression of leptin is associated with chemotherapy resistance and therapy-independent prognosis in gastro-oesophageal adenocarcinomas. British Journal of Cancer, 2014, 110, 1525-1534.	2.9	56
1306	Chemoradiation Therapy versus Chemotherapy Alone for Gastric Cancer after R0 Surgical Resection: A Meta-Analysis of Randomized Trials. Oncology, 2014, 86, 79-85.	0.9	28
1307	Controversies in management of gastric cancer. Current Medicine Research and Practice, 2014, 4, 263-273.	0.1	0
1308	Reevaluating Significance of Perineural Invasion in Gastric Cancer Based on Double Immunohistochemical Staining. Archives of Pathology and Laboratory Medicine, 2014, 138, 229-234.	1.2	26
1309	Proton therapy in adjuvant treatment of gastric cancer: Planning comparison with advanced x-ray therapy and feasibility report. Acta OncolÃ³gica, 2014, 53, 1312-1320.	0.8	16
1310	Indian Council of Medical Research consensus document for the management of gastric cancer. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 239-243.	0.1	11
1311	Anti-angiogenic therapies for advanced esophago-gastric cancer. Indian Journal of Medical and Paediatric Oncology, 2014, 35, 253-262.	0.1	12
1312	Neoadjuvant chemoradiation versus perioperative chemotherapy followed by surgery in resectable adenocarcinomas of the esophagogastric junction: A retrospective single center analysis. Oncology Letters, 2014, 7, 534-540.	0.8	5
1313	Pathological Complete Response and Long-Term Survival in a Very Elderly Patient after Neoadjuvant Chemotherapy for Locally Advanced, Unresectable Gastric Cancer. Case Reports in Oncological Medicine, 2014, 2014, 1-5.	0.2	2
1314	Reply to E.C. Smyth et al. Journal of Clinical Oncology, 2014, 32, 3082-3082.	0.8	1
1315	Characteristics, therapy and outcome in an unselected and prospectively registered cohort of patients with gastro-oesophageal cancer. Acta OncolÃ³gica, 2014, 53, 385-391.	0.8	6
1316	Chemotherapy as palliative treatment for peritoneal carcinomatosis of gastric origin. Acta OncolÃ³gica, 2014, 53, 429-432.	0.8	23
1317	FOLFOX versus EOX as a neoadjuvant chemotherapy regimen for patients with advanced gastric cancer. Experimental and Therapeutic Medicine, 2014, 7, 461-467.	0.8	16
1318	Perioperative Chemotherapy for Gastroesophageal Cancer in British Columbia: A Multicentre Experience. Current Oncology, 2014, 21, 77-83.	0.9	2
1319	Synergistic antitumor effects of combined deguelin and cisplatin treatment in gastric cancer cells. Oncology Letters, 2014, 8, 1603-1607.	0.8	18
1321	Growth and Chemosensitivity of Gastric Adenocarcinoma and Non-Malignant Cell Lines in Response to Novel Anti-Cancer Drug Combinations. Chemotherapy, 2014, 60, 346-352.	0.8	2
1322	Processes of Care in the Multidisciplinary Treatment of Gastric Cancer. JAMA Surgery, 2014, 149, 18.	2.2	36
1325	HER2/neu Testing in Gastric Cancer by Immunohistochemistry: Assessment of Interlaboratory Variation. Archives of Pathology and Laboratory Medicine, 2014, 138, 1495-1502.	1.2	31

#	Article	IF	Citations
1326	Strategies to improve outcomes in esophageal adenocarcinoma. Expert Review of Anticancer Therapy, 2014, 14, 677-687.	1.1	22
1328	Response to chemotherapy in gastric adenocarcinoma with diffusionâ€weighted MRI and ¹⁸Fâ€FDGâ€PET/CT: Correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. Journal of Magnetic Resonance Imaging, 2014, 40, 1147-1157.	1.9	49
1329	CÃ¡ncer gÃ¡strico. Revista MÃ©dica ClÃnica Las Condes, 2014, 25, 106-113.	0.2	0
1330	Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5-fluorouracil and folinic acid for radically resected gastric cancer. Annals of Oncology, 2014, 25, 1373-1378.	0.6	84
1331	Significant involvement of herpesvirus entry mediator in human esophageal squamous cell carcinoma. Cancer, 2014, 120, 808-817.	2.0	37
1332	HER2 in resected gastric cancer: Is there prognostic value?. Journal of Surgical Oncology, 2014, 109, 61-66.	0.8	30
1333	The relevance of the Siewert classification in the era of multimodal therapy for adenocarcinoma of the gastroâ€oesophageal junction. Journal of Surgical Oncology, 2014, 109, 202-207.	0.8	42
1334	Factors influencing response enthusiasm to telephone follow-up in patients with oesophageal carcinoma after oesophagectomy. European Journal of Cancer Care, 2014, 23, 310-316.	0.7	4
1335	Impact of perioperative chemotherapy on oncological outcomes after gastric cancer surgery. British Journal of Surgery, 2014, 101, 1712-1720.	0.1	28
1336	Postoperative chemoâ€radiotherapy versus chemotherapy for resected gastric cancer: A systematic review and metaâ€analysis. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 483-496.	0.9	20
1337	Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. British Journal of Surgery, 2014, 101, 653-660.	0.1	267
1338	Impact of overexpression of Sushi repeatâ€containing protein Xâ€linked 2 gene on outcomes of gastric cancer. Journal of Surgical Oncology, 2014, 109, 836-840.	0.8	17
1339	Trends in the use of evidenceâ€based therapy for resectable gastric cancer. Journal of Surgical Oncology, 2014, 110, 285-290.	0.8	28
1341	Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma. Ecological Management and Restoration, 2014, 27, 380-387.	0.2	41
1342	Surgical resection strategy and the influence of radicality on outcomes in oesophageal cancer. British Journal of Surgery, 2014, 101, 511-517.	0.1	56
1343	Adjuvant therapy for gastric cancer; more questions than answers. Journal of Medical Imaging and Radiation Oncology, 2014, 58, 481-482.	0.9	0
1344	Outcomes in the management of esophageal cancer. Journal of Surgical Oncology, 2014, 110, 599-610.	0.8	68
1345	Implications of inadequate lymph node staging in resectable gastric cancer: A contemporary analysis using the <scp>N</scp>ational <scp>C</scp>ancer <scp>D</scp>ata <scp>B</scp>ase. Cancer, 2014, 120, 2855-2865.	2.0	54

#	Article	IF	Citations
1346	Factors associated with early recurrence and death after esophagectomy for cancer. Journal of Surgical Oncology, 2014, 109, 459-464.	0.8	54
1347	Esophageal Carcinoma. New England Journal of Medicine, 2014, 371, 2499-2509.	13.9	1,051
1348	Clinical audit of gastrectomy for gastric adenocarcinoma: Results of a single institution. Surgical Practice, 2014, 18, 128-135.	0.1	0
1349	Potential Role of Positron Emission Tomography/Magnetic Resonance Imaging in Gastrointestinal and Abdominal Malignancies: Preliminary Experience. Seminars in Roentgenology, 2014, 49, 321-333.	0.2	3
1350	Effect of neoadjuvant chemotherapy on postoperative morbidity and mortality in patients with locally advanced gastric cancer. British Journal of Surgery, 2014, 101, 1560-1565.	0.1	32
1351	Feasibility of Minimally Invasive Esophagectomy After Neoadjuvant Chemoradiation. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2014, 24, 688-692.	0.5	9
1352	Results of the FFCD 9901 Trial in Early-Stage Esophageal Carcinoma: Is It Really About Neoadjuvant Therapy?. Journal of Clinical Oncology, 2014, 32, 2398-2400.	0.8	13
1353	The Current Evidence in Support of Multimodal Treatment of Locally Advanced, Potentially Resectable Esophageal Cancer. Digestive Diseases, 2014, 32, 171-175.	0.8	21
1354	The Role of Radiation Therapy for Resectable Adenocarcinoma of the Gastroesophageal Junction. Oncologist, 2014, 19, 431-431.	1.9	1
1355	TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome. Clinical Cancer Research, 2014, 20, 4689-4704.	3.2	35
1357	GASTRICHIP: D2 resection and hyperthermic intraperitoneal chemotherapy in locally advanced gastric carcinoma: a randomized and multicenter phase III study. BMC Cancer, 2014, 14, 183.	1.1	163
1358	Imagine a world without cancer. BMC Cancer, 2014, 14, 186.	1.1	12
1359	Comparison between better and poorly differentiated locally advanced gastric cancer in preoperative chemotherapy: a retrospective, comparative study at a single tertiary care institute. World Journal of Surgical Oncology, 2014, 12, 280.	0.8	16
1360	Investigational therapies targeting the ErbB family in oesophagogastric cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1349-1363.	1.9	3
1361	Prognostic Classification of Histopathologic Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma. Annals of Surgery, 2014, 260, 779-785.	2.1	57
1362	Total Gastrectomy Risk Model. Annals of Surgery, 2014, 260, 1034-1039.	2.1	167
1363	Single nucleotide polymorphisms in AREG and EREG are prognostic biomarkers in locally advanced gastric cancer patients after surgery with curative intent. Pharmacogenetics and Genomics, 2014, 24, 539-547.	0.7	4
1364	New-onset Atrial Fibrillation Post-surgery for Esophageal and Junctional Cancer. Annals of Surgery, 2014, 260, 772-778.	2.1	68

#	Article	IF	Citations
1365	A Phase II Trial of Induction Epirubicin, Oxaliplatin, and Fluorouracil, Followed by Surgery and Postoperative Concurrent Cisplatin and Fluorouracil Chemoradiotherapy in Patients with Locoregionally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction. Journal of Thoracic Oncology, 2014, 9, 1561-1567.	0.5	7
1366	Gastrointestinal Cancer. Cancer Journal (Sudbury, Mass), 2014, 20, 378-386.	1.0	7
1367	Management of gastric cancer. Current Opinion in Gastroenterology, 2014, 30, 596-602.	1.0	19
1368	Minimally Invasive Management of Postoperative Esophagojejunal Anastomotic Leak. Surgical Laparoscopy, Endoscopy and Percutaneous Techniques, 2014, 24, 183-186.	0.4	3
1369	Management of Localized Esophageal Cancer in the Older Patient. Oncologist, 2014, 19, 367-374.	1.9	42
1370	Evaluation of Quality of Life Following Placement of Self-Expanding Plastic Stents as a Bridge to Surgery in Patients Receiving Neoadjuvant Therapy for Esophageal Cancer. Oncologist, 2014, 19, 259-265.	1.9	31
1371	LASP-1 promotes tumor proliferation and metastasis and is an independent unfavorable prognostic factor in gastric cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1891-1899.	1.2	32
1372	Leitsymptom. , 2014, , 67-100.		0
1374	Case Studies of Postoperative Complications after Digestive Surgery. , 2014, , .		0
1375	In Reply. Oncologist, 2014, 19, 431-431.	1.9	4
1376	Dynamic Reprogramming of Signaling Upon Met Inhibition Reveals a Mechanism of Drug Resistance in Gastric Cancer. Science Signaling, 2014, 7, ra38.	1.6	40
1377	Importance of HER2 Work-Up and Treatment Even in Patients with Poor Performance Status: A Case Report. Case Reports in Oncological Medicine, 2014, 2014, 1-4.	0.2	0
1378	Polarization of ILC2s in Peripheral Blood Might Contribute to Immunosuppressive Microenvironment in Patients with Gastric Cancer. Journal of Immunology Research, 2014, 2014, 1-10.	0.9	102
1379	Dose-finding study on adjuvant chemotherapy with S-1 plus oxaliplatin for gastric cancer. Molecular and Clinical Oncology, 2014, 2, 93-98.	0.4	6
1380	Epirubicin, oxaliplatin, and capectabine is just as "MAGIC"al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy for resectable locally advanced gastro-oesophageal cancer. Journal of Cancer Research and Therapeutics, 2014, 10, 866.	0.3	18
1381	Targeting HER2 amplifications in gastric cancer. Gastrointestinal Cancer: Targets and Therapy, 2014, , 11.	5.5	1
1382	Synthesis, identification and in vivo studies of tumor-targeting agent peptide doxorubicin (PDOX) to treat peritoneal carcinomatosis of gastric cancer with similar efficacy but reduced toxicity. Molecular Cancer, 2014, 13, 44.	7.9	11
1383	Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction. Journal of Clinical Oncology, 2014, 32, 2983-2990.	0.8	213

#	Article	IF	Citations
1384	Physical Activity Is Associated with Reduced Risk of Gastric Cancer: A Systematic Review and Meta-analysis. Cancer Prevention Research, 2014, 7, 12-22.	0.7	39
1385	Low-dose, short-interval target vessel regional chemotherapy through the hepatic artery combined with transarterial embolization in gastric cancer patients with liver metastases after failure of first-line or second-line chemotherapy. Anti-Cancer Drugs, 2014, 25, 92-100.	0.7	6
1386	Assessment of Tumor Regression of Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. American Journal of Surgical Pathology, 2014, 38, 1551-1556.	2.1	52
1387	Optimal Management of Gastric Cancer. Annals of Surgery, 2014, 259, 102-108.	2.1	48
1388	P3 Surgical management of gastric cancer: single centre experience from a developing country. European Journal of Cancer, 2014, 50, S9-S10.	1.3	0
1389	Feasibility of preoperative and postoperative chemoradiotherapy in gastric adenocarcinoma. Two phase II studies done in parallel. FÃ©dÃ©ration Francophone de CancÃ©rologie Digestive 0308. European Journal of Cancer, 2014, 50, 1076-1083.	1.3	9
1390	The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery. European Journal of Surgical Oncology, 2014, 40, 1313-1320.	0.5	135
1391	Gastric cancerâ€: ESMOâ€“ESSOâ€“ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Radiotherapy and Oncology, 2014, 110, 189-194.	0.3	27
1392	Neoadjuvant chemotherapy for gastric cancer in Japan: a standing position by comparing with adjuvant chemotherapy. Surgery Today, 2014, 44, 11-21.	0.7	59
1393	Lymph node ratio is a critical prognostic predictor in gastric cancer treated with S-1 chemotherapy. Gastric Cancer, 2014, 17, 67-75.	2.7	31
1394	Induction of a Pathological Complete Response by Four Courses of Neoadjuvant Chemotherapy for Gastric Cancer: Early Results of the Randomized Phase II COMPASS Trial. Annals of Surgical Oncology, 2014, 21, 213-219.	0.7	64
1395	Phase I trials in patients with relapsed, advanced upper gastrointestinal carcinomas: experience in a specialist unit. Gastric Cancer, 2014, 17, 621-629.	2.7	7
1397	A novel oncolytic viral therapy and imaging technique for gastric cancer using a genetically engineered vaccinia virus carrying the human sodium iodide symporter. Journal of Experimental and Clinical Cancer Research, 2014, 33, 2.	3.5	32
1398	Duodenal stump fistula after gastric surgery for malignancies: a retrospective analysis of risk factors in a single centre experience. Gastric Cancer, 2014, 17, 733-744.	2.7	46
1399	Neoadjuvant Chemotherapy for Gastric Cancer: What are we Trying to Accomplish?. Annals of Surgical Oncology, 2014, 21, 13-15.	0.7	17
1400	Treatment results of curative gastric resection from a specialist Australian unit: low volume with satisfactory outcomes. Gastric Cancer, 2014, 17, 152-160.	2.7	12
1401	Evaluation of HER2-based biology in 1,006 cases of gastric cancer in a Japanese population. Gastric Cancer, 2014, 17, 34-42.	2.7	54
1402	Perioperative epidural analgesia reduces cancer recurrence after gastroâ€oesophageal surgery. Acta Anaesthesiologica Scandinavica, 2014, 58, 281-290.	0.7	55

#	Article	IF	Citations
1403	Quality of life in patients with advanced gastric cancer sequentially treated with docetaxel and irinotecan with 5-fluorouracil and folinic acid (leucovin). Medical Oncology, 2014, 31, 906.	1.2	8
1404	cDNA-Microarray Analysis as a New Tool to Predict Lymph Node Metastasis in Gastric Cancer. World Journal of Surgery, 2014, 38, 2058-2064.	0.8	10
1405	Decision Tools for Radiation Oncology. Medical Radiology, 2014, , .	0.0	2
1406	A Comparison of Five Competing Lymph Node Staging Schemes in a Cohort of Resectable Gastric Cancer Patients. Annals of Surgical Oncology, 2014, 21, 875-882.	0.7	45
1407	Gastrectomy in Advanced Gastric Cancer Effectively Palliates Symptoms and May Improve Survival in Select Patients. Journal of Gastrointestinal Surgery, 2014, 18, 491-496.	0.9	13
1408	A Multifactorial Histopathologic Score for the Prediction of Prognosis of Resected Esophageal Adenocarcinomas After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2014, 21, 915-921.	0.7	28
1409	Determinants of Response to Neoadjuvant Chemotherapy for Esophageal Cancer Using 18F-fluorodeoxiglucose Positron Emission Tomography (18F-FDG-PET). Annals of Surgical Oncology, 2014, 21, 575-582.	0.7	36
1410	Proximal Anastomosis Using the OrVilâ„¢ Circular Stapler in Major Upper Gastrointestinal Surgery. Journal of Gastrointestinal Surgery, 2014, 18, 1345-1349.	0.9	8
1411	A retrospective comparative exploratory study on two Methylentetrahydrofolate Reductase (MTHFR) polymorphisms in esophagogastric cancer: the A1298C MTHFR polymorphism is an independent prognostic factor only in neoadjuvantly treated gastric cancer patients. BMC Cancer, 2014, 14, 58.	1.1	17
1412	miR-449a Regulates Proliferation and Chemosensitivity to Cisplatin by Targeting Cyclin D1 and BCL2 in SGC7901 Cells. Digestive Diseases and Sciences, 2014, 59, 336-345.	1.1	59
1413	MicroRNA-362 induces cell proliferation and apoptosis resistance in gastric cancer by activation of NF-Îºß signaling. Journal of Translational Medicine, 2014, 12, 33.	1.8	96
1414	Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma. BMC Surgery, 2014, 14, 5.	0.6	8
1415	Time to Adjuvant Therapy and Other Variables in Localized Gastric and Gastroesophageal Junction (GEJ) Cancer (IJGC-D-13-00162). Journal of Gastrointestinal Cancer, 2014, 45, 284-290.	0.6	12
1416	Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. Radiation Oncology, 2014, 9, 9.	1.2	13
1417	Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer. Cancer Chemotherapy and Pharmacology, 2014, 73, 281-285.	1.1	19
1420	Re-organisation of oesophago-gastric cancer services in England and Wales: a follow-up assessment of progress and remaining challenges. BMC Research Notes, 2014, 7, 24.	0.6	13
1421	Three-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy. Gastric Cancer, 2014, 17, 348-353.	2.7	28
1422	Safety and efficacy of nimotuzumab in combination with radiotherapy for patients with squamous cell carcinoma of the esophagus. International Journal of Clinical Oncology, 2014, 19, 297-302.	1.0	27

#	Article	IF	Citations
1423	Targeted therapies in gastroesophageal cancer. European Journal of Cancer, 2014, 50, 1247-1258.	1.3	45
1424	Worldwide trends in gastric cancer mortality (1980â€“2011), with predictions to 2015, and incidence by subtype. European Journal of Cancer, 2014, 50, 1330-1344.	1.3	556
1425	Is postoperative adjuvant chemoradiotherapy efficacious and safe for gastric cancer patients with D2 lymphadenectomy? A meta-analysis of the literature. European Journal of Surgical Oncology, 2014, 40, 1614-1621.	0.5	16
1426	Apoptosis and KI 67 index correlate with preoperative chemotherapy efficacy and better predict the survival of gastric cancer patients with combined therapy. Cancer Chemotherapy and Pharmacology, 2014, 73, 885-893.	1.1	15
1427	MicroRNA expression profile of gastric cancer stem cells in the MKN-45 cancer cell line. Acta Biochimica Et Biophysica Sinica, 2014, 46, 92-99.	0.9	33
1428	Unmet needs and challenges in gastric cancer: The way forward. Cancer Treatment Reviews, 2014, 40, 692-700.	3.4	156
1429	Trends in the Surgical Treatment of Gastric Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 569-574.	0.7	20
1430	Genetic variants in fas signaling pathway genes and risk of gastric cancer. International Journal of Cancer, 2014, 134, 822-831.	2.3	26
1431	Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer, 2014, 17, 206-212.	2.7	100
1432	HER2-positive gastric cancer. Gastric Cancer, 2014, 17, 1-12.	2.7	272
1433	Adjuvant treatments for gastric cancer: From practice guidelines to clinical practice. Digestive and Liver Disease, 2014, 46, 72-75.	0.4	10
1434	Is Preoperative Chemotherapy Followed by Surgery the Appropriate Treatment for Signet Ring Cell Containing Adenocarcinomas of the Esophagogastric Junction and Stomach?. Annals of Surgical Oncology, 2014, 21, 1739-1748.	0.7	86
1435	Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Chemotherapy and Pharmacology, 2014, 73, 139-149.	1.1	25
1438	Case on Esophagojejunostomy Leakage Following Extended Total Gastrectomy. , 2014, , 65-71.		0
1439	Making the case for costâ€effectiveness research. Journal of Surgical Oncology, 2014, 109, 509-515.	0.8	12
1440	Signet ring cell adenocarcinomas: Different clinicalâ€“pathological characteristics of oesophageal and gastric locations. European Journal of Surgical Oncology, 2014, 40, 1746-1755.	0.5	25
1441	IMRT limits nephrotoxicity after chemoradiotherapy for gastric cancer. Radiotherapy and Oncology, 2014, 112, 289-294.	0.3	34
1442	CT volumetry for gastric carcinoma: association with TNM stage. European Radiology, 2014, 24, 3105-3114.	2.3	22

#	Article	IF	Citations
1443	Meta-analysis of postoperative morbidity and perioperative mortality in patients receiving neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal and gastro-oesophageal junctional cancers. British Journal of Surgery, 2014, 101, 321-338.	0.1	189
1444	Multimodal treatment of locally advanced esophageal adenocarcinoma: Which regimen should we choose? Outcome analysis of perioperative chemotherapy versus neoadjuvant chemoradiation in 105 patients. Journal of Surgical Oncology, 2014, 109, 287-293.	0.8	29
1445	Endoscopic ultrasound in restaging and predicting pathological response for advanced gastric cancer patients after neoadjuvant chemotherapy. Asia-Pacific Journal of Clinical Oncology, 2014, 10, e28-e32.	0.7	19
1446	Oesophageal cancer. Surgery, 2014, 32, 588-593.	0.1	0
1447	CD44v8-10 Is a Cancer-Specific Marker for Gastric Cancer Stem Cells. Cancer Research, 2014, 74, 2630-2641.	0.4	176
1448	Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer â€“ A propensity score matched analysis. European Journal of Cancer, 2014, 50, 2950-2957.	1.3	34
1449	Improving prognosis after surgery for gastric cancer. Lancet Oncology, The, 2014, 15, 1290-1292.	5.1	8
1450	Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncology, The, 2014, 15, 1389-1396.	5.1	849
1451	Outcome Reporting in Neoadjuvant Surgical Trials: A Systematic Review of the Literature and Proposals for New Standards. Journal of the National Cancer Institute, 2014, 106, dju217-dju217.	3.0	9
1452	miR-133 is a key negative regulator of CDC42â€“PAK pathway in gastric cancer. Cellular Signalling, 2014, 26, 2667-2673.	1.7	49
1453	Impact of response evaluation for resectable esophageal adenocarcinoma â€“ A retrospective cohort study. International Journal of Surgery, 2014, 12, 1025-1030.	1.1	5
1454	Does adjuvant radiotherapy benefit patients with diffuseâ€type gastric cancer? Results from the Surveillance, Epidemiology, and End Results database. Cancer, 2014, 120, 3562-3568.	2.0	24
1455	Development and Validation of a Symptom Scale to Evaluate Postoperative Patients with Esophagogastric Cancer. Journal of the American College of Surgeons, 2014, 219, 895-903.	0.2	21
1456	Stomach Cancer in Niger: First Results from the Niger Cancer Registry. Annals of Oncology, 2014, 25, ii35.	0.6	0
1457	Progress Against GI Cancer During the American Society of Clinical Oncology's First 50 Years. Journal of Clinical Oncology, 2014, 32, 1521-1530.	0.8	36
1458	Adjuvant treatment for gastric cancer: too much is not enough. Lancet Oncology, The, 2014, 15, 788-789.	5.1	9
1459	Sequential paclitaxel followed by tegafur and uracil (UFT) or S-1 versus UFT or S-1 monotherapy as adjuvant chemotherapy for T4a/b gastric cancer (SAMIT): a phase 3 factorial randomised controlled trial. Lancet Oncology, The, 2014, 15, 886-893.	5.1	104
1460	Difficult Decisions in Thoracic Surgery. Difficult Decisions in Surgery: an Evidence-based Approach, 2014, , .	0.0	3

#	Article	IF	Citations
1461	The Role of Radiotherapy in the Management of Upper Gastrointestinal and Hepato-biliary and Pancreatic Cancers: Current Status and Future Directions. Clinical Oncology, 2014, 26, 519-521.	0.6	1
1462	Role of (Chemo)-Radiotherapy in Resectable Gastric Cancer. Clinical Oncology, 2014, 26, 541-550.	0.6	12
1463	Esophageal Diseases. , 2014, , .		0
1464	Gastric tumours. Surgery, 2014, 32, 608-613.	0.1	0
1465	Perioperative therapy for esophageal cancer. General Thoracic and Cardiovascular Surgery, 2014, 62, 531-540.	0.4	12
1466	High pathologic complete remission rate from induction docetaxel, platinum and fluorouracil (DCF) combination chemotherapy for locally advanced esophageal and junctional cancer. Medical Oncology, 2014, 31, 188.	1.2	11
1467	Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer. World Journal of Surgical Oncology, 2014, 12, 188.	0.8	30
1468	Trends in clinical features, postoperative outcomes, and long-term survival for gastric cancer: a Western experience with 1,278 patients over 30Âyears. World Journal of Surgical Oncology, 2014, 12, 217.	0.8	27
1469	Metastatic tumor evolution and organoid modeling implicate TGFBR2as a cancer driver in diffuse gastric cancer. Genome Biology, 2014, 15, 428.	3.8	110
1470	Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901. Journal of Clinical Oncology, 2014, 32, 2416-2422.	0.8	505
1471	Defining the Role of Laparoscopic Gastrectomy for Gastric Cancer. Journal of Clinical Oncology, 2014, 32, 613-614.	0.8	14
1472	Double-blind, placebo-controlled, randomized phase II study of TJ-14 (hangeshashinto) for gastric cancer chemotherapy-induced oral mucositis. Cancer Chemotherapy and Pharmacology, 2014, 73, 1047-1054.	1.1	37
1473	A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemotherapy and Pharmacology, 2014, 73, 1155-1161.	1.1	61
1474	Phase II multicentre study of efficacy and feasibility of dose-intensified preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) in resectable gastroesophageal cancer. Cancer Chemotherapy and Pharmacology, 2014, 74, 141-150.	1.1	8
1475	Secondary gastrectomy for stage IV gastroesophageal adenocarcinoma after induction-chemotherapy. Langenbeck's Archives of Surgery, 2014, 399, 773-781.	0.8	4
1476	A GG allele of 3â€²-side AKT1 SNP is associated with decreased AKT1 activation and better prognosis of gastric cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1399-1411.	1.2	20
1477	Heat shock protein 22 overexpression is associated with the progression and prognosis in gastric cancer. Journal of Cancer Research and Clinical Oncology, 2014, 140, 1305-1313.	1.2	25
1478	Interim endoscopy results during neoadjuvant therapy for gastric cancer correlate with histopathological response and prognosis. Gastric Cancer, 2014, 17, 478-488.	2.7	20

#	Article	IF	Citations
1479	The Prognostic Significance of an R1 Resection in Gastric Cancer Patients Treated with Adjuvant Chemoradiotherapy. Annals of Surgical Oncology, 2014, 21, 1107-1114.	0.7	41
1480	Phase II Study of Docetaxel and S-1 (DS) as Neoadjuvant Chemotherapy for Clinical Stage III Resectable Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 2340-2346.	0.7	35
1481	Morbidity and Mortality Associated with Gastrectomy for Gastric Cancer. Annals of Surgical Oncology, 2014, 21, 3008-3014.	0.7	191
1482	Diagnostic Accuracy and Utility of Intraoperative Microscopic Margin Analysis of Gastric and Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2014, 21, 2580-2586.	0.7	42
1483	Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2014, 21, 3015-3022.	0.7	3
1484	Impact of External-Beam Radiation Therapy on Outcomes Among Patients with Resected Gastric Cancer: A Multi-institutional Analysis. Annals of Surgical Oncology, 2014, 21, 3412-3421.	0.7	20
1485	Adjuvant Therapy for Gastric Cancers: More Answers or More Questions?. Annals of Surgical Oncology, 2014, 21, 3367-3368.	0.7	1
1486	A Multi-institutional Analysis of Open Versus Minimally-Invasive Surgery for Gastric Adenocarcinoma: Results of the US Gastric Cancer Collaborative. Journal of Gastrointestinal Surgery, 2014, 18, 1563-1574.	0.9	17
1487	Patterns of Surveillance Following Curative Intent Therapy for Gastroesophageal Cancer. Journal of Gastrointestinal Cancer, 2014, 45, 325-333.	0.6	19
1488	The prognostic value of ERCC1 expression in gastric cancer patients treated with platinum-based chemotherapy: a meta-analysis. Tumor Biology, 2014, 35, 8721-8731.	0.8	11
1489	Systemic Chemotherapy for Resectable Hepatic Colorectal Metastases: Adjuvant, Neoadjuvant, or Not at All?. Current Surgery Reports, 2014, 2, 1.	0.4	1
1490	Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab. BMC Cancer, 2014, 14, 148.	1.1	42
1491	Long term follow up and retrospective study on 533 gastric cancer cases. BMC Surgery, 2014, 14, 29.	0.6	17
1492	The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer. Radiation Oncology, 2014, 9, 81.	1.2	14
1493	An Updated Meta-Analysis of Randomized Controlled Trial Assessing the Effect of Neoadjuvant Chemotherapy in Advanced Gastric Cancer. Cancer Investigation, 2014, 32, 272-284.	0.6	65
1494	Rates and Patterns of Recurrence after Curative Intent Resection for Gastric Cancer: A United States Multi-Institutional Analysis. Journal of the American College of Surgeons, 2014, 219, 664-675.	0.2	139
1497	Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: Results of the GYMSSA trial. Journal of Surgical Oncology, 2014, 110, 275-284.	0.8	159
1498	Angiogenesis in gastric cancer: hitting the target?. Lancet, The, 2014, 383, 4-6.	6.3	33

#	Article	IF	Citations
1499	Isolated non-hepatic metastasis from upper gastrointestinal adenocarcinoma: A case for surgical resection. International Journal of Surgery Case Reports, 2014, 5, 307-310.	0.2	0
1500	Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database. Surgery, 2014, 156, 298-304.	1.0	105
1501	The Impact of Preoperative Radiochemotherapy on Survival in Advanced Esophagogastric Junction Signet Ring Cell Adenocarcinoma. Annals of Thoracic Surgery, 2014, 97, 303-310.	0.7	31
1502	Gastric cancer: ESMOâ€"ESSOâ€"ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. European Journal of Surgical Oncology, 2014, 40, 584-591.	0.5	162
1503	High expression of integrin-linked kinase predicts aggressiveness and poor prognosis in patients with gastric cancer. Acta Histochemica, 2014, 116, 758-762.	0.9	8
1504	Performance of a Nomogram Predicting Disease-Specific Survival After an R0 Resection for Gastric Cancer in Patients Receiving Postoperative Chemoradiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014, 88, 624-629.	0.4	13
1505	Ginsenoside F2 induces apoptosis in humor gastric carcinoma cells through reactive oxygen species-mitochondria pathway and modulation of ASK-1/JNK signaling cascade in vitro and in vivo. Phytomedicine, 2014, 21, 515-522.	2.3	45
1506	Is tumor size a predictor of preoperative N staging in T2â€"T4a stage advanced gastric cancer?. Surgical Oncology, 2014, 23, 5-10.	0.8	14
1507	P5 Stomach cancer in Niamey: first results from the Niger Cancer Registry. European Journal of Cancer, 2014, 50, S10.	1.3	0
1508	Adjuvant Chemotherapy with Docetaxel, Cisplatin, and Continuous-Infusion 5-Fluorouracil for Gastric Cancer: A Phase II Study. Translational Oncology, 2014, 7, 277-283.	1.7	8
1509	Added value of diffusion-weighted MR imaging to T2-weighted and dynamic contrast-enhanced MR imaging in T staging of gastric cancer. Clinical Imaging, 2014, 38, 122-128.	0.8	27
1510	Genetic susceptibility and gastric cancer risk: The importance of meta-analyses as a statistical tool. GastroenterologÃa Y HepatologÃa, 2014, 37, 421-426.	0.2	10
1512	The critical role of peritoneal cytology in the staging of gastric cancer: An evidenceâ€based review. Journal of Surgical Oncology, 2014, 110, 291-297.	0.8	60
1513	Molecular profiling in gastric cancer: Examining potential targets for chemotherapy. Journal of Surgical Oncology, 2014, 110, 302-306.	0.8	8
1514	A critical review of HER2-positive gastric cancer evaluation and treatment: From trastuzumab, and beyond. Cancer Letters, 2014, 351, 30-40.	3.2	56
1515	Targeted therapy for gastric cancer: Molecular pathways and ongoing investigations. Biochimica Et Biophysica Acta: Reviews on Cancer, 2014, 1846, 232-237.	3.3	59
1516	18F-FDG-PET/CT in assessing response to neoadjuvant chemoradiotherapy for potentially resectable locally advanced esophageal cancer. Annals of Nuclear Medicine, 2014, 28, 295-303.	1.2	20
1517	Preoperative chemoradiotherapy in locally advanced gastric cancer, a phase I/II feasibility and efficacy study. Radiotherapy and Oncology, 2014, 112, 284-288.	0.3	40

#	Article	IF	Citations
1518	Gastric carcinoma at Tanta Cancer Center: A comparative retrospective clinico-pathological study of the elderly versus the non-elderly. Journal of the Egyptian National Cancer Institute, 2014, 26, 127-137.	0.6	19
1519	Update on treatment of gastric cancer. Journal of the Chinese Medical Association, 2014, 77, 345-353.	0.6	45
1520	Role of imaging in predicting response to neoadjuvant chemotherapy in gastric cancer. World Journal of Gastroenterology, 2014, 20, 1650.	1.4	19
1521	Effect of Intensity Modulated Radiotherapy Combined with S-1-Based Chemotherapy in Locally Advanced Gastric Cancer Patients. Oncology Research and Treatment, 2014, 37, 11-16.	0.8	11
1522	Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncology Reports, 2014, 31, 1059-1066.	1.2	18
1523	O-MAX Chemotherapy: High Activity in Metastatic Esophagogastric Adenocarcinoma and Possible Relation to Subclinical Hemolysis. Oncology, 2014, 87, 371-380.	0.9	2
1524	Neoadjuvant Therapy of Gastric Cancer: A Decisive Step Forward. Gastrointestinal Tumors, 2014, 1, 99-104.	0.3	4
1525	Costâ€Utility Analysis of Endoscopic Surveillance of Patients with Gastric Premalignant Conditions. Helicobacter, 2014, 19, 425-436.	1.6	51
1526	Upper gastrointestinal malignancy. InnovAiT, 2014, 7, 683-690.	0.0	0
1527	Increased expression of Lgr5 is associated with chemotherapy resistance in human gastric cancer. Oncology Reports, 2014, 32, 181-188.	1.2	30
1528	Concurrent Neoadjuvant Chemoradiotherapy for Siewert II and III Adenocarcinoma at Gastroesophageal Junction. American Journal of the Medical Sciences, 2015, 349, 472-476.	0.4	24
1529	Seom guidelines for the treatment of gastric cancer 2015. Clinical and Translational Oncology, 2015, 17, 996-1004.	1.2	25
1530	Clinical significance of zinc-finger E-box binding homeobox 1 mRNA levels in peritoneal washing for gastric cancer. Molecular and Clinical Oncology, 2015, 3, 435-441.	0.4	12
1532	Preoperative Standardized Uptake Value of Metastatic Lymph Nodes Measured by 18F-FDG PET/CT Improves the Prediction of Prognosis in Gastric Cancer. Medicine (United States), 2015, 94, e1037.	0.4	35
1533	Perioperative and Palliative Chemotherapy for Esophageal Cancer. Visceral Medicine, 2015, 31, 341-346.	0.5	2
1534	Definitive, Preoperative, and Palliative Radiation Therapy of Esophageal Cancer. Visceral Medicine, 2015, 31, 347-353.	0.5	8
1535	Prognostic significance of prospectively detected bone marrow micrometastases in esophagogastric cancer: 10â€year followâ€up confirms prognostic significance. Cancer Medicine, 2015, 4, 1281-1288.	1.3	6
1536	Synergic effect between 5-fluorouracil and celecoxib on hypoxic gastric cancer cells. Molecular Medicine Reports, 2015, 11, 1160-1166.	1.1	7

#	Article	IF	Citations
1538	Regional Arterial Infusion Chemotherapy improves the Pathological Response rate for advanced gastric cancer with Short-term Neoadjuvant Chemotherapy. Scientific Reports, 2015, 5, 17516.	1.6	8
1540	MicroRNA-197 reverses the drug resistance of fluorouracil-induced SGC7901 cells by targeting mitogen-activated protein kinase 1. Molecular Medicine Reports, 2015, 12, 5019-5025.	1.1	24
1541	Superior antitumor activity of trastuzumab combined with capecitabine plus oxaliplatin in a human epidermal growth factor receptor 2-positive human gastric cancer xenograft model. Molecular and Clinical Oncology, 2015, 3, 987-994.	0.4	9
1542	GI Surgery Annual. GI Surgery Annual, 2015, , .	0.0	0
1543	Investigation of the potential role of preoperative chemotherapy in treatment for gastric cancer with outlet obstruction. Molecular and Clinical Oncology, 2015, 3, 1177-1183.	0.4	5
1544	Omission of Adjuvant Therapy After Gastric Cancer Resection: Development of a Validated Risk Model. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 531-541.	2.3	18
1545	Compliance With Gastric Cancer Guidelines is Associated With Improved Outcomes. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 319-325.	2.3	45
1546	Curative Resection Following Neoadjuvant Chemotherapy for Advanced Gastric Cancer With Preservation of a Right Gastroepiploic Artery Coronary Artery Bypass Graft: A Case Report. International Surgery, 2015, 100, 1138-1143.	0.0	3
1547	Reevaluation of Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Medicine (United States), 2015, 94, e1102.	0.4	26
1549	Regulation of cellular sphingosine-1-phosphate by sphingosine kinase 1 and sphingosine-1-phopshate lyase determines chemotherapy resistance in gastroesophageal cancer. BMC Cancer, 2015, 15, 762.	1.1	38
1551	The impact of taxane-based preoperative chemotherapy in gastroesophageal signet ring cell adenocarcinomas. Journal of Hematology and Oncology, 2015, 8, 52.	6.9	14
1552	Accuracy of EUS and CT imaging in preoperative gastric cancer staging. Journal of Surgical Oncology, 2015, 111, 1016-1020.	0.8	64
1553	Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. British Journal of Surgery, 2015, 102, 1388-1393.	0.1	65
1554	Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therapeutic Advances in Gastroenterology, 2015, 8, 189-205.	1.4	8
1555	TGF-Î² induces HLA-G expression through inhibiting miR-152 in gastric cancer cells. Journal of Biomedical Science, 2015, 22, 107.	2.6	31
1556	FOXM1 and polo-like kinase 1 are co-ordinately overexpressed in patients with gastric adenocarcinomas. BMC Research Notes, 2015, 8, 676.	0.6	10
1557	Survival Benefit of Neoadjuvant Chemotherapy for Resectable Cancer of the Gastric and Gastroesophageal Junction. Journal of Clinical Gastroenterology, 2015, 49, 387-394.	1.1	37
1558	Poor prognostic subgroup in T3N0 stage IIA gastric cancer, suggesting an indication for adjuvant chemotherapy. Journal of Surgical Oncology, 2015, 111, 221-225.	0.8	21

#	Article	IF	Citations
1559	Closing the Audit Cycle: Improving Short Term Outcomes of Oesophagectomy in a Provincial Hospital. Journal of Perioperative Practice, 2015, 25, 111-114.	0.3	4
1560	Multimodality Approaches for the Curative Treatment of Esophageal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 229-238.	2.3	44
1561	Systematic review of enhanced recovery after gastro-oesophageal cancer surgery. Annals of the Royal College of Surgeons of England, 2015, 97, 173-179.	0.3	56
1562	Adjuvant Chemoradiotherapy in Gastric Cancer: A Pooled Analysis of the AIRO Gastrointestinal Group Experience. Tumori, 2015, 101, 91-97.	0.6	2
1563	A phase II trial of perioperative chemotherapy involving a single intraperitoneal administration of paclitaxel followed by sequential Sâ€1 plus intravenous paclitaxel for serosaâ€positive gastric cancer. Journal of Surgical Oncology, 2015, 111, 1041-1046.	0.8	11
1564	Neoadjuvant radiation therapy does not increase perioperative morbidity among patients undergoing gastrectomy for gastric cancer. Journal of Surgical Oncology, 2015, 112, 46-50.	0.8	10
1565	Gefitinib in definitive management of esophageal or gastroesophageal junction cancer: a retrospective analysis of two clinical trials. Ecological Management and Restoration, 2015, 28, 547-551.	0.2	4
1566	Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature. Ecological Management and Restoration, 2015, 28, 612-618.	0.2	23
1567	Mass Spectrometric Analysis of Exhaled Breath for the Identification of Volatile Organic Compound Biomarkers in Esophageal and Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 981-990.	2.1	138
1568	Factors Associated With Recurrence and Survival in Lymph Nodeâ€"negative Gastric Adenocarcinoma. Annals of Surgery, 2015, 262, 999-1005.	2.1	40
1569	Serum microRNA profiles as prognostic or predictive markers in the multimodality treatment of patients with gastric cancer. Oncology Letters, 2015, 10, 869-874.	0.8	8
1570	Clinical significance and prognostic impact of the total diameter of enlarged lymph nodes on preoperative multidetector computed tomography in patients with gastric cancer. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1603-1609.	1.4	5
1571	The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. International Journal of Cancer, 2015, 137, 819-825.	2.3	107
1572	Esophageal anastomotic leak does not affect ability to receive adjuvant treatment. Journal of Surgical Oncology, 2015, 111, 855-861.	0.8	3
1573	Therapeutic value of lymph node dissection for esophageal squamous cell carcinoma after neoadjuvant chemotherapy. Journal of Surgical Oncology, 2015, 112, 60-65.	0.8	23
1574	The importance of the proximal resection margin distance for proximal gastric adenocarcinoma: A multiâ€institutional study of the US Gastric Cancer Collaborative. Journal of Surgical Oncology, 2015, 112, 203-207.	0.8	35
1575	An assessment of feeding jejunostomy tube placement at the time of resection for gastric adenocarcinoma: A sevenâ€institution analysis of 837 patients from the U.S. gastric cancer collaborative. Journal of Surgical Oncology, 2015, 112, 195-202.	0.8	26
1576	Preoperative chemotherapy for resectable thoracic esophageal cancer. The Cochrane Library, 2015, , CD001556.	1.5	86

#	Article	IF	Citations
1577	NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors. International Journal of Cancer, 2015, 137, 678-685.	2.3	94
1578	Surgery of gastric cancer and esophageal cancer: Does age matter?. Journal of Surgical Oncology, 2015, 112, 387-395.	0.8	36
1579	Gastric remnant cancer: A distinct entity or simply another proximal gastric cancer?. Journal of Surgical Oncology, 2015, 112, 877-882.	0.8	17
1580	Neoadjuvant Therapy of DOF Regimen Plus Bevacizumab Can Increase Surgical Resection Ratein Locally Advanced Gastric Cancer. Medicine (United States), 2015, 94, e1489.	0.4	34
1581	Clinical Importance of Supraclavicular Lymph Node Metastasis After Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgery, 2015, 262, 280-285.	2.1	37
1582	Prospective Study of Malabsorption and Malnutrition After Esophageal and Gastric Cancer Surgery. Annals of Surgery, 2015, 262, 803-808.	2.1	118
1583	Management of cancer of the oesophagus. , 0, , 170-184.		0
1585	Effects of Continuing Adjuvant S-1 for 1 Year on the Prognosis of Gastric Cancer Patients: Results from a Prospective Single Center Study. Journal of Gastric Cancer, 2015, 15, 113.	0.9	3
1586	Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers. Therapeutics and Clinical Risk Management, 2015, 11, 1123.	0.9	5
1587	High-dose nimotuzumab improves the survival rate of esophageal cancer patients who underwent radiotherapy. OncoTargets and Therapy, 2015, 9, 117.	1.0	10
1588	Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World Journal of Gastroenterology, 2015, 21, 7343.	1.4	83
1589	Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncology. OncoTargets and Therapy, 2015, 8, 1149.	1.0	5
1590	Perioperative treatments for resectable gastric cancer. Journal of the Korean Medical Association, 2015, 58, 201.	0.1	3
1591	Free intraperitoneal tumor cells and outcome in gastric cancer patients: a systematic review and meta-analysis. Oncotarget, 2015, 6, 35564-35578.	0.8	36
1592	Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy. Oncotarget, 2015, 6, 24750-24779.	0.8	115
1593	Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer: What to Avoid. Preliminary Analysis of a Consecutive Series of Patients. Tumori, 2015, 101, 511-516.	0.6	0
1594	Management of cancer of the stomach. , 0, , 185-195.		0
1595	Clinical utility of ramucirumab in advanced gastric cancer. Biologics: Targets and Therapy, 2015, 9, 93.	3.0	5

#	Article	IF	Citations
1596	Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. International Journal of Nanomedicine, 2015, 10, 3911.	3.3	39
1597	Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine. Yonsei Medical Journal, 2015, 56, 1177.	0.9	49
1598	Perioperative Chemotherapy in Gastroesophageal Cancer. A Retrospective Monocenter Evaluation of 42 Cases. PLoS ONE, 2015, 10, e0122974.	1.1	0
1599	HIF-1Î± Induces Multidrug Resistance in Gastric Cancer Cells by Inducing MiR-27a. PLoS ONE, 2015, 10, e0132746.	1.1	47
1600	Inhibition of mitotic Aurora kinase A by alisertib induces apoptosis and autophagy of human gastric cancer AGS and NCI-N78 cells. Drug Design, Development and Therapy, 2015, 9, 487.	2.0	32
1601	Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	3
1602	An Unusual Course of Metastatic Gastroesophageal Cancer. Case Reports in Oncological Medicine, 2015, 2015, 1-7.	0.2	0
1603	Estimation of an Optimal Chemotherapy Utilisation Rate for Upper Gastrointestinal Cancers: Setting an Evidence-Based Benchmark for the Best-Quality Cancer Care. Gastroenterology Research and Practice, 2015, 2015, 1-10.	0.7	4
1604	Adjuvant Chemoradiation in Gastric Cancer: Long-term Outcomes and Prognostic Factors from a Single Institution. Tumori, 2015, 101, 517-523.	0.6	1
1605	Impact of the Siewert Classification on the Outcome of Patients Treated by Preoperative Chemoradiotherapy for a Nonmetastatic Adenocarcinoma of the Oesophagogastric Junction. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	6
1606	Understanding Complete Pathologic Response in Oesophageal Cancer: Implications for Management and Survival. Gastroenterology Research and Practice, 2015, 2015, 1-9.	0.7	12
1607	Neoadjuvant or adjuvant therapy for gastric cancer. World Journal of Gastrointestinal Oncology, 2015, 7, 102.	0.8	31
1608	Tumor Biology: Is It Time to Redefine Unresectability? An Extraordinary Case of Gastroesophageal Junctional Adenocarcinoma. Cureus, 2015, 7, e420.	0.2	0
1609	High EGFR and low p-Akt expression is associated with better outcome after nimotuzumab-containing treatment in esophageal cancer patients: preliminary clinical result and testable hypothesis. Oncotarget, 2015, 6, 18674-18682.	0.8	19
1610	Race Influences Stage-specific Survival in Gastric Cancer. American Surgeon, 2015, 81, 259-267.	0.4	24
1611	Timing and Pattern of Recurrence after Gastrectomy for Adenocarcinoma. American Surgeon, 2015, 81, 1057-1060.	0.4	4
1613	Predictors of Survival in Patients with Resectable Gastric Cancer Treated with Preoperative Chemoradiation Therapy and Gastrectomy. Journal of the American College of Surgeons, 2015, 221, 83-90.	0.2	37
1614	Cancer survivorship. Current Opinion in Oncology, 2015, 27, 351-357.	1.1	41

#	Article	IF	Citations
1615	Diagnostic value of preoperative CT scan to stratify colon cancer for neoadjuvant therapy. International Journal of Colorectal Disease, 2015, 30, 1067-1073.	1.0	16
1616	Resected gastric cancer with D2 dissection: advances in adjuvant chemoradiotherapy and radiotherapy techniques. Expert Review of Anticancer Therapy, 2015, 15, 703-713.	1.1	4
1617	Postgastrectomy pharmacokinetic changes of S-1 in patients with localized advanced gastric cancer. Journal of Clinical Pharmacology, 2015, 55, 926-935.	1.0	3
1619	The prognostic significance of lymphovascular invasion in patients with resectable gastric cancer: a large retrospective study from Southern China. BMC Cancer, 2015, 15, 370.	1.1	44
1621	Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key. Journal of Clinical Oncology, 2015, 33, 3082-3084.	0.8	11
1622	Comparison of International Guidelines on the Accompanying Therapy for Advanced Gastric Cancer: Reasons for the Differences. Journal of Gastric Cancer, 2015, 15, 10.	0.9	24
1623	Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences. Oncologist, 2015, 20, 1132-1139.	1.9	84
1624	Therapeutic strategies for esophagogastric junction cancer. Formosan Journal of Surgery, 2015, 48, 185-197.	0.1	3
1625	Targeted therapy in gastroesophageal cancers: past, present and future: Figure 1.. Gastroenterology Report, 2015, 3, gov052.	0.6	21
1626	The presence of lymphovascular and perineural infiltration after neoadjuvant therapy and oesophagectomy identifies patients at high risk for recurrence. British Journal of Cancer, 2015, 113, 1427-1433.	2.9	52
1627	Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus. Journal of Thoracic Oncology, 2015, 10, 1349-1356.	0.5	37
1628	Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clinical Radiology, 2015, 70, 1198-1204.	0.5	40
1629	Esophageal Cancer: Molecular Mechanisms, Diagnosis and Treatment. , 2015, , 201-228.		1
1630	Comment on: HÃ¶lscher AH, Bollschweiler E, Bogoevski D, Schmidt H, Semrau R, Izbicki JR. Prognostic impact of neoadjuvant chemoradiation in cT3 oesophageal cancer â€“ A propensity score matched analysis. Eur J Cancer. 2014;50(17):2950â€“7. European Journal of Cancer, 2015, 51, 2095-2096.	1.3	2
1631	Inhibition of sphingosine-1-phosphate phosphatase 1 promotes cancer cells migration in gastric cancer: Clinical implications. Oncology Reports, 2015, 34, 1977-1987.	1.2	18
1632	Establishment and characterization of GCSR1, a multi-drug resistant signet ring cell gastric cancer cell line. International Journal of Oncology, 2015, 46, 2479-2487.	1.4	8
1633	APRIL Induces Cisplatin Resistance in Gastric Cancer Cells via Activation of the NF-ÎºB Pathway. Cellular Physiology and Biochemistry, 2015, 35, 571-585.	1.1	31
1634	Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer. Scientific Reports, 2014, 4, 7592.	1.6	24

#	Article	IF	Citations
1635	PET-CT offers accurate assessment of tumour length in oesophageal malignancy. European Journal of Radiology, 2015, 84, 195-200.	1.2	7
1636	Assessment of the quality of surgery within randomised controlled trials for the treatment of gastro-oesophageal cancer: a systematic review. Lancet Oncology, The, 2015, 16, e23-e31.	5.1	58
1637	Enteral Stents are Safe and Effective to Relieve Malignant Gastric Outlet Obstruction in the Elderly. Journal of Gastrointestinal Cancer, 2015, 46, 42-47.	0.6	4
1638	Accuracy of multidetector-row CT in diagnosing lymph node metastasis in patients with gastric cancer. European Radiology, 2015, 25, 368-374.	2.3	74
1639	Postoperative adjuvant therapy for resectable thoracic esophageal squamous cell carcinoma: a retrospective analysis of 426 cases. Medical Oncology, 2015, 32, 417.	1.2	13
1640	Current Status of Management of Malignant Disease: Current Management of Esophageal Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 964-972.	0.9	60
1641	Retrospective Evaluation of the Efficacy of First-Line Treatment of Advanced Gastric Cancer With Docetaxel and Oxaliplatin. Cancer Investigation, 2015, 33, 16-21.	0.6	4
1642	Laparoscopic Versus Open Gastrectomy for Gastric Adenocarcinoma in the West: A Caseâ€“Control Study. Annals of Surgical Oncology, 2015, 22, 3590-3596.	0.7	124
1643	Emerging mAbs for the treatment of esophagogastric cancer. Expert Opinion on Emerging Drugs, 2015, 20, 63-74.	1.0	1
1644	Induction chemotherapy followed by surgery for advanced oesophageal cancer. European Journal of Surgical Oncology, 2015, 41, 323-332.	0.5	5
1645	Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer. European Journal of Surgical Oncology, 2015, 41, 333-338.	0.5	221
1646	Safety, Efficacy, and Long-Term Follow-Up Evaluation of Perioperative Epirubicin, Cisplatin, and Capecitabine Chemotherapy in Esophageal Resection for Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1555-1563.	0.7	13
1647	Survival benefit and additional value of preoperative chemoradiotherapy in resectable gastric and gastro-oesophageal junction cancer: A direct and adjusted indirect comparison meta-analysis. European Journal of Surgical Oncology, 2015, 41, 282-294.	0.5	33
1648	Combination Approach: the Future of the War Against Cancer. Cell Biochemistry and Biophysics, 2015, 72, 637-641.	0.9	9
1649	Clinical predictors of early cancer-related mortality following neoadjuvant therapy and oesophagectomyâ€. European Journal of Cardio-thoracic Surgery, 2015, 48, 455-460.	0.6	19
1650	Regenerative medicine for oesophageal reconstruction after cancer treatment. Lancet Oncology, The, 2015, 16, e84-e92.	5.1	30
1651	Locally Advanced Gastroesophageal Junction Tumor: A Treatment Dilemma. Oncologist, 2015, 20, 134-142.	1.9	4
1652	Current Status of Management of Malignant Disease: Current Management of Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 782-788.	0.9	27

#	Article	IF	Citations
1653	Should Gastric Cardia Cancers Be Treated with Esophagectomy or Total Gastrectomy? A Comprehensive Analysis of 4,996 NSQIP/SEER Patients. Journal of the American College of Surgeons, 2015, 220, 510-520.	0.2	46
1654	Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. Journal of Clinical Oncology, 2015, 33, 3130-3136.	0.8	370
1655	Barrett's oesophagus and oesophageal adenocarcinoma. Medicine, 2015, 43, 202-209.	0.2	1
1656	Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer, 2015, 18, 597-604.	2.7	29
1657	Prognostic value of differential CCND1 expression in patients with resected gastric adenocarcinoma. Medical Oncology, 2015, 32, 338.	1.2	12
1658	High-Grade Toxicity to Neoadjuvant Treatment for Upper Gastrointestinal Carcinomas: What is the Impact on Perioperative and Oncologic Outcomes?. Annals of Surgical Oncology, 2015, 22, 3632-3639.	0.7	29
1659	Preoperative tumor size is a critical prognostic factor for patients with Borrmann type III gastric cancer. Surgery Today, 2015, 45, 68-77.	0.7	17
1660	Gastric cancer recurrence after resection and adjuvant chemoradiation. Journal of Radiation Oncology, 2015, 4, 79-85.	0.7	1
1661	Survival and Recurrence Patterns after Neoadjuvant Docetaxel, Cisplatin, and 5-Fluorouracil (DCF) for Locally Advanced Esophagogastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 324-330.	0.7	21
1662	Adjuvant and Neoadjuvant Options in Resectable Gastric Cancer: Is There an Optimal Treatment Approach?. Current Oncology Reports, 2015, 17, 18.	1.8	3
1663	Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas. Medical Oncology, 2015, 32, 396.	1.2	10
1664	Comparison of Gastric Cancer Survival Between Caucasian and Asian Patients Treated in the United States: Results from the Surveillance Epidemiology and End Results (SEER) Database. Annals of Surgical Oncology, 2015, 22, 2965-2971.	0.7	86
1665	A Nationwide Retrospective Study of Perioperative Chemotherapy for Gastroesophageal Adenocarcinoma: Tolerability, Outcome, and Prognostic Factors. Annals of Surgical Oncology, 2015, 22, 1540-1547.	0.7	14
1666	Integrins Î±vÎ²3 and Î±vÎ²5 as prognostic, diagnostic, and therapeutic targets in gastric cancer. Gastric Cancer, 2015, 18, 784-795.	2.7	50
1667	Neoadjuvant Chemoradiotherapy Improves Histological Results Compared with Perioperative Chemotherapy in Locally Advanced Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 604-609.	0.7	6
1668	Epirubicin combined with oxaliplatin and 5-day continuous infusion of 5-fluorouracil as a first-line treatment for metastatic gastric cancer: treatment outcomes and analysis of prognostic factors. Journal of Cancer Research and Clinical Oncology, 2015, 141, 109-118.	1.2	7
1669	Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin â€“ a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer, 2015, 15, 73.	1.1	53
1670	Open versus minimally invasive esophagectomy: clinical outcomes for locally advanced esophageal adenocarcinoma. Surgical Endoscopy and Other Interventional Techniques, 2015, 29, 2614-2619.	1.3	37

#	Article	IF	Citations
1671	A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy toÂneoadjuvant therapy for esophagogastric adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2015, 149, 538-547.	0.4	18
1672	Mediastinal lymph node metastasis and recurrence in adenocarcinoma of the esophagogastric junction. Surgery, 2015, 157, 551-555.	1.0	87
1673	Technical Reproducibility of Single-Nucleotide and Size-Based DNA Biomarker Assessment Using DNA Extracted from Formalin-Fixed, Paraffin-Embedded Tissues. Journal of Molecular Diagnostics, 2015, 17, 242-250.	1.2	8
1675	Surgical outcomes in patients with locally advanced gastric cancer treated with S-1 and oxaliplatin as neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2015, 13, 11.	0.8	30
1676	Preoperative treatment with radiochemotherapy for locally advanced gastroesophageal junction cancer and unresectable locally advanced gastric cancer. Radiology and Oncology, 2015, 49, 163-172.	0.6	4
1677	Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncology, The, 2015, 16, 1090-1098.	5.1	1,861
1678	Neoadjuvant chemoradiation in oesophageal cancer. Lancet Oncology, The, 2015, 16, 1008-1009.	5.1	24
1679	Effect of Neoadjuvant Chemotherapy Treatment on Prognosis of Patients with Advanced Gastric Cancer: a Retrospective Study. Chinese Medical Sciences Journal, 2015, 30, 84-89.	0.2	6
1680	Influence of interfraction motion on margins for radiotherapy of gastric cancer. British Journal of Radiology, 2015, 88, 20140610.	1.0	7
1681	Perioperative chemotherapy more of a benefit for overall survival than adjuvant chemotherapy for operable gastric cancer: an updated Meta-analysis. Scientific Reports, 2015, 5, 12850.	1.6	41
1682	Managing Early and Late Postoperative Complications Following Gastric Surgery. , 2015, , 239-249.		0
1683	Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer. British Journal of Cancer, 2015, 113, 603-610.	2.9	30
1684	Overview of multimodal therapy for adenocarcinoma of the esophagogastric junction. General Thoracic and Cardiovascular Surgery, 2015, 63, 549-556.	0.4	13
1687	Prognostic Role of Diffusion-weighted MR Imaging for Resectable Gastric Cancer. Radiology, 2015, 276, 444-452.	3.6	30
1688	Open Methods of Resection and Reconstruction for Subtotal and Total Gastrectomy. , 2015, , 199-209.		0
1689	Hepatectomy Offers Superior Survival Compared with Nonâ€surgical Treatment for â‰¤3ÂMetastatic Tumors with Diameters <3Âcm from Gastric Cancer: A Retrospective Study. World Journal of Surgery, 2015, 39, 2757-2763.	0.8	11
1690	Surgery in oesophago-gastric cancer with metastatic disease: Treatment, prognosis and preoperative patient selection. European Journal of Surgical Oncology, 2015, 41, 1340-1347.	0.5	34
1691	Determinants of improved survival after oesophagectomy for cancer. British Journal of Surgery, 2015, 102, 668-675.	0.1	11

#	Article	IF	Citations
1692	Radiation Treatment for Gastric Cancer. , 2015, , 307-315.		0
1693	Inhibitory effects and mechanism of 5-fluorouracil combined with celecoxib on human gastric cancer xenografts in nude mice. Experimental and Therapeutic Medicine, 2015, 9, 105-111.	0.8	11
1694	Ramucirumab as second-line treatment for patients with metastatic esophagogastric adenocarcinoma. Expert Review of Anticancer Therapy, 2015, 15, 607-614.	1.1	1
1695	Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Oncology Letters, 2015, 9, 999-1005.	0.8	12
1696	Influence of Different Neoadjuvant Chemotherapy Regimens on Response, Prognosis, and Complication Rate in Patients with Esophagogastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 905-914.	0.7	14
1698	Adjuvant and Neoadjuvant Treatment: Standard Treatment and Clinical Trials in the East. , 2015, , 303-306.		0
1699	Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Current Treatment Options in Oncology, 2015, 16, 35.	1.3	14
1700	Angiogenic inhibitors in gastric cancers and gastroesophageal junction carcinomas: A critical insight. Critical Reviews in Oncology/Hematology, 2015, 95, 165-178.	2.0	26
1701	Diagnostic value of a plasma microRNA signature in gastric cancer: a microRNA expression analysis. Scientific Reports, 2015, 5, 11251.	1.6	114
1702	Oncologic Long-Term Results of Robot-Assisted Minimally Invasive Thoraco-Laparoscopic Esophagectomy with Two-Field Lymphadenectomy for Esophageal Cancer. Annals of Surgical Oncology, 2015, 22, 1350-1356.	0.7	123
1703	Comparative Effectiveness in Esophagogastric Cancer. Cancer Treatment and Research, 2015, 164, 121-142.	0.2	1
1704	Peritoneal Carcinomatosis from Gastric Cancer. Updates in Surgery Series, 2015, , 255-269.	0.0	0
1705	Current and Future Therapies for Advanced Gastric Cancer. Clinical Colorectal Cancer, 2015, 14, 239-250.	1.0	28
1706	Impact of postoperative chemotherapy in patients with locally advanced gastroesophageal adenocarcinoma treated with perioperative chemotherapy strategy. American Journal of Surgery, 2015, 210, 15-23.	0.9	10
1707	Validating the prognostic and discriminating value of the TNM-classification for gastric cancer â€“ A critical appraisal. European Journal of Cancer, 2015, 51, 577-586.	1.3	41
1708	703 Adjuvant Therapy Completion Rates in Patients With Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. Gastroenterology, 2015, 148, S-1118-S-1119.	0.6	1
1709	Treatment-related frequency of venous thrombosis in lower esophageal, gastro-esophageal and gastric cancer â€“ a clinical prospective study of outcome and prognostic factors. Thrombosis Research, 2015, 135, 802-808.	0.8	27
1710	Role of mimic of manganese superoxide dismutase in proliferation and apoptosis of gastric carcinoma BGC-823 cells in vitro and in vivo. International Immunopharmacology, 2015, 26, 277-285.	1.7	4

#	Article	IF	Citations
1711	Controversies in the Treatment of Local and Locally Advanced Gastric and Esophageal Cancers. Journal of Clinical Oncology, 2015, 33, 1754-1759.	0.8	77
1712	Chemoradiation in oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2015, 29, 193-209.	1.0	16
1713	Impact of body mass index on perioperative outcomes and survival after resection for gastric cancer. Journal of Surgical Research, 2015, 195, 74-82.	0.8	66
1714	Angiogenic and growth factors in gastric cancer. Journal of Surgical Research, 2015, 194, 420-429.	0.8	32
1715	Tumor profiling of gastric and esophageal carcinoma reveal different treatment options. Cancer Biology and Therapy, 2015, 16, 764-769.	1.5	16
1717	Decreased expression of Bauhinia purpurea lectin is a predictor of gastric cancer recurrence. Surgery Today, 2015, 45, 1299-1306.	0.7	13
1718	Evaluation of Trastuzumab Anti-Tumor Efficacy and its Correlation with HER-2 Status in Patient-Derived Gastric Adenocarcinoma Xenograft Models. Pathology and Oncology Research, 2015, 21, 947-955.	0.9	8
1719	Morbidity after Total Gastrectomy: Analysis of 238 Patients. Journal of the American College of Surgeons, 2015, 220, 863-871e2.	0.2	65
1720	Advantages of staging laparoscopy in gastric cancer: they are so obvious that they are not evident. Future Oncology, 2015, 11, 369-372.	1.1	7
1721	Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Therapeutic Advances in Medical Oncology, 2015, 7, 39-48.	1.4	30
1722	The utility of MRI for pre-operative T and N staging of gastric carcinoma: a systematic review and meta-analysis. British Journal of Radiology, 2015, 88, 20140552.	1.0	24
1723	Droplet digital PCR measurement of HER2 in patients with gastric cancer. British Journal of Cancer, 2015, 112, 1652-1655.	2.9	69
1724	Association of angiogenic factors with prognosis in esophageal cancer. BMC Cancer, 2015, 15, 121.	1.1	28
1725	Surgical techniques, open versus minimally invasive gastrectomy after chemotherapy (STOMACH trial): study protocol for a randomized controlled trial. Trials, 2015, 16, 123.	0.7	51
1726	Circulating Tumor Cells as an Independent Predictor of Survival in Advanced Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 3954-3961.	0.7	60
1727	Outcomes of Gastric Cancer Resection in Octogenarians: A Multi-institutional Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2015, 22, 4371-4379.	0.7	26
1728	The future of trials in surgical oncology. Nature Reviews Clinical Oncology, 2015, 12, 425-431.	12.5	29
1729	Impact of Neoadjuvant Chemotherapy on Postoperative Morbidity after Gastrectomy for Gastric Cancer. Digestive Surgery, 2015, 32, 229-237.	0.6	25

#	Article	IF	Citations
1730	Circulating CD14+HLA-DRâ^'/low myeloid-derived suppressor cell is an indicator of poor prognosis in patients with ESCC. Tumor Biology, 2015, 36, 7987-7996.	0.8	30
1731	Hypermethylated Epidermal growth factor receptor (EGFR) promoter is associated with gastric cancer. Scientific Reports, 2015, 5, 10154.	1.6	16
1732	Systemic control and evaluation of the response to neoadjuvant chemotherapy in resectable thoracic esophageal squamous cell carcinoma with 18F-fluorodeoxyglucose positron emission tomography-positive lymph nodes. Surgery Today, 2015, 45, 335-345.	0.7	5
1734	External Validation of a Score Predictive of Recurrence after Radical Surgery for Non-Cardia Gastric Cancer: Results of a Follow-Up Study. Journal of the American College of Surgeons, 2015, 221, 280-290.	0.2	24
1735	Role of Radiotherapy and Newer Techniques in the Treatment of GI Cancers. Journal of Clinical Oncology, 2015, 33, 1737-1744.	0.8	30
1736	Complete versus incomplete cytoreduction in peritoneal carcinosis from gastric cancer, with consideration to PCI cut-off. Systematic review and meta-analysis. European Journal of Surgical Oncology, 2015, 41, 911-919.	0.5	83
1737	Smad4 Loss in Esophageal Adenocarcinoma Is Associated With an Increased Propensity for Disease Recurrence and Poor Survival. American Journal of Surgical Pathology, 2015, 39, 487-495.	2.1	35
1738	Is There a Role For PET/CT With Esophagogastric Junction Adenocarcinoma?. Clinical Nuclear Medicine, 2015, 40, e201-e207.	0.7	9
1739	A Methylene Blueâ€"assisted Technique for Harvesting Lymph Nodes After Radical Surgery for Gastric Cancer. American Journal of Surgical Pathology, 2015, 39, 266-273.	2.1	20
1740	Robot-assisted surgery for gastric carcinoma: Five years follow-up and beyond. European Journal of Surgical Oncology, 2015, 41, 1106-1113.	0.5	55
1741	Local iontophoretic administration of cytotoxic therapies to solid tumors. Science Translational Medicine, 2015, 7, 273ra14.	5.8	56
1743	Principles of Radiation Therapy. , 2015, , 157-172.		0
1744	Updated evidence on adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2015, 9, 1549-1560.	1.4	47
1745	Personalizing the management of gastroesophageal cancer. Personalized Medicine, 2015, 12, 447-451.	0.8	0
1746	Laparoscopic versus open gastrectomy for gastric cancer, a multicenter prospectively randomized controlled trial (LOGICA-trial). BMC Cancer, 2015, 15, 556.	1.1	92
1747	Multimodality Treatment of T4 Gastric Cancer in the United States: Utilization Trends and Impact on Survival. Annals of Surgical Oncology, 2015, 22, 863-872.	0.7	15
1748	Molecular effects of Lapatinib in the treatment of HER2 overexpressing oesophago-gastric adenocarcinoma. British Journal of Cancer, 2015, 113, 1305-1312.	2.9	23
1749	Impact of age on the feasibility and efficacy of neoadjuvant chemotherapy in patients with locally advanced oesophagogastric cancer. European Journal of Cancer, 2015, 51, 1918-1926.	1.3	13

#	Article	IF	Citations
1750	Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer. Ecological Management and Restoration, 2015, 28, 172-179.	0.2	77
1751	Cancer in the elderly in the Czech Republic. European Journal of Cancer Care, 2015, 24, 163-178.	0.7	10
1752	Does surgery have a role in managing incurable gastric cancer?. Nature Reviews Clinical Oncology, 2015, 12, 676-682.	12.5	96
1753	Western Perspective and Epidemiology of Gastric Cancer. , 2015, , 111-123.		0
1754	TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf		
1755	Perioperative platin-based chemotherapy for locally advanced esophagogastric adenocarcinoma: Postoperative chemotherapy has a substantial impact on outcome. European Journal of Surgical Oncology, 2015, 41, 1300-1307.	0.5	33
1756	Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surgery, 2015, 15, 66.	0.6	21
1757	Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. Future Oncology, 2015, 11, 2247-2249.	1.1	2
1759	Is England closing the international gap in cancer survival?. British Journal of Cancer, 2015, 113, 848-860.	2.9	97
1760	Serum VEGF-A and Tumor Vessel VEGFR-2 Levels Predict Survival in Caucasian but Not Asian Patients Undergoing Resection for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 1508-1515.	0.7	26
1761	A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Annals of Oncology, 2015, 26, 1547-1573.	0.6	635
1763	Efficacy of palliative radiotherapy for gastric bleeding in patients with unresectable advanced gastric cancer: a retrospective cohort study. BMC Palliative Care, 2015, 14, 37.	0.8	63
1764	Recent trends and predictors of multimodality treatment for oesophageal, oesophagogastric junction, and gastric cancer: A Dutch cohort-study. Acta OncolÃ³gica, 2015, 54, 1754-1762.	0.8	15
1765	Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs, 2015, 3, 737-746.	0.5	3
1766	Optimal management of resectable gastric adenocarcinoma. Expert Review of Anticancer Therapy, 2015, 15, 931-941.	1.1	2
1767	MicroRNA-induced drug resistance in gastric cancer. Biomedicine and Pharmacotherapy, 2015, 74, 191-199.	2.5	49
1769	Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. Annals of Surgical Oncology, 2015, 22, 766-771.	0.7	17
1770	Prognosis and Treatment After Diagnosis of Recurrent Esophageal Carcinoma Following Esophagectomy with Curative Intent. Annals of Surgical Oncology, 2015, 22, 1292-1300.	0.7	73

#	Article	IF	Citations
1771	High Impact of Histopathological Remission for Prognosis after Perioperative Chemotherapy with ECF and ECF-Like Regimens for Gastric and Gastroesophageal Adenocarcinoma. Oncology, 2015, 89, 95-102.	0.9	9
1772	The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma. Annals of Surgical Oncology, 2015, 22, 832-839.	0.7	28
1773	Research into cancer metabolomics: Towards a clinical metamorphosis. Seminars in Cell and Developmental Biology, 2015, 43, 52-64.	2.3	36
1774	Management of gastric cancer: East vs west. Current Problems in Cancer, 2015, 39, 315-341.	1.0	7
1775	Neoadjuvant FOLFOX 4 versus FOLFOX 4 with Cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a multicentre randomised controlled phase II trial â€“ the PRODIGE 22 - ECKINOXE trial. BMC Cancer, 2015, 15, 511.	1.1	43
1776	GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells. BMC Cancer, 2015, 15, 550.	1.1	40
1777	Long-term Survival Outcomes of Advanced Gastric Cancer Patients Who Achieved a Pathological Complete Response with Neoadjuvant Chemotherapy: A Systematic Review of the Literature. Annals of Surgical Oncology, 2015, 22, 787-792.	0.7	55
1778	Are We Lacking Economic Evaluations in Gastric Cancer Treatment?. Pharmacoeconomics, 2015, 33, 83-87.	1.7	6
1779	Personalized Surgery for Gastric Adenocarcinoma: A Meta-analysis of D1 versus D2 Lymphadenectomy. Annals of Surgical Oncology, 2015, 22, 1820-1827.	0.7	37
1781	Laparoscopic Distal, Subtotal Gastrectomy for Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2015, 19, 369-374.	0.9	9
1782	Outcome, complications, and mortality of an intrathoracic anastomosis in esophageal cancer in patients without a preoperative selection with a risk score. Langenbeck's Archives of Surgery, 2015, 400, 9-18.	0.8	15
1783	Intraoperative Radiotherapy for Gastrointestinal Malignancies: Contemporary Outcomes With Multimodality Therapy. Current Oncology Reports, 2015, 17, 419.	1.8	1
1784	Gastric carcinoma: stage migration by immunohistochemically detected lymph node micrometastases. Gastric Cancer, 2015, 18, 100-108.	2.7	32
1785	Trends in the management of gastric cancer over a 32-year period: a French population-based study. Gastric Cancer, 2015, 18, 129-137.	2.7	11
1786	The evolution of cancer surgery and future perspectives. Nature Reviews Clinical Oncology, 2015, 12, 115-124.	12.5	226
1787	Bidirectional regulation between TMEFF2 and STAT3 may contribute to <scp>H</scp>elicobacter pyloriâ€associated gastric carcinogenesis. International Journal of Cancer, 2015, 136, 1053-1064.	2.3	24
1788	International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer, 2015, 18, 550-563.	2.7	79
1789	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. Annals of Surgical Oncology, 2015, 22, 224-231.	0.7	50

#	Article	IF	Citations
1790	Use of Endoscopic Ultrasound in the Preoperative Staging of Gastric Cancer: A Multi-Institutional Study of the US Gastric Cancer Collaborative. Journal of the American College of Surgeons, 2015, 220, 48-56.	0.2	58
1791	Surgical Treatment of Adenocarcinomas of the Gastro-esophageal Junction. Annals of Surgical Oncology, 2015, 22, 597-603.	0.7	67
1792	Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin,) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.8	8
1793	Adjuvant or neoadjuvant therapy for operable esophagogastric cancer?. Gastric Cancer, 2015, 18, 1-10.	2.7	21
1794	Preoperative chemotherapy in gastric cancer: expanding the indications, limiting the overuse. Gastric Cancer, 2015, 18, 200-201.	2.7	7
1795	Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer, 2015, 18, 382-389.	2.7	53
1796	Post-therapeutic response evaluation by a combination of endoscopy and CT scan in esophagogastric adenocarcinoma after chemotherapy: better than its reputation. Gastric Cancer, 2015, 18, 314-325.	2.7	14
1797	Improving Outcome in Gastrointestinal and Hepatopancreaticobiliary Surgical Oncology by Preoperative Risk Assessment and Optimization of Perioperative Care. , 2016, , .		1
1798	Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11â€“12 September 2015. Current Oncology, 2016, 23, 425-434.	0.9	3
1799	Sentinel node biopsy using blue dye and technetium99 in advanced gastric cancer: anatomical drainage and clinical application. Brazilian Journal of Medical and Biological Research, 2016, 49, .	0.7	2
1800	MK-2206 co-treatment with 5-fluorouracil or doxorubicin enhances chemosensitivity and apoptosis in gastric cancer by attenuation of Akt phosphorylation. OncoTargets and Therapy, 2016, Volume 9, 4387-4396.	1.0	13
1801	Multidisciplinary management for esophageal and gastric cancer. Cancer Management and Research, 2016, 8, 39.	0.9	38
1802	New advances in targeted gastric cancer treatment. World Journal of Gastroenterology, 2016, 22, 6776.	1.4	74
1803	The current situation for gastric cancer in Chile. Ecancermedicalscience, 2016, 10, 707.	0.6	4
1804	Quality of life: A critical outcome for all surgical treatments of gastric cancer. World Journal of Gastroenterology, 2016, 22, 1101.	1.4	47
1805	Recent developments and innovations in gastric cancer. World Journal of Gastroenterology, 2016, 22, 4307.	1.4	70
1806	Inflammatory microenvironment contributes to epithelial-mesenchymal transition in gastric cancer. World Journal of Gastroenterology, 2016, 22, 6619.	1.4	57
1807	A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Design, Development and Therapy, 2016, 10, 241.	2.0	10

#	Article	IF	Citations
1808	Why a D2 gastrectomy plus adjuvant chemotherapy is insufficient in locally advanced gastric cancer. Ecancermedicalscience, 2016, 10, 706.	0.6	0
1809	Efficacy of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2016, 68, 234.	0.2	0
1810	Up-Regulation of Plasma miR-23b is Associated with Poor Prognosis of Gastric Cancer. Medical Science Monitor, 2016, 22, 356-361.	0.5	27
1811	On the road to standardization of D2 lymph node dissection in a European population of patients with gastric cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 489.	0.8	6
1812	Prophylactic hyperthermic intraperitoneal chemotherapy can be considered in the management of advanced gastric cancer. Journal of Gastrointestinal Oncology, 2016, 7, 1017-1018.	0.6	0
1813	Impact of pathologic tumor response in the treatment of gastric cancer. Translational Gastroenterology and Hepatology, 2016, 1, 71-71.	1.5	2
1814	Pathologic tumor response to neoadjuvant chemotherapy in gastroesophageal cancer: what does it mean?. Translational Gastroenterology and Hepatology, 2016, 1, 75-75.	1.5	4
1815	Use of positron emission tomography scan response to guide treatment change for locally advanced gastric cancer: the Memorial Sloan Kettering Cancer Center experience. Journal of Gastrointestinal Oncology, 2016, 7, 506-514.	0.6	12
1816	A â€œperfectâ€•lymph node staging system requires a â€œperfectâ€•surgery. Translational Gastroenterology and Hepatology, 2016, 1, 10-10.	1.5	9
1817	Worldwide practice in gastric cancer surgery. World Journal of Gastroenterology, 2016, 22, 4041.	1.4	52
1818	Staging laparoscopy improves treatment decision-making for advanced gastric cancer. World Journal of Gastroenterology, 2016, 22, 1859.	1.4	44
1819	PRL3-zumab, a first-in-class humanized antibody for cancer therapy. JCI Insight, 2016, 1, e87607.	2.3	44
1820	A Case Report of Carbohydrate Antigen 19-9 Producing Advanced Gastric Cancer. Cancer and Clinical Oncology, 2016, 5, 49.	0.2	2
1821	Preoperative Chemotherapy for Gastric Cancer: Personal Interventions and Precision Medicine. BioMed Research International, 2016, 2016, 1-10.	0.9	18
1822	Management and Reconstruction of a Gastroesophageal Junction Adenocarcinoma Patient Three Years after Pancreaticoduodenectomy: A Surgical Puzzle. Case Reports in Surgery, 2016, 2016, 1-3.	0.2	1
1823	New utility of an old marker: serum low-density lipoprotein predicts histopathological response of neoadjuvant chemotherapy in locally advanced gastric cancer. OncoTargets and Therapy, 2016, Volume 9, 5041-5047.	1.0	5
1824	Chemotherapy in Elderly Patients with Gastric Cancer. Journal of Cancer, 2016, 7, 88-94.	1.2	36
1825	Development of novel HER2 inhibitors against gastric cancer derived from flavonoid source of Syzygium alternifolium through molecular dynamics and pharmacophore-based screening. Drug Design, Development and Therapy, 2016, Volume 10, 3611-3632.	2.0	16

#	Article	IF	Citations
1826	Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The, 2016, 68, 245.	0.2	8
1827	DO PROXIMAL AND DISTAL GASTRIC TUMOURS BEHAVE DIFFERENTLY?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2016, 29, 232-235.	0.5	11
1828	Esophageal cancer: comparative effectiveness of treatment options. Comparative Effectiveness Research, 0, , 1.	0.2	1
1829	Phase II study of neoadjuvant therapy with nab-paclitaxel and cisplatin followed by surgery in patients with locally advanced esophageal squamous cell carcinoma. Oncotarget, 2016, 7, 50624-50634.	0.8	13
1830	A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis. BMC Gastroenterology, 2016, 16, 8.	0.8	9
1831	Predictive Role of the Number of 18F-FDG-Positive Lymph Nodes Detected by PET/CT for Pre-Treatment Evaluation of Locally Advanced Gastric Cancer. PLoS ONE, 2016, 11, e0166836.	1.1	9
1832	Molecular mechanisms of chemoresistance in gastric cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 673.	0.8	123
1833	Paris Saponin I Sensitizes Gastric Cancer Cell Lines to Cisplatin via Cell Cycle Arrest and Apoptosis. Medical Science Monitor, 2016, 22, 3798-3803.	0.5	40
1834	Impact of Preoperative Neutrophil to Lymphocyte Ratio and Postoperative Infectious Complications on Survival After Curative Gastrectomy for Gastric Cancer. Medicine (United States), 2016, 95, e3125.	0.4	72
1835	Pretreatment Neutrophil to Lymphocyte Ratio Independently Predicts Disease-specific Survival in Resectable Gastroesophageal Junction and Gastric Adenocarcinoma. Annals of Surgery, 2016, 263, 292-297.	2.1	124
1836	Implications of Lymph Node Staging on Selection of Adjuvant Therapy for Gastric Cancer in the United States. Annals of Surgery, 2016, 263, 298-305.	2.1	25
1837	A Novel Prediction Model of Prognosis After Gastrectomy for Gastric Carcinoma. Annals of Surgery, 2016, 264, 114-120.	2.1	37
1838	Is Extended Lymphadenectomy Needed for Elderly Patients With Gastric Adenocarcinoma?. Annals of Surgical Oncology, 2016, 23, 2391-2397.	0.7	9
1839	Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long-term Survival. Annals of Surgery, 2016, 263, 1092-1101.	2.1	110
1840	Tumor regression grade in gastric cancer: Predictors and impact on outcome. Journal of Surgical Oncology, 2016, 114, 434-439.	0.8	45
1841	Open vs robotic radical gastrectomy for locally advanced gastric cancer. International Journal of Medical Robotics and Computer Assisted Surgery, 2016, 12, 502-508.	1.2	30
1842	Sparing Sphincters and Laparoscopic Resection Improve Survival by Optimizing the Circumferential Resection Margin in Rectal Cancer Patients. Medicine (United States), 2016, 95, e2669.	0.4	3
1843	Esophageal reconstruction by colon interposition after esophagectomy for cancer analysis of current indications, operative outcomes, and longâ€term survival. Journal of Surgical Oncology, 2016, 113, 159-164.	0.8	26

#	Article	IF	Citations
1844	A pilot trial of FLOT neoadjuvant chemotherapy for resectable esophagogastric junction adenocarcinoma. Medical Oncology, 2016, 33, 62.	1.2	8
1845	Gastric cancer adjuvant therapy. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 581-591.	1.0	13
1846	Discordant human epidermal growth factor receptor 2 overexpression in primary and metastatic upper gastrointestinal adenocarcinoma signifies poor prognosis. Histopathology, 2016, 68, 230-240.	1.6	17
1847	Management and outcome of cervical versus intrathoracic manifestation of cervical anastomotic leakage after transthoracic esophagectomy for cancer. Ecological Management and Restoration, 2016, 30, n/a-n/a.	0.2	27
1848	The importance of surgical margins in gastric cancer. Journal of Surgical Oncology, 2016, 113, 277-282.	0.8	29
1849	Laparoscopicâ€assisted versus open radical gastrectomy for resectable gastric cancer: Systematic review, metaâ€analysis, and trial sequential analysis of randomized controlled trials. Journal of Surgical Oncology, 2016, 113, 756-767.	0.8	46
1850	Biobanking of fresh-frozen endoscopic biopsy specimens from esophageal adenocarcinoma. Ecological Management and Restoration, 2016, 29, 1100-1106.	0.2	1
1851	The role of adjuvant chemotherapy for patients with stage II and stage III gastric adenocarcinoma after surgery plus D2 lymph node dissection: a real-world observation. SpringerPlus, 2016, 5, 728.	1.2	5
1852	Feasibility and Safety of Transhiatal Approach and D2 Total Gastrectomy after Neoadjuvant Chemotherapy for Adenocarcinoma of the Esophago-Gastric Junction: A Subset Analysis of the COMPASS Trial. Digestive Surgery, 2016, 33, 424-430.	0.6	4
1853	Which is better for gastric cancer patients, perioperative or adjuvant chemotherapy: a meta-analysis. BMC Cancer, 2016, 16, 631.	1.1	25
1854	SEOM Clinical Guideline for the diagnosis and treatment of esophageal cancer (2016). Clinical and Translational Oncology, 2016, 18, 1179-1186.	1.2	24
1855	Effect of prehabilitation in gastro-oesophageal adenocarcinoma: study protocol of a multicentric, randomised, control trialâ€"the PREHAB study. BMJ Open, 2016, 6, e012876.	0.8	53
1856	Upregulation of microRNA-34a enhances the DDP sensitivity of gastric cancer cells by modulating proliferation and apoptosis via targeting MET. Oncology Reports, 2016, 36, 2391-2397.	1.2	45
1857	Original article: role of adjuvant chemotherapy in a perioperative chemotherapy regimen for gastric cancer. BMC Cancer, 2016, 16, 650.	1.1	7
1858	Evaluation of 18F-fluorothymidine positron emission tomography ([18F]FLT-PET/CT) methodology in assessing early response to chemotherapy in patients with gastro-oesophageal cancer. EJNMMI Research, 2016, 6, 81.	1.1	2
1859	Invited Commentary: Misreading Between the Lines. Journal of the American College of Surgeons, 2016, 223, 792-793.	0.2	0
1861	Chemotherapy Effectiveness and Prognosis of Gastric Cancer Influenced by PTPN11 Polymorphisms. Cellular Physiology and Biochemistry, 2016, 39, 1537-1552.	1.1	7
1862	Neoadjuvant Therapy in Rectal Cancer - Biobanking of Preoperative Tumor Biopsies. Scientific Reports, 2016, 6, 35589.	1.6	8

#	Article	IF	Citations
1863	Upregulation of microRNA-375 increases the cisplatin-sensitivity of human gastric cancer cells by regulating ERBB2. Experimental and Therapeutic Medicine, 2016, 11, 625-630.	0.8	44
1864	Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma. Cancer Immunology, Immunotherapy, 2016, 65, 651-662.	2.0	91
1866	The impact of age on nodal metastases and survival in gastric cancer. Journal of Surgical Research, 2016, 202, 428-435.	0.8	7
1867	Human Helicase RECQL4 Drives Cisplatin Resistance in Gastric Cancer by Activating an AKTâ€“YB1â€“MDR1 Signaling Pathway. Cancer Research, 2016, 76, 3057-3066.	0.4	75
1868	Aortic Calcification Increases the Risk of Anastomotic Leakage After Ivor-Lewis Esophagectomy. Annals of Thoracic Surgery, 2016, 102, 247-252.	0.7	55
1869	A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. British Journal of Cancer, 2016, 114, 1326-1333.	2.9	35
1870	High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial. Cancer Discovery, 2016, 6, 838-851.	7.7	222
1871	Personalised Treatment in Gastric Cancer: Myth or Reality?. Current Oncology Reports, 2016, 18, 41.	1.8	16
1872	Neoadjuvant chemoradiotherapy may increase the risk of severe anastomotic complications after esophagectomy with cervical anastomosis. Langenbeck's Archives of Surgery, 2016, 401, 323-331.	0.8	15
1873	Anastomotic leak predicts diminished long-term survival after resection for gastric and esophageal cancer. Surgery, 2016, 160, 191-203.	1.0	64
1874	The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian Journal of Surgical Oncology, 2016, 7, 198-207.	0.3	14
1875	Waiting Time from Diagnosis to Treatment has no Impact on Survival in Patients with Esophageal Cancer. Annals of Surgical Oncology, 2016, 23, 2679-2689.	0.7	30
1876	Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location. Annals of Thoracic Surgery, 2016, 101, 1075-1081.	0.7	18
1877	Novel targets in the treatment of advanced gastric cancer: a perspective review. Therapeutic Advances in Medical Oncology, 2016, 8, 113-125.	1.4	54
1878	Is Linitis Plastica a Contraindication for Surgical Resection: A Multi-Institution Study of the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 1203-1211.	0.7	33
1879	Trends in upper gastro-intestinal cancer among the elderly in Denmark, 1980â€“2012. Acta OncolÃ³gica, 2016, 55, 23-28.	0.8	7
1880	Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncology Reports, 2016, 35, 699-708.	1.2	62
1881	Advanced Surgical Approaches for the Management of Esophageal Carcinoma. , 2016, , 345-362.		0

#	Article	IF	Citations
1882	Targeted therapy in gastric cancer. European Surgery - Acta Chirurgica Austriaca, 2016, 48, 278-284.	0.3	23
1883	Expression levels of HER2 and MRP1 are not prognostic factors of long-term survival in 829 patients with esophageal squamous cell carcinoma. Oncology Letters, 2016, 11, 745-752.	0.8	11
1884	Surgical Oncology Manual. , 2016, , .		1
1885	The association between four SNPs of X-ray repair cross complementing protein 1 and the sensitivity to radiotherapy in patients with esophageal squamous cell carcinoma. Oncology Letters, 2016, 11, 3508-3514.	0.8	4
1886	Recent insights in the therapeutic management of patients with gastric cancer. Digestive and Liver Disease, 2016, 48, 984-994.	0.4	31
1887	Multimodality Therapy Improves Survival in Resected Early Stage Gastric Cancer in the United States. Annals of Surgical Oncology, 2016, 23, 2936-2945.	0.7	19
1888	Increased Survival of Patients with Synchronous Colorectal Peritoneal Metastases Receiving Preoperative Chemotherapy Before Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. Annals of Surgical Oncology, 2016, 23, 2841-2848.	0.7	40
1889	LncRNA GClnc1 Promotes Gastric Carcinogenesis and May Act as a Modular Scaffold of WDR5 and KAT2A Complexes to Specify the Histone Modification Pattern. Cancer Discovery, 2016, 6, 784-801.	7.7	339
1890	Gastric cancer. Lancet, The, 2016, 388, 2654-2664.	6.3	1,560
1891	Cervical esophageal cancer: a gap in cancer knowledge. Annals of Oncology, 2016, 27, 1664-1674.	0.6	75
1893	Video-assisted thoracoscopic esophagectomy: keynote lecture. General Thoracic and Cardiovascular Surgery, 2016, 64, 380-385.	0.4	18
1894	Esophagogastric Adenocarcinoma: Is More Chemotherapy Better?. Current Treatment Options in Oncology, 2016, 17, 21.	1.3	5
1895	Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innovative Surgical Sciences, 2016, 1, 3-11.	0.4	6
1896	ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286). BMC Cancer, 2016, 16, 503.	1.1	234
1897	The effect of neoadjuvant chemotherapy and chemoradiotherapy on exercise capacity and outcome following upper gastrointestinal cancer surgery: an observational cohort study. BMC Cancer, 2016, 16, 710.	1.1	11
1898	Mutational signatures in esophageal adenocarcinoma define etiologically distinct subgroups with therapeutic relevance. Nature Genetics, 2016, 48, 1131-1141.	9.4	332
1899	An update on gastric cancer. Current Problems in Surgery, 2016, 53, 449-490.	0.6	32
1900	The multidisciplinary management of gastro-oesophageal junction tumours. Digestive and Liver Disease, 2016, 48, 1283-1289.	0.4	24

#	Article	IF	Citations
1901	Potentially Curable Cancers of the Esophagus and Stomach. Mayo Clinic Proceedings, 2016, 91, 1307-1318.	1.4	2
1902	The Role of Peri-Operative Therapy in Esophageal and Gastric Cancers. , 2016, , 87-105.		0
1904	Survival results of a randomised two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of S-1 plus cisplatin (SC) and paclitaxel plus cisplatin (PC) followed by D2 gastrectomy for resectable advanced gastric cancer. European Journal of Cancer, 2016, 62, 103-111.	1.3	39
1905	Feasibility of Exercise Training in Cancer Patients Scheduled for Elective Gastrointestinal Surgery. Digestive Surgery, 2016, 33, 439-447.	0.6	19
1906	Cancer of the Esophagus. , 2016, , 843-864.e7.		0
1907	Gastric/GE Junction Cancer. , 2016, , 906-933.e5.		3
1908	Preoperative Body Mass Index May Determine the Prognosis of Advanced Gastric Cancer. Nutrition and Cancer, 2016, 68, 1295-1300.	0.9	21
1909	Docetaxel, Cisplatin, and 5â€Fluorouracil as perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma. Cancer Medicine, 2016, 5, 3085-3093.	1.3	16
1910	MicroRNA-153 inhibits tumor progression in esophageal squamous cell carcinoma by targeting SNAI1. Tumor Biology, 2016, 37, 16135-16140.	0.8	27
1911	Stageâ€directed individualized therapy in esophageal cancer. Annals of the New York Academy of Sciences, 2016, 1381, 50-65.	1.8	15
1912	Outcome of neoadjuvant therapies for cancer of the oesophagus or gastro-oesophageal junction based on a national data registry. British Journal of Surgery, 2016, 103, 1864-1873.	0.1	26
1913	Proteomics approach to identify biomarkers for upper gastrointestinal cancer. Expert Review of Proteomics, 2016, 13, 1041-1053.	1.3	5
1914	Development and Validation of a Six-Gene Recurrence Risk Score Assay for Gastric Cancer. Clinical Cancer Research, 2016, 22, 6228-6235.	3.2	40
1915	Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 2016, 27, v38-v49.	0.6	1,212
1917	Targeting deficient DNA damage repair in gastric cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 1757-1766.	0.9	16
1918	Diagnosis and Management of Oesophageal Cancer in Bariatric Surgical Patients. Journal of Gastrointestinal Surgery, 2016, 20, 1683-1691.	0.9	13
1919	Gastroesophageal Junction Tumors. Annals of Surgical Oncology, 2016, 23, 3798-3800.	0.7	7
1920	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. Journal of Surgical Oncology, 2016, 114, 859-864.	0.8	13

#	Article	IF	Citations
1921	Comparison of neoadjuvant versus a surgery first approach for gastric and esophagogastric cancer. Journal of Surgical Oncology, 2016, 114, 296-303.	0.8	9
1922	Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Medicine, 2016, 5, 1444-1453.	1.3	50
1923	Timing of Adjuvant Chemotherapy and Impact on Survival for Resected Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 4203-4213.	0.7	29
1924	Whatâ€™s the Best Way to Treat GE Junction Tumors? Approach Like Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 3780-3785.	0.7	23
1925	A phase II study of neoadjuvant chemotherapy with Sâ€1 and cisplatin for stage III gastric cancer: KUGC03. Journal of Surgical Oncology, 2016, 113, 36-41.	0.8	17
1926	Predictive factors for recurrence in T2N0 and T3N0 gastric cancer patients. Langenbeck's Archives of Surgery, 2016, 401, 823-828.	0.8	10
1927	MET in gastric cancer â€“ discarding a 10% cutoff rule. Histopathology, 2016, 68, 241-253.	1.6	44
1928	Perioperative outcomes of esophageal cancer surgery in a mid-volume institution in the era of centralization. Langenbeck's Archives of Surgery, 2016, 401, 787-795.	0.8	8
1929	Esophageal cancer: The latest on chemoprevention and state of the art therapies. Pharmacological Research, 2016, 113, 236-244.	3.1	33
1930	SOX9 Elevation Acts with Canonical WNT Signaling to Drive Gastric Cancer Progression. Cancer Research, 2016, 76, 6735-6746.	0.4	115
1931	A Step-Wise Approach to Total Laparoscopic Gastrectomy with Jejunal Pouch Reconstruction: How and Why We Do It. Journal of Gastrointestinal Surgery, 2016, 20, 1908-1915.	0.9	13
1932	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. Digestive and Liver Disease, 2016, 48, 1498-1502.	0.4	8
1933	Role of histological regression grade after two neoadjuvant approaches with or without radiotherapy in locally advanced gastric cancer. British Journal of Cancer, 2016, 115, 655-663.	2.9	33
1934	Identification of key genes associated with gastric cancer based on DNA microarray data. Oncology Letters, 2016, 11, 525-530.	0.8	48
1935	Role of omentectomy as part of radical surgery for gastric cancer. British Journal of Surgery, 2016, 103, 1497-1503.	0.1	50
1936	The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology, 2016, 90, 239-247.	0.9	44
1937	Molecular profiles in foregut oncology. Cancer Genetics, 2016, 209, 537-553.	0.2	0
1938	Targeted Treatment of Esophagogastric Cancer. Oncology Research and Treatment, 2016, 39, 788-794.	0.8	2

#	Article	IF	Citations
1939	Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Ecological Management and Restoration, 2016, 30, 1-7.	0.2	15
1940	Chemoradiotherapy in tumours of the oesophagus and gastro-oesophageal junction. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2016, 30, 551-563.	1.0	12
1941	Survival impact of neoadjuvant therapy in resected pancreatic cancer: A Prospective Cohort Study involving 18,332 patients from the National Cancer Data Base. International Journal of Surgery, 2016, 34, 96-102.	1.1	43
1942	No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base. Journal of the American College of Surgeons, 2016, 223, 784-792e1.	0.2	21
1943	Survival rates in T1 and T2 gastric cancer: A Western report. Journal of Surgical Oncology, 2016, 114, 602-606.	0.8	16
1944	The Role of Induction Therapy for Esophageal Cancer. Thoracic Surgery Clinics, 2016, 26, 295-304.	0.4	1
1945	Current treatment options for esophageal diseases. Annals of the New York Academy of Sciences, 2016, 1381, 139-151.	1.8	11
1947	Gastrectomie per cancro: principi generali diagnostici e terapeutici. EMC - Tecniche Chirurgiche Addominale, 2016, 22, 1-18.	0.1	0
1948	Phase 1/2 Study of the Addition of Cisplatin to Adjuvant Chemotherapy With Image Guided High-Precision Radiation Therapy for Completely Resected Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2016, 96, 994-1002.	0.4	3
1949	Adjuvant chemoradiotherapy combined with cisplatin, 5-fluorouracil and folinic acid for locally advanced gastric cancer. Journal of Oncological Science, 2016, 2, 12-15.	0.1	3
1951	FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophagealâ€“gastric junction. Abdominal Radiology, 2016, 41, 2089-2094.	1.0	7
1952	The physiotherapist and the esophageal cancer patient: from prehabilitation to rehabilitation. Ecological Management and Restoration, 2016, 30, 1-12.	0.2	19
1953	Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World Journal of Surgical Oncology, 2016, 14, 209.	0.8	31
1954	Prognostic impact of extracapsular lymph node involvement after neoadjuvant therapy and oesophagectomy. British Journal of Surgery, 2016, 103, 1658-1664.	0.1	17
1955	ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 2016, 51, 56-64.	0.8	129
1956	Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer. Scientific Reports, 2016, 6, 22172.	1.6	90
1957	Adjuvant Chemotherapy: Whatâ€™s the Rush?. Annals of Surgical Oncology, 2016, 23, 4130-4133.	0.7	0
1958	Quality and outcomes of synchronous twoâ€team Ivorâ€“Lewis oesophagectomy: Revisiting a variant technique. Journal of Surgical Oncology, 2016, 114, 719-724.	0.8	1

#	Article	IF	Citations
1959	Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncology, The, 2016, 17, 1697-1708.	5.1	532
1961	Real-time optical diagnosis of gastric cancer with serosal invasion using multiphoton imaging. Scientific Reports, 2016, 6, 31004.	1.6	18
1962	Gastric Cancer Management â€" East vs. West?. , 2016, , 133-152.		0
1963	The impact of neoadjuvant chemotherapy on cardiopulmonary physical fitness in gastro-oesophageal adenocarcinoma. Annals of the Royal College of Surgeons of England, 2016, 98, 396-400.	0.3	44
1964	Systematic review of partial hepatic resection to treat hepatic metastases in patients with gastric cancer. Medicine (United States), 2016, 95, e5235.	0.4	7
1965	Phase II study of neo-adjuvant chemotherapy for locally advanced gastric cancer. BMJ Open Gastroenterology, 2016, 3, e000095.	1.1	9
1966	Liver Resection and Transplantation for Patients With Hepatocellular Carcinoma Beyond Milan Criteria. Annals of Surgery, 2016, 264, 650-658.	2.1	63
1967	Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clinical Pathology, 2016, 16, 13.	1.8	25
1968	Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomarker Research, 2016, 4, 10.	2.8	25
1969	Different survival outcomes after curative R0-resection for Eastern Asian and European gastric cancer. Medicine (United States), 2016, 95, e4261.	0.4	7
1970	DWI as a Quantitative Biomarker in Predicting Chemotherapeutic Efficacy at Multitime Points on Gastric Cancer Lymph Nodes Metastases. Medicine (United States), 2016, 95, e3236.	0.4	10
1971	Comparison of laparoscopy-assisted and open radical gastrectomy for advanced gastric cancer. Medicine (United States), 2016, 95, e3936.	0.4	34
1972	Perioperative transfusion of leukocyte depleted blood products in gastric cancer patients negatively influences oncologic outcome. Medicine (United States), 2016, 95, e4322.	0.4	18
1973	The impact of neoadjuvant therapy for gastroesophageal adenocarcinoma on postoperative morbidity and mortality. Journal of Surgical Oncology, 2016, 113, 560-564.	0.8	8
1974	Gastric cancer: <scp>A</scp>ustralian outcomes of multiâ€modality treatment with curative intent. ANZ Journal of Surgery, 2016, 86, 386-390.	0.3	3
1975	Improving care for patients with oesophageal and gastric cancer: impact of a statewide multidisciplinary team. ANZ Journal of Surgery, 2016, 86, 270-273.	0.3	11
1976	Evaluation of 64â€Channel Contrastâ€Enhanced Multiâ€detector Row Computed Tomography for Preoperative N Staging in cT2â€4 Gastric Carcinoma. World Journal of Surgery, 2016, 40, 165-171.	0.8	15
1977	Dysphagia is not a Valuable Indicator of Tumor Response after Preoperative Chemotherapy for R0 Resected Patients with Adenocarcinoma of the Gastroesophageal Junction. Scandinavian Journal of Surgery, 2016, 105, 97-103.	1.3	3

#	Article	IF	Citations
1978	Interaction of Postoperative Morbidity and Receipt of Adjuvant Therapy on Long-Term Survival After Resection for Gastric Adenocarcinoma: Results From the U.S. Gastric Cancer Collaborative. Annals of Surgical Oncology, 2016, 23, 2398-2408.	0.7	63
1980	Application of FLEEOX Preoperative Chemotherapy via Intra-arterial and Intravenous Administration in Treatment of Unresectable Locally Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 1421-1427.	0.9	10
1981	Laparoscopic Total Gastrectomy with D2 Lymphadenectomy and Side-to-Side Stapled Esophagojejunostomy. Journal of Gastrointestinal Surgery, 2016, 20, 1523-1529.	0.9	5
1983	Neoadjuvant chemotherapy in controlling lymph node metastasis for locally advanced gastric cancer in a Chinese population. Journal of Chemotherapy, 2016, 28, 59-64.	0.7	10
1984	Pathologic Complete Response Is an Independent Predictor of Improved Survival Following Neoadjuvant Chemoradiation for Esophageal Adenocarcinoma. Journal of Gastrointestinal Surgery, 2016, 20, 1541-1546.	0.9	39
1985	Effect of Pathologic Tumor Response and Nodal Status on Survival in the Medical Research Council Adjuvant Gastric Infusional Chemotherapy Trial. Journal of Clinical Oncology, 2016, 34, 2721-2727.	0.8	214
1986	CRS-HIPEC Prolongs Survival but is Not Curative for Patients with Peritoneal Carcinomatosis of Gastric Cancer. Annals of Surgical Oncology, 2016, 23, 3972-3977.	0.7	46
1987	Overexpressed targeting protein for Xklp2 (TPX2) serves as a promising prognostic marker and therapeutic target for gastric cancer. Cancer Biology and Therapy, 2016, 17, 824-832.	1.5	47
1988	The Impact of Positive Margins on Outcome Among Patients With Gastric Cancer Treated With Radiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2016, 39, 243-247.	0.6	5
1989	The Efficacy of Taxanes- and Oxaliplatin-Based Chemotherapy in the Treatment of Gastric Cancer After D2 Gastrectomy for Different Lauren Types. Medicine (United States), 2016, 95, e2785.	0.4	5
1992	CaracterizaciÃ³n de 130 pacientes sometidos a gastrectomÃa por cÃ¡ncer gÃ¡strico en el Instituto de CancerologÃaâ€“ClÃnica Las AmÃ©ricas de MedellÃn. Revista Colombiana De CancerologÃa, 2016, 20, 73-78.	0.0	1
1993	Molecular targeted photoimmunotherapy for HER2-positive human gastric cancer in combination with chemotherapy results in improved treatment outcomes through different cytotoxic mechanisms. BMC Cancer, 2016, 16, 37.	1.1	34
1994	The association between the duration of fluoropyrimidine-based adjuvant chemotherapy and survival in stage II or III gastric cancer. World Journal of Surgical Oncology, 2016, 14, 102.	0.8	4
1995	Immediate tumor resection in patients with locally advanced gastroesophageal adenocarcinoma with nonresponse to chemotherapy after 4Âweeks of treatment versus resection after completion of chemotherapy (OPTITREAT trial, DRKS00004668): study protocol for a randomized controlled pilot trial. Pilot and Feasibility Studies, 2016, 2, 18.	0.5	1
1996	Interaction of Chemotherapy and Radiation. , 2016, , 63-79.e4.		4
1997	Characterising timing and pattern of relapse following surgery for localised oesophagogastric adenocarcinoma: a retrospective study. BMC Cancer, 2016, 16, 112.	1.1	17
1998	The value of FDGâ€PET in the staging of gastric adenocarcinoma: A single institution retrospective review. Journal of Surgical Oncology, 2016, 113, 640-646.	0.8	14
1999	Does the modified Glasgow Prognostic Score (mGPS) have a prognostic role in esophageal cancer?. Journal of Surgical Oncology, 2016, 113, 732-737.	0.8	20

#	Article	IF	Citations
2000	Significant understaging is seen in clinically staged T2N0 esophageal cancer patients undergoing esophagectomy. Ecological Management and Restoration, 2016, 29, 320-325.	0.2	28
2001	Preoperative locoregional staging of gastric cancer: is there a place for magnetic resonance imaging? Prospective comparison with EUS and multidetector computed tomography. Gastric Cancer, 2016, 19, 216-225.	2.7	44
2002	Risk factors for selection of patients at high risk of recurrence or death after complete surgical resection in stage I gastric cancer. Gastric Cancer, 2016, 19, 226-233.	2.7	32
2003	A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. Gastric Cancer, 2016, 19, 245-254.	2.7	7
2004	The survival difference between gastric cancer patients from the UK and Japan remains after weighted propensity score analysis considering all background factors. Gastric Cancer, 2016, 19, 479-489.	2.7	22
2005	Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncology, The, 2016, 17, 309-318.	5.1	560
2006	A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Annals of Oncology, 2016, 27, 660-667.	0.6	300
2007	Advances in the Management of Gastric and Gastroesophageal Cancers. Current Oncology Reports, 2016, 18, 13.	1.8	7
2008	Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer. Clinical Oncology, 2016, 28, 146-151.	0.6	67
2009	The MSHA strain of Pseudomonas aeruginosa (PA-MSHA) inhibits gastric carcinoma progression by inducing M1 macrophage polarization. Tumor Biology, 2016, 37, 6913-6921.	0.8	16
2010	Clinicopathological characteristics ofRHOAmutations in a Central European gastric cancer cohort. Journal of Clinical Pathology, 2016, 69, 70-75.	1.0	17
2011	Monoclonal antibodies-based treatment in gastric cancer: current status and future perspectives. Tumor Biology, 2016, 37, 127-140.	0.8	9
2012	Surgical management of advanced gastric cancer: An evolving issue. European Journal of Surgical Oncology, 2016, 42, 18-27.	0.5	76
2013	Impact of Positive Margins on Survival in Patients Undergoing Esophagogastrectomy for Esophageal Cancer. Annals of Thoracic Surgery, 2016, 101, 1060-1067.	0.7	27
2014	Total laparoscopic resection for advanced gastric cancer is safe and feasible in the Western population. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 3552-3558.	1.3	12
2015	Immune checkpoints programmed death 1 ligand 1 and cytotoxic T lymphocyte associated molecule 4 in gastric adenocarcinoma. OncoImmunology, 2016, 5, e1100789.	2.1	45
2016	Lymph node ratio as a novel and simple prognostic factor in advanced gastric cancer. European Journal of Surgical Oncology, 2016, 42, 1253-1260.	0.5	65
2017	Cisplatin versus carboplatin: comparative review of therapeutic management in solid malignancies. Critical Reviews in Oncology/Hematology, 2016, 102, 37-46.	2.0	219

#	Article	IF	Citations
2018	Correlation between preoperative endoscopic ultrasound and surgical pathology staging of gastric adenocarcinoma: A single institution retrospective review. Journal of Surgical Oncology, 2016, 113, 42-45.	0.8	13
2019	Correlation analyses between pre- and post-operative adverse events in gastric cancer patients receiving preoperative treatment and gastrectomy. BMC Cancer, 2016, 16, 29.	1.1	1
2020	Medical Practice Variations in Cancer Surgery. , 2016, , 361-381.		0
2021	Feasibility of neoadjuvant S-1 and oxaliplatin followed by surgery for resectable advanced gastric adenocarcinoma. Surgery Today, 2016, 46, 1076-1082.	0.7	19
2022	National Trends in Utilization of Endoscopic Ultrasound for Gastric Cancer: a SEER-Medicare Study. Journal of Gastrointestinal Surgery, 2016, 20, 154-164.	0.9	5
2023	Esophageal Cancer: Role of Imaging in Primary Staging and Response Assessment Post Neoadjuvant Therapy. Seminars in Ultrasound, CT and MRI, 2016, 37, 339-351.	0.7	13
2024	Neoadjuvant systemic therapy for patients with gastric cancer: Current concepts and outcomes. Journal of Oncological Science, 2016, 1, 25-30.	0.1	1
2025	Staging of adenocarcinoma of the gastroesophageal junction. European Journal of Surgical Oncology, 2016, 42, 400-406.	0.5	35
2026	The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clinical Cancer Research, 2016, 22, 2323-2328.	3.2	28
2027	Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Japanese Journal of Radiology, 2016, 34, 35-42.	1.0	3
2028	Cardia and Non-Cardia Gastric Cancer Have Similar Stage-for-Stage Prognoses After R0 Resection: a Large-Scale, Multicenter Study in China. Journal of Gastrointestinal Surgery, 2016, 20, 700-707.	0.9	19
2029	The clinical significance of para-aortic nodal dissection for advanced gastric cancer. European Journal of Surgical Oncology, 2016, 42, 1448-1454.	0.5	15
2030	Adjuvant Therapy Improves Survival for T2N0 Gastric Cancer Patients with Sub-optimal Lymphadenectomy. Annals of Surgical Oncology, 2016, 23, 1956-1962.	0.7	21
2031	Incidence and management of chylothorax after Ivor Lewis esophagectomy for cancer of the esophagus. Journal of Thoracic and Cardiovascular Surgery, 2016, 151, 1398-1404.	0.4	63
2032	Utility of Bromelain and N-Acetylcysteine in Treatment of Peritoneal Dissemination of Gastrointestinal Mucin-Producing Malignancies. , 2016, , .		17
2033	Monoclonal antibodies for treating gastric cancer: promises and pitfalls. Expert Opinion on Biological Therapy, 2016, 16, 759-769.	1.4	6
2034	The Oncological Value of Omentectomy in Gastrectomy for Cancer. Journal of Gastrointestinal Surgery, 2016, 20, 885-890.	0.9	31
2035	Management of Tracheoâ€•or Bronchoesophageal Fistula After Ivorâ€Lewis Esophagectomy. World Journal of Surgery, 2016, 40, 1680-1687.	0.8	37

#	Article	IF	Citations
2036	Is There Any Role of Adjuvant Chemotherapy for T3N0M0 or T1N2M0 Gastric Cancer Patients in Stage II in the 7th TNM but Stage I in the 6th TNM System?. Annals of Surgical Oncology, 2016, 23, 1234-1243.	0.7	18
2037	Adjuvant Therapy Completion Rates in Patients with Gastric Cancer Undergoing Perioperative Chemotherapy Versus a Surgery-First Approach. Journal of Gastrointestinal Surgery, 2016, 20, 172-179.	0.9	16
2038	Frequency of Resection After Preoperative Chemotherapy or Chemoradiotherapy for Gastric Adenocarcinoma. Annals of Surgical Oncology, 2016, 23, 1948-1955.	0.7	10
2039	Feeding jejunostomy tube placement during resection of gastric cancers. Journal of Surgical Research, 2016, 200, 189-194.	0.8	19
2040	Perioperative Treatment, Not Surgical Approach, Influences Overall Survival in Patients with Gastroesophageal Junction Tumors: A Nationwide, Population-Based Study in The Netherlands. Annals of Surgical Oncology, 2016, 23, 1632-1638.	0.7	14
2041	Current concepts and future potential in neoadjuvant chemotherapy for esophageal cancer. Expert Review of Gastroenterology and Hepatology, 2016, 10, 383-392.	1.4	12
2042	Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: Evidence from the American College of Surgeons National Cancer Database. Surgery, 2016, 159, 1099-1112.	1.0	27
2043	Preoperative versus postoperative docetaxelâ€“cisplatinâ€“fluorouracil (TCF) chemotherapy in locally advanced resectable gastric carcinoma: 10-year follow-up of the SAKK 43/99 phase III trial. Annals of Oncology, 2016, 27, 668-673.	0.6	42
2044	Laparoscopy, computerised tomography and fluorodeoxyglucose positron emission tomography in the management of gastric and gastro-oesophageal junction cancers. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 2690-2696.	1.3	15
2045	HER2 Expression in Gastric Adenocarcinomaâ€”a Study in a Tertiary Care Centre in South India. Indian Journal of Surgical Oncology, 2016, 7, 18-24.	0.3	4
2046	Is signet-ring cell carcinoma a specific entity among gastric cancers?. Gastric Cancer, 2016, 19, 1027-1040.	2.7	60
2047	Association Between Clinically Staged Node-Negative Esophageal Adenocarcinoma and Overall Survival Benefit From Neoadjuvant Chemoradiation. JAMA Surgery, 2016, 151, 234.	2.2	37
2048	Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?. Annals of Surgical Oncology, 2016, 23, 626-632.	0.7	15
2049	Postoperative adjuvant treatment for gastric cancer improves long-term survival after curative resection and D2 lymphadenectomy. Results from a Latin American Center. European Journal of Surgical Oncology, 2016, 42, 94-102.	0.5	9
2050	Improved survival in resected oesophageal and gastric adenocarcinomas over a decade: the Royal Marsden experience 2001â€“2010. Gastric Cancer, 2016, 19, 1114-1124.	2.7	8
2051	Rates of lymph node metastasis and survival in T1a gastric adenocarcinoma in Western populations. Gastrointestinal Endoscopy, 2016, 83, 1184-1192.e1.	0.5	32
2052	Targeting HER 2 and angiogenesis in gastric cancer. Expert Review of Anticancer Therapy, 2016, 16, 111-122.	1.1	15
2053	Minimally Invasive Versus Open Total Gastrectomy for Gastric Cancer: A Systematic Review and Metaâ€analysis of Shortâ€Term Outcomes and Completeness of Resection. World Journal of Surgery, 2016, 40, 148-157.	0.8	35

#	Article	IF	Citations
2054	Efficacy of neoadjuvant chemotherapy with docetaxel, cisplatin and S-1 for resectable locally advanced gastric cancer. International Journal of Clinical Oncology, 2016, 21, 102-109.	1.0	12
2055	Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer. European Radiology, 2016, 26, 311-321.	2.3	32
2056	A phase II study of an enhanced recovery after surgery protocol in gastric cancer surgery. Gastric Cancer, 2016, 19, 961-967.	2.7	47
2057	BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer. Gastric Cancer, 2016, 19, 827-838.	2.7	26
2058	Postoperative Morbidity and Mortality Rates are Not Increased for Patients with Gastric and Gastroesophageal Cancer Who Undergo Preoperative Chemoradiation Therapy. Annals of Surgical Oncology, 2016, 23, 156-162.	0.7	29
2059	Assessment of patient-reported outcome measures in the surgical treatment of patients with gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 1920-1929.	1.3	18
2060	Accuracy of staging laparoscopy in detecting peritoneal dissemination in patients with gastroesophageal adenocarcinoma. Ecological Management and Restoration, 2016, 29, 236-240.	0.2	18
2061	Redefining early gastric cancer. Surgical Endoscopy and Other Interventional Techniques, 2016, 30, 24-37.	1.3	35
2062	Impact of Combination Criteria of Nodal Counts and Sizes on Preoperative MDCT in Advanced Gastric Cancer. World Journal of Surgery, 2016, 40, 158-164.	0.8	5
2063	A phase II study of perioperative S-1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer, 2016, 19, 586-596.	2.7	19
2064	Osteopontin, E-cadherin, and Î²-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. Gastric Cancer, 2016, 19, 412-420.	2.7	37
2065	Predictors of outcome after surgery for gastric cancer in a Western cohort. ANZ Journal of Surgery, 2016, 86, 469-474.	0.3	6
2066	Comparative Investigation of Postoperative Complications in Patients With Gastroesophageal Junction Cancer Treated With Preoperative Chemotherapy or Surgery Alone. Scandinavian Journal of Surgery, 2016, 105, 22-28.	1.3	5
2067	Glucose transporters 1, 3, 6, and 10 are expressed in gastric cancer and glucose transporter 3 is associated with UICC stage and survival. Gastric Cancer, 2017, 20, 83-91.	2.7	48
2068	Phase 2 study of adjuvant chemotherapy with docetaxel, capecitabine, and cisplatin in patients with curatively resected stage IIIBâ€“IV gastric cancer. Gastric Cancer, 2017, 20, 182-189.	2.7	6
2069	Lymph Node Burden as a Predictive Factor for Selective Chemoradiotherapy in Patients With Locally Advanced Gastric Cancer After a D2 Dissection. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 375-380.	0.6	8
2070	The Italian Research Group for Gastric Cancer (GIRCG) guidelines for gastric cancer staging and treatment: 2015. Gastric Cancer, 2017, 20, 20-30.	2.7	144
2071	Impact of Extent of Lymphadenectomy on Survival, Post Neoadjuvant Chemotherapy and Transthoracic Esophagectomy. Annals of Surgery, 2017, 265, 750-756.	2.1	53

#	Article	IF	Citations
2072	Advanced gastric adenocarcinoma: optimizing therapy options. Expert Review of Clinical Pharmacology, 2017, 10, 1-9.	1.3	19
2074	Metabolic nodal response as a prognostic marker after neoadjuvant therapy for oesophageal cancer. British Journal of Surgery, 2017, 104, 408-417.	0.1	11
2075	Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study. Clinical and Translational Gastroenterology, 2017, 8, e209.	1.3	17
2076	Potential role of metronomic chemotherapy in the treatment of esophageal and gastroesophageal cancer. Cancer Letters, 2017, 400, 267-275.	3.2	5
2077	Western strategy for EGJ carcinoma. Gastric Cancer, 2017, 20, 60-68.	2.7	47
2078	Curative resection for locally advanced sigmoid colon cancer using neoadjuvant chemotherapy with FOLFOX plus panitumumab: A case report. International Journal of Surgery Case Reports, 2017, 31, 128-131.	0.2	9
2079	Novel Calculator to Estimate Overall Survival Benefit from Neoadjuvant Chemoradiation in Patients with Esophageal Adenocarcinoma. Journal of the American College of Surgeons, 2017, 224, 884-894e1.	0.2	26
2080	Anti-angiogenesis: disappointment in localised oesophagogastric cancer. Lancet Oncology, The, 2017, 18, 278-279.	5.1	4
2081	Validation of micro<scp>RNA</scp> pathway polymorphisms in esophageal adenocarcinoma survival. Cancer Medicine, 2017, 6, 361-373.	1.3	11
2082	Hybrid minimally invasive esophagectomy vs. open esophagectomy: a matched case analysis in 120 patients. Langenbeck's Archives of Surgery, 2017, 402, 323-331.	0.8	44
2083	Molecular classification of gastric cancer. Expert Review of Molecular Diagnostics, 2017, 17, 293-301.	1.5	72
2084	Update on Neoadjuvant Regimens for Patients with Operable Oesophageal/Gastrooesophageal Junction Adenocarcinomas and Squamous Cell Carcinomas. Current Oncology Reports, 2017, 19, 7.	1.8	8
2085	Current Progress in the Adjuvant Treatment of Gastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 225-239.	0.6	11
2086	The Yield of Staging Laparoscopy in Gastric Cancer is Affected by Racial and Ethnic Differences in Disease Presentation. Annals of Surgical Oncology, 2017, 24, 1787-1794.	0.7	17
2087	NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma. European Journal of Cancer, 2017, 74, 38-46.	1.3	37
2088	Weight loss and quality of life in patients surviving 2 years after gastric cancer resection. European Journal of Surgical Oncology, 2017, 43, 1337-1343.	0.5	43
2089	Cryptotanshinone potentiates the antitumor effects of doxorubicin on gastric cancer cells via inhibition of STAT3 activity. Journal of International Medical Research, 2017, 45, 220-230.	0.4	30
2090	Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surgery, 2017, 17, 14.	0.6	27

#	Article	IF	Citations
2091	Management of Gastroesophageal Junction Tumors. Surgical Clinics of North America, 2017, 97, 265-275.	0.5	13
2092	Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEERâ€“Medicare study. Gastric Cancer, 2017, 20, 811-824.	2.7	8
2093	Minimally Invasive Surgical Approaches to Gastric Resection. Surgical Clinics of North America, 2017, 97, 249-264.	0.5	16
2094	It Is Time to Stop Using Epirubicin to Treat Any Patient With Gastroesophageal Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 475-477.	0.8	25
2095	Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity scoreâ€matched analysis comparing toxicity, pathologic outcome, and survival. Journal of Surgical Oncology, 2017, 115, 812-820.	0.8	21
2096	Perioperative chemotherapy for resectable gastric cancer â€“ what is the evidence?. Scandinavian Journal of Gastroenterology, 2017, 52, 647-653.	0.6	11
2097	Comparison of gastric-cancer radiotherapy performed with volumetric modulated arc therapy or single-field uniform-dose proton therapy. Acta OncolÃ³gica, 2017, 56, 832-838.	0.8	11
2098	Increasing survival gap between young and elderly gastric cancer patients. Gastric Cancer, 2017, 20, 919-928.	2.7	37
2099	Effect of neoadjuvant chemotherapy on HER-2 expression in surgically treated gastric and oesophagogastric junction carcinoma: a multicentre Italian study. Updates in Surgery, 2017, 69, 35-43.	0.9	5
2100	Safety and feasibility of minimally invasive gastrectomy during the early introduction in the Netherlands: short-term oncological outcomes comparable to open gastrectomy. Gastric Cancer, 2017, 20, 853-860.	2.7	31
2101	Radiation Therapy for Locally Advanced Esophageal Cancer. Surgical Oncology Clinics of North America, 2017, 26, 257-276.	0.6	15
2102	Mismatch Repair Deficiency, Microsatellite Instability, and Survival. JAMA Oncology, 2017, 3, 1197.	3.4	398
2103	Prognostic factors for survival in patients with pT1 N+ or T2â€“3 N0 gastric cancer in Japan. British Journal of Surgery, 2017, 104, 885-890.	0.1	11
2104	Neoadjuvant chemotherapy for gastric adenocarcinoma in Japan. Surgery Today, 2017, 47, 899-907.	0.7	20
2105	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2â€“3 trial. Lancet Oncology, The, 2017, 18, 357-370.	5.1	244
2106	Analysis of PIK3CA mutations and PI3K pathway proteins in advanced gastric cancer. Journal of Surgical Research, 2017, 212, 195-204.	0.8	27
2107	Exclusive neoadjuvant chemotherapy in locally advanced resectable gastric and gastro-esophageal junction adenocarcinoma. Digestive and Liver Disease, 2017, 49, 552-556.	0.4	6
2108	A High Lymph Node Yield is Associated with Prolonged Survival in Elderly Patients Undergoing Curative Gastrectomy for Cancer: A Dutch Population-Based Cohort Study. Annals of Surgical Oncology, 2017, 24, 2213-2223.	0.7	20

#	Article	IF	Citations
2109	Adjuvant therapy for locally advanced gastric cancer. Surgery Today, 2017, 47, 1295-1302.	0.7	52
2110	Pre-treatment MDCT-based texture analysis for therapy response prediction in gastric cancer: Comparison with tumour regression grade at final histology. European Journal of Radiology, 2017, 90, 129-137.	1.2	55
2111	MACC1 mediates chemotherapy sensitivity of 5-FU and cisplatin via regulating MCT1 expression in gastric cancer. Biochemical and Biophysical Research Communications, 2017, 485, 665-671.	1.0	23
2112	Controversies and Consensus in Preoperative Therapy of Esophageal and Gastroesophageal Junction Cancers. Surgical Oncology Clinics of North America, 2017, 26, 241-256.	0.6	4
2113	Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers. European Journal of Cancer, 2017, 76, 8-16.	1.3	25
2114	Postoperative fluid overload is a risk factor for adverse surgical outcome in patients undergoing esophagectomy for esophageal cancer: a retrospective study in 335 patients. BMC Surgery, 2017, 17, 6.	0.6	39
2115	Differences in the multimodal treatment of gastric cancer: East versus west. Journal of Surgical Oncology, 2017, 115, 603-614.	0.8	72
2116	Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. International Journal of Clinical Oncology, 2017, 22, 476-483.	1.0	73
2117	Pre-operative treatments for adenocarcinoma of the lower oesophagus and gastro-oesophageal junction: a review of the current evidence from randomized trials. Medical Oncology, 2017, 34, 40.	1.2	6
2118	The Role of Fluoropirimidines in Gastrointestinal Tumours: from the Bench to the Bed. Journal of Gastrointestinal Cancer, 2017, 48, 135-147.	0.6	8
2119	Patterns of Initial Recurrence in Gastric Adenocarcinoma in the Era of Preoperative Therapy. Annals of Surgical Oncology, 2017, 24, 2679-2687.	0.7	69
2120	FGF7/FGFR2 signal promotes invasion and migration in human gastric cancer through upregulation of thrombospondin-1. International Journal of Oncology, 2017, 50, 1501-1512.	1.4	94
2121	Quality of life with biweekly docetaxel and capecitabine in advanced gastro-oesophageal cancer. Supportive Care in Cancer, 2017, 25, 2771-2777.	1.0	3
2122	Future Directions in Improving Outcomes for Patients with Gastric and Esophageal Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 545-552.	0.9	7
2123	Management of Locally Advanced Gastroesophageal Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 441-452.	0.9	14
2124	Preoperative Chemoradiotherapy Versus Perioperative Chemotherapy for Patients With Resectable Esophageal or Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2282-2290.	0.7	39
2125	A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis Treated with Preoperative FOLFOX Chemotherapy Followed by Radical Subtotal Gastrectomy and D2 Lymph Node Dissection. Case Reports in Oncology, 2017, 10, 182-191.	0.3	2
2126	Significance of blood neutrophil-to-lymphocyte ratio for prognostic stratification of patients with gastroesophageal junction adenocarcinoma in the era of the 8th edition of the American Joint Committee on Cancer (AJCC8) staging. Medical Oncology, 2017, 34, 116.	1.2	6

#	Article	IF	Citations
2127	Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma. Lancet Oncology, The, 2017, 18, e243.	5.1	1
2128	Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Tumor Biology, 2017, 39, 101042831769757.	0.8	16
2130	Identification of a TLR2-regulated gene signature associated with tumor cell growth in gastric cancer. Oncogene, 2017, 36, 5134-5144.	2.6	56
2131	Early results of a randomized two-by-two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/S-1 and docetaxel/cisplatin/S-1 as neoadjuvant chemotherapy for locally advanced gastric cancer. Annals of Oncology, 2017, 28, 1876-1881.	0.6	55
2132	Multicenter Phase 2 Study of Peri-Irradiation Chemotherapy Plus Intensity Modulated Radiation Therapy With Concurrent Weekly Docetaxel for Inoperable or Medically Unresectable Nonmetastatic Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1096-1105.	0.4	18
2133	A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy. Genome Research, 2017, 27, 902-912.	2.4	27
2134	Current status of ramucirumab in gastroesophageal adenocarcinoma. Future Oncology, 2017, 13, 1585-1592.	1.1	3
2135	Perioperative Chemotherapy in Elderly Patients with Locally Advanced Adenocarcinoma of the Stomach and the Esophagogastric Junction: A Retrospective Cohort Analysis of Toxicity and Efficacy at the National Center for Tumor Diseases, Heidelberg. Oncology, 2017, 92, 291-298.	0.9	3
2136	Role of Rac1 Pathway in Epithelial-to-Mesenchymal Transition and Cancer Stem-like Cell Phenotypes in Gastric Adenocarcinoma. Molecular Cancer Research, 2017, 15, 1106-1116.	1.5	74
2137	MiR-33b-5p sensitizes gastric cancer cells to chemotherapy drugs via inhibiting HMGA2 expression. Journal of Drug Targeting, 2017, 25, 653-660.	2.1	29
2138	Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. British Journal of Surgery, 2017, 104, 1226-1234.	0.1	9
2139	Routine Radiologic Contrast Agent Examination After Gastrectomy for Gastric Cancer Is Not Useful. Journal of Gastrointestinal Surgery, 2017, 21, 801-806.	0.9	7
2140	Persistent Dysphagia After Induction Chemotherapy in Patients with Esophageal Adenocarcinoma Predicts Poor Post-Operative Outcomes. Journal of Gastrointestinal Cancer, 2017, 48, 181-189.	0.6	0
2141	Poor Outcomes of Gastric Cancer Surgery After Admission Through the Emergency Department. Annals of Surgical Oncology, 2017, 24, 1180-1187.	0.7	25
2142	Linear-Stapled Side-to-Side Esophagojejunostomy with Hand-Sewn Closure of the Common Enterotomy After Prophylactic and Therapeutic Total Gastrectomy. Journal of Gastrointestinal Surgery, 2017, 21, 712-722.	0.9	8
2143	Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer. Annals of Surgery, 2017, 266, 297-304.	2.1	80
2144	Resectable pancreatic adenocarcinomas: will neoadjuvant FOLFIRINOX replace upfront surgery in the standard of care?. Future Oncology, 2017, 13, 951-953.	1.1	3
2145	Histological evaluations of primary lesions are independently associated with prognosis in patients with gastric cancer who receive neoadjuvant chemotherapy. Oncology Letters, 2017, 13, 4892-4896.	0.8	4

#	Article	IF	Citations
2146	Impact of Weekday of Esophagectomy on Short-term and Long-term Oncological Outcomes. Annals of Surgery, 2017, 266, 76-81.	2.1	19
2147	Failure to operate on resectable gastric cancer: implications for policy changes and regionalization. Journal of Surgical Research, 2017, 214, 229-239.	0.8	6
2148	Adjuvant radiotherapy improves overall survival in patients with resected gastric adenocarcinoma: A National Cancer Data Base analysis. Cancer, 2017, 123, 3402-3409.	2.0	29
2149	Predictors of overall and recurrence-free survival after neoadjuvant chemotherapy for gastroesophageal adenocarcinoma: Pooled analysis of individual patient data (IPD) from randomized controlled trials (RCTs). European Journal of Surgical Oncology, 2017, 43, 1550-1558.	0.5	16
2150	Five-year survival of Advanced Esophagogastric junction cancer with achieved by complete response preoperative S-1 + CDDP combination therapy and surgical resection. International Cancer Conference Journal, 2017, 6, 60-64.	0.2	2
2151	Oesophageal cancer. Lancet, The, 2017, 390, 2383-2396.	6.3	796
2152	Weight Loss, Satiety, and the Postprandial Gut Hormone Response After Esophagectomy. Annals of Surgery, 2017, 266, 82-90.	2.1	47
2153	Long-term survival based on pathologic response to neoadjuvant therapy in esophageal cancer. Journal of Surgical Research, 2017, 216, 65-72.	0.8	22
2154	Current and future treatment options for esophageal cancer in the elderly. Expert Opinion on Pharmacotherapy, 2017, 18, 1001-1010.	0.9	102
2155	Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery, 2017, 162, 285-294.	1.0	25
2156	Gastric adenocarcinoma. Nature Reviews Disease Primers, 2017, 3, 17036.	18.1	409
2157	Current trends in multimodality treatment of esophageal and gastroesophageal junction cancer â€“ Review article. Surgical Oncology, 2017, 26, 290-295.	0.8	27
2158	Human Epidermal Growth Factor Receptor-2 in Sri Lankan Gastric Carcinoma Patients with Clinicopathological Association and Survival. Digestive Diseases and Sciences, 2017, 62, 2498-2510.	1.1	4
2159	Sequential endoscopic ultrasound identifies predictive variables for relapse-free follow-up after neoadjuvant chemotherapy in gastric cancer. Scandinavian Journal of Gastroenterology, 2017, 52, 754-761.	0.6	8
2160	The Role of Radiotherapy in Localized Esophageal and Gastric Cancer. Hematology/Oncology Clinics of North America, 2017, 31, 453-468.	0.9	17
2161	Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma. Annals of Surgery, 2017, 265, 481-491.	2.1	149
2162	Upregulated miRâ€•132 in Lgr5⁺ gastric cancer stem cellâ€•like cells contributes to cisplatinâ€•resistance via SIRT1/CREB/ABCG2 signaling pathway. Molecular Carcinogenesis, 2017, 56, 2022-2034.	1.3	77
2163	Predictors of Positive Margins After Definitive Resection for Gastric Adenocarcinoma and Impact of Adjuvant Therapies. International Journal of Radiation Oncology Biology Physics, 2017, 98, 1106-1115.	0.4	14

#	Article	IF	Citations
2164	The role of adjuvant platinumâ€based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery. Journal of Surgical Oncology, 2017, 115, 821-829.	0.8	30
2165	Hiatal Hernia After Esophagectomy for Cancer. Annals of Thoracic Surgery, 2017, 103, 1055-1062.	0.7	41
2166	TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Annals of Surgical Oncology, 2017, 24, 2252-2258.	0.7	186
2167	Melatonin treatment induces apoptosis through regulating the nuclear factor-ÎºB and mitogen-activated protein kinase signaling pathways in human gastric cancer SGC7901 cells. Oncology Letters, 2017, 13, 2737-2744.	0.8	27
2168	Esophageal Cancer: New Insights into a Heterogenous Disease. Digestion, 2017, 95, 253-261.	1.2	23
2169	Perioperative chemotherapy versus postoperative chemoradiotherapy in patients with resectable gastric/gastroesophageal junction adenocarcinomas: A survival analysis of 5058 patients. Cancer, 2017, 123, 2909-2917.	2.0	26
2170	Safety and feasibility of thoracoscopic esophagectomy after neoadjuvant chemotherapy for esophageal cancer. Surgery Today, 2017, 47, 1356-1360.	0.7	4
2171	The Profile of Serum microRNAs Predicts Prognosis for Resected Gastric Cancer Patients Receiving Platinum-Based Chemotherapy. Digestive Diseases and Sciences, 2017, 62, 1223-1234.	1.1	12
2172	Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands. Annals of Surgical Oncology, 2017, 24, 1761-1769.	0.7	35
2173	Tumor regression grade and survival after neoadjuvant treatment in gastro-esophageal cancer: A meta-analysis of 17 published studies. European Journal of Surgical Oncology, 2017, 43, 1607-1616.	0.5	101
2174	Trametes robiniophila may induce apoptosis and inhibit MMPs expression in the human gastric carcinoma cell line MKN-45. Oncology Letters, 2017, 13, 841-846.	0.8	3
2175	Development and external validation of preoperative risk models for operative morbidities after total gastrectomy using a Japanese web-based nationwide registry. Gastric Cancer, 2017, 20, 987-997.	2.7	46
2176	Predictive biomarkers along gastric cancer pathogenetic pathways. Expert Review of Anticancer Therapy, 2017, 17, 417-425.	1.1	24
2177	Neoadjuvant Treatment for Locally Invasive Esophageal Cancer. World Journal of Surgery, 2017, 41, 1719-1725.	0.8	3
2178	The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma â€“ A systematic review and meta-analysis. Cancer Treatment Reviews, 2017, 55, 96-106.	3.4	83
2179	Role of Chemotherapy and Radiation Therapy in the Management of Gastric Adenocarcinoma. Surgical Clinics of North America, 2017, 97, 421-435.	0.5	9
2180	East Versus West. Surgical Clinics of North America, 2017, 97, 453-466.	0.5	8
2181	The genetics of gastroesophageal adenocarcinoma and the use of circulating cell free DNA for disease detection and monitoring. Expert Review of Molecular Diagnostics, 2017, 17, 459-470.	1.5	11

#	Article	IF	Citations
2182	Siewert III adenocarcinoma: treatment update. Updates in Surgery, 2017, 69, 319-325.	0.9	15
2183	Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer. European Journal of Surgical Oncology, 2017, 43, 478-484.	0.5	114
2184	A systematic review and network meta-analysis of neoadjuvant therapy combined with surgery for patients with resectable esophageal squamous cell carcinoma. International Journal of Surgery, 2017, 38, 41-47.	1.1	21
2185	Lymphadenectomy with Optimum of 29 Lymph Nodes Retrieved Associated with Improved Survival in Advanced Gastric Cancer: A 25,000-Patient International Database Study. Journal of the American College of Surgeons, 2017, 224, 546-555.	0.2	74
2186	Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study. Annals of Oncology, 2017, 28, 519-527.	0.6	65
2187	Feasibility of Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-Fluorouracil versus Adriamycin, Cisplatin, and 5-Fluorouracil for Resectable Advanced Esophageal Cancer. Oncology, 2017, 92, 101-108.	0.9	34
2188	Histopathological regression of gastric adenocarcinoma after neoadjuvant therapy: a critical review. Apmis, 2017, 125, 79-84.	0.9	30
2189	What is the optimal neoadjuvant treatment for locally advanced oesophageal adenocarcinoma?. Annals of Oncology, 2017, 28, 447-450.	0.6	3
2190	Impact of diagnosis-to-treatment waiting time on survival in esophageal cancer patients â€“ A population-based study in The Netherlands. European Journal of Surgical Oncology, 2017, 43, 461-470.	0.5	10
2191	Treatment strategies in recurrent esophageal or junctional cancer. Ecological Management and Restoration, 2017, 30, 1-9.	0.2	18
2192	Clinical outcomes and benefits for staging of surgical lymph node mapping after esophagectomy. Ecological Management and Restoration, 2017, 30, 1-7.	0.2	17
2193	Predictors and Prognostic Implications of Perioperative Chemotherapy Completion in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1984-1992.	0.9	11
2194	Neoadjuvant chemotherapy in oesophageal adenocarcinoma. Lancet Oncology, The, 2017, 18, e640.	5.1	3
2195	Active surveillance in clinically complete responders after neoadjuvant chemoradiotherapy for esophageal or junctional cancer. Ecological Management and Restoration, 2017, 30, 1-8.	0.2	22
2197	Systematic Review of Exocrine Pancreatic Insufficiency after Gastrectomy for Cancer. Digestive Surgery, 2017, 34, 364-370.	0.6	29
2198	Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma. British Journal of Surgery, 2017, 104, 1816-1828.	0.1	88
2202	Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research, 2017, 23, 7543-7549.	3.2	12
2203	Gastric neoplasms. Surgery, 2017, 35, 635-643.	0.1	2

#	Article	IF	Citations
2204	Adjuvant Chemoradiotherapy for Non-Pretreated Gastric Cancer. Annals of Surgical Oncology, 2017, 24, 3647-3657.	0.7	6
2205	Left Gastric Artery Lymph Nodes Should Be Included in D1 Lymph Node Dissection in Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1563-1570.	0.9	7
2206	Resultados iniciales del registro de carcinomas esÃ³fago-gÃ¡stricos de la Comunidad Valenciana. CirugÃa EspaÃ±ola, 2017, 95, 428-436.	0.1	3
2207	Chemotherapy for advanced gastric cancer. The Cochrane Library, 2017, 2017, CD004064.	1.5	662
2208	Weekday of gastrectomy for cancer in relation to mortality and oncological outcomes â€“ A Dutch population-based cohort study. European Journal of Surgical Oncology, 2017, 43, 1862-1868.	0.5	13
2209	Dose escalation intensity-modulated radiotherapyâ€“based concurrent chemoradiotherapy is effective for advanced-stage thoracic esophageal squamous cell carcinoma. Radiotherapy and Oncology, 2017, 125, 73-79.	0.3	87
2210	An Update on Randomized Clinical Trials in Gastric Cancer. Surgical Oncology Clinics of North America, 2017, 26, 621-645.	0.6	0
2211	The relevance of gastric cancer biomarkers in prognosis and pre- and post- chemotherapy in clinical practice. Biomedicine and Pharmacotherapy, 2017, 95, 1082-1090.	2.5	56
2212	Cyclin D1 overexpression correlates with poor tumor differentiation and prognosis in gastric cancer. Oncology Letters, 2017, 14, 4517-4526.	0.8	55
2213	Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions. Oncology, 2017, 93, 279-286.	0.9	9
2214	External validation of the NUn score for predicting anastomotic leakage after oesophageal resection. Scientific Reports, 2017, 7, 9725.	1.6	9
2215	Liquid Biopsy in Esophageal, Gastric, and Pancreatic Cancers. Current Clinical Pathology, 2017, , 137-150.	0.0	0
2216	Evaluation of Gastric Microcirculation by Laser Speckle Contrast Imaging During Esophagectomy. Journal of the American College of Surgeons, 2017, 225, 395-402.	0.2	28
2217	Squamous cell carcinomas and adenocarcinomas of the esophagus: One treatment does not rule them all. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1446-1447.	0.4	6
2218	Complications after gastrectomy for cancer: Italian perspective. Updates in Surgery, 2017, 69, 285-288.	0.9	10
2219	CÃ¡ncer de esÃ³fago. Medicine, 2017, 12, 1889-1903.	0.0	0
2220	CÃ¡ncer de estÃ³mago. Medicine, 2017, 12, 1904-1910.	0.0	0
2221	The Effects of Neoadjuvant Axitinib on Anthropometric Parameters in Patients With Locally Advanced Non-metastatic Renal Cell Carcinoma. Urology, 2017, 108, 114-121.	0.5	11

#	Article	IF	Citations
2222	Liquid Biopsy in Cancer Patients. Current Clinical Pathology, 2017, , .	0.0	6
2223	The Effect of Neoadjuvant Chemoradiation on Anastomotic Leak and Additional 30-Day Morbidity and Mortality in Patients Undergoing Total Gastrectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2017, 21, 1577-1583.	0.9	16
2224	Oesophageal cancer. Nature Reviews Disease Primers, 2017, 3, 17048.	18.1	671
2225	Postoperative Outcomes of Minimally Invasive Gastrectomy Versus Open Gastrectomy During the Early Introduction of Minimally Invasive Gastrectomy in the Netherlands. Annals of Surgery, 2017, 266, 831-838.	2.1	55
2226	Clinical Significance of Four Molecular Subtypes of Gastric Cancer Identified by The Cancer Genome Atlas Project. Clinical Cancer Research, 2017, 23, 4441-4449.	3.2	342
2227	Does Prolonged Enteral Feeding With Supplemental Omega-3 Fatty Acids Impact on Recovery Post-esophagectomy. Annals of Surgery, 2017, 266, 720-728.	2.1	43
2228	The role of GLI2 - ABCG2 signaling axis for 5Fu resistance in gastric cancer. Journal of Genetics and Genomics, 2017, 44, 375-383.	1.7	41
2229	Neoadjuvant chemotherapy or chemoradiation for patients with advanced adenocarcinoma of the oesophagus? AÂpropensity score-matched study. European Journal of Surgical Oncology, 2017, 43, 1572-1580.	0.5	29
2230	Significance of baseline FDG-PET/CT scan as a method of staging regional lymph nodes in patients with operable distal oesophageal or gastroesophageal junction adenocarcinoma. Acta OncolÃ³gica, 2017, 56, 1224-1232.	0.8	1
2231	Management of gastric cancer in older adults. Journal of Geriatric Oncology, 2017, 8, 403-406.	0.5	7
2232	Preoperative Chemoradiation Therapy Does Not Increase Risk of Anastomotic Leak in Patients With Gastric Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 660-666.	0.4	19
2233	Combined perioperative EOX chemotherapy and postoperative chemoradiotherapy for locally advanced gastric cancer. Molecular and Clinical Oncology, 2017, 7, 211-216.	0.4	4
2234	Prognostic significance of tumor length in patients receiving esophagectomy for esophageal cancer. Journal of Surgical Oncology, 2017, 116, 1114-1122.	0.8	17
2235	Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). ESMO Open, 2017, 2, e000130.	2.0	15
2236	High-throughput Protein and mRNA Expressionâ€“based Classification of Gastric Cancers Can Identify Clinically Distinct Subtypes, Concordant With Recent Molecular Classifications. American Journal of Surgical Pathology, 2017, 41, 106-115.	2.1	85
2237	Trends in net survival from stomach cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S32-S39.	0.6	4
2238	Support Vector Machines Model of Computed Tomography for Assessing Lymph Node Metastasis in Esophageal Cancer with Neoadjuvant Chemotherapy. Journal of Computer Assisted Tomography, 2017, 41, 455-460.	0.5	24
2239	Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): an open-label, randomised phase 3 trial. Lancet Oncology, The, 2017, 18, 1249-1260.	5.1	187

#	Article	IF	Citations
2240	Esophageal squamous cell carcinoma and adenocarcinoma: At the Gates of Mordor. Journal of Thoracic and Cardiovascular Surgery, 2017, 154, 1444-1445.	0.4	3
2241	Prognostic significance of Daxx <scp>NCR</scp> (Nuclear/Cytoplasmic Ratio) in gastric cancer. Cancer Medicine, 2017, 6, 2063-2075.	1.3	21
2242	Targeted next-generation sequencing of commonly mutated genes in esophageal adenocarcinoma patients with long-term survival. Ecological Management and Restoration, 2017, 30, 1-8.	0.2	1
2243	Impact of Centralizing Gastric Cancer Surgery on Treatment, Morbidity, and Mortality. Journal of Gastrointestinal Surgery, 2017, 21, 2000-2008.	0.9	41
2244	Endoscopic Ultrasound as a Pretreatment Clinical Staging Tool for Gastric Cancer: Association with Pathology and Outcome. Annals of Surgical Oncology, 2017, 24, 3658-3666.	0.7	15
2245	Sarcopenia. Annals of Surgery, 2017, 266, 822-830.	2.1	218
2246	Regulating cancer associated fibroblasts with losartan-loaded injectable peptide hydrogel to potentiate chemotherapy in inhibiting growth and lung metastasis of triple negative breast cancer. Biomaterials, 2017, 144, 60-72.	5.7	111
2247	Prognostic Value of Computed Tomographyâ€“Detected Extramural Venous Invasion to Predict Disease-Free Survival in Patients With Gastric Cancer. Journal of Computer Assisted Tomography, 2017, 41, 430-436.	0.5	15
2248	Precision medicine in gastric cancer: where are we now?. Expert Review of Precision Medicine and Drug Development, 2017, 2, 193-204.	0.4	0
2249	Neoadjuvant Chemotherapy and Adjuvant Chemoradiation Therapy in the Treatment of Resected Gastric Adenocarcinoma: A Case Series. Case Reports in Oncology, 2017, 10, 308-315.	0.3	1
2250	The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Current Treatment Options in Oncology, 2017, 18, 69.	1.3	11
2251	Loco-regional staging accuracy in oesophageal cancerâ€”How good are we in the modern era?. European Journal of Radiology, 2017, 97, 71-75.	1.2	19
2252	Neoadjuvant chemotherapy in oesophageal adenocarcinoma â€“ Authors' reply. Lancet Oncology, The, 2017, 18, e641.	5.1	1
2254	Initial Results of the Oesophageal and Gastric Cancer Registry From the Comunidad Valenciana. CirugÃa EspaÃ±ola (English Edition), 2017, 95, 428-436.	0.1	0
2256	Expression and prognostic significance of cyclinâ€‘dependent kinase inhibitor 1A in patients with resected gastric adenocarcinoma. Oncology Letters, 2017, 14, 7473-7482.	0.8	2
2258	Oesophageal cancer. Surgery, 2017, 35, 627-634.	0.1	1
2260	Is There a Rationale for Structural Quality Assurance in Esophageal Surgery. Visceral Medicine, 2017, 33, 135-139.	0.5	9
2261	Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer. Medical Oncology, 2017, 34, 139.	1.2	11

#	Article	IF	Citations
2262	Survival Rates for Patients with Resected Gastric Adenocarcinoma Finally have Increased in the United States. Annals of Surgical Oncology, 2017, 24, 3361-3367.	0.7	11
2263	Hamburg-Glasgow classification: preoperative staging by combination of disseminated tumour load and systemic inflammation in oesophageal carcinoma. British Journal of Cancer, 2017, 117, 612-618.	2.9	6
2264	Preoperative chemotherapy versus chemoradiotherapy inÂlocally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results ofÂa controlled randomised trial. European Journal of Cancer, 2017, 81, 183-190.	1.3	197
2265	Adjuvant radiochemotherapy in locally advanced gastric cancer. Strahlentherapie Und Onkologie, 2017, 193, 1005-1013.	1.0	2
2266	Milestones in gastric cancer. Memo - Magazine of European Medical Oncology, 2017, 10, 33-37.	0.3	1
2267	Inhibition of PI3K suppresses propagation of drug-tolerant cancer cell subpopulations enriched by 5-fluorouracil. Scientific Reports, 2017, 7, 2262.	1.6	8
2268	ICORG 10-14: NEOadjuvant trial in Adenocarcinoma of the oEsophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer, 2017, 17, 401.	1.1	132
2269	Endoscopic ultrasonography compared with multidetector computed tomography for the preoperative staging of gastric cancer: a meta-analysis. World Journal of Surgical Oncology, 2017, 15, 113.	0.8	34
2270	Linked read sequencing resolves complex genomic rearrangements in gastric cancer metastases. Genome Medicine, 2017, 9, 57.	3.6	56
2271	Genomics and epidemiology for gastric adenocarcinomas. Applied Cancer Research, 2017, 37, .	1.0	7
2272	Could a Feeding Jejunostomy be Integrated into a Standardized Preoperative Management of Oeso-gastric Junction Adenocarcinoma?. Annals of Surgical Oncology, 2017, 24, 3324-3330.	0.7	14
2273	MLH1 expression predicts the response to preoperative therapy and is associated with PD-L1 expression in esophageal cancer. Oncology Letters, 2017, 14, 958-964.	0.8	15
2274	Minimally invasive gastrectomy for gastric cancer: A national perspective on oncologic outcomes and overall survival. Surgical Oncology, 2017, 26, 324-330.	0.8	6
2275	Effects of a multimodal rehabilitation programme on inflammation and oxidative stress in oesophageal cancer survivors: the ReStOre feasibility study. Supportive Care in Cancer, 2017, 25, 749-756.	1.0	32
2276	Assessment of HER2 status in patients with gastroesophageal adenocarcinoma treated with epirubicin-based chemotherapy: heterogeneity-related issues and prognostic implications. Gastric Cancer, 2017, 20, 428-437.	2.7	5
2277	Co-morbidities Rather than Age Impact Outcomes in Patients Receiving Preoperative Therapy for Gastroesophageal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2291-2301.	0.7	8
2278	Risk Factors for Anastomotic Stricture Postâ€esophagectomy with a Standardized Sutured Anastomosis. World Journal of Surgery, 2017, 41, 487-497.	0.8	42
2279	How Do We Bridge the West and the East in the Treatment for Gastric Cancer?. Annals of Surgical Oncology, 2017, 24, 864-865.	0.7	4

#	Article	IF	Citations
2280	The effect of perioperative chemotherapy for patients with an adenocarcinoma of the gastroesophageal junction: A propensity score matched analysis. European Journal of Surgical Oncology, 2017, 43, 226-233.	0.5	10
2281	Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. European Journal of Surgical Oncology, 2017, 43, 218-225.	0.5	9
2282	Clinical Significance of the Preâ€therapeutic Nodal Size in Patients Undergoing Neoâ€Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma. World Journal of Surgery, 2017, 41, 184-190.	0.8	7
2283	Treatment of Gastric and Gastroesophageal Cancersâ€"Do We Really Need Anthracyclines?. JAMA Oncology, 2017, 3, 1172.	3.4	6
2284	Impact of clinical tumorâ€"nodeâ€"metastasis staging on survival in gastric carcinoma patients receiving surgery. Gastric Cancer, 2017, 20, 448-456.	2.7	17
2285	Esophageal Adenocarcinoma: Screening, Surveillance, and Management. Annual Review of Medicine, 2017, 68, 213-227.	5.0	30
2286	Gastric cancer: texture analysis from multidetector computed tomography as a potential preoperative prognostic biomarker. European Radiology, 2017, 27, 1831-1839.	2.3	93
2287	Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003). Annals of Oncology, 2017, 28, 116-120.	0.6	94
2288	Value of the prognostic nutritional index in advanced gastric cancer treated with preoperative chemotherapy. Journal of Surgical Research, 2017, 209, 37-44.	0.8	30
2289	18FDG-PET-CT improves specificity of preoperative lymph-node staging in patients with intestinal but not diffuse-type esophagogastric adenocarcinoma. European Journal of Surgical Oncology, 2017, 43, 196-202.	0.5	19
2290	A population-based study on incidence rates, Lauren distribution, stage distribution, treatment, and long-term outcomes for gastric adenocarcinoma in Central Norway 2001â€"2011. Acta OncolÃ³gica, 2017, 56, 39-45.	0.8	23
2291	Global chemotherapy development for gastric cancer. Gastric Cancer, 2017, 20, 92-101.	2.7	38
2292	Postgastrectomy follow-up in the West: evidence base, guidelines, and daily practice. Gastric Cancer, 2017, 20, 135-140.	2.7	17
2293	Recent improvements in the management of esophageal anastomotic leak after surgery for cancer. European Journal of Surgical Oncology, 2017, 43, 258-269.	0.5	124
2294	Multi-institutional prospective feasibility study to explore tolerability and efficacy of oral nutritional supplements for patients with gastric cancer undergoing gastrectomy (CCOG1301). Gastric Cancer, 2017, 20, 718-727.	2.7	45
2295	Predicting Pathologic Response of Esophageal Cancer to Neoadjuvant Chemotherapy: The Implications of Metabolic Nodal Response for Personalized Therapy. Journal of Nuclear Medicine, 2017, 58, 266-275.	2.8	27
2296	Esophageal cancer's 100 most influential manuscripts: a bibliometric analysis. Ecological Management and Restoration, 2017, 30, 1-8.	0.2	14
2297	Efficacy and safety of chemoradiation therapy compared with chemotherapy for esophageal carcinoma. Medicine (United States), 2017, 96, e8929.	0.4	2

#	Article	IF	Citations
2298	Comparison of changes in renal function with dosimetric parameters in gastric cancer patients treated with adjuvant chemoradiotherapy. Japanese Journal of Radiology, 2017, 35, 733-739.	1.0	1
2299	Neoadjuvant treatment with cisplatin and S-1 in elderly patients with oesophagogastric adenocarcinoma and locoregional disease: Two case reports and review of the literature. Molecular and Clinical Oncology, 2017, 7, 1069-1072.	0.4	5
2301	Feasibility of high-intensity interval training with hyperoxia vs. intermittent hyperoxia and hypoxia in cancer patients undergoing chemotherapy â€“ Study protocol of a randomized controlled trial. Contemporary Clinical Trials Communications, 2017, 8, 213-217.	0.5	7
2303	Overexpression of microRNA-15 increases the chemosensitivity of colon cancer cells to 5-fluorouracil and oxaliplatin by inhibiting the nuclear factor-ÎºB signalling pathway and inducing apoptosis. Experimental and Therapeutic Medicine, 2018, 15, 2655-2660.	0.8	12
2304	Cytoreductive surgery and Hyperthermic intra-operative peritoneal chemotherapy with Cisplatin for gastric peritoneal Carcinomatosis Monocentric phase-2 nonrandomized prospective clinical trial. BMC Cancer, 2017, 17, 771.	1.1	6
2305	Survival following operative management of gastric linitis plastica compared with non-operative management. Annals of the Royal College of Surgeons of England, 2017, 99, 228-232.	0.3	9
2306	Patterns of recurrence in oesophageal cancer following oesophagectomy in the era of neoadjuvant chemotherapy. BJS Open, 2017, 1, 182-190.	0.7	18
2307	Validity of studies suggesting postsurgical chemotherapy for resectable gastric cancer: critical appraisal of randomised trials. BMJ Open Gastroenterology, 2017, 4, e000138.	1.1	6
2308	Mechanisms for DNAâ€‘damaging agentâ€‘induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways. Oncology Letters, 2018, 15, 1758-1762.	0.8	2
2309	Efficacy and safety of intraperitoneal chemotherapy in patients with advanced gastric cancer: a cumulative meta-analysis of randomized controlled trials. Oncotarget, 2017, 8, 81125-81136.	0.8	10
2310	The influence of neoadjuvant chemotherapy on gastric cancer patientsâ€™ postoperative infectious complications: What is the negative role played by the intestinal barrier dysfunction?. Oncotarget, 2017, 8, 43376-43388.	0.8	11
2311	Gastric Cancer in Southern Europe: High-Risk Disease. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 261-266.	1.8	2
2312	10. Gastrointestinale Onkologie im Alter. , 2017, , .		0
2313	Clinical Outcomes after Surgery for Linitis Plastica of the Stomach: Analysis of a Population Cancer Registry. American Surgeon, 2017, 83, 23-29.	0.4	10
2314	The screening and analysis of protein signatures and signaling associated with chemoresistance based on Protein Pathway Array technology in gastric cancer. Oncology Reports, 2017, 39, 307-315.	1.2	10
2315	Gastric Adenocarcinoma: A Multimodal Approach. Frontiers in Surgery, 2017, 4, 42.	0.6	12
2316	CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. Diagnostic and Interventional Radiology, 2017, 23, 257-262.	0.7	7
2317	Selective Gastric Cancer Patients with Peritoneal Seeding Benefit from Gastrectomy after Palliative Chemotherapy: A Propensity Score Matching Analysis. Journal of Cancer, 2017, 8, 2231-2237.	1.2	11

#	Article	IF	Citations
2318	Interpreting whole genome and exome sequencing data of individual gastric cancer samples. BMC Genomics, 2017, 18, 517.	1.2	11
2319	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. Journal of Gastric Cancer, 2017, 17, 21.	0.9	10
2320	Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. Journal of Cancer, 2017, 8, 3498-3505.	1.2	11
2321	What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer?. Annals of Cardiothoracic Surgery, 2017, 6, 167-174.	0.6	23
2322	Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits. International Journal of Molecular Sciences, 2017, 18, 1622.	1.8	92
2323	Robot-Assisted Hybrid Esophagectomy Is Associated with a Shorter Length of Stay Compared to Conventional Transthoracic Esophagectomy: A Retrospective Study. Minimally Invasive Surgery, 2017, 2017, 1-6.	0.1	11
2324	Perioperative Therapy of Oesophagogastric Adenocarcinoma: Mainstay and Future Directions. Gastroenterology Research and Practice, 2017, 2017, 1-6.	0.7	9
2325	Effects of neoadjuvant chemotherapy combined with radiotherapy in patients with advanced esophageal carcinoma. Oncology Letters, 2017, 14, 2803-2807.	0.8	1
2326	Impact of Stem Cell Genes in Gastric Cancer. , 2017, , .		0
2327	Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer. PLoS ONE, 2017, 12, e0171827.	1.1	24
2328	Evaluations of primary lesions by endoscopy clearly distinguishes prognosis in patients with gastric cancer who receive chemotherapy. PLoS ONE, 2017, 12, e0173663.	1.1	7
2329	A 17-molecule set as a predictor of complete response to neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil in esophageal cancer. PLoS ONE, 2017, 12, e0188098.	1.1	12
2330	Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS ONE, 2017, 12, e0183891.	1.1	19
2331	Randomized controlled trial of S-1 maintenance therapyÂin metastatic esophagogastric cancer â€“ the multinational MATEO study. BMC Cancer, 2017, 17, 509.	1.1	12
2332	Treatment of localized gastric and gastroesophageal adenocarcinoma: the role of accurate staging and preoperative therapy. Journal of Hematology and Oncology, 2017, 10, 149.	6.9	37
2334	New chemotherapies in gastric adenocarcinoma. Memo - Magazine of European Medical Oncology, 2017, 10, 132-135.	0.3	0
2335	Activation of STAT3 in Gastric Cancer Development. , 2017, , 161-177.		0
2336	Grifolin exhibits anti-cancer activity by inhibiting the development and invasion of gastric tumor cells. Oncotarget, 2017, 8, 21454-21460.	0.8	18

#	Article	IF	Citations
2337	MicroRNA-744 inhibits tumor cell proliferation and invasion of gastric cancer via targeting brain-derived neurotrophic factor. Molecular Medicine Reports, 2017, 16, 5055-5061.	1.1	11
2338	Neoadjuvante Chemotherapie und adjuvante Radiochemotherapie in der Behandlung des resezierten Adenokarzinoms des Magens: Eine Fallserie. Karger Kompass Onkologie, 2017, 4, 113-117.	0.0	0
2339	Nutritional Management of Esophageal Cancer Patients. , 0, , .		4
2340	The spectrum of gastric cancer as seen in a large quaternary hospital in KwaZulu-Natal, South Africa. South African Medical Journal, 2017, 107, 130.	0.2	5
2341	Intraoperative radiotherapy: review of techniques and results. Ecancermedicalscience, 2017, 11, 750.	0.6	63
2342	Tumor response evaluation after neoadjuvant chemotherapy in locally advanced gastric adenocarcinoma: a prospective, multi-center cohort study. Journal of Gastrointestinal Oncology, 2017, 8, 1018-1025.	0.6	42
2343	Surgical anatomy of the omental bursa and the stomach based on a minimally invasive approach: different approaches and technical steps to resection and lymphadenectomy. Journal of Thoracic Disease, 2017, 9, S809-S816.	0.6	11
2344	First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II study. Oncotarget, 2017, 8, 111795-111806.	0.8	6
2345	Body Composition as a Prognostic Factor of Neoadjuvant Chemotherapy Toxicity and Outcome in Patients with Locally Advanced Gastric Cancer. Journal of Gastric Cancer, 2017, 17, 74.	0.9	102
2346	Greater Lymph Node Retrieval Improves Survival in Node-Negative Resected Gastric Cancer in the United States. Journal of Gastric Cancer, 2017, 17, 306.	0.9	19
2347	The prognostic value of neutrophil–lymphocyte ratio is superior to derived neutrophil–lymphocyte ratio in advanced gastric cancer treated with preoperative chemotherapy and sequential R0 resection: a 5-year follow-up. OncoTargets and Therapy, 2017, Volume 10, 2655-2664.	1.0	21
2348	A Case of Advanced Gastric Cancer with Para-Aortic Lymph Node Metastasis from Co-Occurring Prostate Cancer. Journal of Gastric Cancer, 2017, 17, 93.	0.9	0
2349	Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma. Annals of the Royal College of Surgeons of England, 2017, 99, 378-384.	0.3	4
2350	Consideration of clinicopathologic features improves patient stratification for multimodal treatment of gastric cancer. Oncotarget, 2017, 8, 79594-79603.	0.8	3
2351	Radiomic analysis in contrast-enhanced CT: predict treatment response to chemoradiotherapy in esophageal carcinoma. Oncotarget, 2017, 8, 104444-104454.	0.8	62
2352	Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). Journal of Clinical Oncology, 2017, 35, 3671-3677.	0.8	112
2354	The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Journal of Gastrointestinal Oncology, 2017, 8, 683-695.	0.6	12
2355	Preoperative accuracy of gastric cancer staging in patient selection for preoperative therapy: race may affect accuracy of endoscopic ultrasonography. Journal of Gastrointestinal Oncology, 2017, 8, 1009-1017.	0.6	20

#	Article	IF	Citations
2356	Does histology really influence gastric cancer prognosis?. Journal of Gastrointestinal Oncology, 2017, 8, 1026-1036.	0.6	15
2357	A phase III, multicenter randomized controlled trial of neo-adjuvant chemotherapy paclitaxel plus cisplatin versus surgery alone for stage IIAâ€“IIIB esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2017, 9, 200-204.	0.6	13
2358	Robot-assisted minimally invasive thoraco-laparoscopic esophagectomy for esophageal cancer in the upper mediastinum. Journal of Thoracic Disease, 2017, 9, S834-S842.	0.6	32
2359	Predictive factors in the evaluation of treatment response to neoadjuvant chemoradiotherapy in patients with advanced esophageal squamous cell cancer. Journal of Thoracic Disease, 2017, 9, S773-S780.	0.6	14
2360	Deciding on the neoadjuvant approach for esophageal adenocarcinomas. Journal of Thoracic Disease, 2017, 9, 1818-1821.	0.6	0
2361	Gastro-esophageal junction cancers: what is the best minimally invasive approach?. Journal of Thoracic Disease, 2017, 9, S751-S760.	0.6	6
2362	Predictive factors for post-operative respiratory infections after esophagectomy for esophageal cancer: outcome of randomized trial. Journal of Thoracic Disease, 2017, 9, S861-S867.	0.6	22
2363	When to resect following neoadjuvant therapy for esophageal cancerâ€”issues and limitations in addressing this decision. Journal of Thoracic Disease, 2017, 9, E727-E729.	0.6	1
2364	Prognostic role of initial pan-endoscopic tumor length at diagnosis in operable esophageal squamous cell carcinoma undergoing esophagectomy with or without neoadjuvant concurrent chemoradiotherapy. Journal of Thoracic Disease, 2017, 9, 3193-3207.	0.6	6
2365	Should cT2 esophageal cancer get neoadjuvant treatment before surgery?. Journal of Thoracic Disease, 2017, 9, 2819-2823.	0.6	6
2366	Should cT2N0M0 be managed as a localized or locally advanced esophageal carcinoma?. Journal of Thoracic Disease, 2017, 9, 2829-2834.	0.6	0
2367	Adjuvant chemotherapy following trimodality therapy for esophageal carcinomaâ€”Is the evidence sufficient?. Journal of Thoracic Disease, 2017, 9, 3626-3629.	0.6	7
2368	Regorafenib in gastric cancer. Translational Gastroenterology and Hepatology, 2017, 2, 16-16.	1.5	2
2369	Different regimens of perioperative chemotherapy for esophagogastric and gastric adenocarcinoma: does a triplet therapy with taxane generate a survival benefit?. Translational Gastroenterology and Hepatology, 2017, 2, 25-25.	1.5	0
2370	Minimally invasive surgery for gastric cancer in USA: current status and future perspectives. Translational Gastroenterology and Hepatology, 2017, 2, 38-38.	1.5	13
2371	Recent trends of gastric cancer treatment in Turkey. Translational Gastroenterology and Hepatology, 2017, 2, 31-31.	1.5	8
2372	Gastric cancer treatment: similarity and difference between China and Korea. Translational Gastroenterology and Hepatology, 2017, 2, 36-36.	1.5	20
2373	Gastric cancer treatment in the world: Germany. Translational Gastroenterology and Hepatology, 2017, 2, 53-53.	1.5	31

#	Article	IF	Citations
2374	Sarcopenia related to neoadjuvant chemotherapy and perioperative outcomes in resected gastric cancer: a multi-institutional analysis. Journal of Gastrointestinal Oncology, 2017, 8, 589-595.	0.6	41
2375	Neoadjuvant treatment of locally advanced esophageal and junctional cancer: the evidence-base, current key questions and clinical trials. Journal of Thoracic Disease, 2017, 9, S697-S704.	0.6	28
2376	The extent of lymphadenectomy in esophageal resection for cancer should be standardized. Journal of Thoracic Disease, 2017, 9, S713-S723.	0.6	48
2377	Prognostic impact of nodal status and therapeutic implications. Translational Gastroenterology and Hepatology, 2017, 2, 15-15.	1.5	8
2378	Decision making, quality of life and prophylactic gastrectomy in carriers of pathogenic CDH1 mutations. Translational Gastroenterology and Hepatology, 2017, 2, 21-21.	1.5	4
2379	Robotic gastrectomy for gastric cancer. Translational Gastroenterology and Hepatology, 2017, 2, 57-57.	1.5	32
2380	Histopathological regression after taxane based neoadjuvant chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. Translational Gastroenterology and Hepatology, 2017, 2, 46-46.	1.5	0
2381	Prognostic gene expression profiling in esophageal cancer: a systematic review. Oncotarget, 2017, 8, 5566-5577.	0.8	36
2382	The appropriate treatment for elderly gastric cancer patients. Art of Surgery, 0, 1, 1-1.	0.0	5
2383	Neoadjuvant chemotherapy in advanced gastric and esophago-gastric cancer. Meta-analysis of randomized trials. International Journal of Surgery, 2018, 51, 120-127.	1.1	106
2384	Prospective cohort study of neoadjuvant therapy toxicity in the treatment of oesophageal adenocarcinoma. International Journal of Surgery, 2018, 52, 126-130.	1.1	6
2385	Using textbook outcome as a measure of quality of care in oesophagogastric cancer surgery. British Journal of Surgery, 2018, 105, 561-569.	0.1	73
2386	[18F]Fluorodeoxyglucose PET/CT and prediction of histopathological response to neoadjuvant chemotherapy for adenocarcinoma of the oesophagus and oesophagogastric junction. British Journal of Surgery, 2018, 105, 419-428.	0.1	7
2387	Dose modifications in adjuvant chemotherapy for solid organ malignancies: A systematic review of clinical trials. Asia-Pacific Journal of Clinical Oncology, 2018, 14, 125-133.	0.7	5
2388	The neutrophil-to-lymphocyte ratio (NLR) predicts short-term and long-term outcomes in gastric cancer patients. European Journal of Surgical Oncology, 2018, 44, 607-612.	0.5	173
2389	Chilean Gastric Cancer Task Force. Medicine (United States), 2018, 97, e0419.	0.4	11
2390	Chemotherapy for Esophageal Adenocarcinoma. Methods in Molecular Biology, 2018, 1756, 19-34.	0.4	1
2393	Central Lymph Node Metastasis in Gastric Cancer Is Predictive of Survival After Preoperative Therapy. Journal of Gastrointestinal Surgery, 2018, 22, 1325-1333.	0.9	14

#	Article	IF	Citations
2394	Morbidity and mortality according to age following gastrectomy for gastric cancer. British Journal of Surgery, 2018, 105, 1163-1170.	0.1	33
2395	Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States. Gastric Cancer, 2018, 21, 889-899.	2.7	43
2396	Which Side Effects Should Be Described to Patients Before Neoadjuvant Radio-Chemotherapy Treatment?. , 2018, , 247-251.		0
2397	Perioperative chemotherapy with or without epidermal growth factor receptorÂblockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801). European Journal of Cancer, 2018, 93, 119-126.	1.3	33
2398	Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial. Lancet Oncology, The, 2018, 19, 616-628.	5.1	397
2399	A CRITICal period for chemoradiotherapy in gastric cancer. Lancet Oncology, The, 2018, 19, 581-583.	5.1	4
2400	Enhanced recovery after surgery in gastric cancer: which are the main achievements from the Italian experience?. Updates in Surgery, 2018, 70, 257-264.	0.9	10
2401	Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clinical and Translational Radiation Oncology, 2018, 10, 13-22.	0.9	18
2402	Evaluation of comparative effectiveness research: a practical tool. Journal of Comparative Effectiveness Research, 2018, 7, 503-515.	0.6	13
2403	Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. Journal of Gastroenterology, 2018, 53, 1186-1195.	2.3	67
2404	Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network metaâ€analysis. International Journal of Cancer, 2018, 143, 430-437.	2.3	79
2405	Efficacy of Adjuvant S-1 Versus XELOX Chemotherapy for Patients with Gastric Cancer After D2 Lymph Node Dissection: A Retrospective, Multi-Center Observational Study. Annals of Surgical Oncology, 2018, 25, 1176-1183.	0.7	27
2408	Diet and supplements in cancer prevention and treatment: Clinical evidences and future perspectives. Critical Reviews in Oncology/Hematology, 2018, 123, 57-73.	2.0	41
2409	Health-related quality of life after open transhiatal and transthoracic oesophagectomy for cancer. British Journal of Surgery, 2018, 105, 230-236.	0.1	10
2410	Surgical morbidity and mortality after neoadjuvant chemotherapy in the CRITICS gastric cancer trial. European Journal of Surgical Oncology, 2018, 44, 613-619.	0.5	43
2411	Correlation of clinical and pathological staging and response to neoadjuvant therapy in resected pancreatic cancer. International Journal of Surgery, 2018, 52, 221-228.	1.1	7
2412	CD44v6 increases gastric cancer malignant phenotype by modulating adipose stromal cell-mediated ECM remodeling. Integrative Biology (United Kingdom), 2018, 10, 145-158.	0.6	20
2413	Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches. Expert Review of Anticancer Therapy, 2018, 18, 327-338.	1.1	4

#	Article	IF	Citations
2414	Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006â€2014. Cancer, 2018, 124, 998-1007.	2.0	46
2415	Comprehensive Analysis of the Neutrophilâ€toâ€Lymphocyte Ratio for Preoperative Prognostic Prediction Nomogram in Gastric Cancer. World Journal of Surgery, 2018, 42, 2530-2541.	0.8	11
2416	Hospital variation and the impact of postoperative complications on the use of perioperative chemo(radio)therapy in resectable gastric cancer. Results from the Dutch Upper GI Cancer Audit. European Journal of Surgical Oncology, 2018, 44, 532-538.	0.5	9
2417	Helicobacter pylori infection is associated with favorable outcome in advanced gastric cancer patients treated with Sâ€1 adjuvant chemotherapy. Journal of Surgical Oncology, 2018, 117, 947-956.	0.8	17
2418	Neoadjuvant chemoradiation for esophageal cancer. Strahlentherapie Und Onkologie, 2018, 194, 435-443.	1.0	5
2419	Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma. European Journal of Cancer, 2018, 90, 26-33.	1.3	17
2420	The optimal lymph node dissection in patients with adenocarcinoma of the esophagogastric junction. Surgical Oncology, 2018, 27, 36-43.	0.8	11
2421	The impact of advanced age on short-term outcomes following gastric cancer resection: an ACS-NSQIP analysis. Gastric Cancer, 2018, 21, 710-719.	2.7	28
2422	Factors contributing to variation in the use of multimodality treatment in patients with gastric cancer: A Dutch population based study. European Journal of Surgical Oncology, 2018, 44, 260-267.	0.5	3
2423	Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis. Cancer Biology and Therapy, 2018, 19, 169-174.	1.5	14
2424	After neoadjuvant chemotherapy platelet/lymphocyte ratios negatively correlate with prognosis in gastric cancer patients. Journal of Clinical Laboratory Analysis, 2018, 32, e22364.	0.9	18
2425	Predictive factors of thromboembolic complications in patients with esophagogatric adenocarcinoma undergoing preoperative chemotherapy. Acta OncolÃ³gica, 2018, 57, 790-798.	0.8	12
2426	Comparison of preoperative concurrent chemoradiotherapy with chemotherapy alone in patients with locally advanced siewert II andÂIII adenocarcinoma of the esophagogastric junction. European Journal of Surgical Oncology, 2018, 44, 502-508.	0.5	5
2427	EGFR and AKT1 overexpression are mutually exclusive and associated with a poor survival in resected gastric adenocarcinomas. Cancer Biomarkers, 2018, 21, 731-741.	0.8	16
2428	A comparison of the left thoracoabdominal and Ivorâ€“Lewis esophagectomy. Ecological Management and Restoration, 2018, 31, .	0.2	10
2429	Recurrence following curative intended surgery for an adenocarcinoma in the gastroesophageal junction: a retrospective study. Ecological Management and Restoration, 2018, 31, .	0.2	4
2430	Complications during neoadjuvant therapy and prognosis following surgery for esophageal cancer. Ecological Management and Restoration, 2018, 31, .	0.2	7
2431	A novel pretherapeutic gene expression-based risk score for treatment guidance in gastric cancer. Annals of Oncology, 2018, 29, 127-132.	0.6	16

#	Article	IF	Citations
2432	Mid/Distal Esophageal Cancer and Gastroesophageal Junction Cancer (Siewert Type I and II). Practical Guides in Radiation Oncology, 2018, , 21-50.	0.0	0
2433	Gastric Cancer (Siewert Type III). Practical Guides in Radiation Oncology, 2018, , 53-91.	0.0	0
2434	Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nature Communications, 2018, 9, 1777.	5.8	245
2435	Evaluation of PET and laparoscopy in STagIng advanced gastric cancer: a multicenter prospective study (PLASTIC-study). BMC Cancer, 2018, 18, 450.	1.1	28
2436	Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. World Journal of Surgical Oncology, 2018, 16, 27.	0.8	64
2437	Clinicopathological and prognostic significance of high circulating lymphocyte ratio in patients receiving neoadjuvant chemotherapy for advanced gastric cancer. Scientific Reports, 2018, 8, 6223.	1.6	12
2438	Clinical significance of esophageal invasion length for the prediction of mediastinal lymph node metastasis in Siewert type II adenocarcinoma: A retrospective singleâ€institution study. Annals of Gastroenterological Surgery, 2018, 2, 187-196.	1.2	29
2439	Does Proton Therapy Offer Demonstrable Clinical Advantages for Treating Thoracic Tumors?. Seminars in Radiation Oncology, 2018, 28, 114-124.	1.0	7
2440	The association among HER2, MET and FOXP3 expression and tumor regression grading in gastric adenocarcinoma. Apmis, 2018, 126, 389-395.	0.9	5
2441	Surgical Protocol for Esophageal Adenocarcinoma. Methods in Molecular Biology, 2018, 1756, 35-50.	0.4	0
2442	The Concentration of Iodine in Perigastric Adipose Tissue: A Novel Index for the Assessment of Serosal Invasion in Patients with Gastric Cancer after Neoadjuvant Chemotherapy. Digestion, 2018, 98, 87-94.	1.2	3
2443	Early brain metastasis of advanced gastric cancer with a pathological complete response to neoadjuvant chemotherapy followed by surgery: A case report and literature review. Cancer Biology and Therapy, 2018, 19, 875-878.	1.5	4
2444	Upper Gastrointestinal Surgery: Robotic Surgery versus Laparoscopic Procedures for Esophageal Malignancy. Visceral Medicine, 2018, 34, 10-15.	0.5	17
2446	Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer. British Journal of Surgery, 2018, 105, 900-906.	0.1	40
2447	Cutoff values of major surgical complications rates after gastrectomy. Updates in Surgery, 2018, 70, 251-255.	0.9	6
2448	Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study. Targeted Oncology, 2018, 13, 227-234.	1.7	33
2449	Neoadjuvant therapy reduces cardiopulmunary function in patients undegoing oesophagectomy. International Journal of Surgery, 2018, 53, 86-92.	1.1	17
2450	Adjuvant Chemotherapy Versus Chemoradiotherapy Versus Surgery Alone for Early Gastric Cancer with One or Two Lymph Node Metastasis. Annals of Surgical Oncology, 2018, 25, 1616-1624.	0.7	17

#	Article	IF	Citations
2451	Customization of therapy for gastroesophageal adenocarcinoma patients. Chronic Diseases and Translational Medicine, 2018, 4, 8-17.	0.9	1
2452	Impact of peri-operative blood transfusion on post-operative infections after radical gastrectomy for gastric cancer: a propensity score matching analysis focusing on the timing, amount of transfusion and role of leukocyte depletion. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1143-1154.	1.2	29
2453	Different Chemosensitization Approaches in Gastric Cancer. , 2018, , 267-319.		4
2454	Downregulation of microRNA-17-5p inhibits drug resistance of gastric cancer cells partially through targeting p21. Oncology Letters, 2018, 15, 4585-4591.	0.8	23
2455	Induction therapy for locally advanced distal esophageal adenocarcinoma: Is radiation Always necessary?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 2697-2707.	0.4	3
2456	Predictive biomarkers for the treatment of resectable esophageal and esophago-gastric junction adenocarcinoma: from hypothesis generation to clinical validation. Expert Review of Molecular Diagnostics, 2018, 18, 357-370.	1.5	6
2457	Upper gastrointestinal malignancies in 2017: current perspectives and future approaches. Future Oncology, 2018, 14, 947-962.	1.1	9
2458	Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis. Lancet Oncology, The, 2018, 19, 629-638.	5.1	172
2459	Underutilization of Treatment for Regional Gastric Cancer Among the Elderly in the USA. Journal of Gastrointestinal Surgery, 2018, 22, 955-963.	0.9	16
2460	Preoperative chemoradiation for an ascending colon tumour: novel approach to achieve a complete resection. ANZ Journal of Surgery, 2018, 88, E342-E344.	0.3	0
2461	Correlation Between Standardized Uptake Value in Preneoadjuvant and Postneoadjuvant Chemoradiotherapy and Tumor Regression Grade in Patients With Locally Advanced Esophageal Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 254-258.	0.6	13
2462	Assessing quality of care in oesophagoâ€gastric cancer surgery in Australia. ANZ Journal of Surgery, 2018, 88, 290-295.	0.3	16
2463	Characteristics of Gastric Cancer in Lebanon: a Descriptive Study from a Single Institutional Experience. Journal of Gastrointestinal Cancer, 2018, 49, 21-24.	0.6	8
2464	Assessment of the Albumin-Bilirubin (ALBI) Grade as a Prognostic Indicator for Hepatocellular Carcinoma Patients Treated With Radioembolization. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 861-866.	0.6	57
2465	Significance of SYT8 For the Detection, Prediction, and Treatment of Peritoneal Metastasis From Gastric Cancer. Annals of Surgery, 2018, 267, 495-503.	2.1	81
2466	The Role of Definitive Radiotherapy in Craniopharyngioma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 807-812.	0.6	25
2467	Evaluating Candidacy for Hypofractionated Radiation Therapy, Accelerated Partial Breast Irradiation, and Endocrine Therapy After Breast Conserving Surgery. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 526-531.	0.6	9
2468	Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 838-844.	0.6	2

#	Article	IF	Citations
2469	Concurrent Chemoradiotherapy in the Adjuvant Treatment of High-risk Primary Salivary Gland Malignancies. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 888-893.	0.6	28
2470	Phase I Trial Using Induction Ciplatin, Docetaxel, 5-FU and Erlotinib Followed by Cisplatin, Bevacizumab and Erlotinib With Concurrent Radiotherapy for Advanced Head and Neck Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 441-446.	0.6	12
2471	Location and Grade of Prostate Cancer Diagnosed by Transperineal Template-guided Mapping Biopsy After Negative Transrectal Ultrasound-guided Biopsy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 723-729.	0.6	12
2472	Patient-reported Urinary, Bowel, and Sexual Function After Hypofractionated Intensity-modulated Radiation Therapy for Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 558-567.	0.6	27
2473	Antitumoral potential, antioxidant activity and carotenoid content of two Southern Italy tomato cultivars extracts: San Marzano and Corbarino. Journal of Cellular Physiology, 2018, 233, 1266-1277.	2.0	34
2474	Third-line Salvage Chemotherapy for Recurrent Carcinoma of the Cervix is Associated With Minimal Response Rate and High Toxicity. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 797-801.	0.6	3
2475	Adjuvant Radiotherapy Versus Wait-and-See Strategy for Pathologic T3 or Margin-Positive Prostate Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 730-738.	0.6	17
2476	Survival of Patients With Multiple Intracranial Metastases Treated With Stereotactic Radiosurgery. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 425-431.	0.6	28
2477	Chemoradiation Versus Chemotherapy in Uterine Carcinosarcoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 784-791.	0.6	20
2478	A prospective multi-institutional validity study to evaluate the accuracy of clinical diagnosis of pathological stage III gastric cancer (JCOG1302A). Gastric Cancer, 2018, 21, 68-73.	2.7	110
2479	The utility of routine pre-chemotherapy screening with cardiac gated blood pool scan for patients at low risk of anthracycline toxicity. Journal of Oncology Pharmacy Practice, 2018, 24, 264-271.	0.5	2
2480	Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 471-475.	0.6	20
2481	Phase II Study of Adjuvant Chemoradiotherapy Using Docetaxel/Cisplatin/5-Fluorouracil Before and After Intensity-modulated Radiotherapy With Concurrent Docetaxel in Patients With Completely (R0) Resected Gastric Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 619-625.	0.6	3
2482	HER2 Status in Gastric and Gastroesophageal Junction Cancer: Results of the Large, Multinational HER-EAGLE Study. Applied Immunohistochemistry and Molecular Morphology, 2018, 26, 239-245.	0.6	32
2483	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 632-637.	0.6	14
2484	Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 549-557.	0.6	4
2485	Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer, 2018, 21, 338-344.	2.7	31
2486	Prognostic Value of Perineural Invasion in Resected Gastric Cancer Patients According to Lauren Histotype. Pathology and Oncology Research, 2018, 24, 393-400.	0.9	27

#	Article	IF	Citations
2487	Obesity is Independently Associated With Increased Risk of Hepatocellular Cancerâ€“related Mortality. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 874-881.	0.6	164
2488	Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 485-491.	0.6	36
2489	Accuracy of Clinical Staging and Outcome With Primary Resection for Local-Regionally Limited Esophageal Adenocarcinoma. Annals of Surgery, 2018, 267, 484-488.	2.1	5
2490	Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Annals of Surgery, 2018, 267, 105-113.	2.1	103
2491	Short-term outcomes after laparoscopic versus open transhiatal resection of Siewert type II adenocarcinoma of the esophagogastric junction. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 383-390.	1.3	29
2492	Surgical strategies in true adenocarcinoma of the esophagogastric junction (AEG II): thoracoabdominal or abdominal approach?. Gastric Cancer, 2018, 21, 303-314.	2.7	70
2493	Selective survival advantage associated with primary tumor resection for metastatic gastric cancer in a Western population. Gastric Cancer, 2018, 21, 324-337.	2.7	28
2494	Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer, 2018, 21, 74-83.	2.7	44
2495	Diagnostic staging laparoscopy in gastric cancer: a prospective cohort at a cancer institute in Japan. Surgical Endoscopy and Other Interventional Techniques, 2018, 32, 268-275.	1.3	43
2496	Nutritional optimization during neoadjuvant therapy prior to surgical resection of esophageal cancerâ€”a narrative review. Ecological Management and Restoration, 2018, 31, 1-11.	0.2	46
2497	Perioperative chemotherapy vs. neoadjuvant chemoradiation inÂgastroesophageal junction adenocarcinoma. Strahlentherapie Und Onkologie, 2018, 194, 125-135.	1.0	13
2499	Time to initiation or duration of S-1 adjuvant chemotherapy; which really impacts on survival in stage II and III gastric cancer?. Gastric Cancer, 2018, 21, 446-452.	2.7	33
2500	Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer. Gut, 2018, 67, 1780-1792.	6.1	19
2501	Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). Gastric Cancer, 2018, 21, 421-427.	2.7	28
2502	Optimal Therapy in Locally Advanced Esophageal Cancer: a National Cancer Database Analysis. Journal of Gastrointestinal Surgery, 2018, 22, 187-193.	0.9	6
2503	Neoadjuvant Chemotherapy Improves Survival in Patients with Clinical T4b Colon Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 242-249.	0.9	74
2504	Diffuse Calcified Gastric Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 753-754.	0.9	0
2505	Tumor regression grading of gastrointestinal cancers after neoadjuvant therapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 175-186.	1.4	78

#	Article	IF	Citations
2506	An application study of low-dose computed tomography perfusion imaging for evaluation of the efficacy of neoadjuvant chemotherapy for advanced gastric adenocarcinoma. Gastric Cancer, 2018, 21, 413-420.	2.7	18
2507	Management of Patients With Adenocarcinoma or Squamous Cancer of the Esophagus. Gastroenterology, 2018, 154, 437-451.	0.6	75
2508	Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer, 2018, 21, 703-709.	2.7	48
2509	Targeted and imaging-guided in vivo photodynamic therapy for tumors using dual-function, aggregation-induced emission nanoparticles. Nano Research, 2018, 11, 2756-2770.	5.8	32
2510	Medical management of gastric cancer: a 2017 update. Cancer Medicine, 2018, 7, 123-133.	1.3	145
2511	Influence of induction chemotherapy in trimodality therapy-eligible oesophageal cancer patients: secondary analysis of a randomised trial. British Journal of Cancer, 2018, 118, 331-337.	2.9	10
2512	Prognostic Significance of Serum Inflammatory Markers in Gastric Cancer. Journal of Gastrointestinal Surgery, 2018, 22, 595-605.	0.9	24
2513	Phase II trial of preoperative chemoradiation plus perioperative SOX chemotherapy in patients with locally advanced gastric cancer. Journal of Surgical Oncology, 2018, 117, 692-698.	0.8	16
2514	Adoption of evidenceâ€based novel therapies in the treatment of gastric cancer: A national observational study. Cancer, 2018, 124, 1122-1131.	2.0	10
2515	Diagnostic staging laparoscopy in gastric cancer treatment: A costâ€effectiveness analysis. Journal of Surgical Oncology, 2018, 117, 1288-1296.	0.8	23
2516	Adjuvant Statin Therapy for Esophageal Adenocarcinoma: A Cost-Utility Analysis. Pharmacoeconomics, 2018, 36, 349-358.	1.7	6
2518	Factors influencing health-related quality of life after gastrectomy for cancer. Gastric Cancer, 2018, 21, 524-532.	2.7	45
2519	Gastric cancer diagnosis after presentation to the ED: The independent association of presenting location and outcomes. American Journal of Surgery, 2018, 216, 286-292.	0.9	13
2520	Expression and prognostic significance of human epidermal growth factor receptors 1, 2 and 3 in oesophageal and gastric adenocarcinomas preneoadjuvant and postneoadjuvant treatment. Journal of Clinical Pathology, 2018, 71, 451-462.	1.0	9
2521	Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma?. Journal of Surgical Oncology, 2018, 117, 659-670.	0.8	10
2522	A phase II Study Evaluating Combined Neoadjuvant Cetuximab and Chemotherapy Followed by Chemoradiotherapy and Concomitant Cetuximab in Locoregional Oesophageal Cancer Patients. Targeted Oncology, 2018, 13, 69-78.	1.7	0
2523	Histopathologic Features are more Important Prognostic Factors than Primary Tumour Location in Gastro-oesophageal Adenocarcinoma Treated with Preoperative Chemoradiation and Surgery. Pathology and Oncology Research, 2018, 24, 373-383.	0.9	5
2525	Surgicopathological Quality Control and Protocol Adherence to Lymphadenectomy in the CRITICS Gastric Cancer Trial. Annals of Surgery, 2018, 268, 1008-1013.	2.1	27

#	Article	IF	Citations
2526	Can the addition of radiotherapy postoperatively increase clinical outcome of patients with gastric cancer? A systematic review of the literature and meta-analysis. Oncotarget, 2018, 9, 10734-10744.	0.8	8
2527	The effect of perigastric lipolymphatic tissue grouping by surgeon on the number of pathologic sampled lymph nodes after radical gastrectomy. Medicine (United States), 2018, 97, e11411.	0.4	3
2528	Reply to L. Fornaro et al. Journal of Clinical Oncology, 2018, 36, 1179-1180.	0.8	0
2529	CALGB 80101 and the Final Call for Preoperative Chemotherapy in Gastric Cancer. Journal of Clinical Oncology, 2018, 36, 1178-1179.	0.8	3
2531	Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial. Journal of Clinical Oncology, 2018, 36, 268-275.	0.8	91
2532	Is There a Precise Adjuvant Therapy for Esophagogastric Carcinoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2018, 38, 280-291.	1.8	4
2533	Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. Journal of Gastrointestinal Oncology, 2018, 9, 517-526.	0.6	2
2534	Impact of pathological complete response following neoadjuvant chemoradiotherapy in esophageal cancer. Journal of Thoracic Disease, 2018, 10, 4069-4076.	0.6	28
2535	The comparison of predictive factors regarding prognoses and invasion of thymic neuroendocrine tumors preoperatively and postoperatively. Journal of Thoracic Disease, 2018, 10, 1657-1669.	0.6	6
2536	Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country. Journal of Gastrointestinal Oncology, 2018, 9, 64-72.	0.6	7
2537	Role of lymph node ratio in selection of adjuvant treatment (chemotherapy vs. chemoradiation) in patients with resected gastric cancer. Journal of Gastrointestinal Oncology, 2018, 9, 708-717.	0.6	6
2538	Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study. Journal of Gastrointestinal Oncology, 2018, 9, 35-45.	0.6	8
2539	Lymph node metastases near the celiac trunk should be considered separately from other nodal metastases in patients with cancer of the esophagus or gastroesophageal junction after neoadjuvant treatment and surgery. Journal of Thoracic Disease, 2018, 10, 1511-1521.	0.6	3
2540	Outcomes by Treatment Modality in Elderly Patients with Localized Gastric and Esophageal Cancer. Current Oncology, 2018, 25, 366-370.	0.9	7
2541	Clinical fate of T0N1 esophageal cancer: results from the National Cancer Database. Journal of Gastrointestinal Oncology, 2018, 9, 880-886.	0.6	3
2542	Proton beam therapy for gastrointestinal cancers: past, present, and future. Journal of Gastrointestinal Oncology, 2018, 9, 962-971.	0.6	17
2543	How many lymph nodes are enough?â€"defining the extent of lymph node dissection in stage Iâ€"III gastric cancer using the National Cancer Database. Journal of Gastrointestinal Oncology, 2018, 9, 1168-1175.	0.6	8
2544	Routine pre- and post-neoadjuvant chemotherapy fitness testing is not indicated for oesophagogastric cancer surgery. Annals of the Royal College of Surgeons of England, 2018, 100, 515-519.	0.3	6

#	Article	IF	Citations
2545	Postoperative morbidity and mortality in patients receiving neoadjuvant chemotherapy for locally advanced gastric cancers. Medicine (United States), 2018, 97, e12932.	0.4	15
2546	AKR1B10 expression predicts response of gastric cancer to neoadjuvant chemotherapy. Oncology Letters, 2018, 17, 773-780.	0.8	9
2548	Advances in radiotherapy for esophageal cancer. Annals of Translational Medicine, 2018, 6, 79-79.	0.7	30
2550	Lauren Histology and Lymphatic Permeation are Critical Prognostic Factors in Borrmann Type I Gastric Cancer. International Surgery, 2018, 103, 95-104.	0.0	1
2551	Podocalyxin-like protein as a predictive biomarker for benefit of neoadjuvant chemotherapy in resectable gastric and esophageal adenocarcinoma. Journal of Translational Medicine, 2018, 16, 290.	1.8	7
2552	HER2 Positive Gastric Carcinomas and Their Clinico-Pathological Characteristics. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1187-1192.	0.1	2
2553	SEPROGADIC â€“ serum protein-based gastric cancer prediction model for prognosis and selection of proper adjuvant therapy. Scientific Reports, 2018, 8, 16892.	1.6	7
2554	Impact of postoperative TNM stages after neoadjuvant therapy on prognosis of adenocarcinoma of the gastro-oesophageal junction tumours. World Journal of Gastroenterology, 2018, 24, 1429-1439.	1.4	2
2555	Towards risk-adapted perioperative treatment of gastroesophageal cancer. Annals of Oncology, 2018, 29, 2282-2284.	0.6	0
2556	Chemotherapy and novel targeted therapies for operable esophageal and gastroesophageal junctional cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 45-52.	1.0	13
2557	A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial. Annals of Oncology, 2018, 29, 2356-2362.	0.6	32
2558	miR-126 Functions as a Tumor Suppressor by Targeting SRPK1 in Human Gastric Cancer. Oncology Research, 2018, 26, 1345-1353.	0.6	12
2559	Role of Self-expanding Stents in the Treatment of Intrathoracic Dehiscence After Ivor Lewis Esophagectomy. CirugÃa EspaÃ±ola (English Edition), 2018, 96, 555-559.	0.1	0
2560	miR-23b-3p and miR-130a-5p affect cell growth, migration and invasion by targeting CB1R via the Wnt/β-catenin signaling pathway in gastric carcinoma. OncoTargets and Therapy, 2018, Volume 11, 7503-7512.	1.0	53
2561	Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group. BMC Cancer, 2018, 18, 1298.	1.1	63
2562	Ten-year survival outcomes of patients with potentially resectable gastric cancer: impact of clinicopathologic and treatment-related risk factors. Annals of Gastroenterology, 2018, 32, 99-106.	0.4	6
2563	Severe Infection of <i>Pseudomonas aeruginosa</i> during Eculizumab Therapy for Paroxysmal Nocturnal Hemoglobinuria. Internal Medicine, 2018, 57, 127-130.	0.3	12
2564	New therapeutic options opened by the molecular classification of gastric cancer. World Journal of Gastroenterology, 2018, 24, 1942-1961.	1.4	33

#	Article	IF	Citations
2565	Papel de las endoprÃ³tesis autoexpandibles en el tratamiento de la dehiscencia intratorÃ¡cica tras el procedimiento de Ivor Lewis. CirugÃa EspaÃ±ola, 2018, 96, 555-559.	0.1	2
2566	The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy. Frontiers in Oncology, 2018, 8, 610.	1.3	6
2567	T and N Staging of Gastric Cancer Using Dual-Source Computed Tomography. Gastroenterology Research and Practice, 2018, 2018, 1-10.	0.7	13
2568	A randomised controlled trial to assess whether prehabilitation improves fitness in patients undergoing neoadjuvant treatment prior to oesophagogastric cancer surgery: study protocol. BMJ Open, 2018, 8, e023190.	0.8	28
2569	Neoadjuvant chemoradiotherapy for resectable oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 37-44.	1.0	15
2570	MicroRNAâ€'218 enhances gastric cancer cell cisplatin sensitivity by targeting survivin. Experimental and Therapeutic Medicine, 2018, 16, 4796-4802.	0.8	10
2571	Oesophagectomy: The expanding role of minimally invasive surgery in oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 75-80.	1.0	9
2572	Peri-operative patient optimization for oesophageal cancer surgeryÂâ€“ÂFrom prehabilitation to enhanced recovery. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 61-73.	1.0	8
2573	Molecular pathways in the development and treatment of oesophageal cancer. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 36-37, 9-15.	1.0	21
2574	Effect of Early Adjuvant Chemotherapy on Survival of Advanced Gastric Cancer Patients: a Propensity Score-matched Analysis. Journal of Gastric Cancer, 2018, 18, 58.	0.9	9
2575	Neoadjuvant therapy for esophageal cancer: Who, when, and what?. Cancer, 2018, 124, 4276-4278.	2.0	8
2576	ASO Author Reflections: Multimodal Treatment of Upper Gastrointestinal Signet Ring Cell Containing Cancerâ€"Better Together. Annals of Surgical Oncology, 2018, 25, 761-762.	0.7	0
2577	Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. Journal of Gastrointestinal Oncology, 2018, 9, 560-572.	0.6	9
2578	Sarcopenia and Post-Operative Morbidity and Mortality in Patients with Gastric Cancer. Journal of Gastric Cancer, 2018, 18, 242.	0.9	42
2579	A Phase I/II Study of NAC with Docetaxel, Cisplatin, and S-1 for Stage III Gastric Cancer. Anticancer Research, 2018, 38, 6015-6021.	0.5	4
2580	Genomeâ€wide identification of a novel mi<scp>RNA</scp>â€based signature to predict recurrence in patients with gastric cancer. Molecular Oncology, 2018, 12, 2072-2084.	2.1	28
2581	Cutting-edge evidence of adjuvant treatments for gastric cancer. Expert Review of Gastroenterology and Hepatology, 2018, 12, 1109-1122.	1.4	3
2582	Establishment and Characterization of gc-006-03, a Novel Human Signet Ring Cell Gastric Cancer Cell Line Derived from Metastatic Ascites. Journal of Cancer, 2018, 9, 3236-3246.	1.2	5

#	Article	IF	Citations
2583	Computed tomography scan efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study. Cancer Management and Research, 2018, Volume 10, 3825-3831.	0.9	8
2584	From standardization to personalized medicine: Moving beyond cookie-cutter treatment of esophageal cancer. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 1736-1738.	0.4	2
2585	Effects of proton pump inhibitors on reversing multidrug resistance via downregulating V-ATPases/PI3K/Akt/mTOR/HIF-1α signaling pathway through TSC1/2 complex and Rheb in human gastric adenocarcinoma cells in vitro and in vivo. OncoTargets and Therapy, 2018, Volume 11, 6705-6722.	1.0	40
2586	Efficiency of All-Trans Retinoic Acid on Gastric Cancer: A Narrative Literature Review. International Journal of Molecular Sciences, 2018, 19, 3388.	1.8	35
2587	Platelet-to-lymphocyte ratio and lymphocyte-to-white blood cell ratio predict the efficacy of neoadjuvant chemotherapy and the prognosis of locally advanced gastric cancer patients treated with the oxaliplatin and capecitabine regimen. OncoTargets and Therapy, 2018, Volume 11, 7061-7075.	1.0	14
2588	North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis. European Journal of Surgical Oncology, 2018, 44, 1982-1989.	0.5	6
2589	Computed tomography-based radiomics for prediction of neoadjuvant chemotherapy outcomes in locally advanced gastric cancer: A pilot study. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 406-414.	0.7	51
2590	Down-regulation of CASC2 contributes to cisplatin resistance in gastric cancer by sponging miR-19a. Biomedicine and Pharmacotherapy, 2018, 108, 1775-1782.	2.5	47
2591	A Case of Complete Remission from Advanced Gastric Adenocarcinoma with Synchronous Liver Metastasis in Response to EOX Chemotherapy. Case Reports in Gastrointestinal Medicine, 2018, 2018, 1-7.	0.2	1
2592	microRNAs expression profile related with response to preoperative radiochemotherapy in patients with locally advanced gastric cancer. BMC Cancer, 2018, 18, 1048.	1.1	26
2593	A rationale multidisciplinary approach for treatment of esophageal and gastroesophageal junction cancer: Accurate review of management and perspectives. Critical Reviews in Oncology/Hematology, 2018, 132, 161-168.	2.0	6
2594	Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study. BMC Cancer, 2018, 18, 1006.	1.1	54
2595	Xiao Tan He Wei Decoction reverses MNNG-induced precancerous lesions of gastric carcinoma in vivo and vitro: Regulation of apoptosis through NF-Î²B pathway. Biomedicine and Pharmacotherapy, 2018, 108, 95-102.	2.5	41
2597	CT volumetry for gastric adenocarcinoma: association with lymphovascular invasion and T-stages. Oncotarget, 2018, 9, 12432-12442.	0.8	6
2598	The Role of Surgical Resection for Stage IV Gastric Cancer With Synchronous Hepatic Metastasis. Journal of Surgical Research, 2018, 232, 422-429.	0.8	21
2599	Feasibility of Intravenous Iron Isomaltoside to Improve Anemia and Quality of Life During Palliative Chemotherapy for Esophagogastric Adenocarcinoma. Nutrition and Cancer, 2018, 70, 1106-1117.	0.9	7
2600	CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer, 2018, 18, 877.	1.1	115
2601	Screening Patients with Esophageal Cancer to Determine Eligibility for Adjuvant Treatment Trials. Anticancer Research, 2018, 38, 5247-5251.	0.5	0

#	Article	IF	Citations
2603	The effect of preoperative treatments on lymph node counts after total gastrectomy in esophagogastric adenocarcinoma. Journal of Surgical Oncology, 2018, 118, 657-663.	0.8	3
2604	Adjuvant Chemotherapy Improves Survival in Stage III Gastric Cancer after D2 Surgery. Journal of Cancer, 2018, 9, 81-91.	1.2	20
2605	Quercetin induced cell apoptosis and altered gene expression in AGS human gastric cancer cells. Environmental Toxicology, 2018, 33, 1168-1181.	2.1	68
2606	The Art of War and oncology: applying the principles of strategy and tactics to greater effect in the era of targeted therapy. Annals of Translational Medicine, 2018, 6, 168-168.	0.7	1
2607	Gastrointestinal Cancersâ€"Carving Out the Optimal Local Therapies in the Gastrointestinal Tract. International Journal of Radiation Oncology Biology Physics, 2018, 102, 233-242.	0.4	0
2608	Relationship between the Body Mass Index and Tumor Site Postoperative Complications and Prognosis in Gastric Adenocarcinoma. American Surgeon, 2018, 84, 1861-1868.	0.4	2
2609	Multimodal analgesia using intrathecal diamorphine, and paravertebral and rectus sheath catheters are as effective as thoracic epidural for analgesia post-open two-phase esophagectomy within an enhanced recovery program. Ecological Management and Restoration, 2018, 31, .	0.2	17
2610	Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: Should lymph node retrieval guidelines be altered?. Journal of Surgical Oncology, 2018, 117, 1708-1715.	0.8	6
2611	Surgical treatment of esophageal cancer in the era of multimodality management. Annals of the New York Academy of Sciences, 2018, 1434, 192-209.	1.8	97
2612	Prognostic Significance of Post-Operative Morbidity Severity Score After Potentially Curative D2 Gastrectomy for Carcinoma. Journal of Gastrointestinal Surgery, 2018, 22, 1516-1527.	0.9	19
2615	Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA. Phytomedicine, 2018, 51, 58-67.	2.3	62
2616	Prognostic impact of extranodal extension in stage 1B gastric carcinomas. Surgical Oncology, 2018, 27, 299-305.	0.8	7
2617	BST2 promotes cell proliferation, migration and induces NF-Î°B activation in gastric cancer. Biotechnology Letters, 2018, 40, 1015-1027.	1.1	25
2620	Molecular Diagnostics in Esophageal and Gastric Neoplasms. Clinics in Laboratory Medicine, 2018, 38, 357-365.	0.7	6
2621	Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus. Journal of Surgical Oncology, 2018, 117, 1687-1696.	0.8	20
2622	Radiotherapy and Chemoradiotherapy. , 2018, , 283-297.		0
2624	Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas. Annals of Surgical Oncology, 2018, 25, 2418-2427.	0.7	21
2625	Potentially curable gastric adenocarcinoma treated without surgery. European Journal of Cancer, 2018, 98, 23-29.	1.3	8

#	Article	IF	Citations
2626	Prognostic significance of circumferential resection margin involvement in patients receiving potentially curative treatment forÂoesophageal cancer. European Journal of Surgical Oncology, 2018, 44, 1268-1277.	0.5	9
2627	Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future. Annals of Oncology, 2018, 29, 1377-1385.	0.6	13
2628	Radical Gastrectomy: Still the Cornerstone of Curative Treatment for Gastric Cancer in the Perioperative Chemotherapy Eraâ€"A Single Institute Experience over a Decade. International Journal of Surgical Oncology, 2018, 2018, 1-6.	0.3	4
2629	Tailored treatment for signet ring cell gastric cancer. Updates in Surgery, 2018, 70, 167-171.	0.9	16
2630	Adjuvant therapy in resectable gastric cancerâ€"the CRITICS trial. Lancet Oncology, The, 2018, 19, e329.	5.1	0
2631	Adjuvant therapy in resectable gastric cancerâ€"the CRITICS trial. Lancet Oncology, The, 2018, 19, e328.	5.1	3
2632	The ypT category does not impact overall survival in node negative gastric cancer. Journal of Surgical Oncology, 2018, 117, 1721-1728.	0.8	19
2633	Radiation Therapy in Gastric Cancer. , 2018, , 1-13.		0
2634	Multimodal treatment in locally advanced gastric cancer. Updates in Surgery, 2018, 70, 173-179.	0.9	44
2635	Chemical Therapy. , 2018, , 263-281.		0
2636	The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surgery Today, 2018, 48, 994-1003.	0.7	16
2637	GI Cancersâ€"Modulating the Modern Management of Gastrointestinal Malignancies: A Look at Liver Metastases, Rectal Cancer, Esophagogastric Cancer, and Anal Cancer. International Journal of Radiation Oncology Biology Physics, 2018, 101, 749-758.	0.4	0
2638	Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study. Gastroenterology Research and Practice, 2018, 2018, 1-10.	0.7	21
2639	Staging of Esophageal Cancer: Implications for Therapy. , 2018, , 29-43.		1
2640	Ramucirumab for the treatment of gastric adenocarcinoma. Expert Opinion on Orphan Drugs, 2018, 6, 449-455.	0.5	0
2641	Etiologic and Clinicopathological Correlates of Gastric Carcinoma in the Egyptian Delta. Indian Journal of Surgical Oncology, 2018, 9, 472-476.	0.3	2
2642	18Fâ€'fluorodeoxyglucose positron emission tomographyÌ¸computed tomography for the prediction of survival in patients with advanced esophageal cancer who have undergone neoadjuvant chemotherapy. Molecular and Clinical Oncology, 2018, 8, 434-440.	0.4	0
2643	A comparison of the operative outcomes of D1 and D2 gastrectomy performed at a single Western center with multiple surgeons: a retrospective analysis with propensity score matching. World Journal of Surgical Oncology, 2018, 16, 136.	0.8	15

#	Article	IF	Citations
2644	Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Management and Research, 2018, Volume 10, 239-248.	0.9	745
2645	Efficacy and safety assessment of apatinib in patients with advanced gastric cancer: a meta-analysis. OncoTargets and Therapy, 2018, Volume 11, 4149-4158.	1.0	8
2646	Optimal management of resected gastric cancer. Cancer Management and Research, 2018, Volume 10, 1605-1618.	0.9	16
2647	Tips and Tricks in Thoracic Surgery. , 2018, , .		2
2649	Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with gastric cancer and peritoneal carcinomatosis. European Journal of Surgical Oncology, 2018, 44, 1805-1810.	0.5	38
2650	Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma. British Journal of Surgery, 2018, 105, 1639-1649.	0.1	52
2651	Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics, 2018, 19, 1047-1068.	0.6	12
2652	Psoriasin overexpression confers drug resistance to cisplatin by activating ERK in gastric cancer. International Journal of Oncology, 2018, 53, 1171-1182.	1.4	5
2653	Future Directions in Esophageal Cancer. , 2018, , 193-200.		0
2654	CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2018, 31, e1373.	0.5	10
2655	Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer. OncoTargets and Therapy, 2018, Volume 11, 2259-2267.	1.0	12
2656	Angiogenesis and Anti-Angiogenic Therapy in Gastric Cancer. International Journal of Molecular Sciences, 2018, 19, 43.	1.8	72
2657	Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis. Journal of Gastric Cancer, 2018, 18, 69.	0.9	15
2658	Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer, 2018, 18, 702.	1.1	19
2659	Preoperative therapy and long-term survival in gastric cancer: One size does not fit all. Surgical Oncology, 2018, 27, 575-583.	0.8	11
2660	Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy. Annals of Surgical Oncology, 2018, 25, 2720-2730.	0.7	21
2661	Oesophageal Tumours: Benign and Malignant. , 2018, , 367-379.		0
2662	Comparative effectiveness of preoperative, postoperative and perioperative treatments for resectable gastric cancer: A network meta-analysis of the literature from the past 20 years. Surgical Oncology, 2018, 27, 563-574.	0.8	36

#	Article	IF	Citations
2663	Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis. BMC Cancer, 2018, 18, 118.	1.1	46
2664	Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiation Oncology, 2018, 13, 74.	1.2	18
2665	Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer, 2018, 18, 108.	1.1	25
2666	A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. Journal of Experimental and Clinical Cancer Research, 2018, 37, 97.	3.5	45
2667	Treatment outcome of anti-angiogenesis through VEGF-pathway in the management of gastric cancer: a systematic review of phase II and III clinical trials. BMC Research Notes, 2018, 11, 21.	0.6	38
2668	Hyponatremia in patients with esophageal cancer treated with chemotherapy including cisplatin. Esophagus, 2018, 15, 209-216.	1.0	5
2669	ypTNM staging after neoadjuvant chemotherapy in the Chinese gastric cancer population: an evaluation on the prognostic value of the AJCC eighth edition cancer staging system. Gastric Cancer, 2018, 21, 977-987.	2.7	26
2670	18FDG-PET-CT identifies histopathological non-responders after neoadjuvant chemotherapy in locally advanced gastric and cardia cancer: cohort study. BMC Cancer, 2018, 18, 548.	1.1	25
2671	The Impact of Pathological Tumor Regression and Nodal Status on Survival and Systemic Disease in Patients Undergoing Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2018, 25, 2409-2417.	0.7	18
2672	Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006â€“2014 using propensity score matching. Gastric Cancer, 2018, 21, 1004-1013.	2.7	30
2673	Neoadjuvant chemotherapy for gastric cancer. Is it a must or a fake?. World Journal of Gastroenterology, 2018, 24, 274-289.	1.4	88
2674	A prospective phase I study of hypo-fractionated neoadjuvant radiotherapy for locally advanced gastric cancer. BMC Cancer, 2018, 18, 803.	1.1	5
2675	Comparative Effectiveness of Neoadjuvant Treatments for Resectable Gastroesophageal Cancer: A Network Meta-Analysis. Frontiers in Pharmacology, 2018, 9, 872.	1.6	17
2676	Management of resectable esophageal and gastric (mixed adeno)neuroendocrine carcinoma: A nationwide cohort study. European Journal of Surgical Oncology, 2018, 44, 1955-1962.	0.5	29
2677	Cancer of the gastroesophageal junction: a diagnosis, classification, and management review. Annals of the New York Academy of Sciences, 2018, 1434, 132-138.	1.8	64
2678	Current challenges in gastric cancer surgery: European perspective. Surgical Oncology, 2018, 27, 650-656.	0.8	25
2679	Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus. British Journal of Surgery, 2018, 105, 1793-1798.	0.1	11
2680	Laparoscopic or open distal gastrectomy after neoadjuvant chemotherapy for advanced gastric cancer: study protocol for a randomised phase II trial. BMJ Open, 2018, 8, e021633.	0.8	6

#	Article	IF	Citations
2681	Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy. ESMO Open, 2018, 3, e000386.	2.0	11
2682	Timing of surgery after neoadjuvant chemotherapy for gastric cancer: Impact on outcomes. World Journal of Gastroenterology, 2018, 24, 257-265.	1.4	38
2683	The clinical impact of Hangeshashinto (TJ-14) in the treatment of chemotherapy-induced oral mucositis in gastric cancer and colorectal cancer: Analyses of pooled data from two phase II randomized clinical trials (HANGESHA-G and HANGESHA-C). Journal of Cancer, 2018, 9, 1725-1730.	1.2	17
2684	Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy. PLoS ONE, 2018, 13, e0202207.	1.1	5
2685	Locally advanced gastric cancer: total iodine uptake to predict the response of primary lesion to neoadjuvant chemotherapy. Journal of Cancer Research and Clinical Oncology, 2018, 144, 2207-2218.	1.2	22
2686	Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 950-958.	2.3	9
2687	Does Chemoradiation Benefit Patients With Gastric Cancer Managed Without Surgery?. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1027-1028.	2.3	0
2688	Overall survival before and after centralization of gastric cancer surgery in the Netherlands. British Journal of Surgery, 2018, 105, 1807-1815.	0.1	67
2689	Mediastinal lymphadenectomy for esophageal cancer: Differences between two countries, Japan and the Netherlands. Annals of Gastroenterological Surgery, 2018, 2, 176-181.	1.2	9
2690	Adenocarcinoma of the oesophagus: neoadjuvant chemoradiation and radical surgery. Strahlentherapie Und Onkologie, 2018, 194, 1007-1016.	1.0	6
2691	Gastric cancer: French intergroup clinical practice guidelines for diagnosis, treatments and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO). Digestive and Liver Disease, 2018, 50, 768-779.	0.4	73
2692	Serum miR-126 level combined with multi- detector computed tomography in the preoperative prediction of lymph node metastasis of gastric cancer. Cancer Biomarkers, 2018, 22, 773-780.	0.8	7
2693	Perioperative ECX chemotherapy in older adults with gastroesophageal adenocarcinoma. Journal of Geriatric Oncology, 2018, 9, 569-574.	0.5	4
2694	Outcome of Patients Treated Within and Outside a Randomized Clinical Trial on Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: Extrapolation of a Randomized Clinical Trial (CROSS). Annals of Surgical Oncology, 2018, 25, 2441-2448.	0.7	32
2695	Impact of incremental circumferential resection margin distance on overall survival and recurrence in oesophageal adenocarcinoma. BJS Open, 2018, 2, 229-237.	0.7	20
2696	Repeat staging laparoscopy for gastric cancer after preoperative therapy. Journal of Surgical Oncology, 2018, 118, 61-67.	0.8	18
2697	MiR-208a enhances cell proliferation and invasion of gastric cancer by targeting SFRP1 and negatively regulating MEG3. International Journal of Biochemistry and Cell Biology, 2018, 102, 31-39.	1.2	26
2698	Clinical Trials in CRS and HIPEC: Ongoing Trials and Future Directives. , 2018, , 433-445.		0

#	Article	IF	Citations
2699	Role of HIPEC in the Prevention of Peritoneal Metastasis from Colorectal, Gastric and Appendiceal Cancer. , 2018, , 15-30.		1
2700	Early Postoperative Intraperitoneal Chemotherapy: Current Role and Future Perspectives. , 2018, , 103-133.		1
2701	Timing of postoperative chemotherapy in patients undergoing perioperative chemotherapy and gastrectomy for gastric cancer. Surgical Oncology, 2018, 27, 421-427.	0.8	9
2702	Correlation of pathological complete response with survival after neoadjuvant chemotherapy in gastric or gastroesophageal junction cancer treated with radical surgery: A meta-analysis. PLoS ONE, 2018, 13, e0189294.	1.1	57
2703	Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions. Cancer Treatment Reviews, 2018, 69, 90-100.	3.4	21
2704	Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Annals of the New York Academy of Sciences, 2018, 1434, 342-359.	1.8	56
2705	Laparoscopic proximal gastrectomy for gastric neoplasms. Journal of Surgical Oncology, 2018, 118, 95-100.	0.8	2
2706	Gastric Cardiac Cancer. , 2018, , .		2
2707	Utilidad clÃ¬nica de la ampliaciÃ³n del margen proximal en gastrectomÃas totales por adenocarcinoma gÃ¡strico. Revista De GastroenterologÃa De MÃ©xico, 2019, 84, 136-142.	0.4	2
2708	International consensus on a complications list after gastrectomy for cancer. Gastric Cancer, 2019, 22, 172-189.	2.7	78
2709	Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients. Annals of Surgery, 2019, 269, 261-268.	2.1	98
2710	Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification. Clinical and Translational Oncology, 2019, 21, 232-238.	1.2	4
2711	Current choices and prospects in management of postoperative esophageal cancer patients. Asian Journal of Surgery, 2019, 42, 81-84.	0.2	0
2712	Radiomics in esophageal and gastric cancer. Abdominal Radiology, 2019, 44, 2048-2058.	1.0	59
2713	Tumor Platinum Concentrations and Pathological Responses Following Cisplatin-Containing Chemotherapy in Gastric Cancer Patients. Journal of Gastrointestinal Cancer, 2019, 50, 801-807.	0.6	9
2714	Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial. Ecological Management and Restoration, 2019, 32, .	0.2	11
2716	Targeting Vascular Endothelial Growth Factor in Oesophagogastric Cancer: A Review of Progress to Date and Immunotherapy Combination Strategies. Frontiers in Oncology, 2019, 9, 618.	1.3	9
2717	Clinical Implications of Conversion Surgery After Induction Therapy for T4b Thoracic Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2019, 26, 4737-4743.	0.7	25

#	Article	IF	Citations
2718	COMplot, A Graphical Presentation of Complication Profiles and Adverse Effects for the Curative Treatment of Gastric Cancer: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2019, 9, 684.	1.3	10
2720	Pathological Tumor Regression Grade Classifications in Gastrointestinal Cancers: Role on Patientsâ€™ Prognosis. International Journal of Surgical Pathology, 2019, 27, 816-835.	0.4	8
2721	Systemic neoadjuvant chemotherapy in modern pancreatic cancer treatment: a systematic review and meta-analysis. Annals of the Royal College of Surgeons of England, 2019, 101, 453-462.	0.3	33
2722	Adjuvant chemotherapy is associated with improved survival in patients with nodal metastases after neoadjuvant therapy and esophagectomy. Journal of Thoracic Disease, 2019, 11, 2546-2554.	0.6	14
2723	Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy. Stem Cell Research, 2019, 40, 101536.	0.3	18
2724	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. Radiotherapy and Oncology, 2019, 140, 143-149.	0.3	7
2725	Postoperative morbidity and mortality after neoadjuvant chemotherapy versus upfront surgery for locally advanced gastric cancer: a propensity score matching analysis . Cancer Management and Research, 2019, Volume 11, 6011-6018.	0.9	21
2726	Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study. BMC Cancer, 2019, 19, 675.	1.1	35
2727	Mucosal-Associated Invariant T Cells Display Diminished Effector Capacity in Oesophageal Adenocarcinoma. Frontiers in Immunology, 2019, 10, 1580.	2.2	45
2728	History of Esophagogastric Junction Cancer Treatment and Current Surgical Management in Western Countries. Journal of Gastric Cancer, 2019, 19, 139.	0.9	12
2729	Comparison on Clinicopathological Features, Treatments and Prognosis between Proximal Gastric Cancer and Distal Gastric Cancer: A National Cancer Data Base Analysis. Journal of Cancer, 2019, 10, 3145-3153.	1.2	27
2730	The optimal strategy of multimodality therapies for resectable gastric cancer: evidence from a network meta-analysis. Journal of Cancer, 2019, 10, 3094-3101.	1.2	9
2731	Measuring the impact of oesophagectomy on physical functioning and physical activity participation: a prospective study. BMC Cancer, 2019, 19, 682.	1.1	35
2732	Association of skeletal muscle loss with the long-term outcomes of esophageal cancer patients treated with neoadjuvant chemotherapy. Surgery Today, 2019, 49, 1022-1028.	0.7	22
2733	Diagnosis of Mixed Adenoneuroendocrine Carcinoma (MANEC) after Neoadjuvant Chemotherapy for Pancreatic and Gastric Adenocarcinoma: Two Case Reports and a Review of the Literature. Case Reports in Oncology, 2019, 12, 434-442.	0.3	14
2734	Integrated assessment of PD-L1 expression and molecular classification facilitates therapy selection and prognosis prediction in gastric cancer . Cancer Management and Research, 2019, Volume 11, 6397-6410.	0.9	13
2735	Effect of neoadjuvant chemoradiation on preoperative pulmonary physiology, postoperative respiratory complications and quality of life in patients with oesophageal cancer. British Journal of Surgery, 2019, 106, 1341-1351.	0.1	18
2736	Adenocarcinoma of the oesophagogastric junction Siewert II: An oesophageal cancer better cured with total gastrectomy. European Journal of Surgical Oncology, 2019, 45, 2473-2481.	0.5	17

#	Article	IF	Citations
2737	A Bayesian Network Meta-Analysis for Identifying the Optimal Taxane-Based Chemotherapy Regimens for Treating Gastric Cancer. Frontiers in Pharmacology, 2019, 10, 717.	1.6	3
2738	Clinical usefulness of extending the proximal margin in total gastrectomies for gastric adenocarcinoma. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2019, 84, 136-142.	0.1	1
2739	Characteristics and Survival of Gastric Cancer Patients with Pathologic Complete Response to Preoperative Therapy. Annals of Surgical Oncology, 2019, 26, 3602-3610.	0.7	32
2740	Oxaliplatin plus Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Adenocarcinoma in Combination with D2 Gastrectomy: NEO-CLASSIC Study. Oncologist, 2019, 24, 1311-e989.	1.9	20
2741	Ramucirumab and paclitaxel in patients with gastric cancer and prior trastuzumab: subgroup analysis from RAINBOW study. Future Oncology, 2019, 15, 2723-2731.	1.1	29
2742	Selecting treatment sequence for patients with incidental gallbladder cancer: a neoadjuvant approach versus upfront surgery. Updates in Surgery, 2019, 71, 217-225.	0.9	11
2743	Prevention and Treatment of Peritoneal Metastases from Gastric Cancer. , 2019, , 277-291.		2
2744	The postoperative lean body mass loss at one month leads to a poor survival in patients with locally advanced gastric cancer. Journal of Cancer, 2019, 10, 2450-2456.	1.2	11
2745	An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer, 2019, 22, 1301-1307.	2.7	29
2746	Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction. British Journal of Surgery, 2019, 106, 1204-1215.	0.1	6
2747	Multimodal Treatment Strategies in Esophagogastric Junction Cancer: a Western Perspective. Journal of Gastric Cancer, 2019, 19, 148.	0.9	8
2748	Staging of Gastric Cancer: Current Revision and Future Proposal. , 2019, , 45-55.		0
2749	Surgery After Neoadjuvant Chemotherapy. , 2019, , 245-251.		0
2750	Radiation Therapy for Gastric Cancer. , 2019, , 359-366.		0
2751	Lymph-node ratio is an important clinical determinant for selecting the appropriate adjuvant chemotherapy regimen for curative D2-resected gastric cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2157-2166.	1.2	14
2752	Temporal validation of metabolic nodal response of esophageal cancer to neoadjuvant chemotherapy as an independent predictor of unresectable disease, survival, and recurrence. European Radiology, 2019, 29, 6717-6727.	2.3	8
2754	Treatment in Esophagogastric Junction Cancer: Past, Present and Future. CirugÃa EspaÃ±ola (English) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.1	2
2755	Elective nodal irradiationâ€,versus involved-field irradiation in patients with esophageal cancer receiving neoadjuvant chemoradiotherapy: a network meta-analysis. Radiation Oncology, 2019, 14, 176.	1.2	8

#	Article	IF	Citations
2756	Prophylactic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancerâ€"A Systematic Review. Journal of Clinical Medicine, 2019, 8, 1685.	1.0	29
2757	Preoperative N stage evaluation in advanced gastric cancer patients using multidetector CT: can the sum of the diameters of metastatic LNs be used for N stage evaluation?. Clinical Radiology, 2019, 74, 782-789.	0.5	7
2758	Adjuvant Chemotherapy of Gastric Cancer. , 2019, , .		0
2759	Metachronous Signet Ring Cell Bladder Metastasis as First Sing of Cancer Recurrence. Urology, 2019, 134, e1-e2.	0.5	1
2760	Bridging the gap: how do we improve long-term survival of locally-advanced esophageal cancer patients?. Journal of Thoracic Disease, 2019, 11, S1841-S1843.	0.6	0
2761	Survival After Induction Chemotherapy and Esophagectomy Is Not Improved by Adjuvant Chemotherapy. Annals of Thoracic Surgery, 2019, 108, 1505-1513.	0.7	11
2762	Efficacy and clinical monitoring strategies for immune checkpoint inhibitors and targeted cytokine immunotherapy for locally advanced and metastatic colorectal cancer. Cytokine and Growth Factor Reviews, 2019, 49, 1-9.	3.2	11
2763	Preparation, characterization and mechanical properties of continuous mullite fibers derived from the diphasic sol-gel route. Journal of Sol-Gel Science and Technology, 2019, 92, 75-83.	1.1	12
2765	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. Cancers, 2019, 11, 1662.	1.7	37
2766	Positive nodeâ€ratio in curativeâ€intent treatment for gastric cancer is a strong independent prognostic factor for 5â€year overall survival. Journal of Surgical Oncology, 2020, 121, 777-783.	0.8	7
2767	Optimizing adjuvant therapies for the treatment of gastric cancer: with a special focus on Asia. Expert Review of Anticancer Therapy, 2019, 19, 939-945.	1.1	6
2768	Sâ€1 plus docetaxel: a safe and effective chemotherapy regimen for stage III gastric cancer. Cancer Communications, 2019, 39, 1-3.	3.7	0
2769	Three-Dimensional Conformal Radiotherapy-Based or Intensity-Modulated Radiotherapy-Based Concurrent Chemoradiotherapy in Patients with Thoracic Esophageal Squamous Cell Carcinoma. Cancers, 2019, 11, 1529.	1.7	10
2770	Risk factors for loss of bone mineral density after curative esophagectomy. Archives of Osteoporosis, 2019, 14, 6.	1.0	11
2772	Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer. Expert Opinion on Biological Therapy, 2019, 19, 1135-1141.	1.4	26
2773	Gastric cancer: Translating novels concepts into clinical practice. Cancer Treatment Reviews, 2019, 79, 101889.	3.4	60
2777	Perioperative chemotherapy versus neoadjuvant chemoradiation for patients with adenocarcinoma of the distal esophagus in Austria: a retrospective analysis. World Journal of Surgical Oncology, 2019, 17, 146.	0.8	6
2778	Application value of CyTOF 2 mass cytometer technology at single-cell level in human gastric cancer cells. Experimental Cell Research, 2019, 384, 111568.	1.2	4

#	Article	IF	Citations
2779	A high-throughput screen to identify novel synthetic lethal compounds for the treatment of E-cadherin-deficient cells. Scientific Reports, 2019, 9, 12511.	1.6	13
2780	Molecular subtyping of gastric cancer with respect to the growth pattern of lymph-node metastases. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2689-2697.	1.2	13
2781	Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: A pooled analysis of four randomised trials. European Journal of Cancer, 2019, 121, 40-47.	1.3	43
2782	Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. Journal of Clinical Oncology, 2019, 37, 3392-3400.	0.8	293
2783	Treatment Algorithm for Patients With Gastric Adenocarcinoma: An Austrian Consensus on Systemic Therapy. Anticancer Research, 2019, 39, 4589-4596.	0.5	4
2784	Cisplatin induces chemoresistance through the PTGS2-mediated anti-apoptosis in gastric cancer. International Journal of Biochemistry and Cell Biology, 2019, 116, 105610.	1.2	26
2785	Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery. Oncology, 2019, 97, 348-355.	0.9	20
2786	The evolving role of radiation therapy for resectable and unresectable gastric cancer. Translational Gastroenterology and Hepatology, 2019, 4, 64-64.	1.5	9
2787	Significance of the Glasgow Prognostic Score in Predicting the Postoperative Outcome of Patients with Stage III Gastric Cancer. Journal of Clinical Medicine, 2019, 8, 1448.	1.0	22
2788	Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. JAMA Surgery, 2019, 154, 1093.	2.2	118
2789	Mouse Models of Human Gastric Cancer Subtypes With Stomach-Specific CreERT2-Mediated Pathway Alterations. Gastroenterology, 2019, 157, 1599-1614.e2.	0.6	50
2790	Attachment orientations, filial piety and future parent support provision among Mainland Chinese college students. Current Psychology, 2023, 42, 15958-15966.	1.7	7
2791	Upregulation of the long non-coding RNA FAM83H-AS1 in gastric cancer and its clinical significance. Pathology Research and Practice, 2019, 215, 152616.	1.0	12
2792	Tumour-associated macrophages-derived CXCL8 determines immune evasion through autonomous PD-L1 expression in gastric cancer. Gut, 2019, 68, 1764-1773.	6.1	219
2794	Predictors of survival outcome following radical gastrectomy for gastric cancer. ANZ Journal of Surgery, 2019, 89, 84-89.	0.3	9
2795	Stageâ€matched survival differences by ethnicity among gastric cancer patients of Asian ancestry treated in the United States. Journal of Surgical Oncology, 2019, 119, 737-748.	0.8	7
2796	Four courses versus eight courses of adjuvant S-1 for patients with stage II gastric cancer (JCOG1104) Tj ETQq0 0 0 rgBT /Overlock 10 T Hepatology, 2019, 4, 208-216.	3.7	73
2797	National Trends in Multimodality Therapy for Locally Advanced Gastric Cancer. Journal of Surgical Research, 2019, 237, 41-49.	0.8	5

#	Article	IF	Citations
2799	Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial. Yonsei Medical Journal, 2019, 60, 132.	0.9	31
2801	The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study. Journal of Gastrointestinal Surgery, 2019, 23, 1729-1741.	0.9	9
2802	Prognostic significance of positive circumferential resection margin post neoadjuvant chemotherapy in patients with esophageal or gastro-esophageal junction adenocarcinoma. European Journal of Surgical Oncology, 2019, 45, 439-445.	0.5	17
2803	Should Multidisciplinary Treatment Differ for Esophageal Adenocarcinoma Versus Esophageal Squamous Cell Cancer?. Annals of Surgical Oncology, 2019, 26, 1014-1027.	0.7	11
2804	Minimally Invasive Esophageal Cancer Surgery. Surgical Oncology Clinics of North America, 2019, 28, 177-200.	0.6	15
2805	Adjuvant and neoadjuvant cancer therapies: A historical review and a rational approach to understand outcomes. Seminars in Oncology, 2019, 46, 83-99.	0.8	23
2806	Hypofractionated Radiotherapy in Oesophageal Cancer for Patients Unfit for Systemic Therapy: A Retrospective Single-Centre Analysis. Clinical Oncology, 2019, 31, 356-364.	0.6	21
2807	Prospective Randomized Controlled Study Comparing Primary Surgery Versus Neoadjuvant Chemotherapy Followed by Surgery in Gastric Carcinoma. Indian Journal of Surgical Oncology, 2019, 10, 245-250.	0.3	8
2808	Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiation Oncology, 2019, 14, 84.	1.2	13
2809	Paravertebral catheter analgesia for minimally invasive Ivor Lewis oesophagectomy. Journal of Thoracic Disease, 2019, 11, S786-S793.	0.6	9
2810	A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients . Cancer Management and Research, 2019, Volume 11, 3993-4003.	0.9	4
2812	Prognostic implication of molecular subtypes and response to neoadjuvant chemotherapy in 760 gastric carcinomas: role of Epsteinâ€“Barr virus infection and highâ€•and lowâ€•microsatellite instability. Journal of Pathology: Clinical Research, 2019, 5, 227-239.	1.3	63
2813	Mebendazole induces apoptosis via C-MYC inactivation in malignant ascites cell line (AGP01). Toxicology in Vitro, 2019, 60, 305-312.	1.1	18
2814	Safety and Efficacy of the Addition of Lapatinib to Perioperative Chemotherapy for Resectable HER2-Positive Gastroesophageal Adenocarcinoma. JAMA Oncology, 2019, 5, 1181.	3.4	12
2815	Neoadjuvant Treatment for Gastric Cancer. , 2019, , 343-352.		0
2816	Study protocol of a randomized phase III trial of comparing preoperative chemoradiation with preoperative chemotherapy in patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma: PREACT. BMC Cancer, 2019, 19, 606.	1.1	23
2817	Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery. Annals of Surgical Oncology, 2019, 26, 3618-3626.	0.7	26
2818	A novel prognosis prediction model after completion gastrectomy for remnant gastric cancer: Development and validation using international multicenter databases. Surgery, 2019, 166, 314-321.	1.0	4

#	Article	IF	Citations
2819	Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Cancer Chemotherapy and Pharmacology, 2019, 84, 635-646.	1.1	32
2820	Multimodality management of locally advanced gastric cancerâ€"the timing and extent of surgery. Translational Gastroenterology and Hepatology, 2019, 4, 42-42.	1.5	14
2821	Esophagogastric Junction (EGJ) Carcinoma: An Updated Review. GI Surgery Annual, 2019, , 1-62.	0.0	0
2822	The neutrophil/lymphocyte ratio as a predictor of peritoneal metastasis during staging laparoscopy for advanced gastric cancer: a retrospective cohort analysis. World Journal of Surgical Oncology, 2019, 17, 108.	0.8	20
2823	Updates on Management of Gastric Cancer. Current Oncology Reports, 2019, 21, 67.	1.8	292
2824	Minimal length of proximal resection margin in adenocarcinoma of the esophagogastric junction: a systematic review of the literature. Updates in Surgery, 2019, 71, 401-409.	0.9	17
2825	Elevated X-linked inhibitor of apoptosis protein (XIAP) expression uncovers detrimental prognosis in subgroups of neoadjuvant treated and T-cell rich esophageal adenocarcinoma. BMC Cancer, 2019, 19, 531.	1.1	12
2826	Blast from the past: Perioperative use of the Maruyama computer program for prediction of lymph node involvement in the surgical treatment of gastric cancer following neoadjuvant chemotherapy. European Journal of Surgical Oncology, 2019, 45, 1957-1963.	0.5	1
2827	Multimodal treatments for resectable gastric cancer: A systematic review and network meta-analysis. European Journal of Surgical Oncology, 2019, 45, 1796-1805.	0.5	8
2828	Quality of life in patients with upper GI malignancies managed by a strategy of chemoradiotherapy alone versus surgery. Surgical Oncology, 2019, 30, 33-39.	0.8	4
2829	Melatonin inhibits lung metastasis of gastric cancer in vivo. Biomedicine and Pharmacotherapy, 2019, 117, 109018.	2.5	26
2830	EORTC-1203-GITCG - the a€œINNOVATIONa€•trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer, 2019, 19, 494.	1.1	86
2831	Optimizing Therapies in the Perioperative Management of Gastric Cancer. Current Treatment Options in Oncology, 2019, 20, 57.	1.3	13
2832	Relationship Between Sarcopenia and Prognosis in Patient With Concurrent Chemo-Radiation Therapy for Esophageal Cancer. Frontiers in Oncology, 2019, 9, 366.	1.3	19
2833	A Model Shows Utility in Predicting Postoperative Recurrence and Distant Metastasis in Curatively Resected Esophageal Squamous Cell Cancer. Cancer Control, 2019, 26, 107327481985296.	0.7	2
2834	Linkage between EMT and stemness state through molecular association between TWIST1 and NY-ESO1 in esophageal squamousÂcell carcinoma. Biochimie, 2019, 163, 84-93.	1.3	12
2835	Gastric Cancer â€" From Aetiology to Management: Differences Between the East and the West. Clinical Oncology, 2019, 31, 570-577.	0.6	22
2836	Optimal radiation dosing in concurrent neoadjuvant chemoradiation for resectable esophageal cancer: a meta-analysis. Journal of Gastrointestinal Oncology, 2019, 10, 391-399.	0.6	14

#	Article	IF	Citations
2837	Development and validation of a staging system for gastric adenocarcinoma after neoadjuvant chemotherapy and gastrectomy with D2 lymphadenectomy. British Journal of Surgery, 2019, 106, 1187-1196.	0.1	12
2838	A Randomized Phase II Study of S-1 Adjuvant Chemotherapy With or Without Hochu-ekki-to, a Japanese Herbal Medicine, for Stage II/III Gastric Cancer: The KUGC07 (SHOT) Trial. Frontiers in Oncology, 2019, 9, 294.	1.3	7
2839	Extended thoracic lymph node dissection in robotic-assisted minimal invasive esophagectomy (RAMIE) for patients with superior mediastinal lymph node metastasis. Annals of Cardiothoracic Surgery, 2019, 8, 218-225.	0.6	22
2840	Combined Modality Treatment for Locally Advanced Gastric Cancer: Current Evidences and New Perspectives. Current Clinical Pathology, 2019, , 133-145.	0.0	0
2841	The efficacy of treatment options for patients with gastric cancer and peritoneal metastasis. Gastric Cancer, 2019, 22, 1226-1237.	2.7	36
2842	Tumor blood supply may predict neoadjuvant chemotherapy response and survival in patients with gastric cancer. Journal of International Medical Research, 2019, 47, 2524-2532.	0.4	14
2843	Docetaxel, oxaliplatin, leucovorin, and 5-fluorouracil (FLOT) as preoperative and postoperative chemotherapy compared with surgery followed by chemotherapy for patients with locally advanced gastric cancer: a propensity score-based analysis . Cancer Management and Research, 2019, Volume 11, 3009-3020.	0.9	28
2844	Late start and insufficient S-1 dose in adjuvant chemotherapy can lead to poor prognosis in stage II/III gastric cancer. International Journal of Clinical Oncology, 2019, 24, 1190-1196.	1.0	18
2845	Gastric Adenocarcinoma. , 2019, , 712-718.		1
2846	Real-life data on improvement of survival after perioperative chemotherapy versus surgery alone on resectable adenocarcinoma of the stomach â€“ a single-center study. Zeitschrift Fur Gastroenterologie, 2019, 57, 606-610.	0.2	6
2847	Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer With Peritoneal Metastases (CYTO-CHIP study): A Propensity Score Analysis. Journal of Clinical Oncology, 2019, 37, 2028-2040.	0.8	218
2848	Postoesophagectomy chylothorax: A singleâ€centre, 14â€year review. Surgical Practice, 2019, 23, 87-94.	0.1	2
2849	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. PLoS ONE, 2019, 14, e0215970.	1.1	3
2850	Is curative gastrectomy justified for gastric cancer with cytology positive as the only stage IV factor?. Langenbeck's Archives of Surgery, 2019, 404, 599-604.	0.8	5
2851	The optimal neoadjuvant treatment of locally advanced esophageal cancer. Journal of Thoracic Disease, 2019, 11, S621-S631.	0.6	16
2852	Acute Tumor Transition Angle on Computed Tomography Predicts Chromosomal Instability Status of Primary Gastric Cancer: Radiogenomics Analysis from TCGA and Independent Validation. Cancers, 2019, 11, 641.	1.7	9
2853	Gastroesophageal Junction Adenocarcinoma: Is There an Optimal Management?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2019, 39, e88-e95.	1.8	17
2854	Hybrid Minimally Invasive Esophagectomy for Esophageal Cancer. New England Journal of Medicine, 2019, 380, e28.	13.9	7

#	Article	IF	Citations
2855	Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers, 2019, 11, 530.	1.7	17
2856	Evaluation of the response of breast cancer patients to neoadjuvant chemotherapy by combined contrastâ€enhanced ultrasonography and ultrasound elastography. Experimental and Therapeutic Medicine, 2019, 17, 3655-3663.	0.8	15
2857	Transhiatal distal esophagectomy for Siewert type II cardia cancer can be a treatment option in selected patients. European Journal of Surgical Oncology, 2019, 45, 1943-1949.	0.5	9
2858	Total neoadjuvant therapy for rectal cancer. Seminars in Colon and Rectal Surgery, 2019, 30, 63-67.	0.2	0
2859	Nomogram for predicting disease-free survival among a multicenter cohort of Chinese patients with locally advanced rectal cancer . Cancer Management and Research, 2019, Volume 11, 2471-2483.	0.9	10
2860	Gastric Cancer In The Precision Medicine Era. Current Clinical Pathology, 2019, , .	0.0	2
2861	National trend of gastric cancer mortality in China (2003â€“2015): a populationâ€based study. Cancer Communications, 2019, 39, 1-5.	3.7	92
2862	Characteristic and outcomes of patients with pathologic complete response after preoperative treatment in borderline and locally advanced pancreatic adenocarcinoma: An AGEO multicentric retrospective cohort. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, 663-668.	0.7	12
2863	Resection of hepatic and pulmonary metastasis from metastatic esophageal and gastric cancer: a nationwide study. Ecological Management and Restoration, 2019, 32, .	0.2	13
2864	Hyperthermic intraperitoneal chemotherapy (HIPEC) in combined treatment of locally advanced and intraperitonealy disseminated gastric cancer: A retrospective cooperative Centralâ€Eastern European study. Cancer Medicine, 2019, 8, 2877-2885.	1.3	40
2865	Squamous cell carcinoma antigen 1 is associated to poor prognosis in esophageal cancer through immune surveillance impairment and reduced chemosensitivity. Cancer Science, 2019, 110, 1552-1563.	1.7	21
2866	Porphyrin-Based Nanomedicines for Cancer Treatment. Bioconjugate Chemistry, 2019, 30, 1585-1603.	1.8	115
2867	Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for isolated resectable colorectal peritoneal metastases: protocol of a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6). BMC Cancer, 2019, 19, 390.	1.1	83
2868	Comparison of toxicity and effectiveness between fixed-dose and body surface area-based dose capecitabine. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983896.	1.4	10
2869	The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications, 2019, 39, 1-31.	3.7	418
2870	Induction/reversal of drug resistance in gastric cancer by non-coding RNAs (Review). International Journal of Oncology, 2019, 54, 1511-1524.	1.4	21
2871	Changes in gut hormones, glycaemic response and symptoms after oesophagectomy. British Journal of Surgery, 2019, 106, 735-746.	0.1	16
2872	The Potential Clinical Implications of Circulating Tumor Cells and Circulating Tumor Microemboli in Gastric Cancer. Oncologist, 2019, 24, e854-e863.	1.9	29

#	Article	IF	Citations
2873	Double Contrast-Enhanced Ultrasonography in Preoperative T Staging of Gastric Cancer: A Comparison With Endoscopic Ultrasonography. Frontiers in Oncology, 2019, 9, 66.	1.3	18
2874	S-1 in Patients with Advanced Esophagogastric Adenocarcinoma: Results from the Safety Compliance Observatory on Oral fluoroPyrimidines (SCOOP) Study. Drugs in R and D, 2019, 19, 141-148.	1.1	4
2875	Finnish National Esophago-Gastric Cancer Cohort (FINEGO) for studying outcomes after oesophageal and gastric cancer surgery: a protocol for a retrospective, population-based, nationwide cohort study in Finland. BMJ Open, 2019, 9, e024094.	0.8	19
2876	Stenosis of the celiac trunk is associated with anastomotic leak after Ivorâ€“Lewis esophagectomy. Ecological Management and Restoration, 2019, 32, .	0.2	12
2877	Characterisation of an Isogenic Model of Cisplatin Resistance in Oesophageal Adenocarcinoma Cells. Pharmaceuticals, 2019, 12, 33.	1.7	9
2878	Randomized phase III trial of gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer, the short-term safety and surgical results: Japan Clinical Oncology Group Study (JCOG0501). Gastric Cancer, 2019, 22, 1044-1052.	2.7	89
2879	Expression of PD-L1 and PD-1 in Chemoradiotherapy-NaÃ¨ve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Frontiers in Oncology, 2019, 9, 136.	1.3	36
2880	Limited Sensitivity of Circulating Tumor DNA Detection by Droplet Digital PCR in Non-Metastatic Operable Gastric Cancer Patients. Cancers, 2019, 11, 396.	1.7	20
2881	Differences in Esophageal Cancer Surgery in Terms of Surgical Approach and Extent of Lymphadenectomy: Findings of an International Survey. Annals of Surgical Oncology, 2019, 26, 2063-2072.	0.7	30
2882	Perioperative Treatment in Resectable Gastric Cancer: Current Perspectives and Future Directions. Cancers, 2019, 11, 399.	1.7	46
2883	Billroth II reconstruction in gastric cancer surgery: A good option for Western patients. American Journal of Surgery, 2019, 218, 940-945.	0.9	5
2884	MicroRNA-574-3p regulates epithelial mesenchymal transition and cisplatin resistance via targeting ZEB1 in human gastric carcinoma cells. Gene, 2019, 700, 110-119.	1.0	55
2886	Neoadjuvant treatment strategy for locally advanced thoracic esophageal cancer. Annals of Gastroenterological Surgery, 2019, 3, 269-275.	1.2	35
2887	Immune activation by DNA damage predicts response to chemotherapy and survival in oesophageal adenocarcinoma. Gut, 2019, 68, 1918-1927.	6.1	18
2888	Increase of CD45-positive Immune Cells in Liver Parenchyma Indicates a More Favorable Prognosis for Patients With Barrett's Cancer. Anticancer Research, 2019, 39, 1191-1196.	0.5	3
2889	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. European Journal of Cancer, 2019, 112, 1-8.	1.3	23
2890	Downstaging of lymph node metastasis after neoadjuvant intraperitoneal and systemic chemotherapy in gastric carcinoma with peritoneal metastasis. European Journal of Surgical Oncology, 2019, 45, 1493-1497.	0.5	11
2891	Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG â€“PET and histopathology. Surgical Oncology, 2019, 28, 42-49.	0.8	5

#	Article	IF	Citations
2892	Hepatic blood flow by perfusion computed tomography as an imaging biomarker for patients with gastric cancer. Oncology Letters, 2019, 17, 3267-3276.	0.8	1
2893	Decreased total psoas muscle area after neoadjuvant therapy is a predictor of increased mortality in patients undergoing oesophageal cancer resection. ANZ Journal of Surgery, 2019, 89, 515-519.	0.3	17
2894	Perioperative FLOT: new standard for gastric cancer?. Lancet, The, 2019, 393, 1914-1916.	6.3	11
2895	Cancer-associated fibroblasts-derived IL-8 mediates resistance to cisplatin in human gastric cancer. Cancer Letters, 2019, 454, 37-43.	3.2	161
2896	Clinicopathological features and prognosis of young gastric cancer patients following radical gastrectomy: a propensity score matching analysis. Scientific Reports, 2019, 9, 5943.	1.6	14
2897	Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis. Annals of Surgical Oncology, 2019, 26, 1805-1813.	0.7	31
2898	Gastric tumours. Medicine, 2019, 47, 309-313.	0.2	7
2899	Optimal management of gastroesophageal junction cancer. Cancer, 2019, 125, 1990-2001.	2.0	29
2900	Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet, The, 2019, 393, 1948-1957.	6.3	1,494
2901	Advanced gastric cancer with lymph node metastasis successfully treated using multimodal therapy: a case report. Digestive Medicine Research, 2019, 2, 1-1.	0.2	0
2902	Exploratory radiomic features from integrated 18F-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging are associated with contemporaneous metastases in oesophageal/gastroesophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 1478-1484.	3.3	17
2903	The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2375-2384.	0.7	16
2904	Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. Journal of Gastric Cancer, 2019, 19, 1.	0.9	328
2905	Multimodal treatments for resectable esophagogastric junction cancer: a systematic review and network meta-analysis. Therapeutic Advances in Medical Oncology, 2019, 11, 175883591983896.	1.4	4
2906	Recurrence after preoperative chemotherapy and surgery for gastric adenocarcinoma: a multicenter study. Gastric Cancer, 2019, 22, 1263-1273.	2.7	45
2907	Does neoadjuvant chemotherapy cancel out the negative survival impact induced by surgical complications after gastrectomy?. Gastric Cancer, 2019, 22, 1274-1284.	2.7	6
2908	Poor compliance with perioperative chemotherapy for resectable gastric cancer and its impact on survival. European Journal of Surgical Oncology, 2019, 45, 1926-1933.	0.5	11
2909	Barrett's oesophagus and oesophageal adenocarcinoma. Medicine, 2019, 47, 275-285.	0.2	2

#	Article	IF	Citations
2910	Combined Modality Therapy for Management of Esophageal Cancer. Surgical Clinics of North America, 2019, 99, 479-499.	0.5	14
2911	Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial. Journal of Clinical Oncology, 2019, 37, 1296-1304.	0.8	258
2912	Actual compliance to adjuvant chemotherapy in gastric cancer. Annals of Surgical Treatment and Research, 2019, 96, 185.	0.4	10
2913	Multidisciplinary Therapy of Esophageal Cancer. Surgical Clinics of North America, 2019, 99, 419-437.	0.5	9
2914	Cancer-induced spiculation on computed tomography: a significant preoperative prognostic factor for colorectal cancer. Surgery Today, 2019, 49, 629-636.	0.7	4
2915	Oxaliplatin in perioperative chemotherapy for gastric and gastroesophageal junction (GEJ) adenocarcinoma. Expert Review of Gastroenterology and Hepatology, 2019, 13, 285-291.	1.4	10
2916	Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: aÂmeta-analysis. Strahlentherapie Und Onkologie, 2019, 195, 695-706.	1.0	8
2917	Prognostic value of neoadjuvant treatment response in locally advanced esophageal adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1682-1693.e1.	0.4	18
2918	Gastric Lavage Malignant Cells (yGL) and Hypohemoglobinemia (yAnemia) as New Systems of Tumor Regression Grading and Prognostic Prediction for Gastric Cancer After Neoadjuvant Treatment. Anticancer Research, 2019, 39, 1019-1027.	0.5	4
2919	CapeOX perioperative chemotherapy versus postoperative chemotherapy for locally advanced resectable colon cancer: protocol for a two-period randomised controlled phase III trial. BMJ Open, 2019, 9, e017637.	0.8	8
2920	Moscatilin Inhibits Growth of Human Esophageal Cancer Xenograft and Sensitizes Cancer Cells to Radiotherapy. Journal of Clinical Medicine, 2019, 8, 187.	1.0	12
2921	Gastrointestinal Cancers. , 2019, , 265-311.		0
2923	Reduced acute and late toxicities with intensity-modulated radiation therapy compared to three-dimensional conformal radiation therapy in post-operative gastric cancer. Journal of Radiation Oncology, 2019, 8, 73-80.	0.7	1
2924	Safety and feasibility of preoperative exercise training during neoadjuvant treatment before surgery for adenocarcinoma of the gastro-oesophageal junction. BJS Open, 2019, 3, 74-84.	0.7	43
2925	The prognostic value of a Surgical Outcome Risk Tool in patients after radical gastrectomy for gastric cancer and its guiding significance for postoperative chemotherapy. Surgical Oncology, 2019, 28, 128-134.	0.8	3
2926	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. Yonsei Medical Journal, 2019, 60, 235.	0.9	11
2927	Long-term survival of patients with locally advanced esophageal squamous cell carcinoma receiving esophagectomy following neoadjuvant chemotherapy: a cohort study . Cancer Management and Research, 2019, Volume 11, 1299-1308.	0.9	6
2928	Nationwide Outcome of Gastrectomy with En-Bloc Partial Pancreatectomy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 2327-2337.	0.9	10

#	Article	IF	Citations
2929	Novel Genomic-Based Strategies to Personalize Lymph Node Radiation Therapy. Seminars in Radiation Oncology, 2019, 29, 111-125.	1.0	4
2930	CT-Detected Extramural Vessel Invasion and Regional Lymph Node Involvement in Stage T4a Gastric Cancer for Predicting Progression-Free Survival. American Journal of Roentgenology, 2019, 212, 1030-1036.	1.0	13
2931	KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncology, 2019, 15, 943-952.	1.1	133
2932	Prognostic Value of Nodal Response After Preoperative Treatment of Gastric Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 161-168.	2.3	17
2933	Imaging strategies in the management of gastric cancer: current role and future potential of MRI. British Journal of Radiology, 2019, 92, 20181044.	1.0	61
2934	Evaluation of treatment and outcomes for Hispanic patients with gastric cancer at Commission on Cancerâ€accredited centers in the United States. Journal of Surgical Oncology, 2019, 119, 941-947.	0.8	3
2935	<scp>REV</scp>7 confers radioresistance of esophagus squamous cell carcinoma by recruiting <scp>PRDX</scp>2. Cancer Science, 2019, 110, 962-972.	1.7	26
2936	Clinicopathological features and impact of adjuvant chemotherapy on the longâ€term survival of patients with multiple gastric cancers: a propensity score matching analysis. Cancer Communications, 2019, 39, 1-11.	3.7	4
2937	Updates in Non-traumatic Urological Emergencies. , 2019, , 469-481.		0
2938	Response to Neoadjuvant Treatment is Influenced by Grade in Gastric Cancer. American Surgeon, 2019, 85, 1419-1422.	0.4	2
2939	How I treat gastric adenocarcinoma. ESMO Open, 2019, 4, e000521.	2.0	16
2941	The downstaging approach to irresectable oesophageal and gastric cancer: a single centre experience. Journal of Gastrointestinal Oncology, 2019, 10, 499-505.	0.6	1
2942	Percentage of tumor-infiltrating lymphocytes after chemoradiation therapy for locally advanced esophageal squamous cell carcinoma: a biomarker for pathological response rates and cancer-specific survival?. Annals of Translational Medicine, 2019, 7, S310-S310.	0.7	0
2943	Survival outcomes of patients with pathological stage I gastric cancer using the competing risks survival method. Journal of Gastrointestinal Oncology, 2019, 10, 1110-1119.	0.6	4
2944	A Case of Advanced Gastric Cancer with Folfiri as a Preoperative Chemotherapy. Case Reports in Oncological Medicine, 2019, 2019, 1-4.	0.2	5
2945	For radiation therapy before surgery in esophageal cancer, dose matters, and with each answer comes more questions. Journal of Thoracic Disease, 2019, 11, 5662-5663.	0.6	0
2946	Prediction of a positive circumferential resection margin at surgery following neoadjuvant chemotherapy for adenocarcinoma of the oesophagus. BJS Open, 2019, 3, 767-776.	0.7	3
2947	â€œRealâ€lifeâ€•outcome of gastrointestinal tumor therapies: A singleâ€center comparative study. Cancer Reports, 2019, 2, .	0.6	0

#	Article	IF	Citations
2948	7. Maligne Erkrankungen Des Gastrointestinaltrakts. , 2019, , 145-192.		0
2949	DNA epigenetic signature predictive of benefit from neoadjuvant chemotherapy in oesophageal adenocarcinoma: results from the MRC OE02 trial. European Journal of Cancer, 2019, 123, 48-57.	1.3	5
2950	Less may be more: shifting paradigm toward minimally invasive gastrectomy for locally advanced gastric cancer. Translational Gastroenterology and Hepatology, 2019, 4, 79-79.	1.5	0
2951	Tumor-suppressing potential of stingless bee propolis in in vitro and in vivo models of differentiated-type gastric adenocarcinoma. Scientific Reports, 2019, 9, 19635.	1.6	21
2952	Efficacy of capecitabine and oxaliplatin versus S-1 as adjuvant chemotherapy in gastric cancer after D2 lymph node dissection according to lymph node ratio and N stage. BMC Cancer, 2019, 19, 1232.	1.1	13
2953	Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Frontiers in Oncology, 2019, 9, 1308.	1.3	82
2954	Early recognition of anorexia through patient-generated assessment predicts survival in patients with oesophagogastric cancer. PLoS ONE, 2019, 14, e0224540.	1.1	13
2955	Adjuvant chemotherapy for poor pathologic response after pre-operative chemoradiation in esophageal cancer: infeasible and illogical. Journal of Thoracic Disease, 2019, 11, S1855-S1860.	0.6	1
2956	Lymph node regression after neoadjuvant chemotherapy: A predictor of survival in gastric cancer. Journal of Surgical Oncology, 2020, 121, 795-803.	0.8	24
2957	Survival Trends of Patients With Surgically Resected Gastric Cardia Cancer From 1988 to 2015. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 581-587.	0.6	6
2958	The Role of the Lymph Node Ratio in Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Cancers, 2019, 11, 1914.	1.7	18
2959	Controversies in preoperative therapy in esophageal cancer: Current evidence and ongoing research. Annals of Gastroenterological Surgery, 2019, 3, 592-597.	1.2	7
2960	Clinical significance of pulmonary nodules in decision-making and management of patients diagnosed with esophageal cancer. Ecological Management and Restoration, 2019, 33, .	0.2	1
2962	Robot-assisted Minimally Invasive Thoracolaparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy for Resectable Esophageal Cancer. Annals of Surgery, 2019, 269, 621-630.	2.1	436
2963	Expression of LGR5, FZD7, TROY, and MIST1 in Perioperatively Treated Gastric Carcinomas and Correlation with Therapy Response. Disease Markers, 2019, 2019, 1-15.	0.6	3
2964	Intratumoral Immune Response to Gastric Cancer Varies by Molecular and Histologic Subtype. American Journal of Surgical Pathology, 2019, 43, 851-860.	2.1	47
2965	A case of locally advanced gastric cancer treated with nivolumab, trastuzumab, plus chemotherapy in a neoadjuvant setting. Chinese Medical Journal, 2019, 132, 1370-1371.	0.9	2
2966	A Qualitative Review of Neoadjuvant Chemotherapy in Resectable Pancreatic Adenocarcinoma. Pancreas, 2019, 48, 973-984.	0.5	11

#	Article	IF	Citations
2967	Indications for adjuvant chemotherapy in patients with AJCC stage IIa T3N0M0 and T1N2M0 gastric cancerâ€"an east and west multicenter study. BMC Gastroenterology, 2019, 19, 205.	0.8	6
2968	Value of Prognostic Nutritional Index as a Predictor of Lymph Node Metastasis in Gastric Cancer. Anticancer Research, 2019, 39, 6843-6849.	0.5	15
2970	Esophageal cancer practice guidelines 2017 edited by the Japan Esophageal Society: part 1. Esophagus, 2019, 16, 1-24.	1.0	394
2971	Surgical outcomes of oesophagectomy or gastrectomy due to cancer for patients â‰¥75â€‰years of age: a singleâ€centre cohort study. ANZ Journal of Surgery, 2019, 89, 228-233.	0.3	8
2972	Retrospective study on efficacy of a paclitaxel combined with a leucovorin and fluorouracil regimen for advanced gastric cancer. Tumori, 2019, 105, 509-515.	0.6	6
2973	Prognostic Value of the Number of Lymph Nodes Examined in Patients with Node-Negative Gastric Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 460-467.	0.9	10
2974	Towards an Organ-Sparing Approach for Locally Advanced Esophageal Cancer. Digestive Surgery, 2019, 36, 462-469.	0.6	23
2975	Histopathologic tumor regression grading in patients with gastric carcinoma submitted to neoadjuvant treatment: results of a Delphi survey. Human Pathology, 2019, 84, 26-34.	1.1	22
2976	Integrative molecular analysis of colorectal cancer and gastric cancer: What have we learnt?. Cancer Treatment Reviews, 2019, 73, 31-40.	3.4	15
2977	Fully robotic Ivorâ€"Lewis esophagectomy (RAMIE4) for esophageal cancer after emergency surgery and ligation of the gastroduodenal artery. Journal of International Medical Research, 2019, 47, 1025-1029.	0.4	0
2978	Accuracy of endoscopic ultrasound in gastric adenocarcinoma patient selection for neoadjuvant therapy. United European Gastroenterology Journal, 2019, 7, 278-286.	1.6	4
2979	What Constitutes Optimal Management of T1N0 Esophageal Adenocarcinoma?. Annals of Surgical Oncology, 2019, 26, 714-731.	0.7	9
2980	The Influence of Age on Complications and Overall Survival After Ivor Lewis Totally Minimally Invasive Esophagectomy. Journal of Gastrointestinal Surgery, 2019, 23, 1293-1300.	0.9	18
2981	D2 lymphadenectomy for gastric cancer as an independent prognostic factor of 10-year overall survival. European Journal of Surgical Oncology, 2019, 45, 446-453.	0.5	9
2982	Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran. Journal of Gastrointestinal Cancer, 2019, 50, 907-912.	0.6	0
2983	â€œFour-Step Procedureâ€•of laparoscopic exploration for gastric cancer in West China Hospital: a retrospective observational analysis from a high-volume institution in China. Surgical Endoscopy and Other Interventional Techniques, 2019, 33, 1674-1682.	1.3	14
2984	Intratumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. Annals of Oncology, 2019, 30, 266-273.	0.6	48
2985	Beyond the PD-L1 horizon: In search for a good biomarker to predict success of immunotherapy in gastric and esophageal adenocarcinoma. Cancer Letters, 2019, 442, 279-286.	3.2	34

#	Article	IF	Citations
2986	Influence of the surgical technique on survival in the treatment of carcinomas of the true cardia (Siewert Type II) - Right thoracoabdominal vs. transhiatal-abdominal approach. European Journal of Surgical Oncology, 2019, 45, 416-424.	0.5	11
2987	Reâ€emerging role of macroscopic appearance in treatment strategy for gastric cancer. Annals of Gastroenterological Surgery, 2019, 3, 122-129.	1.2	7
2988	Early response evaluation of neoadjuvant therapy with PET/MRI to predict resectability in patients with adenocarcinoma of the esophagogastric junction. Abdominal Radiology, 2019, 44, 836-844.	1.0	8
2989	Diagnostic performance of MRI- versus MDCT-categorized T3cd/T4 for identifying high-risk stage II or stage III colon cancers: a pilot study. Abdominal Radiology, 2019, 44, 1675-1685.	1.0	15
2990	Surgical Oncology and Geriatric Patients. Clinics in Geriatric Medicine, 2019, 35, 53-63.	1.0	5
2991	Neoadjuvant chemoradiation for patients with advanced oesophageal cancer â€“ which response grading system best impacts prognostic discrimination?. Histopathology, 2019, 74, 731-743.	1.6	20
2992	A Diagnostic Algorithm That Combines Quantitative 18F-FDG PET Parameters and Contrast-Enhanced CT Improves Posttherapeutic Locoregional Restaging and Prognostication of Survival in Patients With Esophageal Cancer. Clinical Nuclear Medicine, 2019, 44, e13-e21.	0.7	9
2993	European validation of the Yonsei Gastric Cancer Prognosis Prediction Model after gastrectomy: Validation with the Netherlands Cancer Registry. European Journal of Surgical Oncology, 2019, 45, 983-988.	0.5	5
2994	Reshaping the critical role of surgeons in oncology research. Nature Reviews Clinical Oncology, 2019, 16, 327-332.	12.5	3
2995	Pathological evaluation of neoadjuvant chemotherapy in advanced gastric cancer. World Journal of Surgical Oncology, 2019, 17, 3.	0.8	19
2996	Different prognostic implication of ypTNM stage and pTNM stage for gastric cancer: a propensity score-matched analysis. BMC Cancer, 2019, 19, 80.	1.1	9
2997	Gastric cancer trends in Estonia 1995â€“2014 by age, subsite, morphology and stage. Acta OncolÃ³gica, 2019, 58, 283-289.	0.8	7
2998	A Simplified Two-Step Technique for Extended Lymphadenectomy During Resection of Gastroesophageal Malignancy: Early Results Compared to En Bloc Dissection. Journal of Gastrointestinal Surgery, 2019, 23, 393-401.	0.9	1
2999	S-1 combined with paclitaxel may benefit advanced gastric cancer: Evidence from a systematic review and meta-analysis. International Journal of Surgery, 2019, 62, 34-43.	1.1	5
3000	The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers, 2019, 11, 80.	1.7	30
3001	A randomized clinical trial on the antitumoral effects of low molecular weight heparin in the treatment of esophageal cancer. Journal of Cellular Physiology, 2019, 234, 4191-4199.	2.0	24
3002	Gastric Cancer Etiology and Management in Asia and the West. Annual Review of Medicine, 2019, 70, 353-367.	5.0	114
3003	Prevalence of False-Negative Results of Intraoperative Consultation on Surgical Margins During Resection of Gastric and Gastroesophageal Adenocarcinoma. JAMA Surgery, 2019, 154, 126.	2.2	25

#	Article	IF	Citations
3004	Low- vs. High-Dose Neoadjuvant Radiation in Trimodality Treatment of Locally Advanced Esophageal Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 885-894.	0.9	21
3006	Quantifying postoperative mobilisation following oesophagectomy. Physiotherapy, 2019, 105, 126-133.	0.2	14
3007	Tumour deposits are a significant prognostic factor in gastric cancer â€“ a systematic review and metaâ€anâ€alysis. Histopathology, 2019, 74, 809-816.	1.6	12
3008	Clinical Impact of the Location of Lymph Node Metastases After Neoadjuvant Chemotherapy for Middle and Lower Thoracic Esophageal Cancer. Annals of Surgical Oncology, 2019, 26, 200-208.	0.7	31
3009	Oxaliplatin, 5-Fluorouracil and Nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: A GERCOR phase II study (FOXAGAST). European Journal of Cancer, 2019, 107, 46-52.	1.3	14
3010	Co-operative groups in the development of chemotherapy for gastric cancer. Japanese Journal of Clinical Oncology, 2019, 49, 210-227.	0.6	2
3011	Prognostic significance of microsatelliteâ€instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. International Journal of Cancer, 2019, 144, 1697-1703.	2.3	51
3012	Impact of upfront randomization for postoperative treatment on quality of surgery in the CRITICS gastric cancer trial. Gastric Cancer, 2019, 22, 369-376.	2.7	4
3013	Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients. Journal of Gastroenterology, 2019, 54, 108-121.	2.3	14
3014	Endoscopic Ultrasound in Esophageal and Gastric Cancer. , 2019, , 79-99.e8.		0
3015	Guidelines for Perioperative Care in Esophagectomy: Enhanced Recovery After Surgery (ERAS^{Â®}) Society Recommendations. World Journal of Surgery, 2019, 43, 299-330.	0.8	395
3016	Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma. Surgery Today, 2019, 49, 150-157.	0.7	4
3017	Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience. Clinical Colorectal Cancer, 2019, 18, 64-71.e1.	1.0	10
3018	A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1, followed by gastrectomy with D2 lymph node dissection for high-risk advanced gastric cancer: results of the KDOG1001 trial. Gastric Cancer, 2019, 22, 598-606.	2.7	26
3019	Laparoscopic Resection for Adenocarcinoma of the Stomach or Gastroesophageal Junction Improves Postoperative Outcomes: a Propensity Score Matching Analysis. Journal of Gastrointestinal Surgery, 2019, 23, 730-738.	0.9	5
3020	Could the inhibition of IL-17 or IL-18 be a potential therapeutic opportunity for gastric cancer?. Cytokine, 2019, 118, 8-18.	1.4	17
3021	Multivisceral Resection for Locally Advanced Gastric and Gastroesophageal Junction Cancersâ€”11-Year Experience at a High-Volume North American Center. Journal of Gastrointestinal Surgery, 2019, 23, 43-50.	0.9	9
3022	Human gastric cancer modelling using organoids. Gut, 2019, 68, 207-217.	6.1	204

#	Article	IF	Citations
3023	The postoperative part of perioperative chemotherapy fails to provide a survival benefit in completely resected esophagogastric adenocarcinoma. Surgical Oncology, 2020, 33, 177-188.	0.8	23
3024	PPM1D Functions as Oncogene and is Associated with Poor Prognosis in Esophageal Squamous Cell Carcinoma. Pathology and Oncology Research, 2020, 26, 387-395.	0.9	13
3025	Predictive Value of ERCC1, ERCC2, and XRCC Expression for Patients with Locally Advanced or Metastatic Gastric Cancer Treated with Neoadjuvant mFOLFOX-4 Chemotherapy. Pathology and Oncology Research, 2020, 26, 1105-1116.	0.9	11
3026	A Systematic Review and Meta-analysis of Physical Exercise Prehabilitation in Major Abdominal Surgery (PROSPERO 2017 CRD42017080366). Journal of Gastrointestinal Surgery, 2020, 24, 1375-1385.	0.9	115
3027	Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer, 2020, 23, 175-183.	2.7	12
3028	Primary Tumor Location Is a Predictor of Poor Prognosis in Patients with Locally Advanced Esophagogastric Cancer Treated with Perioperative Chemotherapy. Journal of Gastrointestinal Cancer, 2020, 51, 484-490.	0.6	6
3029	Effects of Neoadjuvant Chemotherapy Toxicity and Postoperative Complications on Short-term and Long-term Outcomes After Curative Resection of Gastric Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 1278-1289.	0.9	9
3030	Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study. Journal of Gastrointestinal Cancer, 2020, 51, 189-195.	0.6	2
3031	National trends in total vs subtotal gastrectomy for middle and distal third gastric cancer. American Journal of Surgery, 2020, 219, 691-695.	0.9	2
3032	Comparative Effectiveness of Lymphadenectomy Strategies During Curative Resection for Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2020, 24, 2212-2218.	0.9	0
3033	Urgent Surgery for Gastric Adenocarcinoma: AÂStudy of the National Cancer Database. Journal of Surgical Research, 2020, 245, 619-628.	0.8	15
3034	Correlation between Skeletal Muscle Mass and Adverse Events of Neoadjuvant Chemotherapy in Patients with Gastric Cancer. Oncology, 2020, 98, 29-34.	0.9	10
3035	Efficacy of Postoperative Chemotherapy After Resection that Leaves No Macroscopically Visible Disease of Gastric Cancer with Positive Peritoneal Lavage Cytology (CY1) or Localized Peritoneum Metastasis (P1a): A Multicenter Retrospective Study. Annals of Surgical Oncology, 2020, 27, 284-292.	0.7	28
3036	Recent progress in multidisciplinary treatment for patients with esophageal cancer. Surgery Today, 2020, 50, 12-20.	0.7	246
3037	Overexpression of Cullin4A correlates with a poor prognosis and tumor progression in esophageal squamous cell carcinoma. International Journal of Clinical Oncology, 2020, 25, 446-455.	1.0	6
3038	The Survival Benefit From the Addition of Radiation to Chemotherapy in Gastric Cancer Patients Following Surgical Resection. Clinical Oncology, 2020, 32, 110-120.	0.6	6
3039	A Phase II Study of Perioperative Capecitabine plus Oxaliplatin Therapy for Clinical SS/SE N1â€3 M0 Gastric Cancer (OGSG 1601). Oncologist, 2020, 25, 119.	1.9	10
3040	Evaluation of the prognostic impact of pathologic response to preoperative chemotherapy using Mandardâ€™s Tumor Regression Grade (TRG) in gastric adenocarcinoma. Digestive and Liver Disease, 2020, 52, 107-114.	0.4	24

#	Article	IF	Citations
3041	Association among the prognostic nutritional index, completion of adjuvant chemotherapy, and cancer-specific survival after curative resection of stage II/III gastric cancer. European Journal of Clinical Nutrition, 2020, 74, 555-564.	1.3	16
3042	Prognostic Value of Lymph Node Yield After Neoadjuvant Chemoradiation for Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 534-542.	0.7	9
3043	Perioperative chemotherapy for locally advanced gastric cancer in Japan: current and future perspectives. Surgery Today, 2020, 50, 30-37.	0.7	57
3044	Laparoscopic versus open subtotal gastrectomy for adenocarcinoma of the stomach in a Western population: peri-operative and 5-year oncological outcomes. Surgical Endoscopy and Other Interventional Techniques, 2020, 34, 3818-3826.	1.3	5
3045	Prognostic factors associated with survival in a large cohort of gastric cancer patients resected over a decade at a single Italian center: the Cremona experience. Clinical and Translational Oncology, 2020, 22, 1004-1012.	1.2	11
3046	Postoperative complication rate and survival of patients with gastric cancer undergoing immunonutrition: A retrospective study. Nutrition, 2020, 70, 110590.	1.1	14
3047	Improvements in esophageal and gastric cancer care in Sweden-population-based results 2007â€“2016 from a national quality register. Ecological Management and Restoration, 2020, 33, .	0.2	24
3048	Impact of Lymphadenectomy on Survival After Unimodality Transthoracic Esophagectomy for Adenocarcinoma of Esophagus. Annals of Surgical Oncology, 2020, 27, 692-700.	0.7	9
3049	Benefits of Surgery After Neoadjuvant Intraperitoneal and Systemic Chemotherapy for Gastric Cancer Patients With Peritoneal Metastasis: A Meta-Analysis. Journal of Surgical Research, 2020, 245, 234-243.	0.8	15
3050	No Difference in Survival between Neo-Adjuvant Chemotherapy and Neo-Adjuvant Chemoradiation Therapy in Gastric Cardia Cancer Patients: A Contemporary View from the National Cancer Database. Digestive Surgery, 2020, 37, 249-257.	0.6	6
3051	Is Preoperative G-Tube Use Safe for Esophageal Cancer Patients?. Journal of the American College of Nutrition, 2020, 39, 301-306.	1.1	4
3052	Sensibilidad del trago de contraste hidrosoluble para la detecciÃ³n de fugas de anastomosis esofagoyeyunal. Revista De GastroenterologÃa De MÃ©xico, 2020, 85, 118-122.	0.4	0
3053	MAGIC versus MacDonald treatment regimens for gastric cancer: Trends and predictors of multimodal therapy for gastric cancer usingÂthe National Cancer Database. American Journal of Surgery, 2020, 219, 129-135.	0.9	6
3054	Influence of Tumor Location on Lymph Node Metastasis and Survival for Early Gastric Cancer: a Population-Based Study. Journal of Gastrointestinal Surgery, 2020, 24, 1978-1986.	0.9	10
3055	Molecular profiling in gastroesophageal cancerâ€"clinical routine and future perspective. Memo - Magazine of European Medical Oncology, 2020, 13, 440-444.	0.3	3
3056	Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancerâ€"Our Experience from a Tertiary Care Center from Northeast India. Indian Journal of Surgical Oncology, 2020, 11, 66-70.	0.3	2
3057	Trainee performance in radical gastrectomy and its effect on outcomes. BJS Open, 2020, 4, 86-90.	0.7	5
3058	Neoadjuvant Chemotherapy for Locally Advanced T4 Colon Cancer: A Nationwide Propensity-Score Matched Cohort Analysis. Digestive Surgery, 2020, 37, 292-301.	0.6	30

#	Article	IF	Citations
3059	The Uptake and Efficacy of Neoadjuvant Therapy in Older Adults with Locally Advanced Esophogastric Cancer. Journal of Gastrointestinal Cancer, 2020, 51, 893-900.	0.6	3
3060	Impact of postoperative complications on long-term outcomes of patients following surgery for gastric cancer: A systematic review and meta-analysis of 64 follow-up studies. Asian Journal of Surgery, 2020, 43, 719-729.	0.2	20
3061	Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002). Gastric Cancer, 2020, 23, 520-530.	2.7	8
3062	Association between time interval from neoadjuvant chemoradiotherapy to surgery and complete histological tumor response in esophageal and gastroesophageal junction cancer: a national cohort study. Ecological Management and Restoration, 2020, 33, .	0.2	16
3063	Laparoscopic Versus Open Gastrectomy for Cancer: A Western Center Cohort Study. Journal of Surgical Research, 2020, 247, 372-379.	0.8	2
3064	Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf non-metastatic gastric cancer. Surgical Oncology, 2020, 32, 2-7.	0.8	11
3065	Varying practices in tumor regression grading of gastrointestinal carcinomas after neoadjuvant therapy: results of an international survey. Modern Pathology, 2020, 33, 676-689.	2.9	31
3066	PD-1 and PD-L1 inhibitors in oesophago-gastric cancers. Cancer Letters, 2020, 469, 142-150.	3.2	34
3067	What is the most useful body composition parameter for predicting toxicities of preoperative chemotherapy for gastric cancer?. Surgery Today, 2020, 50, 509-515.	0.7	7
3068	Gastric cancer during pregnancy: A report on 13 cases and review of the literature with focus on chemotherapy during pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2020, 99, 79-88.	1.3	18
3069	Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy. Cancer, 2020, 126, 37-45.	2.0	11
3071	Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker. Cancers, 2020, 12, 86.	1.7	11
3072	The impact of race and socioeconomic status on the presentation, management and outcomes for gastric cancer patients: Analysis from a metropolitan area in the southeast United States. Journal of Surgical Oncology, 2020, 121, 494-502.	0.8	7
3073	Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. Frontiers in Oncology, 2019, 9, 1452.	1.3	9
3074	Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 486-493.	0.8	5
3075	Postoperative D-dimer elevation affects tumor recurrence and the long-term survival in gastric cancer patients who undergo gastrectomy. International Journal of Clinical Oncology, 2020, 25, 584-594.	1.0	13
3076	A real-life analysis on the indications and prognostic relevance of perioperative chemotherapy in locally advanced resectable gastric adenocarcinoma. Clinical and Translational Oncology, 2020, 22, 1335-1344.	1.2	5
3077	Therapy Resistance in Neoadjuvantly Treated Gastric Cancer and Cancer of the Gastroesophageal Junction is Associated with an Increased Expression of Immune Checkpoint Inhibitorsâ€"Comparison Against a Therapy NaÃ¯ve Cohort. Translational Oncology, 2020, 13, 165-176.	1.7	12

#	Article	IF	Citations
3078	Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma. Clinical Nuclear Medicine, 2020, 45, 38-43.	0.7	8
3079	The role of palliative interventional radiotherapy (brachytherapy) in esophageal cancer: An AIRO (Italian Association of Radiotherapy and Clinical Oncology) systematic review focused on dysphagia-free survival. Brachytherapy, 2020, 19, 104-110.	0.2	18
3080	Value of individual surgeon performance metrics as quality assurance measures in oesophagogastric cancer surgery. BJS Open, 2020, 4, 91-100.	0.7	7
3081	Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 243-252.	0.9	9
3082	Cancer of the Esophagus. , 2020, , 1174-1196.e6.		5
3083	Cancer of the Stomach. , 2020, , 1197-1210.e3.		0
3084	A modified Delphi process to establish future research priorities in malignant oesophagogastric surgery. Journal of the Royal College of Surgeons of Edinburgh, 2020, 18, 321-326.	0.8	9
3085	IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. Advances in Radiation Oncology, 2020, 5, 369-376.	0.6	5
3086	Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer. Annals of Surgical Oncology, 2020, 27, 662-670.	0.7	2
3087	Recent advances on smallâ€molecule nanomedicines for cancer treatment. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2020, 12, e1607.	3.3	14
3088	Gastroesophageal cancer: Navigating the immune and genetic terrain to improve clinical outcomes. Cancer Treatment Reviews, 2020, 84, 101950.	3.4	19
3089	Gastro-oesophageal junction: to FLOT or to CROSS?. Acta OncolÃ³gica, 2020, 59, 233-236.	0.8	7
3091	National Underutilization of Neoadjuvant Chemotherapy for Gastric Cancer. Journal of Gastrointestinal Surgery, 2020, 24, 949-958.	0.9	9
3092	Adherence with operative standards in the treatment of gastric cancer in the United States. Gastric Cancer, 2020, 23, 550-560.	2.7	21
3093	Novel Radiotherapy Technologies in the Treatment of Gastrointestinal Malignancies. Hematology/Oncology Clinics of North America, 2020, 34, 29-43.	0.9	2
3094	Baseline neutrophilâ€“lymphocyte ratio holds no prognostic value for esophageal and junctional adenocarcinoma in patients treated with neoadjuvant chemotherapy. Ecological Management and Restoration, 2020, 33, .	0.2	3
3096	Return to Intended Oncologic Treatment (RIOT) in Resected Gastric Cancer Patients. Journal of Gastrointestinal Surgery, 2020, 24, 19-27.	0.9	17
3097	Schistosomiasis Misleading Gastric Cancer Treatment. Journal of Gastrointestinal Cancer, 2020, 51, 643-646.	0.6	1

#	Article	IF	Citations
3098	Dual Erb B Inhibition in Oesophago-gastric Cancer (DEBIOC): A phase I dose escalating safety study and randomised dose expansion of AZD8931 in combination with oxaliplatin and capecitabine chemotherapy in patients with oesophagogastric adenocarcinoma. European Journal of Cancer, 2020, 124, 131-141.	1.3	7
3099	Predicting lymph node metastases with endoscopic resection in cT2N0M0 oesophageal cancer: A systematic review and metaâ€analysis. United European Gastroenterology Journal, 2020, 8, 35-43.	1.6	7
3100	Management of Liver Oligometastatic Esophageal Cancer: Overview and Critical Analysis of the Different Loco-Regional Treatments. Cancers, 2020, 12, 20.	1.7	8
3101	Preservation of Epsteinâ€“Barr virus status and mismatch repair protein status along the metastatic course of gastric cancer. Histopathology, 2020, 76, 740-747.	1.6	13
3102	A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer . Cancer Management and Research, 2020, Volume 12, 8491-8496.	0.9	1
3103	Three-Dimensional Culture Systems in Gastric Cancer Research. Cancers, 2020, 12, 2800.	1.7	18
3104	Adverse Biology in Adenocarcinoma of the Esophagus and Esophagogastric Junction Impacts Survival and Response to Neoadjuvant Therapy Independent of Anatomic Subtype. Annals of Surgery, 2020, 272, 814-819.	2.1	12
3105	Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma. Annals of the New York Academy of Sciences, 2020, 1482, 213-224.	1.8	51
3106	Identification of the Prognostic Value of Immune-Related Genes in Esophageal Cancer. Frontiers in Genetics, 2020, 11, 989.	1.1	16
3107	Establishment of Decision Rules and Risk Assessment Model for Preoperative Prediction of Lymph Node Metastasis in Gastric Cancer. Frontiers in Oncology, 2020, 10, 1638.	1.3	11
3108	Hospital clinical staging accuracy for upper gastrointestinal malignancy. Journal of Surgical Oncology, 2020, 122, 1630-1638.	0.8	5
3109	Neoadjuvant Chemotherapy in Pancreatic Cancer: An Appraisal of the Current High-Level Evidence. Pharmacology, 2021, 106, 143-153.	0.9	61
3110	Precision Medicine to Treat Advanced Gastroesophageal Adenocarcinoma: A Work in Progress. Journal of Clinical Medicine, 2020, 9, 3049.	1.0	12
3111	Gastric neoplasms. Surgery, 2020, 38, 711-721.	0.1	0
3112	Preventative and Therapeutic Effects of Metformin in Gastric Cancer: A New Contribution of an Old Friend . Cancer Management and Research, 2020, Volume 12, 8545-8554.	0.9	9
3113	Decreased heart dose with deep inspiration breath hold for the treatment of gastric lymphoma with IMRT. Clinical and Translational Radiation Oncology, 2020, 24, 79-82.	0.9	10
3114	Performance of the American College of Surgeons NSQIP Surgical Risk Calculator for Total Gastrectomy. Journal of the American College of Surgeons, 2020, 231, 650-656.	0.2	7
3115	Adjuvant Systemic Chemotherapy vs Active Surveillance Following Up-front Resection of Isolated Synchronous Colorectal Peritoneal Metastases. JAMA Oncology, 2020, 6, e202701.	3.4	27

#	Article	IF	Citations
3116	The effect of a pre- and post-operative exercise programme versus standard care on physical fitness of patients with oesophageal and gastric cancer undergoing neoadjuvant treatment prior to surgery (The PERIOP-OG Trial): Study protocol for a randomised controlled trial. Trials, 2020, 21, 638.	0.7	13
3117	Outcomes and survival following neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus: Inverse propensity score weighted analysis. European Journal of Surgical Oncology, 2020, 46, 2248-2256.	0.5	15
3118	Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review. Techniques in Coloproctology, 2020, 24, 1001-1015.	0.8	30
3120	Clinical characteristics and surgical treatment of esophageal cancer spinal metastasis â€“ A single center 10-year retrospective study. Clinical Neurology and Neurosurgery, 2020, 197, 106071.	0.6	5
3121	Locoregional gastric cancer: a narrative review of multidisciplinary management. Annals of Translational Medicine, 2020, 8, 1108-1108.	0.7	9
3122	Feasibility and Safety of Laparoscopic Radical Colectomy for T4b Colon Cancer at a University Hospital in Vietnam. BioMed Research International, 2020, 2020, 1-8.	0.9	4
3123	Neoadjuvant FLOT versus SOX phase II randomized clinical trial for patients with locally advanced gastric cancer. Nature Communications, 2020, 11, 6093.	5.8	60
3124	Towards Personalization in the Curative Treatment of Gastric Cancer. Frontiers in Oncology, 2020, 10, 614907.	1.3	10
3125	Linking Circulating Serum Proteins with Clinical Outcomes in Esophageal Adenocarcinomaâ€”An Emerging Role for Chemokines. Cancers, 2020, 12, 3356.	1.7	13
3126	Impact of perioperative chemotherapy on postoperative morbidity after gastrectomy for gastric cancer. CirugÃa EspaÃ±ola, 2020, 99, 521-521.	0.1	2
3127	The Preoperative Enhanced Degree of Contrast-enhanced CT Images: A Potential Independent Predictor in Gastric Adenocarcinoma Patients After Radical Gastrectomy . Cancer Management and Research, 2020, Volume 12, 11989-11999.	0.9	0
3128	Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: A pooled analysis of 3265 individual patient data from four large randomised trials (OE02,) Tj ETQq1 1 0.784314 rgBT /Overlo		
3129	Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer: Analysis of the ARTIST phase III trial. Radiotherapy and Oncology, 2020, 152, 19-25.	0.3	9
3130	Neoadjuvant chemotherapy for gastric cancer. Has the time to decelerate the enthusiasm passed us by?. Seminars in Oncology, 2020, 47, 355-360.	0.8	8
3131	Neoadjuvant Chemotherapy without Radiation in Colorectal Cancer. Clinics in Colon and Rectal Surgery, 2020, 33, 287-297.	0.5	10
3132	Perioperative versus postoperative chemotherapy for gastric cancer: A propensity score matched analysis. Asia-Pacific Journal of Clinical Oncology, 2020, 16, e252-e256.	0.7	3
3133	Multidisciplinary treatment of esophageal cancer: The role of active surveillance after neoadjuvant chemoradiation. Annals of Gastroenterological Surgery, 2020, 4, 352-359.	1.2	4
3134	Invited Commentary. Journal of the American College of Surgeons, 2020, 230, 924-925.	0.2	0

#	Article	IF	Citations
3135	A cohort study and meta-analysis of the evidence for consideration of Lauren subtype when prescribing adjuvant or palliative chemotherapy for gastric cancer. Therapeutic Advances in Medical Oncology, 2020, 12, 175883592093035.	1.4	14
3136	Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis . Cancer Management and Research, 2020, Volume 12, 6641-6653.	0.9	9
3137	The Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Esophageal Cancer Patients: A Systematic Review and Metaâ€Analysis. World Journal of Surgery, 2020, 44, 4161-4174.	0.8	12
3138	Longitudinal monitoring of circulating tumour DNA improves prognostication and relapse detection in gastroesophageal adenocarcinoma. British Journal of Cancer, 2020, 123, 1271-1279.	2.9	27
3139	Endoscopic tumour morphology impacts survival in adenocarcinoma of the oesophagus. European Journal of Surgical Oncology, 2020, 46, 2257-2261.	0.5	1
3140	Health-related quality of life in curatively-treated patients with esophageal or gastric cancer: A systematic review and meta-analysis. Critical Reviews in Oncology/Hematology, 2020, 154, 103069.	2.0	32
3142	Oesophageal cancer. Surgery, 2020, 38, 702-710.	0.1	3
3143	Treatment Selection and Survival Outcomes in Locally Advanced Proximal Gastric Cancer: A National Cancer Data Base Analysis. Frontiers in Oncology, 2020, 10, 537051.	1.3	5
3144	Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?. Cancers, 2020, 12, 3077.	1.7	4
3145	Circ_0000260 Regulates the Development and Deterioration of Gastric Adenocarcinoma with Cisplatin Resistance by Upregulating MMP11 via Targeting MiR-129-5p . Cancer Management and Research, 2020, Volume 12, 10505-10519.	0.9	27
3146	Prognostic and Predictive Value of NAR Score in Gastric Cancer. Journal of Gastrointestinal Cancer, 2021, 52, 1054-1060.	0.6	0
3147	Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. Scientific Reports, 2020, 10, 14514.	1.6	31
3148	Prognostic Value of Changes in Preoperative and Postoperative Serum CA19-9 Levels in Gastric Cancer. Frontiers in Oncology, 2020, 10, 1432.	1.3	12
3149	Observational Study Comparing Efficacy and Safety between Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy for Patients with Unresectable Locally Advanced or Metastatic Gastric Cancer. Journal of Oncology, 2020, 2020, 1-10.	0.6	5
3150	Which is the optimal management for locally advanced gastric cancer patients with TRG 0 and 1 after R0 resection?. Annals of Translational Medicine, 2020, 8, 948-948.	0.7	4
3151	Surgical outcomes and survival for T4 gastric cancer extending to the transverse colon. Annals of Translational Medicine, 2020, 8, 947-947.	0.7	0
3152	Primary results of a randomized twoâ€byâ€two factorial phase II trial comparing neoadjuvant chemotherapy with two and four courses of cisplatin/Sâ€1 and docetaxel/cisplatin/Sâ€1 as neoadjuvant chemotherapy for advanced gastric cancer. Annals of Gastroenterological Surgery, 2020, 4, 540-548.	1.2	10
3153	Boosting Chemodynamic Therapy by the Synergistic Effect of Co-Catalyze and Photothermal Effect Triggered by the Second Near-Infrared Light. Nano-Micro Letters, 2020, 12, 180.	14.4	49

#	Article	IF	Citations
3154	Treatment of Gastric Cancer. Cancers, 2020, 12, 2627.	1.7	13
3155	Gastric cancer. Lancet, The, 2020, 396, 635-648.	6.3	2,084
3156	Individualized prediction of survival benefits from perioperative chemoradiotherapy for patients with resectable gastric cancer. Cancer Medicine, 2020, 9, 7137-7150.	1.3	3
3157	Effects of high-intensity exercise training on physical fitness, quality of life and treatment outcomes after oesophagectomy for cancer of the gastro-oesophageal junction: PRESET pilot study. BJS Open, 2020, 4, 855-864.	0.7	9
3158	Indications of neoadjuvant chemotherapy for locally advanced Gastric Cancer patients based on pre-treatment clinicalpathological and laboratory parameters. Journal of Cancer, 2020, 11, 6000-6008.	1.2	7
3159	RACE-trial: neoadjuvant radiochemotherapy versus chemotherapy for patients with locally advanced, potentially resectable adenocarcinoma of the gastroesophageal junction - a randomized phase III joint study of the AIO, ARO and DGAV. BMC Cancer, 2020, 20, 886.	1.1	32
3161	Systems Biology of Gastric Cancer: Perspectives on the Omics-Based Diagnosis and Treatment. Frontiers in Molecular Biosciences, 2020, 7, 203.	1.6	16
3162	Histopathologic Response Is a Positive Predictor of Overall Survival in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancersâ€"Analysis from a Large Single Center Cohort in Germany. Cancers, 2020, 12, 2244.	1.7	9
3163	Comparison of overall survival of gastric neoplasms containing neuroendocrine carcinoma components with gastric adenocarcinoma: a propensity score matching study. BMC Cancer, 2020, 20, 777.	1.1	9
3164	Relationship between initial management strategy and survival in patients with gastric outlet obstruction due to gastric cancer. Journal of Surgical Oncology, 2020, 122, 1373-1382.	0.8	5
3165	Improving clinical management of colon cancer through CONNECTION, a nation-wide colon cancer registry and stratification effort (CONNECTION II trial): rationale and protocol of a single arm intervention study. BMC Cancer, 2020, 20, 776.	1.1	9
3166	Oncologic Benefit of Adjuvant Chemoradiation after D2 Gastrectomy: A Stepwise Hierarchical Pooled Analysis and Systematic Review. Cancers, 2020, 12, 2125.	1.7	4
3167	Significance of Lymph Node Resection After Neoadjuvant Therapy in Pancreatic, Gastric, and Rectal Cancers. Annals of Surgery, 2020, 272, 438-446.	2.1	12
3168	Pattern of Recurrence and Patient Survival after Perioperative Chemotherapy with 5-FU, Leucovorin, Oxaliplatin and Docetaxel (FLOT) for Locally Advanced Esophagogastric Adenocarcinoma in Patients Treated Outside Clinical Trials. Journal of Clinical Medicine, 2020, 9, 2654.	1.0	17
3169	Survival Advantages in Gastric Cancer Patients Receiving Preoperative SOX Regimen Chemotherapy. Cancer Biotherapy and Radiopharmaceuticals, 2020, , .	0.7	1
3170	Maintenance Chemotherapy with S-1 Following SOX Regimen Chemotherapy Improves Prognosis of Stage 3 Gastric Cancer After D2 Gastrectomy: A 5-Year Analysis . OncoTargets and Therapy, 2020, Volume 13, 12661-12666.	1.0	1
3171	Pathologic Complete Response Following Neoadjuvant Therapy for Gastric Adenocarcinoma: A National Cancer Database Analysis on Incidence, Predictors, and Outcomes. American Surgeon, 2021, 87, 1145-1154.	0.4	14
3172	Identification of the Prognostic Value of Tumor Microenvironment-Related Genes in Esophageal Squamous Cell Carcinoma. Frontiers in Molecular Biosciences, 2020, 7, 599475.	1.6	20

#	Article	IF	Citations
3173	Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Frontiers in Oncology, 2020, 10, 570268.	1.3	3
3174	Efficacy of Postoperative FOLFOX Versus XELOX Chemotherapy for Gastric Cancer and Prognostic Value of Plateletâ€"Lymphocyte Ratio in Patients Receiving XELOX. Frontiers in Oncology, 2020, 10, 584772.	1.3	7
3175	Intratumoral interleukin-9 delineates a distinct immunogenic class of gastric cancer patients with better prognosis and adjuvant chemotherapeutic response. OncoImmunology, 2020, 9, 1856468.	2.1	8
3176	Gastrointestinal side effects of upper gastrointestinal cancer surgery. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2020, 48-49, 101706.	1.0	3
3177	Preoperative Chemoradiotherapy Versus Postoperative Chemoradiotherapy for Patients With Locally Advanced Gastric Cancer: A Retrospective Study Based on Propensity Score Analyses. Frontiers in Oncology, 2020, 10, 560115.	1.3	2
3178	Treatment Patterns for Gastroesophageal Junction Adenocarcinoma in the United States. Journal of Clinical Medicine, 2020, 9, 3495.	1.0	6
3179	Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node. Technology in Cancer Research and Treatment, 2020, 19, 153303382095940.	0.8	2
3180	Tumor Regression in Lymph Node Metastases of Esophageal Adenocarcinomas after Neoadjuvant Therapy. Gastrointestinal Disorders, 2020, 2, 397-407.	0.4	0
3181	Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States. Clinical and Translational Medicine, 2020, 10, e203.	1.7	13
3182	Targeted therapies for gastroesophageal cancers. Annals of Translational Medicine, 2020, 8, 1104-1104.	0.7	9
3183	Recent Developments of Systemic Chemotherapy for Gastric Cancer. Cancers, 2020, 12, 1100.	1.7	31
3184	From biology to surgery: One step beyond histology for tailored surgical treatments of gastric cancer. Surgical Oncology, 2020, 34, 86-95.	0.8	4
3185	Old drug, new clinical use, no manâ€™s land for the indication: an awareness call from European experts. ESMO Open, 2020, 5, e000615.	2.0	10
3186	Serum proteome profiling reveals SOX3 as a candidate prognostic marker for gastric cancer. Journal of Cellular and Molecular Medicine, 2020, 24, 6750-6761.	1.6	16
3187	Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinomaâ€"experience at two centres. Journal of Gastrointestinal Oncology, 2020, 11, 366-375.	0.6	9
3188	Survival of esophageal and gastric cancer patients with adjuvant and palliative chemotherapyâ€"a retrospective analysis of a register-based patient cohort. European Journal of Clinical Pharmacology, 2020, 76, 1029-1041.	0.8	3
3189	Association Between Lymph Node Ratio and Survival in Patients with Pathological Stage II/III Gastric Cancer. Annals of Surgical Oncology, 2020, 27, 4235-4247.	0.7	27
3190	Long Noncoding RNA DLGAP1-AS1 Promotes the Aggressive Behavior of Gastric Cancer by Acting as a ceRNA for microRNA-628-5p and Raising Astrocyte Elevated Gene 1 Expression . Cancer Management and Research, 2020, Volume 12, 2947-2960.	0.9	17

#	Article	IF	Citations
3191	A feasibility study to investigate the utility of a home-based exercise intervention during and after neo-adjuvant chemotherapy for oesophago-gastric cancerâ€"the ChemoFit study protocol. Pilot and Feasibility Studies, 2020, 6, 50.	0.5	14
3192	Predictors of outcomes in patients with gastric cancer treated with contemporary multimodality strategiesâ€"a single institution experience. Journal of Gastrointestinal Oncology, 2020, 11, 411-420.	0.6	0
3193	Non-coding RNAs underlying chemoresistance in gastric cancer. Cellular Oncology (Dordrecht), 2020, 43, 961-988.	2.1	29
3194	Signet ring gastric and esophageal adenocarcinomas: characteristics and prognostic implications. Ecological Management and Restoration, 2020, 33, .	0.2	7
3195	Causes of death in patients diagnosed with gastric adenocarcinoma in Sweden, 1970â€2014: A populationâ€based study. Cancer Science, 2020, 111, 2451-2459.	1.7	10
3196	Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. Journal of Surgical Oncology, 2020, 122, 422-432.	0.8	8
3197	Efficacy of Three-Drug Induction Chemotherapy Followed by Preoperative Chemoradiation in Patients with Localized Gastric Adenocarcinoma. Oncology, 2020, 98, 542-548.	0.9	5
3198	FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers. JAMA Oncology, 2020, 6, 1231.	3.4	12
3199	Should adenosquamous esophageal cancer be treated like adenocarcinoma or squamous cell carcinoma?. Journal of Surgical Oncology, 2020, 122, 412-421.	0.8	5
3200	D1-plus vs D2 nodal dissection in gastric cancer: a propensity score matched comparison and review of published literature. BMC Surgery, 2020, 20, 126.	0.6	8
3201	Clinical Outcome in Patients with Carcinoma of the Esophagogastric Junction Treated with Neoadjuvant Radiochemotherapy or Perioperative Chemotherapy: A Two-Center Retrospective Analysis. Oncology, 2020, 98, 706-713.	0.9	4
3202	The addition of chemoradiation to adjuvant chemotherapy is associated with improved survival in lymph node-positive gastric cancer. Surgical Oncology, 2020, 34, 134-139.	0.8	3
3203	Tumor Regression Grade in Gastric Cancer After Preoperative Therapy. Journal of Gastrointestinal Surgery, 2021, 25, 1380-1387.	0.9	19
3204	Palliative care for advanced gastric cancer. Expert Review of Anticancer Therapy, 2020, 20, 575-580.	1.1	14
3205	Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 2677-2694.	0.8	169
3206	Multidisciplinary Approach in Improving Survival Outcome of Early-Stage Gastric Cancer. Journal of Surgical Research, 2020, 255, 285-296.	0.8	9
3207	Amplification of KRAS and its heterogeneity in non-Asian gastric adenocarcinomas. BMC Cancer, 2020, 20, 587.	1.1	6
3208	Targeting Wnt Signaling for the Treatment of Gastric Cancer. International Journal of Molecular Sciences, 2020, 21, 3927.	1.8	46

#	Article	IF	Citations
3209	The adaptive immune and immune checkpoint landscape of neoadjuvant treated esophageal adenocarcinoma using digital pathology quantitation. BMC Cancer, 2020, 20, 500.	1.1	20
3210	International trends in oesophageal cancer survival by histological subtype between 1995 and 2014. Gut, 2021, 70, gutjnl-2020-321089.	6.1	29
3211	The Cancer-Immune Set Point in Oesophageal Cancer. Frontiers in Oncology, 2020, 10, 891.	1.3	15
3212	Gastric Cancer: Epidemiology, Risk Factors, Classification, Genomic Characteristics and Treatment Strategies. International Journal of Molecular Sciences, 2020, 21, 4012.	1.8	639
3213	The impact of negative lymph nodes in the survival outcomes of pN+ patients following radical gastrectomy: the inverse lymph node ratio as a better score to study negative lymph nodes. Updates in Surgery, 2020, 72, 1031-1040.	0.9	3
3214	The Role of Cardiopulmonary Exercise Testing as a Risk Assessment Tool in Patients Undergoing Oesophagectomy: A Systematic Review and Meta-analysis. Annals of Surgical Oncology, 2020, 27, 3783-3796.	0.7	15
3215	Relevant issues in tumor regression grading of histopathological response to neoadjuvant treatment in adenocarcinomas of the esophagus and gastroesophageal junction. Ecological Management and Restoration, 2020, 33, .	0.2	20
3216	Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial. BMC Cancer, 2020, 20, 224.	1.1	23
3217	A Review of Research Progress in Multidrug-Resistance Mechanisms in Gastric Cancer . OncoTargets and Therapy, 2020, Volume 13, 1797-1807.	1.0	38
3218	Neoadjuvant Treatment in Pancreatic Cancer. Frontiers in Oncology, 2020, 10, 245.	1.3	145
3219	Quality of Life After Curative Resection for Gastric Cancer: Survey Metrics and Implications of Surgical Technique. Journal of Surgical Research, 2020, 251, 168-179.	0.8	18
3220	Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research. World Journal of Surgical Oncology, 2020, 18, 51.	0.8	18
3221	Clinical impact of FDG PET/CT in alimentary tract malignancies: an updated review. Abdominal Radiology, 2020, 45, 1018-1035.	1.0	22
3222	Gastric Cancer with Radiographically Occult Metastatic Disease: Biology, Challenges, and Diagnostic Approaches. Cancers, 2020, 12, 592.	1.7	3
3223	Current status of perioperative chemotherapy for locally advanced gastric cancer and JCOG perspectives. Japanese Journal of Clinical Oncology, 2020, 50, 528-534.	0.6	19
3225	Immunotherapy and radiation therapy for gastrointestinal malignancies: hope or hype?. Translational Gastroenterology and Hepatology, 2020, 5, 21-21.	1.5	2
3226	Neoadjuvant strategies in resectable carcinoma esophagus: a meta-analysis of randomized trials. World Journal of Surgical Oncology, 2020, 18, 59.	0.8	27
3227	Significance of Neoadjuvant Downstaging in Carcinoma of Esophagus and Gastroesophageal Junction. Annals of Surgical Oncology, 2020, 27, 3182-3192.	0.7	15

#	Article	IF	Citations
3228	Older versus younger adults with gastric cancer receiving perioperative treatment: Results from the CRITICS trial. European Journal of Cancer, 2020, 130, 146-154.	1.3	17
3229	The real risk of nodal disease in T1 oesophageal adenocarcinoma. European Surgery - Acta Chirurgica Austriaca, 2020, 52, 110-117.	0.3	4
3230	OSeac: An Online Survival Analysis Tool for Esophageal Adenocarcinoma. Frontiers in Oncology, 2020, 10, 315.	1.3	7
3231	Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 2020, 20, 305-324.	1.1	0
3232	Surgery for Gastric Cancer: State of the Art. Indian Journal of Surgery, 2020, , 1.	0.2	1
3233	Neoadjuvant chemotherapy with gemcitabine plus cisplatin followed by radical liver resection versus immediate radical liver resection alone with or without adjuvant chemotherapy in incidentally detected gallbladder carcinoma after simple cholecystectomy or in front of radical resection of BTC (ICC/ECC) â€“ a phase III study of the German registry of incidental gallbladder carcinoma platform (GB)â€“ the AIO/ CALGB/ ACO- GAIN-trial â€“. BMC Cancer, 2020, 20, 122.	1.1	45
3234	Multi-omics characterization of molecular features of gastric cancer correlated with response to neoadjuvant chemotherapy. Science Advances, 2020, 6, eaay4211.	4.7	60
3235	A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction. International Journal of Clinical Oncology, 2020, 25, 1090-1097.	1.0	3
3236	Nationwide study of the impact of D2 lymphadenectomy on survival after gastric cancer surgery. BJS Open, 2020, 4, 424-431.	0.7	6
3237	Surveillance and outcomes after curative resection for gastroesophageal adenocarcinoma. Cancer Medicine, 2020, 9, 3023-3032.	1.3	7
3238	Histological intratumoral heterogeneity in pretreatment esophageal cancer biopsies predicts survival benefit from neoadjuvant chemotherapy: results from the UK MRC OE02 trial. Ecological Management and Restoration, 2020, 33, .	0.2	1
3239	Comparison of Esophagectomy outcomes between a National Center, a National Audit Collaborative, and an International database using the Esophageal Complications Consensus Group (ECCG) standardized definitions. Ecological Management and Restoration, 2021, 34, .	0.2	12
3240	The additive value of restaging-CT during neoadjuvant chemotherapy for gastric cancer. European Journal of Surgical Oncology, 2020, 46, 1247-1253.	0.5	19
3241	Mixed Type Histology as a Predictive Factor for Esophagojejunostomy Leak in Advanced Gastric Cancer. Cancers, 2020, 12, 1701.	1.7	4
3242	Basics and Frontiers on Pancreatic Cancer for Radiation Oncology: Target Delineation, SBRT, SIB Technique, MRgRT, Particle Therapy, Immunotherapy and Clinical Guidelines. Cancers, 2020, 12, 1729.	1.7	26
3244	Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Laurenâ€™s Classification in Panâ€“Cancer Analysis Era?. Cancers, 2020, 12, 1749.	1.7	9
3245	Multimodality treatment for localized gastric cancer: state of the art and new insights. Current Opinion in Oncology, 2020, 32, 347-355.	1.1	19
3246	FLOT Neoadjuvant Chemotherapy Followed by Laparoscopic D2 Gastrectomy in the Treatment of Locally Resectable Advanced Gastric Cancer. Canadian Journal of Gastroenterology and Hepatology, 2020, 2020, 1-8.	0.8	5

#	Article	IF	Citations
3247	The efficacy and safety of neoadjuvant chemotherapy on patients with advanced gastric cancer: A multicenter randomized clinical trial. Cancer Medicine, 2020, 9, 5731-5745.	1.3	21
3248	Relevant Clinical Trials for GI Surgeons: a Review of Recent Findings. Journal of Gastrointestinal Surgery, 2020, 24, 2318-2335.	0.9	0
3249	Emerging precision therapies for gastric cancer. Expert Review of Precision Medicine and Drug Development, 2020, 5, 299-311.	0.4	1
3250	Editorial: Adjuvant chemotherapy for gastrointestinal cancers: we can do much better. Current Opinion in Oncology, 2020, 32, 344-346.	1.1	0
3251	High levels of tumor-infiltrating lymphocytes showed better clinical outcomes in FOLFOX-treated gastric cancer patients. Pharmacogenomics, 2020, 21, 751-759.	0.6	3
3252	Pembrolizumab for the treatment of esophageal cancer. Expert Opinion on Biological Therapy, 2020, 20, 1143-1150.	1.4	14
3253	ASO Author Reflections: A Surgery-First Approach for Patients With Clinical Stage 1 Signet Ring Cell Gastric Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 781-782.	0.7	1
3254	Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis. Journal of Cancer Research and Clinical Oncology, 2020, 146, 555-568.	1.2	5
3255	Impact of Postoperative Complication and Completion of Multimodality Therapy on Survival in Patients Undergoing Gastrectomy for Advanced Gastric Cancer. Journal of the American College of Surgeons, 2020, 230, 912-924.	0.2	42
3256	Perioperative outcomes and survival of octogenarians undergoing curative resection for esophagogastric adenocarcinoma. Journal of Surgical Oncology, 2020, 121, 1015-1021.	0.8	2
3257	The Correlation Between Computed Tomography Volumetry and Prognosis of Advanced Gastric Cancer Treated with Neoadjuvant Chemotherapy . Cancer Management and Research, 2020, Volume 12, 759-768.	0.9	2
3259	Gastrointestinal Cancers: Moving the Needle for Rectal, Gastroesophageal, Pancreaticobiliary, and Liver Cancers. International Journal of Radiation Oncology Biology Physics, 2020, 106, 653-662.	0.4	1
3260	Limited Usefulness of 18F-FDG PET/CT in Predicting Tumor Regression After Preoperative Chemotherapy for Noncardia Gastric Cancer. Clinical Nuclear Medicine, 2020, 45, 177-181.	0.7	2
3261	The clinical value and usage of inflammatory and nutritional markers in survival prediction for gastric cancer patients with neoadjuvant chemotherapy and D2 lymphadenectomy. Gastric Cancer, 2020, 23, 540-549.	2.7	48
3262	VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.8	57
3263	Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates in Surgery, 2020, 72, 1-19.	0.9	2
3265	Challenges in the treatment of gastric cancer in the older patient. Cancer Treatment Reviews, 2020, 85, 101980.	3.4	76
3266	Prediction of neoadjuvant chemotherapeutic efficacy in patients with locally advanced gastric cancer by serum IgG glycomics profiling. Clinical Proteomics, 2020, 17, 4.	1.1	22

#	Article	IF	Citations
3267	A 16â€mRNA signature optimizes recurrenceâ€free survival prediction of Stages II and III gastric cancer. Journal of Cellular Physiology, 2020, 235, 5777-5786.	2.0	8
3268	Evaluation of the Association of Perioperative UGT1A1 Genotypeâ€“Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma. JAMA Network Open, 2020, 3, e1921290.	2.8	26
3269	Impact of neoadjuvant chemotherapy on surgical and pathological results of gastric cancer patients: A caseâ€control study. Journal of Surgical Oncology, 2020, 121, 833-839.	0.8	18
3270	Higher lymph node harvest in patients with a pathologic complete response after neoadjuvant therapy for esophageal cancer is associated with improved survival. Journal of Surgical Oncology, 2020, 121, 654-661.	0.8	12
3271	Does hipec improve outcomes in gastric cancer patients treated with perioperative chemotherapy and radical surgery? A propensityâ€score matched analysis. Journal of Surgical Oncology, 2020, 121, 823-832.	0.8	10
3272	Does delayed initiation of adjuvant chemotherapy following the curative resection affect the survival outcome of gastric cancer patients: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2020, 46, 1103-1110.	0.5	14
3273	SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clinical and Translational Oncology, 2020, 22, 236-244.	1.2	28
3274	White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer. Nature Communications, 2020, 11, 525.	5.8	158
3275	Shortâ€term and longâ€term outcomes of oesophagogastric surgery for cancer in obese and normal weight patients. ANZ Journal of Surgery, 2020, 90, 277-282.	0.3	3
3276	The AGITG GAP Study: A Phase II Study of Perioperative Gemcitabine and Nab-Paclitaxel for Resectable Pancreas Cancer. Annals of Surgical Oncology, 2020, 27, 2506-2515.	0.7	18
3277	Thirty-year trends in clinicopathologic characteristics and prognosis after gastrectomy for gastric cancer: A single institution in Northern China. Journal of Cancer, 2020, 11, 1056-1062.	1.2	15
3278	Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4. Journal of Gastrointestinal Cancer, 2020, 51, 703-708.	0.6	2
3279	In vivo antitumour activity of Britanin against gastric cancer through nuclear factor-ÎºB-mediated immune response. Journal of Pharmacy and Pharmacology, 2020, 72, 607-618.	1.2	7
3280	Targeting hallmarks of cancer to enhance radiosensitivity in gastrointestinal cancers. Nature Reviews Gastroenterology and Hepatology, 2020, 17, 298-313.	8.2	151
3281	New Treatment Options for Advanced Gastroesophageal Tumours: Mature for the Current Practice?. Cancers, 2020, 12, 301.	1.7	7
3282	Prognostic Biomarkers in Early-stage Gastric Adenocarcinoma Treated With Adjuvant Chemoradiotherapy. Cancer Genomics and Proteomics, 2020, 17, 277-290.	1.0	4
3283	The neutrophil/lymphocyte ratio as a predictor of successful conversion surgery for stage IV gastric cancer: a retrospective study. BMC Cancer, 2020, 20, 363.	1.1	8
3284	Prognostic Factors for Para-aortic Lymph Node Dissection After Neoadjuvant Chemotherapy for Gastric Cancer. Anticancer Research, 2020, 40, 2351-2357.	0.5	2

#	Article	IF	Citations
3286	The potential and challenges of patient-derived organoids in guiding the multimodality treatment of upper gastrointestinal malignancies. Open Biology, 2020, 10, 190274.	1.5	9
3289	Management of Gastric Adenocarcinoma for General Surgeons. Surgical Clinics of North America, 2020, 100, 523-534.	0.5	20
3290	Reflux Disease and Adenocarcinoma of the Esophagus and Cardia: Global Management and Surgical Treatment. Journal of Laparoendoscopic and Advanced Surgical Techniques - Part A, 2020, 30, 869-874.	0.5	1
3291	Neoadjuvant therapy strategies for advanced gastric cancer: Current innovations and future challenges. Chronic Diseases and Translational Medicine, 2020, 6, 147-157.	0.9	9
3292	Postoperative complications and mobilisation following major abdominal surgery with vs. without fitness tracker-based feedback (EXPELLIARMUS): study protocol for a student-led multicentre randomised controlled trial (CHIR-Net SIGMA study group). Trials, 2020, 21, 293.	0.7	9
3293	Significance of nodal dissection and nodal positivity in gastric cancer. Translational Gastroenterology and Hepatology, 2020, 5, 17-17.	1.5	12
3294	Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903). BMC Cancer, 2020, 20, 303.	1.1	13
3295	Betulinic acid triggers apoptosis and inhibits migration and invasion of gastric cancer cells by impairing EMT progress. Cell Biochemistry and Function, 2020, 38, 702-709.	1.4	14
3296	Neoadjuvant chemotherapy improves the survival of patients with neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma of the stomach. Journal of Cancer Research and Clinical Oncology, 2020, 146, 2135-2142.	1.2	23
3297	Global updates in the treatment of gastric cancer: a systematic review. Part 2: perioperative management, multimodal therapies, new technologies, standardization of the surgical treatment and educational aspects. Updates in Surgery, 2020, 72, 355-378.	0.9	16
3298	Long noncoding RNA LINC00339 promotes the oncogenicity of gastric cancer by regulating SRY-box 9 expression via sponging of microRNA-539. Cell Cycle, 2020, 19, 1143-1157.	1.3	4
3299	Are Immunohistochemical Markers Useful in Phenotypic Gastric Cancer Classification?. Oncology, 2020, 98, 566-574.	0.9	13
3300	Trastuzumab with FLOT Regimen for the Perioperative Treatment of Resectable HER2 + Advanced Gastric Cancer: A Retrospective Study . Cancer Management and Research, 2020, Volume 12, 2481-2489.	0.9	5
3301	Impact of Postoperative Complications on Recurrence in Patients With Stage II/III Gastric Cancer Who Received Adjuvant Chemotherapy With S-1. Anticancer Research, 2020, 40, 1683-1690.	0.5	3
3302	Prognostic Significance of Lymphatic, Venous and Perineural Invasion After Neoadjuvant Chemotherapy in Patients with Gastric Adenocarcinoma. Annals of Surgical Oncology, 2020, 27, 3296-3304.	0.7	14
3303	ASO Author Reflections: Assessing the Impact of Neoadjuvant Therapy: A Real View Perspective. Annals of Surgical Oncology, 2020, 27, 3193-3194.	0.7	0
3304	The Prognostic Value of the Perioperative Systemic Inflammation Score for Patients With Advanced Gastric Cancer. Anticancer Research, 2020, 40, 1503-1512.	0.5	15
3305	The role of MRI in the diagnosis and treatment of gastric cancer. Diagnostic and Interventional Radiology, 2020, 26, 176-182.	0.7	42

#	Article	IF	Citations
3306	Trimodality therapy for resectable gastric cancer: analysis of the benefit in radiation. International Journal of Surgery Oncology, 2021, 2, 06.	0.2	0
3307	Impact of Lymph Nodes Examined on Survival in ypN0 Gastric Cancer Patients: a Population-Based Study. Journal of Gastrointestinal Surgery, 2021, 25, 919-925.	0.9	9
3308	Gastric cancer management in elderly patients: a population-based study of treatment patterns and outcomes in gastric cancer patients â‰¥ 75 years from Alberta, Canada. American Journal of Surgery, 2021, 221, 839-843.	0.9	8
3309	Short- and long-term outcomes of laparoscopic versus open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy. Surgical Endoscopy and Other Interventional Techniques, 2021, 35, 1682-1690.	1.3	24
3310	FOXD1â€AS1 regulates FOXD1 translation and promotes gastric cancer progression and chemoresistance by activating the PI3K/AKT/mTOR pathway. Molecular Oncology, 2021, 15, 299-316.	2.1	47
3311	The impact of age on patients undergoing transthoracic esophagectomy for cancer. Ecological Management and Restoration, 2021, 34, .	0.2	5
3312	Posttherapy topographical nodal status, ypN-site, predicts survival of patients who received neoadjuvant chemotherapy followed by curative surgical resection for non-type 4 locally advanced gastric cancer: supplementary analysis of JCOG1004-A. Gastric Cancer, 2021, 24, 197-204.	2.7	5
3313	Health economic analysis of curativeâ€intent gastrectomy for gastric carcinoma and the costs related to postâ€operative complications. ANZ Journal of Surgery, 2021, 91, E1-E6.	0.3	4
3314	Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S. Tumori, 2021, 107, 150-159.	0.6	8
3315	Should Signet Ring Cell Histology Alter the Treatment Approach for Clinical Stage I Gastric Cancer?. Annals of Surgical Oncology, 2021, 28, 97-105.	0.7	6
3316	Clinical Outcomes and Prognostic Factors in Gastric Carcinoma Patients with Curative Surgery Followed by Adjuvant Treatment: Real-World Scenario. Journal of Gastrointestinal Cancer, 2021, 52, 616-624.	0.6	0
3317	Dynamic Changes in Pre- and Postoperative Levels of Inflammatory Markers and Their Effects on the Prognosis of Patients with Gastric Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 387-396.	0.9	36
3318	Influence of race and sociodemographic factors on declining resection for gastric cancer: A national study. American Journal of Surgery, 2021, 221, 155-161.	0.9	8
3319	Low level of microsatellite instability correlates with short disease-free survival of gastric cancer patients undergoing neoadjuvant chemotherapy. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 231-240.	1.4	1
3320	Impact of postoperative complications on survival outcomes in patients with gastric cancer: exploratory analysis of a randomized controlled JCOG1001 trial. Gastric Cancer, 2021, 24, 214-223.	2.7	32
3321	Management of Nonmalignant Tracheo- and Bronchoesophageal Fistula after Esophagectomy. Thoracic and Cardiovascular Surgeon, 2021, 69, 216-222.	0.4	13
3322	Operative Results and Perioperative Morbidity After Intensified Neoadjuvant Chemotherapy with FLOT for Gastroesophageal Adenocarcinoma Impact of Intensified Neoadjuvant Treatment. Journal of Gastrointestinal Surgery, 2021, 25, 58-66.	0.9	7
3323	Short-term outcomes of gastrectomy after neoadjuvant chemotherapy for clinical stage III gastric cancer: propensity score-matched analysis of a multi-institutional database. Surgery Today, 2021, 51, 821-828.	0.7	4

#	Article	IF	Citations
3324	Gastrointestinal. , 2021, , 135-144.e6.		0
3325	Open versus minimally invasive total gastrectomy after neoadjuvant chemotherapy: results of a European randomized trial. Gastric Cancer, 2021, 24, 258-271.	2.7	79
3326	Prognostic Significance of Complete Pathologic Response Obtained with Chemotherapy Versus Chemoradiotherapy in Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 766-773.	0.7	9
3327	The T-Cell-Inflammation Status Can Predict Outcomes of Adjuvant Chemotherapy in Patients with Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 1407-1416.	0.7	4
3328	Modern oncological and operative outcomes in oesophageal cancer: the St. Jamesâ€™s hospital experience. Irish Journal of Medical Science, 2021, 190, 297-305.	0.8	8
3329	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Preoperative Therapy for Resectable Gastric Adenocarcinoma: A Propensity Score-Matched Analysis of a Large, Single-Institution Experience. Annals of Surgical Oncology, 2021, 28, 758-765.	0.7	7
3330	Multivisceral Resection for Locally Advanced Gastric Cancer. Journal of Gastrointestinal Surgery, 2021, 25, 609-622.	0.9	10
3331	The Evolving Management of Peritoneal Surface Malignancies. Current Problems in Surgery, 2021, 58, 100860.	0.6	2
3332	Role of neoadjuvant radiochemotherapy for esophageal cancers over pre/peri-operative chemotherapy in the era of COVID-19 and beyond. Radiotherapy and Oncology, 2021, 154, e15-e16.	0.3	2
3333	Modified ypTNM Staging Classification for Gastric Cancer after Neoadjuvant Therapy: A Multi-Institutional Study. Oncologist, 2021, 26, e99-e110.	1.9	11
3334	Total Neoadjuvant Therapy for Operable Pancreatic Cancer. Annals of Surgical Oncology, 2021, 28, 2246-2256.	0.7	29
3335	A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer. Translational Oncology, 2021, 14, 100901.	1.7	7
3336	Immunotherapy in gastroesophageal cancers: Current state and future directions. Journal of Oncology Pharmacy Practice, 2021, 27, 395-404.	0.5	2
3337	Evolution of Esophagectomy for Cancer Over 30 Years: Changes in Presentation, Management and Outcomes. Annals of Surgical Oncology, 2021, 28, 3011-3022.	0.7	28
3338	Curative resection for adenocarcinoma of the gastro-esophageal junction following neo-adjuvant chemotherapyâ€"thoraco-abdominal vs. trans-abdominal approach. Langenbeck's Archives of Surgery, 2021, 406, 613-621.	0.8	2
3339	Staging laparoscopy in gastric cancer surgery. A population-based cohort study in patients undergoing gastrectomy with curative intent. European Journal of Surgical Oncology, 2021, 47, 1441-1448.	0.5	12
3340	Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies. Critical Reviews in Oncology/Hematology, 2021, 157, 103190.	2.0	5
3341	Gastric organoidsâ€"an in vitro model system for the study of gastric development and road to personalized medicine. Cell Death and Differentiation, 2021, 28, 68-83.	5.0	56

#	Article	IF	Citations
3342	Extensive peritoneal lavage with saline after curative gastrectomy for gastric cancer (EXPEL): a multicentre randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 120-127.	3.7	31
3343	Gastrectomy with or without neoadjuvant S-1 plus cisplatin for type 4 or large type 3 gastric cancer (JCOG0501): an open-label, phase 3, randomized controlled trial. Gastric Cancer, 2021, 24, 492-502.	2.7	79
3344	Lack of National Adoption of Evidence-Based Treatment for Resectable Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 36-47.	0.9	1
3345	Oligometastatic recurrence as a prognostic factor after curative resection of esophageal squamous cell carcinoma. Surgery Today, 2021, 51, 798-806.	0.7	7
3346	Adjuvant radiotherapy for gastric cancerâ€"end of the road?. Annals of Oncology, 2021, 32, 287-289.	0.6	16
3347	Short-term results of a phase II study of preoperative docetaxel/cisplatin/S-1 therapy for locally advanced gastric cancer. Japanese Journal of Clinical Oncology, 2021, 51, 371-378.	0.6	0
3348	Response rate and diagnostic accuracy of early PETâ€CT during neoâ€adjuvant therapies in oesophageal adenocarcinoma: A systematic review and metaâ€analysis. International Journal of Clinical Practice, 2021, 75, e13906.	0.8	0
3349	Neoadjuvant chemotherapy and radiation therapy in veterinary cancer treatment: a review. Journal of Small Animal Practice, 2021, 62, 237-243.	0.5	8
3350	En bloc resection of locally perforated colonic malignancy with removal of iliopsoas and femoral nerve and primary anastomosis. ANZ Journal of Surgery, 2021, 91, E232-E234.	0.3	0
3351	Longâ€term results of a randomized controlled trial comparing neoadjuvant Adriamycin, cisplatin, and 5â€fluorouracil vs docetaxel, cisplatin, and 5â€fluorouracil followed by surgery for esophageal cancer (OGSG1003). Annals of Gastroenterological Surgery, 2021, 5, 75-82.	1.2	16
3352	Conditional survival in patients with esophageal or gastroesophageal junction cancer after receiving various treatment modalities. Cancer Medicine, 2021, 10, 659-674.	1.3	2
3353	Executive Summary of the American Radium Society Appropriate Use Criteria for Operable Esophageal and Gastroesophageal Junction Adenocarcinoma: Systematic Review and Guidelines. International Journal of Radiation Oncology Biology Physics, 2021, 109, 186-200.	0.4	8
3354	Novel molecular targets in gastric adenocarcinoma. , 2021, 220, 107714.		22
3355	High tumor mutation burden in a patient with metastatic gastric cancer sensitive to trastuzumab: a case report. Annals of Palliative Medicine, 2021, 10, 5846-5852.	0.5	2
3356	Impact of Neoadjuvant Therapy on Minimally Invasive Surgical Outcomes in Advanced Gastric Cancer: An International Propensity Score-Matched Study. Annals of Surgical Oncology, 2021, 28, 1428-1436.	0.7	11
3357	Intra-tumor metabolic heterogeneity of gastric cancer on 18F-FDG PETCT indicates patient survival outcomes. Clinical and Experimental Medicine, 2021, 21, 129-138.	1.9	12
3358	Peri-operative Outcomes and Survival Following Palliative Gastrectomy for Gastric Cancer: a Systematic Review and Meta-analysis. Journal of Gastrointestinal Cancer, 2021, 52, 41-56.	0.6	13
3359	Multimodality approaches to control esophageal cancer: development of chemoradiotherapy, chemotherapy, and immunotherapy. Esophagus, 2021, 18, 25-32.	1.0	53

#	Article	IF	Citations
3360	The value of intravoxel incoherent motion diffusion-weighted imaging in predicting the pathologic response to neoadjuvant chemotherapy in locally advanced esophageal squamous cell carcinoma. European Radiology, 2021, 31, 1391-1400.	2.3	9
3361	Evaluation of the Implementation of FDG-PET/CT and Staging Laparoscopy for Gastric Cancer in The Netherlands. Annals of Surgical Oncology, 2021, 28, 2384-2393.	0.7	10
3363	Intraoperative blood loss as an independent prognostic factor for curative resection after neoadjuvant chemotherapy for gastric cancer: a single-center retrospective cohort study. Surgery Today, 2021, 51, 293-302.	0.7	2
3364	Analysis of the Survival Impact of Postoperative Chemotherapy After Preoperative Chemotherapy and Resection for Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 1417-1427.	0.7	8
3365	Prognostic significance of serum inflammatory markers in esophageal cancer. Esophagus, 2021, 18, 267-277.	1.0	10
3366	Case studies highlighting the multiple facets of gastric cancer: one diagnosis, multiple approaches. , 2021, , 317-342.		0
3367	Is Prophylactic Hyperthermic Intraperitoneal Chemotherapy Beneficial to the Long-Term Survival of Patients After Radical Gastric Cancer Surgery: A Systematic Review and Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
3368	Magenkarzinom. , 2021, , 94-102.		0
3369	Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. Journal of Surgical Oncology, 2021, 123, 911-922.	0.8	7
3370	The efficacy and safety of definitive concurrent chemoradiotherapy for nonâ€operable esophageal cancer. Cancer Medicine, 2021, 10, 1275-1288.	1.3	3
3371	Prognostic value of pathological tumor regression grade in locally advanced gastric cancer: New perspectives from a singleâ€center experience. Journal of Surgical Oncology, 2021, 123, 923-931.	0.8	17
3372	Inestabilidad microsatelital y cÃ¡ncer gÃ¡strico. Revista Colombiana De Cirugia, 2021, 36, 120-131.	0.2	0
3373	Inhibitory Effect of Crocin Against Gastric Carcinoma via Regulating TPM4 Gene. OncoTargets and Therapy, 2021, Volume 14, 111-122.	1.0	11
3374	T cells, B cells, and PD-L1 expression in esophageal and gastric adenocarcinoma before and after neoadjuvant chemotherapy: relationship with histopathological response and survival. OncoImmunology, 2021, 10, 1921443.	2.1	14
3375	Circulating Tumor Cells in Gastric Cancer. , 2021, , 103-126.		0
3376	Maag en duodenum. , 2021, , 177-191.		0
3377	OUP accepted manuscript. British Journal of Surgery, 2021, 108, e328-e329.	0.1	0
3378	Trastuzumab + FOLFOX6/FLOT as perioperative therapy for HER2-positive resectable gastric cancer and cardioesophageal transition: RussTrastPraÑtik study (interim analysis). Medical Alphabet, 2021, , 46-51.	0.0	1

#	Article	IF	Citations
3379	Gastric Adenocarcinoma at the Joliot Curie Institute in Dakar: Epidemiological, Diagnostic and Therapeutic Aspects about 54 Cases. Journal of Cancer Therapy, 2021, 12, 136-145.	0.1	0
3380	Evolving therapies in advanced oesophago-gastric cancers and the increasing role of immunotherapy. Expert Review of Anticancer Therapy, 2021, 21, 535-546.	1.1	9
3382	Histologic Lymph Nodes Regression after Preoperative Chemotherapy as Prognostic Factor in Non-metastatic Advanced Gastric Adenocarcinoma. Journal of Cancer, 2021, 12, 1669-1677.	1.2	5
3383	Preoperative EUS evaluation of the response to neoadjuvant therapy for gastric and esophagogastric junction cancer is correlated with survival: A single retrospective study of 97 patients. Endoscopic Ultrasound, 2021, 10, 103.	0.6	8
3384	Minimally invasive gastrectomy after neoadjuvant chemotherapy: a literature review. Annals of Laparoscopic and Endoscopic Surgery, 0, 7, 10-10.	0.5	0
3386	Total neoadjuvant chemotherapy with FLOT scheme in resectable adenocarcinoma of the gastro-oesophageal junction or gastric adenocarcinoma: impact on pathological complete response and safety. Ecancermedicalscience, 2021, 15, 1168.	0.6	7
3387	Response to Zhong-Qing et al Regarding â€œGI Cancers Lymph Node Status Significance After Neoadujuvant Chemotherapy: An Unsolved Problemâ€• Annals of Surgery, 2021, 274, e859-e860.	2.1	0
3389	CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermiaâ€‘induced damage. Molecular Medicine Reports, 2021, 23, .	1.1	3
3390	Endoscopic ultrasound efficacy in staging gastric linitis plastica lesion: a retrospective multicentric French study. Annals of Translational Medicine, 2021, 9, 50-50.	0.7	3
3391	Robotic gastrointestinal surgery: learning curve, educational programs and outcomes. Updates in Surgery, 2021, 73, 799-814.	0.9	12
3393	Current status and future perspectives on neoadjuvant therapy in gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2021, 33, 181-192.	0.7	8
3394	BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2021, 34, e1563.	0.5	12
3395	Feasibility and Safety of Perioperative Chemotherapy With Fluorouracil Plus Leucovorin, Oxaliplatin, and Docetaxel for Locally Advanced Gastric Cancer Patients in China. Frontiers in Oncology, 2020, 10, 567529.	1.3	6
3396	Evaluating the benefit of adjuvant radiotherapy after extensive lymph node dissection for gastric cancer: a single-institute retrospective study. Tzu Chi Medical Journal, 2021, 33, 288.	0.4	0
3397	BÃ¶sartige Ã–sophagustumoren. , 2021, , 48-54.		0
3398	Synchronous peritoneal metastases of gastric cancer origin: incidence, treatment and survival of a nationwide Dutch cohort. Gastric Cancer, 2021, 24, 800-809.	2.7	29
3399	Tumor characteristics and clinical outcome of peritoneal metastasis of gastric origin treated with a hyperthermic intraperitoneal chemotherapy procedure in the PERISCOPE I trial. Journal of Surgical Oncology, 2021, 123, 904-910.	0.8	14
3400	Inductive Preoperative Chemotherapy for Peritoneal Metastases of Tumors of the Upper GI Tract. , 2021, , 61-68.		0

#	Article	IF	Citations
3401	Indication of CRS and HIPEC in Gastric Cancer-Related Peritoneal Metastasis. , 2021, , 189-201.		0
3402	Neoadjuvant Chemotherapy for Intrahepatic Cholangiocarcinoma: A Propensity Score Survival Analysis Supporting Use in Patients with High-Risk Disease. Annals of Surgical Oncology, 2021, 28, 1939-1949.	0.7	31
3403	Inaccurate Clinical Stage Is Common for Gastric Adenocarcinoma and Is Associated with Undertreatment and Worse Outcomes. Annals of Surgical Oncology, 2021, 28, 2831-2843.	0.7	10
3405	Impact of the Interval Between Neoadjuvant Chemotherapy and Gastrectomy on Short- and Long-Term Outcomes for Patients with Advanced Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 4444-4455.	0.7	11
3406	Marked loss of adipose tissue during neoadjuvant therapy as a predictor for poor prognosis in patients with gastric cancer: A retrospective cohort study. Journal of Human Nutrition and Dietetics, 2021, 34, 585-594.	1.3	11
3407	Treatment at an Academic Cancer Center Confers Better Survival by Stage for Signet-Ring Cell and Non-signet-Ring Cell Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 4423-4432.	0.7	3
3409	Prognostic models for stage Iâ€“III esophageal cancer: a comparison between existing calculators. Journal of Gastrointestinal Oncology, 2021, 12, 0-0.	0.6	4
3410	Oesofagus. , 2021, , 157-175.		0
3411	The protocol of a prospective, multicenter, randomized, controlled phase III study evaluating different cycles of oxaliplatin combined with S-1 (SOX) as neoadjuvant chemotherapy for patients with locally advanced gastric cancer: RESONANCE-II trial. BMC Cancer, 2021, 21, 20.	1.1	21
3412	A radiomics-based model for predicting prognosis of locally advanced gastric cancer in the preoperative setting. Scientific Reports, 2021, 11, 1879.	1.6	20
3413	Laparoscopic D2 gastrectomy in advanced gastric cancer: Postoperative outcomes and longâ€term survival analysis. Asian Journal of Endoscopic Surgery, 2021, 14, 707-716.	0.4	2
3414	Does Pathological Stage and Nodal Involvement Influence Long Term Oncological Outcomes after CROSS Regimen for Adenocarcinoma of the Esophagogastric Junction? A Multicenter Retrospective Analysis. Cancers, 2021, 13, 666.	1.7	1
3415	Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers, 2021, 13, 582.	1.7	22
3416	History and emerging trends in chemotherapy for gastric cancer. Annals of Gastroenterological Surgery, 2021, 5, 446-456.	1.2	25
3417	A Phase II Study Demonstrates No Feasibility of Adjuvant Treatment with Six Cycles of S-1 and Oxaliplatin in Resectable Esophageal Adenocarcinoma, with ERCC1 as Biomarker for Response to SOX. Cancers, 2021, 13, 839.	1.7	2
3418	Prospective study of surgical site infections post-open esophageal cancer surgery, and the impact of care bundles. Ecological Management and Restoration, 2021, 34, .	0.2	2
3419	Outcomes of Neoadjuvant Chemotherapy for Clinical Stages 2 and 3 Gastric Cancer Patients: Analysis of Timing and Site of Recurrence. Annals of Surgical Oncology, 2021, 28, 4829-4838.	0.7	14
3420	Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. Annals of Gastroenterological Surgery, 2021, 5, 162-172.	1.2	21

#	Article	IF	Citations
3422	STAT3Î² Enhances Sensitivity to Concurrent Chemoradiotherapy by Inducing Cellular Necroptosis in Esophageal Squamous Cell Carcinoma. Cancers, 2021, 13, 901.	1.7	15
3423	An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. Frontiers in Immunology, 2020, 11, 621623.	2.2	7
3425	Redefining High-Volume Gastric Cancer Centers: The Impact of Operative Volume on Surgical Outcomes. Annals of Surgical Oncology, 2021, 28, 4839-4847.	0.7	17
3426	Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins. Acta OncolÃ³gica, 2021, 60, 672-680.	0.8	3
3427	The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma. Frontiers in Molecular Biosciences, 2021, 8, 600373.	1.6	3
3428	The Landmark Series: Multimodal Therapy for Esophageal Cancer. Annals of Surgical Oncology, 2021, 28, 3375-3382.	0.7	24
3429	Clinicopathological factors affecting the effect of neoadjuvant chemotherapy in patients with gastric cancer. World Journal of Surgical Oncology, 2021, 19, 44.	0.8	18
3430	Current treatment and recent progress in gastric cancer. Ca-A Cancer Journal for Clinicians, 2021, 71, 264-279.	157.7	759
3431	The Therapeutic Effects of Dihydroartemisinin on Cisplatin-Resistant Gastric Cancer Cells. Current Pharmaceutical Biotechnology, 2022, 23, 276-286.	0.9	6
3432	Role of CT in the prediction of pathological complete response in gastric cancer after neoadjuvant chemotherapy. Abdominal Radiology, 2021, 46, 3011-3018.	1.0	11
3433	Clinical TNM staging for esophageal, gastric, and colorectal cancers in the era of neoadjuvant therapy: A systematic review of the literature. Annals of Gastroenterological Surgery, 2021, 5, 404-418.	1.2	11
3434	Survival analysis of elderly patients over 65 years old with stage II/III gastric cancer treated with adjuvant chemotherapy after laparoscopic D2 gastrectomy: a retrospective cohort study. BMC Cancer, 2021, 21, 196.	1.1	10
3435	Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbeck's Archives of Surgery, 2021, 406, 1071-1080.	0.8	6
3436	Discovery and validation of an expression signature for recurrence prediction in high-risk diffuse-type gastric cancer. Gastric Cancer, 2021, 24, 655-665.	2.7	6
3438	Neoadjuvant Chemoradiotherapy Followed by Esophagectomy with Three-Field Lymph Node Dissection for Thoracic Esophageal Squamous Cell Carcinoma Patients with Clinical Stage III and with Supraclavicular Lymph Node Metastasis. Cancers, 2021, 13, 983.	1.7	14
3439	Impact of Palliative Gastrectomy in Patients with Incurable Gastric Cancer. Medicina (Lithuania), 2021, 57, 198.	0.8	3
3440	Effect of Babao Dan on angiogenesis of gastric cancer in vitro by regulating VEGFA/VEGFR2 signaling pathway. Translational Cancer Research, 2021, 10, 953-965.	0.4	5
3441	Psoas muscle depletion during preoperative chemotherapy for advanced gastric cancer has a negative impact on longâ€term outcomes after gastrectomy. Asia-Pacific Journal of Clinical Oncology, 2022, 18, 61-69.	0.7	4

#	Article	IF	Citations
3442	Survival benefit of perioperative chemotherapy for T1â€“3N0M0 stage esophageal cancer: a SEER database analysis. Journal of Thoracic Disease, 2021, 13, 995-1004.	0.6	2
3443	Time to Rethink Upfront Surgery for Resectable Intrahepatic Cholangiocarcinoma? Implications from the Neoadjuvant Experience. Annals of Surgical Oncology, 2021, 28, 6725-6735.	0.7	23
3444	Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Annals of Translational Medicine, 2021, 9, 513-513.	0.7	4
3445	Novel Histologic Categorization Based on Lauren Histotypes Conveys Prognostic Information for Gastroesophageal Junction Cancersâ€”Analysis from a Large Single Center Cohort in Germany. Cancers, 2021, 13, 1303.	1.7	1
3446	Clinical Relevance of Splenic Hilar Lymph Node Dissection for Proximal Gastric Cancer: A Propensity Score-Matching Case-Control Study. Annals of Surgical Oncology, 2021, 28, 6649-6662.	0.7	4
3447	Impact of Pancreatic Resection on Survival in Locally Advanced Resectable Gastric Cancer. Cancers, 2021, 13, 1289.	1.7	4
3448	Predictors and significance of histologic response to neoadjuvant therapy for gastric cancer. Journal of Surgical Oncology, 2021, 123, 1716-1723.	0.8	5
3449	Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers, 2021, 13, 1304.	1.7	2
3450	High GP73 Expression Correlates with Poor Response to Neoadjuvant Chemotherapy and Survival in Gastric Cancer: A Tissue Microarray Study. Pathology and Oncology Research, 2021, 27, 603838.	0.9	0
3451	Three decades of oesophagogastric cancer care: now a curable disease. British Journal of Surgery, 2021, 108, 595-597.	0.1	2
3452	Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Langenbeck's Archives of Surgery, 2021, 406, 1847-1857.	0.8	6
3453	Albendazole Exhibits Anti-Neoplastic Actions against Gastric Cancer Cells by Affecting STAT3 and STAT5 Activation by Pleiotropic Mechanism(s). Biomedicines, 2021, 9, 362.	1.4	12
3454	A network meta-analysis for neoadjuvant and adjuvant treatments for resectable squamous cell carcinoma of esophagus. Scientific Reports, 2021, 11, 6800.	1.6	6
3455	Perioperative trastuzumab, capecitabine and oxaliplatin in patients with HER2-positive resectable gastric or gastro-oesophageal junction adenocarcinoma: NEOHX phase II trial. European Journal of Cancer, 2021, 145, 158-167.	1.3	26
3456	Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastroâ€esophageal junction from a tertiary cancer care center in India. Journal of Surgical Oncology, 2021, 123, 1547-1557.	0.8	3
3457	Two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for treating locally advanced esophageal cancer: short-term outcomes of a multicenter randomized phase II trial. Esophagus, 2021, 18, 825-834.	1.0	14
3458	Recent advances in immune therapies for gastric cancer. Cancer Gene Therapy, 2021, 28, 924-934.	2.2	16
3459	Laparoscopic Versus Open Gastrectomy for Gastric Cancer (LOGICA): A Multicenter Randomized Clinical Trial. Journal of Clinical Oncology, 2021, 39, 978-989.	0.8	107

#	Article	IF	Citations
3461	Neoadjuvant chemoradiotherapy improves survival in locally advanced adenocarcinoma of esophagogastric junction compared with neoadjuvant chemotherapy: a propensity score matching analysis. BMC Surgery, 2021, 21, 137.	0.6	9
3462	How multimodal treatment improves surgery for oesophageal cancerâ€"a narrative review. Digestive Medicine Research, 0, 4, 10-10.	0.2	0
3463	Optimization of detection of residual disease after neoadjuvant therapy in patients with esophageal cancer. Annals of Esophagus, 0, 4, 6-6.	0.4	1
3464	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of oesophageal cancer. Ecancermedicalscience, 2021, 15, 1195.	0.6	1
3465	Development and Validation of a Prognostic Nomogram for Gastric Signet Ring Cell Carcinoma: A Multicenter Population-Based Study. Frontiers in Oncology, 2021, 11, 603031.	1.3	8
3467	Role of Radiation Therapy in Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 4151-4157.	0.7	9
3468	Postoperative Changes in Nutritional and Functional Status of Gastroesophageal Cancer Patients. Journal of the American College of Nutrition, 2021, , 1-9.	1.1	7
3469	Determinants of Survival for Patients with Neoadjuvant-Treated Node-Negative Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 6638-6648.	0.7	0
3470	Does neoadjuvant FOLFOX chemotherapy improve the prognosis of highâ€risk Stage II and III colon cancers? Three years' followâ€up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Disease, 2021, 23, 1357-1369.	0.7	23
3472	CMPK1 Regulated by miR-130b Attenuates Response to 5-FU Treatment in Gastric Cancer. Frontiers in Oncology, 2021, 11, 637470.	1.3	8
3473	Comparison of Perioperative Chemotherapy versus Postoperative Chemoradiotherapy for Operable Stomach Cancer: A Western Canadian Province Experience. Current Oncology, 2021, 28, 1262-1273.	0.9	1
3474	Nomogram for predicting the overall survival of the patients with oesophageal signet ring cell carcinoma. Journal of Thoracic Disease, 2021, 13, 1315-1326.	0.6	0
3476	Adjuvant chemotherapy is superior to chemoradiation after D2 surgery for gastric cancer in the per-protocol analysis of the randomized CRITICS trial. Annals of Oncology, 2021, 32, 360-367.	0.6	40
3477	Sexual Difference Matters: Females with High Microsatellite Instability Show Increased Survival after Neoadjuvant Chemotherapy in Gastric Cancer. Cancers, 2021, 13, 1048.	1.7	10
3478	Treatment approach, hospital practice patterns, and receipt of multimodality therapy as measures of quality for locally advanced gastric cancer. Journal of Surgical Oncology, 2021, 123, 1724-1735.	0.8	4
3479	An investigation on gastric cancer staging using CT structured report. European Journal of Radiology, 2021, 136, 109550.	1.2	1
3480	Perioperative outcomes and survival in elderly patients agedâ€‰â‰¥â€‰75Âyears undergoing gastrectomy for gastric cancer: an 18-year retrospective analysis in a single Western centre. Langenbeck's Archives of Surgery, 2021, 406, 1057-1069.	0.8	3
3481	Isolated brachioradialis metastasis of gastric adenocarcinoma after R0 resection. World Journal of Surgical Oncology, 2021, 19, 83.	0.8	0

#	Article	IF	Citations
3482	Treatment Strategies of Gastric Cancerâ€"Molecular Targets for Anti-angiogenic Therapy: a State-of-the-art Review. Journal of Gastrointestinal Cancer, 2021, 52, 476-488.	0.6	7
3483	Neoadjuvant chemoradiotherapy or chemotherapy alone for oesophageal cancer: population-based cohort study. British Journal of Surgery, 2021, 108, 403-411.	0.1	18
3484	Neoadjuvant and adjuvant multimodality therapies in resectable esophagogastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2021, 22, 1429-1441.	0.9	2
3485	Stage III colon cancer: is neoadjuvant chemotherapy ready for prime time?â€"A narrative review of neoadjuvant chemotherapy for colon cancer. Digestive Medicine Research, 0, 4, 16-16.	0.2	1
3486	Prognostic Value of Gastric Signet Ring Cell Carcinoma: a Population-Based Propensity Score-Matched Analysis. Indian Journal of Surgery, 0, , 1.	0.2	0
3487	Impact of Smoking Status on Perioperative Morbidity, Mortality, and Long-Term Survival Following Transthoracic Esophagectomy for Esophageal Cancer. Annals of Surgical Oncology, 2021, 28, 4905-4915.	0.7	9
3488	Long-Term Outcomes of Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer/Esophagogastric Junction Cancer: A Systematic Review and Meta-Analysis. Anti-Cancer Agents in Medicinal Chemistry, 2021, 21, .	0.9	4
3489	Comparison of Long- and Short-term Outcomes in 845 Open and Minimally Invasive Gastrectomies for Gastric Cancer in the United States. Annals of Surgical Oncology, 2021, 28, 3532-3544.	0.7	17
3490	The Role of Neoadjuvant Chemotherapy in Locally Advanced Colon Cancer. Cancer Management and Research, 2021, Volume 13, 2567-2579.	0.9	25
3491	Nivolumab for the treatment of esophageal cancer. Expert Opinion on Biological Therapy, 2021, 21, 1-7.	1.4	9
3492	Esophageal Cancer in Elderly Patients, Current Treatment Options and Outcomes; A Systematic Review and Pooled Analysis. Cancers, 2021, 13, 2104.	1.7	21
3493	Landscape of interventional clinical trials involving gastrectomy for gastric cancer. Ecancermedicalscience, 2021, 15, 1218.	0.6	2
3494	MicroRNA Changes in Gastric Carcinogenesis: Differential Dysregulation during Helicobacter pylori and EBV Infection. Genes, 2021, 12, 597.	1.0	8
3495	Association of Obesity with Worse Operative and Oncologic Outcomes for Patients Undergoing Gastric Cancer Resection. Annals of Surgical Oncology, 2021, 28, 7040-7050.	0.7	0
3496	Management of Locally Advanced Esophageal Cancer. Journal of the Nepal Medical Association, 2021, 59, 409-416.	0.1	2
3497	Prognostic relevance of lymph node regression on survival in esophageal cancer: a systematic review and meta-analysis. Ecological Management and Restoration, 2022, 35, .	0.2	9
3498	Prediction Model of Tumor Regression Grade for Advanced Gastric Cancer After Preoperative Chemotherapy. Frontiers in Oncology, 2021, 11, 607640.	1.3	10
3499	High expression of COL5A2, a member of COL5 family, indicates the poor survival and facilitates cell migration in gastric cancer. Bioscience Reports, 2021, 41, .	1.1	25

#	Article	IF	Citations
3500	Invited Commentary. Journal of the American College of Surgeons, 2021, 232, 514-516.	0.2	0
3501	Amplification of the human epidermal growth factor receptor 2 (HER2) gene is associated with a microsatellite stable status in Chinese gastric cancer patients. Journal of Gastrointestinal Oncology, 2021, 12, 377-387.	0.6	4
3502	Review of management and treatment of peritoneal metastases from gastric cancer origin. Journal of Gastrointestinal Oncology, 2021, 12, S20-S29.	0.6	7
3503	The Discordance of Clinical and Pathologic Staging in Locally Advanced Gastric Adenocarcinoma. Journal of Gastrointestinal Surgery, 2021, 25, 1363-1369.	0.9	9
3504	Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 7208-7218.	0.7	6
3505	Short-term outcomes of laparoscopic versus open total gastrectomy after neoadjuvant chemotherapy: a cohort study using the propensity score matching method. Journal of Gastrointestinal Oncology, 2021, 12, 237-248.	0.6	9
3506	Minimally invasive total adventitial resection of the cardia for tumours of the oesophagogastric junction. Langenbeck's Archives of Surgery, 2021, 406, 2273-2285.	0.8	1
3507	The Sensitivity Prediction of Neoadjuvant Chemotherapy for Gastric Cancer. Frontiers in Oncology, 2021, 11, 641304.	1.3	13
3508	Development and evaluation of a ceMDCT-based preoperative risk stratification model to predict disease-free survival after radical surgery in patients with gastric cancer. Abdominal Radiology, 2021, 46, 4079-4089.	1.0	5
3509	Retrospective Evaluation of Factors Affecting Lymph Node Retrieval Following Gastrectomies with Oncologic Intent. Rambam Maimonides Medical Journal, 2021, 12, e0012.	0.4	0
3511	Maintenance in gastric cancer: New life for an old issue?. Critical Reviews in Oncology/Hematology, 2021, 160, 103307.	2.0	4
3512	Comparative Outcomes of Laparoscopic Gastrectomy and Open Gastrectomy for Scirrhous Gastric Cancer: A Multicenter Retrospective Cohort Study. Annals of Surgery Open, 2021, 2, e063.	0.7	2
3513	The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients. Journal of Gastrointestinal Oncology, 2021, 12, 297-306.	0.6	0
3514	Prediction of Survival Outcomes Based on Preoperative Clinical Parameters in Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 7027-7037.	0.7	7
3515	The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy. Cureus, 2021, 13, e14639.	0.2	1
3516	Interventions and Outcomes for Neoadjuvant Treatment of T4 Colon Cancer: A Scoping Review. Current Oncology, 2021, 28, 2065-2078.	0.9	2
3517	Impact of pathological response after neoadjuvant chemotherapy on adjuvant therapy decisions and patient outcomes in gastrointestinal cancers. Cancer Reports, 2021, 4, e1412.	0.6	4
3518	Minimally Invasive Oncologic Upper Gastrointestinal Surgery can be Performed Safely on all Weekdays: A Nationwide Cohort Study. World Journal of Surgery, 2021, 45, 2816-2829.	0.8	4

#	Article	IF	Citations
3519	Neoadjuvant radiotherapy for locoregional Siewert type II gastroesophageal junction adenocarcinoma: A propensity scores matching analysis. PLoS ONE, 2021, 16, e0251555.	1.1	1
3520	Could neoadjuvant chemotherapy increase postoperative complication risk of laparoscopic total gastrectomy? A mono-institutional propensity score-matched study in China. World Journal of Gastrointestinal Surgery, 2021, 13, 429-442.	0.8	2
3521	Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. Molecules, 2021, 26, 3157.	1.7	23
3522	Neoadjuvant chemotherapy in locally advanced colon cancer: a systematic review and meta-analysis. International Journal of Colorectal Disease, 2021, 36, 2063-2070.	1.0	46
3523	Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatmentâ€"Oncological and Surgical Perspective. Cancers, 2021, 13, 2509.	1.7	11
3524	Optimal care and survival for signet-ring cell and non-signet-ring cell gastric cancer are more achievable at academic cancer centers. American Journal of Surgery, 2021, 222, 969-975.	0.9	0
3525	Thinking through the multimodal treatment of localized oesophageal cancer: the point of view of the surgeon. Current Opinion in Oncology, 2021, 33, 353-361.	1.1	0
3526	Molecular Determinants of Gastrointestinal Cancers. Advances in Oncology, 2021, 1, 311-325.	0.1	0
3527	Comparison of short-term outcomes from the International Oesophago-Gastric Anastomosis Audit (OGAA), the Esophagectomy Complications Consensus Group (ECCG), and the Dutch Upper Gastrointestinal Cancer Audit (DUCA). BJS Open, 2021, 5, .	0.7	4
3528	Evolving treatment paradigms in esophageal cancer. Annals of Translational Medicine, 2021, 9, 903-903.	0.7	9
3529	Chemoradiotherapy Followed by Active Surveillance Versus Standard Esophagectomy for Esophageal Cancer. Annals of Surgery, 2022, 275, 467-476.	2.1	21
3530	Preoperative chemoradiotherapy versus chemotherapy for adenocarcinoma of the esophagus and esophagogastric junction (AEG): systematic review with individual participant data (IPD) network meta-analysis (NMA). The Cochrane Library, 0, , .	1.5	1
3532	Intratumoral CXCR5+CD8+T associates with favorable clinical outcomes and immunogenic contexture in gastric cancer. Nature Communications, 2021, 12, 3080.	5.8	34
3533	The â€œReal R0â€• A Resection Margin Smaller Than 0.1 cm is Associated with a Poor Prognosis After Oncologic Esophagectomy. Annals of Surgical Oncology, 2021, 28, 7095-7106.	0.7	6
3534	Perioperative chemotherapy for locally advanced operable gastric cancer (literature review). Practical Oncology, 2021, 4, 5-10.	0.1	0
3535	Impact of body composition on clinical outcomes in people with gastric cancer undergoing radical gastrectomy after neoadjuvant treatment. Nutrition, 2021, 85, 111135.	1.1	19
3536	Proteomic Analysis Reveals That Metformin Suppresses PSMD2, STIP1, and CAP1 for Preventing Gastric Cancer AGS Cell Proliferation and Migration. ACS Omega, 2021, 6, 14208-14219.	1.6	5
3537	Salvage Treatment Using Antiâ€"PD-1/CTLA-4 Immunotherapy After Failure of Neoadjuvant Chemotherapy in Microsatellite Instable Gastroesophageal Carcinoma. Oncologist, 2021, 26, 461-464.	1.9	1

#	Article	IF	Citations
3538	Advanced gastric cancer with abdominal wall invasion treated with curative resection after chemotherapy: a case report. Journal of Medical Case Reports, 2021, 15, 230.	0.4	2
3539	Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy for the treatment of esophageal squamous cell carcinoma: a propensity score-matched study from the National Cancer Center in China. Journal of Cancer Research and Clinical Oncology, 2022, 148, 943-954.	1.2	21
3540	Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic review and meta-analysis. Gland Surgery, 2021, 10, 1564-1575.	0.5	10
3541	Does Cardiopulmonary Testing Help Predict Long-Term Survival After Esophagectomy?. Annals of Surgical Oncology, 2021, 28, 7291-7297.	0.7	6
3542	ADP ribosylation factor guanylate kinase 1 promotes the malignant phenotype of gastric cancer by regulating focal adhesion kinase activation. Life Sciences, 2021, 273, 119264.	2.0	3
3543	A Phase II Study of the Combination of Oxaliplatin, Capecitabine, and Trastuzumab and Chemoradiotherapy in the Adjuvant Setting in Operated Patients With HER2-positive Gastric or Gastroesophageal Junction Cancer (TOXAG Study). American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 301-307.	0.6	8
3544	Consolidation Therapy in Esophageal Cancer. Surgical Clinics of North America, 2021, 101, 483-488.	0.5	4
3545	The efficacy of adjuvant chemotherapy with capecitabine and cisplatin after surgery in locally advanced esophageal squamous cell carcinoma: a multicenter randomized phase III trial. Ecological Management and Restoration, 2021, , .	0.2	2
3547	Appendiceal tumors with glandular and neuroendocrine features exhibiting peritoneal metastases - Critical evaluation of outcome following cytoreductive surgery with perioperative chemotherapy. European Journal of Surgical Oncology, 2021, 47, 1278-1285.	0.5	5
3548	The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study. NIHR Open Research, 2021, 1, 1.	0.0	2
3549	The challenge of offering potentially curative treatment to patients with esophageal cancer and a history of liver transplantation: A literature review and case report. Surgery, 2021, 169, 1379-1385.	1.0	0
3550	Potential survival benefits of open over laparoscopic radical gastrectomy for gastric cancer patients beyond three years after surgery: result from multicenter in-depth analysis based on propensity matching. Surgical Endoscopy and Other Interventional Techniques, 2021, , 1.	1.3	5
3551	Clinical impact of abdominal versus mediastinal metastases as a prognostic factor for poor outcomes following esophageal cancer surgery: a retrospective study. BMC Cancer, 2021, 21, 725.	1.1	0
3552	Chemotherapy regimens induce inhibitory immune checkpoint protein expression on stem-like and senescent-like oesophageal adenocarcinoma cells. Translational Oncology, 2021, 14, 101062.	1.7	12
3553	The Immune Subtypes and Landscape of Gastric Cancer and to Predict Based on the Whole-Slide Images Using Deep Learning. Frontiers in Immunology, 2021, 12, 685992.	2.2	33
3554	Neoadjuvant treatment in esophageal cancerâ€"established treatments and new developments reviewed. Annals of Esophagus, 0, 4, 20-20.	0.4	1
3556	TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. Cancers, 2021, 13, 2839.	1.7	31
3557	Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. The Lancet Digital Health, 2021, 3, e371-e382.	5.9	29

#	Article	IF	Citations
3558	GASTRIC CANCER: A 5 YEAR RETROSPECTIVE ANALYSIS OF CLINICAL, PATHOLOGICAL AND TREATMENT ASPECTS FROM A TERTIARY CARE CENTER IN SOUTH INDIA.. , 2021, , 129-132.		0
3559	MicroRNAs as the critical regulators of cisplatin resistance in gastric tumor cells. Genes and Environment, 2021, 43, 21.	0.9	18
3560	A DNA-damage immune response assay combined with PET biomarkers predicts response to neo-adjuvant chemotherapy and survival in oesophageal adenocarcinoma. Scientific Reports, 2021, 11, 13061.	1.6	0
3561	A Pilot Study of Perioperative Cisplatin-Capecitabine Chemotherapy With Preoperative Chemoradiation for Resectable Gastric Cancers. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 475-481.	0.6	0
3562	Techniques of Esophageal Anastomoses for Esophagectomy. Surgical Clinics of North America, 2021, 101, 511-524.	0.5	2
3563	Surveillance Following Treatment of Esophageal Cancer. Surgical Clinics of North America, 2021, 101, 499-509.	0.5	5
3564	Clinical effect of enteral nutrition support during neoadjuvant chemotherapy on the preservation of skeletal muscle mass in patients with esophageal cancer. Clinical Nutrition, 2021, 40, 4380-4385.	2.3	18
3565	Uncommon presentation of leptomeningeal carcinomatosis from gastric cancer: a case report. Digestive Medicine Research, 0, 4, 40-40.	0.2	1
3566	Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma. Annals of Surgery, 2021, 274, 544-548.	2.1	12
3567	A good preoperative immune prognostic index is predictive of better long-term outcomes after laparoscopic gastrectomy compared with open gastrectomy for stage II gastric cancer in elderly patients. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 1814-1826.	1.3	3
3568	Survival and complications after neoadjuvant chemotherapy or chemoradiotherapy for esophageal cancer: a meta-analysis. Future Oncology, 2021, 17, 2257-2274.	1.1	26
3569	Is there a difference in utilization of a perioperative treatment approach for gastric cancer between safety net hospitals and tertiary referral centers?. Journal of Surgical Oncology, 2021, 124, 551-559.	0.8	2
3570	Perioperative chemotherapy in locally advanced gastric cancer in Chile: from evidence to daily practice. Ecancermedicalscience, 2021, 15, 1244.	0.6	1
3571	Comparison of neoadjuvant chemotherapy followed by surgery vs. surgery alone for locally advanced gastric cancer: a meta-analysis. Chinese Medical Journal, 2021, 134, 1669-1680.	0.9	11
3572	Trimodality Approach for Esophageal Malignancies. Surgical Clinics of North America, 2021, 101, 453-465.	0.5	2
3573	Salvage Esophagectomy. Surgical Clinics of North America, 2021, 101, 467-482.	0.5	4
3574	Surgery and adjuvant therapy after esophagectomy. Annals of Esophagus, 0, 4, 17-17.	0.4	2
3575	Efficacy and safety of neoadjuvant chemotherapy and immunotherapy in locally resectable advanced esophageal squamous cell carcinoma. Journal of Thoracic Disease, 2021, 13, 3518-3528.	0.6	49

#	Article	IF	Citations
3576	Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. Journal of Clinical Oncology, 2021, 39, 1995-2004.	0.8	291
3577	Surgery alone, adjuvant tegafur/gimeracil/octeracil (S-1), or platinum-based chemotherapies for resectable gastric cancer: real-world experience and a propensity score matching analysis. BMC Cancer, 2021, 21, 796.	1.1	1
3578	Results and Molecular Correlates from a Pilot Study of Neoadjuvant Induction FOLFIRINOX Followed by Chemoradiation and Surgery for Gastroesophageal Adenocarcinomas. Clinical Cancer Research, 2021, 27, 6343-6353.	3.2	8
3579	Long-Term Outcomes of Laparoscopic Radical Gastrectomy for Highly Advanced Gastric Cancer: Final Report of a Prospective Phase II Trial (KLGC04). Annals of Surgical Oncology, 2021, 28, 8962-8972.	0.7	7
3580	Treatment Switch in Poor Responders with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Annals of Surgical Oncology, 2021, 28, 8892-8907.	0.7	3
3581	Expressivity of Interleukin-8 and Gastric Cancer Prognosis Susceptibility: A Systematic Review and Meta-Analysis. Dose-Response, 2021, 19, 155932582110371.	0.7	3
3582	Impact of chemotherapy on prognosis of resectable pathological T3N0M0 esophageal cancer patients: a population-based study. Future Oncology, 2021, 17, 3925-3940.	1.1	1
3583	Prediction of long-term survival after gastrectomy using random survival forests. British Journal of Surgery, 2021, 108, 1341-1350.	0.1	11
3584	Cytotoxic Tâ€lymphocyteâ€associated protein 4 in gastric cancer: Prognosis and association with PDâ€L1 expression. Journal of Surgical Oncology, 2021, 124, 1040-1050.	0.8	9
3585	Effectiveness and Safety of Apatinib Plus Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer. JAMA Network Open, 2021, 4, e2116240.	2.8	25
3586	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. Annals of Surgical Oncology, 2021, , 1.	0.7	6
3587	Disruption in general surgery: Randomized controlled trials and changing paradigms. Surgery, 2021, 170, 1862-1866.	1.0	5
3588	Oncological outcomes of laparoscopic versus open gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: a retrospective multicenter study. World Journal of Surgical Oncology, 2021, 19, 206.	0.8	14
3589	The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications, 2021, 41, 747-795.	3.7	323
3590	Advances in Systemic Therapy for Gastric Cancer. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, 607-623.	0.6	11
3591	Esophagogastric junction adenocarcinoma: Preoperative chemoradiation or perioperative chemotherapy?. World Journal of Clinical Oncology, 2021, 12, 557-564.	0.9	6
3592	Borderline resectable pancreatic cancer and vascular resections in the era of neoadjuvant therapy. World Journal of Clinical Cases, 2021, 9, 5398-5407.	0.3	4
3593	Shifting sands: the role of radiotherapy for patients with gastric and gastroesophageal adenocarcinoma. Translational Gastroenterology and Hepatology, 2021, 6, 50-50.	1.5	1

#	Article	IF	Citations
3594	The value of restaging CT following neoadjuvant chemotherapy for resectable gastric cancer. A population-based study. World Journal of Surgical Oncology, 2021, 19, 212.	0.8	13
3595	FLOT-regimen Chemotherapy and Transthoracic en bloc Resection for Esophageal and Junctional Adenocarcinoma. Annals of Surgery, 2021, 274, 814-820.	2.1	18
3596	Genomic Analysis of Response to Neoadjuvant Chemotherapy in Esophageal Adenocarcinoma. Cancers, 2021, 13, 3394.	1.7	9
3597	Evolution of gastrectomy for cancer over 30-years: Changes in presentation, management, and outcomes. Surgery, 2021, 170, 2-10.	1.0	9
3598	Esophagectomy versus definitive chemoradiotherapy as initial treatment for clinical stage I esophageal cancer: a systematic review and meta-analysis. Ecological Management and Restoration, 2021, , .	0.2	0
3599	Complete response to neoadjuvant pembrolizumab and capecitabine in microsatellite stable, Epstein-Barr virus-positive, locally advanced gastric adenocarcinoma: case report. AME Case Reports, 2021, 5, 30-30.	0.2	2
3600	CRIP1 cooperates with BRCA2 to drive the nuclear enrichment of RAD51 and to facilitate homologous repair upon DNA damage induced by chemotherapy. Oncogene, 2021, 40, 5342-5355.	2.6	19
3601	Neoadjuvant Therapy for Resectable Pancreatic Cancer. Annals of Surgery, 2021, 274, 713-720.	2.1	48
3602	Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial. Lancet Oncology, The, 2021, 22, 1081-1092.	5.1	178
3603	Clinical assessment of tumor regression grade systems in gastroesophageal adenocarcinoma following neoadjuvant chemotherapy. Pathology Research and Practice, 2021, 224, 153538.	1.0	0
3604	Body composition parameters predict pathological response and outcomes in locally advanced gastric cancer after neoadjuvant treatment: A multicenter, international study. Clinical Nutrition, 2021, 40, 4980-4987.	2.3	7
3605	Phase II study of S-1 and oxaliplatin as neoadjuvant chemotherapy for locally advanced adenocarcinoma of the gastric or esophagogastric junction: KSCC1601. Gastric Cancer, 2022, 25, 180-187.	2.7	10
3606	Thirty years of esophageal cancer surgery in Oulu University Hospital. Journal of Thoracic Disease, 2021, 13, 4638-4649.	0.6	0
3607	The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma. Journal of Surgical Oncology, 2021, 124, 1296-1305.	0.8	0
3608	Cardiopulmonary exercise testing has greater prognostic value than sarcopenia in oesophagoâ€gastric cancer patients undergoing neoadjuvant therapy and surgical resection. Journal of Surgical Oncology, 2021, 124, 1306-1316.	0.8	8
3609	Sex differences in tumor characteristics, treatment, and outcomes of gastric and esophageal cancer surgery: nationwide cohort data from the Dutch Upper GI Cancer Audit. Gastric Cancer, 2022, 25, 22-32.	2.7	15
3610	Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching. Gastric Cancer, 2021, 24, 1355-1364.	2.7	25
3611	Neoadjuvant chemoradiotherapy plus postoperative adjuvant XELOX chemotherapy versus postoperative adjuvant chemotherapy with XELOX regimen for local advanced gastric cancer-A randomized, controlled study. British Journal of Radiology, 2021, 94, 20201088.	1.0	6

#	Article	IF	Citations
3612	Clinical biomarkers in adjuvant chemotherapy for gastric cancer after D2 dissection by a pooled analysis of individual patient data from large randomized controlled trials. Gastric Cancer, 2021, 24, 1184-1193.	2.7	5
3613	Coincidental splenic irradiation and risk of functional hyposplenism in oesophageal cancer treatment. Journal of Medical Imaging and Radiation Oncology, 2021, 65, 925-930.	0.9	1
3614	Relationship between fatty liver change and nutritional status after total gastrectomy in gastric cancer patients: a retrospective study. BMC Surgery, 2021, 21, 325.	0.6	0
3616	Development and Validation of a Computed Tomographyâ€"Based Radiomics Signature to Predict Response to Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. JAMA Network Open, 2021, 4, e2121143.	2.8	45
3617	Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial. European Journal of Cancer, 2021, 153, 153-161.	1.3	8
3618	Prognostic value of tumor regression grade following the administration of neoadjuvant chemotherapy as treatment for gastric/gastroesophageal adenocarcinoma: A meta-analysis of 14 published studies. European Journal of Surgical Oncology, 2021, 47, 1996-2003.	0.5	7
3619	Comparison of totally laparoscopic and laparoscopic assisted gastrectomy after neoadjuvant chemotherapy in locally advanced gastric cancer. European Journal of Surgical Oncology, 2021, 47, 2023-2030.	0.5	9
3620	Health related quality of life following open versus minimally invasive total gastrectomy for cancer: Results from a randomized clinical trial. European Journal of Surgical Oncology, 2022, 48, 553-560.	0.5	5
3621	Prognostic performance of different lymph node classification systems in young gastric cancer. Journal of Gastrointestinal Oncology, 2021, 12, 1285-1300.	0.6	9
3622	Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study. BMC Cancer, 2021, 21, 974.	1.1	6
3623	Impact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: A multiâ€institutional propensity scoreâ€matched study. Journal of Surgical Oncology, 2021, 124, 1338-1346.	0.8	15
3624	Neoadjuvant Chemotherapy Versus Direct Surgery for Locally Advanced Gastric Cancer With Serosal Invasion (cT4NxM0): A Propensity Score-Matched Analysis. Frontiers in Oncology, 2021, 11, 718556.	1.3	5
3625	Perioperative chemotherapy versus adjuvant chemotherapy strategies in resectable gastric and gastroesophageal cancer: A Markov decision analysis. European Journal of Surgical Oncology, 2022, 48, 403-410.	0.5	3
3626	Prognostic impact of a microscopic positive margin in patients undergoing gastrectomy for gastric cancer: a propensity scoreâ€matched analysis of a multiâ€institutional dataset. Surgery Today, 2022, 52, 559-566.	0.7	2
3627	Comprehensive Immunohistochemical Study of the SWI/SNF Complex Expression Status in Gastric Cancer Reveals an Adverse Prognosis of SWI/SNF Deficiency in Genomically Stable Gastric Carcinomas. Cancers, 2021, 13, 3894.	1.7	9
3628	Disparities and survival in newly diagnosed gastric cancer in Hispanic patients in the United States: a propensity score matched analysis. Journal of Gastrointestinal Oncology, 2021, 12, 1308-1325.	0.6	4
3629	Tumor mutation burden is correlated with response and prognosis in microsatellite-stable (MSS) gastric cancer patients undergoing neoadjuvant chemotherapy. Gastric Cancer, 2021, 24, 1342-1354.	2.7	13
3631	Trimodality Versus Bimodality Therapy in Patients With Locally Advanced Esophageal Carcinoma: Commentary on the American Society of Clinical Oncology Practice Guidelines. Practical Radiation Oncology, 2021, 11, 429-433.	1.1	2

#	Article	IF	Citations
3632	Nutritional Support Indications in Gastroesophageal Cancer Patients: From Perioperative to Palliative Systemic Therapy. A Comprehensive Review of the Last Decade. Nutrients, 2021, 13, 2766.	1.7	22
3633	Structured and shared CT radiological report of gastric cancer: a consensus proposal by the Italian Research Group for Gastric Cancer (GIRCG) and the Italian Society of Medical and Interventional Radiology (SIRM). European Radiology, 2022, 32, 938-949.	2.3	4
3634	Proteomic analysis to identify markers for response to neoadjuvant treatment in esophageal and gastroesophageal cancer. Cancer Reports, 2022, 5, e1489.	0.6	2
3635	Gastric cancer with positive peritoneal cytology: survival benefit after induction chemotherapy and conversion to negative peritoneal cytology. World Journal of Surgical Oncology, 2021, 19, 245.	0.8	20
3637	Effect of neoadjuvant treatment combined with radical gastrectomy on postoperative complications and prognosis of gastric cancer patients. Scandinavian Journal of Gastroenterology, 2021, 56, 1343-1348.	0.6	5
3638	Impact of perioperative chemotherapy on postoperative morbidity after gastrectomy for gastric cancer. CirugÃa EspaÃ±ola (English Edition), 2021, 99, 521-526.	0.1	1
3639	Impact of anaemia in oesophago-gastric cancer patients undergoing curative treatment by means of neoadjuvant chemotherapy and surgery. Surgical Oncology, 2021, 38, 101585.	0.8	1
3640	Is the United States Ready for Regionalized Cancer Care?. Journal of Clinical Oncology, 2021, 39, JCO.21.01692.	0.8	1
3641	Treatment burden of robotic gastrectomy for locally advanced gastric cancer (LAGC): a single western experience. Annals of Translational Medicine, 2021, 9, 1408-1408.	0.7	1
3642	Stroma <scp>A</scp>Reactive <scp>I</scp>nvasion <scp>F</scp>ront <scp>A</scp>reas (<scp>SARIFA</scp>) â€“ a new prognostic biomarker in gastric cancer related to tumorâ€promoting adipocytes. Journal of Pathology, 2022, 256, 71-82.	2.1	11
3643	Low muscularity increases the risk for postâ€operative pneumonia and delays recovery from complications after oesophagoâ€gastric cancer resection. ANZ Journal of Surgery, 2021, 91, 2683-2689.	0.3	8
3644	Prognostic significance of surgeryâ€induced sarcopenia in the survival of gastric cancer patients: a sexâ€specific analysis. Journal of Cachexia, Sarcopenia and Muscle, 2021, 12, 1897-1907.	2.9	22
3645	Commentary: Not a â€œcheckmate,â€•but great progress. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 438-439.	0.4	1
3646	Naples Prognostic Score Predicts Tumor Regression Grade in Resectable Gastric Cancer Treated with Preoperative Chemotherapy. Cancers, 2021, 13, 4676.	1.7	11
3647	PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 2021, 39, 2903-2913.	0.8	154
3648	Neoadjuvant Docetaxel, Oxaliplatin, and S-1 in Resectable Advanced Gastric Cancer. Journal of Clinical Oncology, 2021, 39, 3883-3884.	0.8	3
3649	Neo-adjuvant chemotherapy and its anaesthetic implications for surgeryâ€”a narrative review. Digestive Medicine Research, 0, 4, 55-55.	0.2	0
3650	Gastroesophageal adenocarcinoma in older adults: A comprehensive narrative review of management by the young international society of geriatric oncology. Journal of Geriatric Oncology, 2021, , .	0.5	0

#	Article	IF	Citations
3651	Risk Factors for Metachronous Isolated Peritoneal Metastasis after Preoperative Chemotherapy and Potentially Curative Gastric Cancer Resection: Results from the CRITICS Trial. Cancers, 2021, 13, 4626.	1.7	6
3652	Signet ring cell cancer of stomach and gastro-esophageal junction: molecular alterations, stage-stratified treatment approaches, and future challenges. Langenbeck's Archives of Surgery, 2022, 407, 87-98.	0.8	5
3653	Prognosis of poorly cohesive gastric cancer after complete cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (CYTO-CHIP study). British Journal of Surgery, 2021, 108, 1225-1235.	0.1	25
3654	Is D2 Lymphadenectomy Alone Suitable for Gastric Cancer With Bulky N2 and/or Para-Aortic Lymph Node Metastases After Preoperative Chemotherapy?. Frontiers in Oncology, 2021, 11, 709617.	1.3	3
3655	Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma. Surgery, 2021, 170, 1711-1717.	1.0	7
3656	Anastomotic stricture after Ivor Lewis esophagectomy: An evaluation of incidence, risk factors, and treatment. Surgery, 2022, 171, 393-398.	1.0	2
3657	Towards Personalized Treatment Strategies for Esophageal Adenocarcinoma; A Review on the Molecular Characterization of Esophageal Adenocarcinoma and Current Research Efforts on Individualized Curative Treatment Regimens. Cancers, 2021, 13, 4881.	1.7	6
3658	A Phase II Trial of Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma: A Big Ten Cancer Research Consortium Study. Frontiers in Oncology, 2021, 11, 736620.	1.3	19
3659	Characteristics and Research Waste Among Randomized Clinical Trials in Gastric Cancer. JAMA Network Open, 2021, 4, e2124760.	2.8	5
3660	Reply to D.-C. Mo et al. Journal of Clinical Oncology, 2021, 39, 3884-3886.	0.8	1
3661	Surgery by a minimally invasive approach is associated with improved textbook outcomes in oesophageal and gastric cancer. European Journal of Surgical Oncology, 2021, 47, 2332-2339.	0.5	19
3662	Myosteatosis predicts higher complications and reduced overall survival following radical oesophageal and gastric cancer surgery. European Journal of Surgical Oncology, 2021, 47, 2295-2303.	0.5	18
3663	Combined Therapy of Locally Advanced Oesophageal and Gastroâ€“Oesophageal Junction Adenocarcinomas: State of the Art and Aspects of Predictive Factors. Cancers, 2021, 13, 4591.	1.7	0
3664	Inhibition of Wnt/Î²-Catenin Signaling Sensitizes Esophageal Cancer Cells to Chemoradiotherapy. International Journal of Molecular Sciences, 2021, 22, 10301.	1.8	9
3665	Multidisciplinary treatment strategy for locally advanced gastric cancer: A systematic review. Surgical Oncology, 2021, 38, 101599.	0.8	3
3666	Neoadjuvant versus Postoperative Chemoradiotherapy is Associated with Improved Survival for Patients with Resectable Gastric and Gastroesophageal Cancer. Annals of Surgical Oncology, 2022, 29, 242-252.	0.7	4
3667	Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma. British Journal of Surgery, 2021, 108, 1332-1340.	0.1	7
3668	Efficacy and Prognostic Analysis of 315 Stage Iâ€“IVa Esophageal Cancer Patients Treated with Simultaneous Integrated Boost-Intensity-Modulated Radiation Therapy. Cancer Management and Research, 2021, Volume 13, 6969-6975.	0.9	4

#	Article	IF	Citations
3669	Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surgical Oncology Clinics of North America, 2021, 30, 657-671.	0.6	0
3670	Outcomes of patients with nonmetastatic gastric adenocarcinoma according to perioperative treatment strategy: a real-world, population-based study. Journal of Comparative Effectiveness Research, 2021, 10, 1143-1151.	0.6	0
3671	Efficacy and Safety of Additional S-1 Chemotherapy to S-1 plus Oxaliplatin Regimen Chemotherapy for Stage III Gastric Carcinoma after Radical Resection. Cancer Investigation, 2021, , 1-11.	0.6	1
3672	Benchmarks for nodal yield and ratio for node-positive gastric cancer. Surgery, 2021, 170, 1231-1239.	1.0	6
3673	Partial Gastrectomy is Associated with Improved Overall Survival in Signet-Ring Cell Gastric Cancer. Journal of Surgical Research, 2021, 266, 27-34.	0.8	2
3674	Interobserver agreement of a gastric adenocarcinoma tumor regression grading system that incorporates assessment of lymph nodes. Human Pathology, 2021, 116, 94-101.	1.1	9
3675	Development and validation of deep learning classifiers to detect Epstein-Barr virus and microsatellite instability status in gastric cancer: a retrospective multicentre cohort study. The Lancet Digital Health, 2021, 3, e654-e664.	5.9	69
3676	Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trial. International Journal of Surgery, 2021, 94, 106112.	1.1	0
3677	Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery for carcinoma of the oesophagus or the gastro-oesophageal junction. European Journal of Cancer, 2021, 157, 278-290.	1.3	8
3679	The Prognostic Value of Lymph Node Ratio after Neoadjuvant Chemotherapy in Patients with Locally Advanced Gastric Adenocarcinoma. Journal of Gastric Cancer, 2021, 21, 49.	0.9	4
3680	Significance of Lauren Classification in Patients Undergoing Neoadjuvant/Perioperative Chemotherapy for Locally Advanced Gastric or Gastroesophageal Junction Cancersâ€"Analysis from a Large Single Center Cohort in Germany. Cancers, 2021, 13, 290.	1.7	6
3681	Vitamin D modulation and microRNAs in gastric cancer: prognostic and therapeutic role. Translational Cancer Research, 2021, 10, 0-0.	0.4	6
3682	Effect of Additional Trastuzumab in Neoadjuvant and Adjuvant Treatment for Patients with Resectable HER2-Positive Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 4413-4422.	0.7	6
3683	Failure to Cure in Patients Undergoing Surgery for Gastric Cancer: A Nationwide Cohort Study. Annals of Surgical Oncology, 2021, 28, 4484-4496.	0.7	4
3684	Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110295.	1.4	7
3685	Current state of chemotherapy and immunotherapy regimens in gastric cancer. , 2021, , 289-316.		0
3686	5-Fu-Based Doublet Regimen in Patients Receiving Perioperative or Postoperative Chemotherapy for Locally Advanced Gastric Cancer: When to Start and How Long Should the Regimen Last?. Cancer Management and Research, 2021, Volume 13, 147-161.	0.9	6
3687	The Performance of a Dual-Energy CT Derived Radiomics Model in Differentiating Serosal Invasion for Advanced Gastric Cancer Patients After Neoadjuvant Chemotherapy: Iodine Map Combined With 120-kV Equivalent Mixed Images. Frontiers in Oncology, 2020, 10, 562945.	1.3	14

#	Article	IF	Citations
3688	Adjuvant Durvalumab Following Trimodality Therapy for Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. SSRN Electronic Journal, 0, , .	0.4	0
3689	The Predictive Values of Pretreatment Controlling Nutritional Status (CONUT) Score in Estimating Short- and Long-term Outcomes for Patients with Gastric Cancer Treated with Neoadjuvant Chemotherapy and Curative Gastrectomy. Journal of Gastric Cancer, 2021, 21, 155.	0.9	9
3690	Prognosis after surgery for gastric adenocarcinoma in the Swedish Gastric Cancer Surgery Study (SWEGASS). Acta OncolÃ³gica, 2021, 60, 513-520.	0.8	12
3691	Impact of Treatment Sequencing on Survival for Patients with Locally Advanced Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 2856-2865.	0.7	3
3692	Perioperative FLOT chemotherapy plus surgery for oligometastatic esophagogastric adenocarcinoma: surgical outcome and overall survival. BMC Surgery, 2021, 21, 35.	0.6	2
3693	Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis. Journal of Cancer, 2021, 12, 1179-1189.	1.2	2
3695	The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study. Journal of Cancer, 2021, 12, 379-386.	1.2	8
3696	Improvement of the Photodynamic Efficacy Based on Zr-MOF Loaded PPa. Hans Journal of Chemical Engineering and Technology, 2021, 11, 55-65.	0.0	1
3697	A nomogram to predict the prognosis of patients with unresected rectal adenocarcinoma undergoing chemoradiotherapy: a population-based study. Journal of Cancer, 2021, 12, 4745-4761.	1.2	6
3698	ASO Author Reflections: Gastrectomy Within 30 Days After Neoadjuvant Chemotherapy is Associated with the Highest Rate of Major Pathologic Response in Advanced Gastric Cancer. Annals of Surgical Oncology, 2021, 28, 4456-4457.	0.7	1
3699	Worldwide Practice in Gastric Cancer Surgery: A 6-Year Update. Digestive Surgery, 2021, 38, 266-274.	0.6	12
3700	CD90 affects the biological behavior and energy metabolism level of gastric cancer cells by targeting the PI3K/AKT/HIFâ€1Î± signaling pathway. Oncology Letters, 2021, 21, 191.	0.8	9
3701	Selfâ€assembling bile pigments for cancer diagnosis and therapy. Aggregate, 2021, 2, 84-94.	5.2	24
3702	Trends of Clinician Adherence to Evidence-Based Recommendations for Multidisciplinary Oncology Care for Patients With Esophageal Cancer. JAMA Oncology, 2020, 6, 1290.	3.4	5
3704	Machine learning to predict early recurrence after oesophageal cancer surgery. British Journal of Surgery, 2020, 107, 1042-1052.	0.1	35
3705	Conditional survival after neoadjuvant chemoradiotherapy and surgery for oesophageal cancer. British Journal of Surgery, 2020, 107, 1053-1061.	0.1	26
3706	Perirenal fat thickness as a predictor of postoperative complications after laparoscopic distal gastrectomy for gastric cancer. BJS Open, 2020, 4, 865-872.	0.7	9
3707	Conditional survival of patients with gastric cancer who undergo curative resection: A multiâ€institutional analysis in China. Cancer, 2018, 124, 916-924.	2.0	28

#	Article	IF	Citations
3708	New developments in the pathogenesis, diagnosis, therapy and prevention of gastric cancer. , 2008, , 214-220.		1
3710	Induction Therapy for Resectable Esophageal Cancer. , 2011, , 203-212.		1
3711	Magenkarzinom. , 2008, , 173-184.		1
3712	Multimodality Therapy for Adenocarcinoma of the Esophagus, Gastric Cardia, and Upper Gastric Third. Recent Results in Cancer Research, 2009, 182, 155-166.	1.8	2
3713	Metabolic Response Evaluation by PET During Neoadjuvant Treatment for Adenocarcinoma of the Esophagus and Esophagogastric Junction. Recent Results in Cancer Research, 2009, 182, 167-177.	1.8	7
3714	Magenkarzinom. , 2010, , 521-562.		2
3716	Radiotherapy of Gastroesophageal Junction Cancer. Recent Results in Cancer Research, 2012, 196, 187-199.	1.8	3
3717	Can Adjuvant Chemoradiotherapy Replace Extended Lymph Node Dissection in Gastric Cancer?. Recent Results in Cancer Research, 2012, 196, 229-240.	1.8	6
3718	Predicting the Response to Chemotherapy in Gastric Adenocarcinoma: Who Benefits from Neoadjuvant Chemotherapy?. Recent Results in Cancer Research, 2012, 196, 241-268.	1.8	23
3719	Adjuvant Chemotherapy: An Option for Asian Patients Only?. Recent Results in Cancer Research, 2012, 196, 291-305.	1.8	2
3720	Selecting the Best Treatment for an Individual Patient. Recent Results in Cancer Research, 2012, 196, 307-318.	1.8	8
3721	Neoadjuvant Treatment for Resectable Locally Advanced Gastric Cancer. , 2012, , 155-166.		1
3722	Sarcopenia during neoadjuvant therapy for oesophageal cancer: characterising the impact on muscle strength and physical performance. Supportive Care in Cancer, 2018, 26, 1569-1576.	1.0	42
3723	EUS in the Evaluation of Gastric Tumors. , 2015, , 129-150.		2
3724	Cancer of the Stomach. , 2008, , 1431-1464.		3
3725	Adenocarcinoma and Other Tumors of the Stomach. , 2010, , 887-906.e8.		7
3726	Gastric Adenocarcinoma. , 2011, , 80-84.		1
3728	Interaction of Chemotherapy and Radiation. , 2012, , 65-82.		9

#	Article	IF	Citations
3729	Gastric/GE Junction Cancer. , 2012, , 903-933.		4
3730	Surgical Treatment of Cancer of the Esophagus and Esophagogastric Junction. , 2013, , 416-437.		1
3731	Adenocarcinoma of the Stomach, Duodenum, and Small Intestine. , 2013, , 773-780.		2
3732	Preoperative Chemoradiation Versus Chemotherapy in Gastroesophageal Junction Adenocarcinoma. Annals of Thoracic Surgery, 2020, 110, 398-405.	0.7	15
3733	Tratamientos oncolÃ³gicos en el cÃ¡ncer de uniÃ³n esofagogÃ¡strica: pasado, presente y futuro. CirugÃa EspaÃ±ola, 2019, 97, 459-464.	0.1	8
3734	Delaying adjuvant chemotherapy in advanced gastric cancer patients: Risk factors and its impact on survival outcome. Current Problems in Cancer, 2020, 44, 100577.	1.0	6
3735	G3BP1 interacts with YWHAZ to regulate chemoresistance and predict adjuvant chemotherapy benefit in gastric cancer. British Journal of Cancer, 2021, 124, 425-436.	2.9	28
3736	The importance of Epstein-Barr virus infection in the systemic treatment of patients with gastric cancer. Seminars in Oncology, 2020, 47, 127-137.	0.8	7
3738	How to Prevent Sarcopenia Occurrence during Neoadjuvant Chemotherapy for Oesogastric Adenocarcinoma?. Nutrition and Cancer, 2021, 73, 802-808.	0.9	8
3739	Comparison of multimodal analgesia with thoracic epidural after transthoracic oesophagectomy. British Journal of Surgery, 2021, 108, 58-65.	0.1	6
3740	A â€œJust Enoughâ€•Gross Proximal Margin Length Ensuring Pathologically Complete Resection in Distal Gastrectomy for Gastric Cancer. Annals of Surgery Open, 2020, 1, e026.	0.7	8
3741	Complete pathologic response with combination oxaliplatin and 5-fluorouracil chemotherapy in an older patient with advanced gastric cancer. Anti-Cancer Drugs, 2011, 22, 1024-1026.	0.7	2
3742	A Risk Score System to Preoperatively Predict TNM Stages in Gastric Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 130-134.	0.6	7
3743	Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers. Annals of Surgery, 2020, 271, 637-645.	2.1	65
3744	The Effect of Postoperative Complications After Minimally Invasive Esophagectomy on Long-term Survival. Annals of Surgery, 2021, 274, e1129-e1137.	2.1	54
3745	The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	7
3746	Acute Kidney Injury After Esophageal Cancer Surgery. Annals of Surgery, 2022, 275, e683-e689.	2.1	9
3747	WIN 55,212-2 Inhibits the Epithelial Mesenchymal Transition of Gastric Cancer Cells via COX-2 Signals. Cellular Physiology and Biochemistry, 2016, 39, 2149-2157.	1.1	23

#	Article	IF	Citations
3748	CT-based radiomics scores predict response to neoadjuvant chemotherapy and survival in patients with gastric cancer. BMC Cancer, 2020, 20, 468.	1.1	40
3749	Laparoscopic Gastrectomy with Enhanced Recovery After Surgery Protocol: Single-Center Experience. Medical Science Monitor, 2017, 23, 1421-1427.	0.5	26
3750	Recent advances in preoperative management of esophageal adenocarcinoma. F1000Research, 2017, 6, 501.	0.8	1
3751	Recent advances in the management of gastric adenocarcinoma patients. F1000Research, 2018, 7, 1365.	0.8	26
3752	Recent advances in treating oesophageal cancer. F1000Research, 2020, 9, 1189.	0.8	50
3753	Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers. PLoS ONE, 2012, 7, e43236.	1.1	13
3754	Adjuvant Chemotherapy for Elderly Patients with Gastric Cancer after D2 Gastrectomy. PLoS ONE, 2013, 8, e53149.	1.1	22
3755	Postoperative Chemoradiotherapy Combined with Epirubicin-Based Triplet Chemotherapy for Locally Advanced Adenocarcinoma of the Stomach or Gastroesophageal Junction. PLoS ONE, 2013, 8, e54233.	1.1	4
3756	Optimal Duration of Fluorouracil-Based Adjuvant Chemotherapy for Patients with Resectable Gastric Cancer. PLoS ONE, 2013, 8, e83196.	1.1	17
3757	Relationship between P53 Status and Response to Chemotherapy in Patients with Gastric Cancer: A Meta-Analysis. PLoS ONE, 2014, 9, e95371.	1.1	23
3758	Heat Shock Protein 60 Overexpression Is Associated with the Progression and Prognosis in Gastric Cancer. PLoS ONE, 2014, 9, e107507.	1.1	57
3759	Metachronous Second Primary Malignancies after Head and Neck Cancer in a Korean Cohort (1993-2010). PLoS ONE, 2015, 10, e0134160.	1.1	22
3760	MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma. PLoS ONE, 2015, 10, e0134180.	1.1	33
3761	Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1 and 3 in Gastric and Esophageal Adenocarcinoma. PLoS ONE, 2016, 11, e0148101.	1.1	25
3762	Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS ONE, 2017, 12, e0181845.	1.1	7
3763	GNB2L1 and its O-GlcNAcylation regulates metastasis via modulating epithelial-mesenchymal transition in the chemoresistance of gastric cancer. PLoS ONE, 2017, 12, e0182696.	1.1	18
3764	Comparison of capecitabine and oxaliplatin with S-1 as adjuvant chemotherapy in stage III gastric cancer after D2 gastrectomy. PLoS ONE, 2017, 12, e0186362.	1.1	15
3765	Protein expression-based classification of gastric cancer by immunohistochemistry of tissue microarray. PLoS ONE, 2020, 15, e0238836.	1.1	8

#	Article	IF	Citations
3766	Peri-operative Chemotherapy in Patients with Oesophageal and Gastro-oesophageal Junction Cancer â€“ Three Years of Experience. Prague Medical Report, 2013, 114, 57-71.	0.4	2
3767	Gastric Perforation in a Patient Receiving Neoadjuvant Chemoradiotherapy. World Journal of Oncology, 2015, 6, 383-386.	0.6	3
3768	Prognostic factors for survival in patients with gastric cancer: single instution experience. Ä°stanbul Kuzey Klinikleri, 2019, 7, 146-152.	0.1	11
3769	The impact of blood transfusion on perioperative outcomes following gastric cancer resection: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database. Canadian Journal of Surgery, 2016, 59, 322-329.	0.5	43
3770	ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER?. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2019, 32, e1464.	0.5	3
3771	Tratamento paliativo do adenocarcinoma gÃ¡strico. Arquivos Brasileiros De Cirurgia Digestiva: ABCD = Brazilian Archives of Digestive Surgery, 2011, 24, 74-80.	0.5	1
3773	The predictive factors of gastric cancer recurrence after the completion of adjuvant chemotherapy in advanced gastric cancer. Revista Espanola De Enfermedades Digestivas, 2019, 111, 537-542.	0.1	10
3774	TITLE: ï¿½From Laurenï¿½s diffuse gastric cancer to WHOï¿½s poorly cohesive carcinoma.ï¿½ Clinicopathological and prognostic characteristics. Revista Espanola De Enfermedades Digestivas, 2020, 113, 324-331.	0.1	6
3775	Immune-related gene signature predicts overall survival of gastric cancer patients with varying microsatellite instability status. Aging, 2021, 13, 2418-2435.	1.4	11
3776	Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget, 2016, 7, 64757-64765.	0.8	12
3777	Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer: a propensity-matched analysis. Oncotarget, 2016, 7, 76316-76326.	0.8	1
3778	Efficacy of preoperative chemotherapy regimens in patients with initially unresectable locally advanced gastric adenocarcinoma: capecitabine and oxaliplatin (XELOX) or with epirubicin (EOX). Oncotarget, 2016, 7, 76298-76307.	0.8	8
3779	Individual patient oesophageal cancer 3D models for tailored treatment. Oncotarget, 2017, 8, 24224-24236.	0.8	12
3780	A novel grade-lymph node ratio model predicts the prognosis of the advanced gastric cancer patients after neoadjuvant radiotherapy. Oncotarget, 2017, 8, 14058-14067.	0.8	4
3781	Biopsy proportion of tumour predicts pathological tumour response and benefit from chemotherapy in resectable oesophageal carcinoma: results from the UK MRC OE02 trial. Oncotarget, 2016, 7, 77565-77575.	0.8	12
3782	Approaches and genetic determinants in predicting response to neoadjuvant chemotherapy in locally advanced gastric cancer. Oncotarget, 2017, 8, 30477-30494.	0.8	17
3783	Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. Oncotarget, 2017, 8, 574-582.	0.8	42
3784	Squamous cell carcinoma antigen (SCCA) is up-regulated during Barrettâ€™s carcinogenesis and predicts esophageal adenocarcinoma resistance to neoadjuvant chemotherapy. Oncotarget, 2017, 8, 24372-24379.	0.8	10

#	Article	IF	Citations
3785	Leukocytosis and neutrophilia predict outcome in locally advanced esophageal cancer treated with definitive chemoradiation. Oncotarget, 2017, 8, 11579-11588.	0.8	36
3786	Silence of cancer susceptibility candidate 9 inhibits gastric cancer and reverses chemoresistance. Oncotarget, 2017, 8, 15393-15398.	0.8	54
3787	GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancer. Oncotarget, 2017, 8, 27412-27427.	0.8	29
3788	The optimal chemotherapeutic regimen in D2-resected locally advanced gastric cancer: a propensity score-matched analysis. Oncotarget, 2017, 8, 66559-66568.	0.8	3
3789	Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer. Oncotarget, 2017, 8, 47518-47532.	0.8	39
3790	Time to local recurrence as a predictor of survival in unrecetable gastric cancer patients after radical gastrectomy. Oncotarget, 2017, 8, 89203-89213.	0.8	9
3791	Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget, 2017, 8, 81430-81440.	0.8	14
3792	The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget, 2017, 8, 72108-72126.	0.8	53
3793	HGF/MET-directed therapeutics in gastroesophageal cancer: a review of clinical and biomarker development. Oncotarget, 2014, 5, 2866-2880.	0.8	56
3794	The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. Oncotarget, 2017, 8, 72157-72166.	0.8	20
3795	Prognostic factors associated with locally advanced gastric cancer patients treated with neoadjuvant chemotherapy followed by surgical resection. Oncotarget, 2017, 8, 75186-75194.	0.8	4
3796	Myeloid ecotropic viral integration site 1 inhibits cell proliferation, invasion or migration in human gastric cancer. Oncotarget, 2017, 8, 90050-90060.	0.8	14
3797	Prognostic effect of adjuvant chemoradiotherapy for patients with gastric cancer: an updated evidence of randomized controlled trials. Oncotarget, 2017, 8, 102880-102887.	0.8	4
3798	A novel inflammation-based prognostic index for patients with esophageal squamous cell carcinoma: neutrophil lymphocyte ratio/albumin ratio. Oncotarget, 2017, 8, 103535-103542.	0.8	14
3799	Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget, 2014, 5, 6620-6632.	0.8	35
3800	High protein and mRNA expression levels of TUBB3 (class III ÃŸ-tubulin) are associated with aggressive tumor features in esophageal adenocarcinomas. Oncotarget, 2017, 8, 115179-115189.	0.8	13
3801	Association between PIK3CA alteration and prognosis of gastric cancer patients: a meta-analysis. Oncotarget, 2018, 9, 7651-7659.	0.8	14
3802	RPN2 is effective biomarker to predict the outcome of combined chemotherapy docetaxel and cisplatin for advanced gastric cancer. Oncotarget, 2018, 9, 15208-15218.	0.8	15

#	Article	IF	Citations
3803	Glucose transporter 1 expression as a marker of prognosis in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 18518-18528.	0.8	13
3804	Leukaemia inhibitory factor is associated with treatment resistance in oesophageal adenocarcinoma. Oncotarget, 2018, 9, 33634-33647.	0.8	22
3805	The role of different adjuvant therapies in locally advanced gastric adenocarcinoma. Oncotarget, 2018, 9, 34022-34029.	0.8	6
3806	Vitamin D receptor as a marker of prognosis in oesophageal adenocarcinoma: a prospective cohort study. Oncotarget, 2018, 9, 34347-34356.	0.8	7
3807	The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget, 2015, 6, 34402-34413.	0.8	47
3808	Toll-like receptor 2: therapeutic target for gastric carcinogenesis. Oncotarget, 2012, 3, 1260-1261.	0.8	7
3809	Preclinical evidence of multiple mechanisms underlying trastuzumab resistance in gastric cancer. Oncotarget, 2016, 7, 18424-18439.	0.8	45
3810	Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma. Oncotarget, 2016, 7, 19748-19761.	0.8	34
3811	miR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting of FBW7 ubiquitin ligase expression. Oncotarget, 2016, 7, 35284-35292.	0.8	57
3812	Strategies to improve treatment outcome in gastric cancer: A retrospective analysis of patients from two high-volume hospitals in Korea and China. Oncotarget, 2016, 7, 44660-44675.	0.8	21
3813	Reduced genomic tumor heterogeneity after neoadjuvant chemotherapy is related to favorable outcome in patients with esophageal adenocarcinoma. Oncotarget, 2016, 7, 44084-44095.	0.8	10
3814	Recent trend in gastric cancer treatment in the USA. Journal of Cancer Metastasis and Treatment, 2018, 4, 18.	0.5	4
3815	The frontline of esophageal cancer treatment: questions to be asked and answered. Annals of Translational Medicine, 2018, 6, 83-83.	0.7	20
3816	Translational research and application of basic biology to clinical trial development in GI cancers. Annals of Translational Medicine, 2018, 6, 164-164.	0.7	6
3817	Graded histologic response after neoadjuvant chemotherapy is an optimal criterion for treatment change in patients with locally advanced gastric cancer. Annals of Translational Medicine, 2019, 7, 546-546.	0.7	6
3818	Society for Translational Medicine Expert consensus on the selection of surgical approaches in the management of thoracic esophageal carcinoma. Journal of Thoracic Disease, 2019, 11, 319-328.	0.6	10
3819	The emerging field of radiomics in esophageal cancer: current evidence and future potential. Translational Cancer Research, 2016, 5, 410-423.	0.4	31
3820	The necessity of adjuvant radiotherapy for locally advanced gastric cancer in China. Translational Cancer Research, 2019, 8, 676-682.	0.4	2

#	Article	IF	Citations
3821	Impact of the time from the completion of neoadjuvant chemotherapy to surgery on the outcomes of patients with gastric cancer. Translational Cancer Research, 2019, 8, 1853-1862.	0.4	11
3822	Management of gastric cancer in Indian population. Translational Gastroenterology and Hepatology, 2017, 2, 64-64.	1.5	19
3823	CapOX as neoadjuvant chemotherapy for locally advanced operable colon cancer patients: a prospective single-arm phase II trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2016, 28, 589-597.	0.7	35
3824	Extent of lymphadenectomy has no impact on postoperative complications after gastric cancer surgery in Sweden. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 313-322.	0.7	4
3825	Postoperative complications and weight loss following jejunostomy tube feeding after total gastrectomy for advanced adenocarcinomas. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2017, 29, 333-340.	0.7	8
3826	Oxaliplatin plus S-1 or capecitabine as neoadjuvant or adjuvant chemotherapy for locally advanced gastric cancer with D2 lymphadenectomy: 5-year follow-up results of a phase IIâ^'III randomized trial. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 516-525.	0.7	30
3827	Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2018, 30, 526-536.	0.7	17
3828	Risk-stratification model to select conversion surgery for advanced gastric cancer patients. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 178-187.	0.7	4
3829	Implications of clinical research on adjuvant chemotherapy for gastric cancer: Where to go next?. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2019, 31, 892-900.	0.7	13
3830	Current status of esophageal cancer treatment. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2020, 32, 271-286.	0.7	14
3831	Current Management of Locally Advanced Junction Esophagogastric Adenocarcinoma. Chirurgia (Romania), 2018, 113, 38.	0.2	4
3832	Sarcopenia is a Predictive Factor for Postoperative Morbidity and Mortality in Patients Having Radical Gastrectomy for Cancer. Chirurgia (Romania), 2018, 113, 678.	0.2	10
3833	Current Management of Gastric Cancer in Europe. Chirurgia (Romania), 2018, 113, 758.	0.2	2
3834	The Value of Staging Laparoscopy for Optimal Multidisciplinary Treatment in Patients with Gastric Cancer. Chirurgia (Romania), 2018, 113, 789.	0.2	6
3835	The Esophageal Cancer and the PI3K/AKT/mTOR Signaling Regulatory microRNAs: a Novel Marker for Prognosis, and a Possible Target for Immunotherapy. Current Pharmaceutical Design, 2019, 24, 4646-4651.	0.9	37
3836	Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma. Anticancer Research, 2016, 36, 5543-5550.	0.5	20
3837	Clinical Assessment of Sarcopenia and Changes in Body Composition During Neoadjuvant Chemotherapy for Esophageal Cancer. Anticancer Research, 2017, 37, 3053-3059.	0.5	34
3838	Randomized Controlled Trial of Adjuvant Chemotherapy with Fluoropyrimidines Versus Surgery-alone for Gastric Cancer. Anticancer Research, 2017, 37, 3061-3067.	0.5	5

#	Article	IF	Citations
3839	Effect of Neoadjuvant Chemoradiotherapy on Lymph Node Micrometastases in Thoracic Esophageal Cancer. Anticancer Research, 2018, 38, 893-900.	0.5	7
3840	Fibrinogen Levels Are Associated with Lymph Node Involvement and Overall Survival in Gastric Cancer Patients. Anticancer Research, 2018, 38, 1097-1104.	0.5	16
3841	Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Research Protocols, 2017, 6, e136.	0.5	17
3842	Reversal of Multidrug Resistance in an Epirubicin-Resistant Gastric Cancer Cell Subline. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1237-1242.	0.5	4
3843	Image-guided radiotherapy for esophageal cancer. Imaging in Medicine, 2012, 4, 515-525.	0.0	2
3844	Advanced gastric cancer: the value of systemic and intraperitoneal chemotherapy. Acta Biomedica, 2018, 89, 104-109.	0.2	16
3845	Evaluation of Combination Chemotherapy with 5-FU, Doxorubicin and CDDP in Patients with Advanced Esophageal Cancer. Nihon Kikan Shokudoka Gakkai Kaiho, 2008, 59, 539-544.	0.0	3
3846	Gastric cancer--actual multimodality treatment strategies. Polski Przeglad Chirurgiczny, 2012, 84, 461-9.	0.2	1
3847	Recent Topics and Perspectives on Esophageal Cancer in Japan. JMA Journal, 2018, 1, 30-39.	0.6	7
3848	Update on the Treatment of Gastric Cancer. JMA Journal, 2018, 1, 40-49.	0.6	22
3849	Barrett's Adenocarcinoma of the Esophagus. Deutsches Ärzteblatt International, 2011, 108, 313-9.	0.6	20
3850	Treatment Strategies in Gastric Cancer. Deutsches Ärzteblatt International, 2011, 108, 698-705; quiz 706.	0.6	64
3851	The Epidemiology, Diagnosis, and Treatment of Barrettâ€™s Carcinoma. Deutsches Ärzteblatt International, 2015, 112, 224-33; quiz 234.	0.6	13
3852	Optimal Timing to Surgery After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Frontiers in Oncology, 2020, 10, 613988.	1.3	18
3853	Microsatellite Status Affects Tumor Response and Survival in Patients Undergoing Neoadjuvant Chemotherapy for Clinical Stage III Gastric Cancer. Frontiers in Oncology, 2020, 10, 614785.	1.3	10
3854	Preoperative or Perioperative Docetaxel, Oxaliplatin, and Capecitabine (GASTRODOC Regimen) in Patients with Locally-Advanced Resectable Gastric Cancer: A Randomized Phase-II Trial. Cancers, 2020, 12, 2790.	1.7	15
3855	Gastric Cancer Treatments and Survival Trends in the United States. Current Oncology, 2021, 28, 138-151.	0.9	8
3856	Inhibition or Reversal of the Epithelial-Mesenchymal Transition in Gastric Cancer: Pharmacological Approaches. International Journal of Molecular Sciences, 2021, 22, 277.	1.8	26

#	Article	IF	Citations
3857	The 3rd Annual Ontario Thoracic Cancer Conference at Niagara-on-the-Lake. Current Oncology, 2008, 15, 155-161.	0.9	8
3858	Treatment and survival in a population-based sample of patients diagnosed with gastroesophageal adenocarcinoma. World Journal of Gastroenterology, 2008, 14, 3165.	1.4	10
3859	Multidisciplinary management of gastric and gastroesophageal cancers. World Journal of Gastroenterology, 2008, 14, 3773.	1.4	40
3860	Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World Journal of Gastroenterology, 2009, 15, 4962.	1.4	74
3861	Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma-a rationale for a molecular targeting strategy?. World Journal of Gastroenterology, 2007, 13, 3605.	1.4	32
3862	Neoadjuvant chemoradiotherapy for esophageal cancer: Impact on extracapsular lymph node involvement. World Journal of Gastroenterology, 2010, 16, 1986.	1.4	27
3863	R0 resection in the treatment of gastric cancer: Room for improvement. World Journal of Gastroenterology, 2010, 16, 3358.	1.4	45
3864	Neoadjuvant treatment of esophageal cancer. World Journal of Gastroenterology, 2010, 16, 3793.	1.4	55
3865	Technological advances in radiotherapy for esophageal cancer. World Journal of Gastroenterology, 2010, 16, 5555.	1.4	21
3866	Surgical outcome after docetaxel-based neoadjuvant chemotherapy in locally-advanced gastric cancer. World Journal of Gastroenterology, 2010, 16, 868-74.	1.4	69
3867	Targeting key signalling pathways in oesophageal adenocarcinoma: a reality for personalised medicine?. World Journal of Gastroenterology, 2011, 17, 2781-90.	1.4	16
3868	Survival trends in gastric cancer patients of Northeast China. World Journal of Gastroenterology, 2011, 17, 3257-62.	1.4	17
3869	MicroRNAs as a potential prognostic factor in gastric cancer. World Journal of Gastroenterology, 2011, 17, 3976.	1.4	93
3870	Collagen-based biological glue after Appleby operation for advanced gastric cancer. World Journal of Gastroenterology, 2011, 17, 4044.	1.4	2
3871	Caspase-cleaved cytokeratin-18 and tumour regression in gastro-oesophageal adenocarcinomas treated with neoadjuvant chemotherapy. World Journal of Gastroenterology, 2012, 18, 1915.	1.4	10
3872	Normal carcinoembryonic antigen indicates benefit from perioperative chemotherapy to gastric carcinoma patients. World Journal of Gastroenterology, 2012, 18, 3910.	1.4	17
3873	Multimodality approach for locally advanced esophageal cancer. World Journal of Gastroenterology, 2012, 18, 5679.	1.4	21
3874	Human epidermal growth factor receptor-2 in oesophageal cancers: An observational study. World Journal of Gastroenterology, 2012, 18, 6447.	1.4	3

#	Article	IF	Citations
3875	Multidisciplinary approach for patients with esophageal cancer. World Journal of Gastroenterology, 2012, 18, 6737.	1.4	21
3876	Contrast-enhanced ultrasonography assessment of gastric cancer response to neoadjuvant chemotherapy. World Journal of Gastroenterology, 2012, 18, 7026.	1.4	29
3877	Effectiveness of 5-flurouracil-based neoadjuvant chemotherapy in locally-advanced gastric/gastroesophageal cancer: A meta-analysis. World Journal of Gastroenterology, 2012, 18, 7384.	1.4	35
3878	Chemotherapy and resection for gastric cancer with synchronous liver metastases. World Journal of Gastroenterology, 2013, 19, 2097.	1.4	39
3879	Clinicopathological features and outcomes of patients with gastric cancer: A single-center experience. World Journal of Gastroenterology, 2013, 19, 2154.	1.4	11
3880	Efficacy of adjuvant XELOX and FOLFOX6 chemotherapy after D2 dissection for gastric cancer. World Journal of Gastroenterology, 2013, 19, 3309.	1.4	12
3881	Personalizing therapies for gastric cancer: Molecular mechanisms and novel targeted therapies. World Journal of Gastroenterology, 2013, 19, 6383.	1.4	26
3882	Characteristics and prognosis of gastric cancer in patients aged â‰¥ 70 years. World Journal of Gastroenterology, 2013, 19, 6568.	1.4	74
3883	Retrospective analysis of adjuvant chemotherapy for curatively resected gastric cancer. World Journal of Gastroenterology, 2014, 20, 3356.	1.4	1
3884	Extent of lymphadenectomy and perioperative therapies: Two open issues in gastric cancer. World Journal of Gastroenterology, 2014, 20, 3889.	1.4	16
3885	What make differences in the outcome of adjuvant treatments for resected gastric cancer?. World Journal of Gastroenterology, 2014, 20, 11567.	1.4	10
3886	Towards personalized perioperative treatment for advanced gastric cancer. World Journal of Gastroenterology, 2014, 20, 11586.	1.4	25
3887	Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World Journal of Gastroenterology, 2014, 20, 12355.	1.4	12
3888	Multimodality treatment of potentially curative gastric cancer: Geographical variations and future prospects. World Journal of Gastroenterology, 2014, 20, 12892.	1.4	17
3889	Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: Is radiotherapy necessary after D2-dissection?. World Journal of Gastroenterology, 2014, 20, 12900.	1.4	7
3890	Medical management of gastric cancer: A 2014 update. World Journal of Gastroenterology, 2014, 20, 13637.	1.4	36
3891	MicroRNAs: Promising chemoresistance biomarkers in gastric cancer with diagnostic and therapeutic potential. World Journal of Gastroenterology, 2014, 20, 13658.	1.4	32
3892	Clinical management of advanced gastric cancer: The role of new molecular drugs. World Journal of Gastroenterology, 2014, 20, 14537.	1.4	41

#	Article	IF	Citations
3893	Novel CD9-targeted therapies in gastric cancer. World Journal of Gastroenterology, 2015, 21, 3206-3213.	1.4	31
3894	Adjuvant therapy for gastric cancer: What have we learned since INT0116?. World Journal of Gastroenterology, 2015, 21, 3850.	1.4	13
3895	Treatment of esophagogastric junction carcinoma: An unsolved debate. World Journal of Gastroenterology, 2015, 21, 4427-4431.	1.4	4
3896	Modern imaging techniques for preoperative detection of distant metastases in gastric cancer. World Journal of Gastroenterology, 2015, 21, 10502.	1.4	35
3897	Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World Journal of Gastroenterology, 2015, 21, 1222.	1.4	6
3898	Towards curative therapy in gastric cancer: Faraway, so close!. World Journal of Gastroenterology, 2015, 21, 11609.	1.4	12
3899	Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World Journal of Gastroenterology, 2015, 21, 13294.	1.4	10
3900	Histological evaluation for chemotherapeutic responses of metastatic lymph nodes in gastric cancer. World Journal of Gastroenterology, 2015, 21, 13500.	1.4	15
3901	Neoadjuvant chemoradiotherapy followed by D2 gastrectomy in locally advanced gastric cancer. World Journal of Gastroenterology, 2015, 21, 2711.	1.4	23
3902	Radical gastrectomy with hepatoarterial catheter implantation for late-stage gastric cancer. World Journal of Gastroenterology, 2015, 21, 2754.	1.4	8
3903	Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World Journal of Gastroenterology, 2016, 22, 1114.	1.4	75
3904	Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients?. World Journal of Gastroenterology, 2016, 22, 1131.	1.4	8
3905	Advanced gastric cancer: What we know and what we still have to learn. World Journal of Gastroenterology, 2016, 22, 1139.	1.4	59
3906	Personalized medicine in gastric cancer: Where are we and where are we going?. World Journal of Gastroenterology, 2016, 22, 1160.	1.4	37
3907	Seventh tumor-node-metastasis staging of gastric cancer: Five-year follow-up. World Journal of Gastroenterology, 2016, 22, 7748.	1.4	9
3908	Preoperative therapy in locally advanced esophageal cancer. World Journal of Gastroenterology, 2016, 22, 8750.	1.4	15
3909	Prognostic value of circulating tumor cells in esophageal cancer. World Journal of Gastroenterology, 2017, 23, 1310.	1.4	18
3910	Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World Journal of Gastroenterology, 2020, 26, 2427-2439.	1.4	13

#	Article	IF	Citations
3911	Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. World Journal of Gastroenterology, 2020, 26, 375-382.	1.4	12
3912	Chemoradiotherapy with FOLFOX for esophageal squamous cell cancer with synchronous rectal cancer: Four case reports and a literature review. Molecular and Clinical Oncology, 2020, 12, 23-30.	0.4	5
3913	MicroRNAâ€‘381 regulates the growth of gastric cancer cell by targeting TWIST1. Molecular Medicine Reports, 2019, 20, 4376-4382.	1.1	6
3914	Association of serum levels of deoxyribose 1â€‘phosphate and Sâ€‘lactoylglutathione with neoadjuvant chemotherapy sensitivity in patients with gastric cancer: A metabolomics study. Oncology Letters, 2020, 19, 2231-2242.	0.8	4
3915	Open vs. laparoscopic surgery for locally advanced gastric cancer after neoadjuvant therapy: Shortâ€‘term and longâ€‘term survival outcomes. Oncology Letters, 2020, 20, 861-867.	0.8	13
3916	Recent Advances in Chemotherapy of Gastric Cancer. Korean Journal of Medicine, 2012, 82, 417.	0.1	3
3917	Adjuvant Chemotherapy in Gastric Cancer. Korean Journal of Medicine, 2012, 83, 291.	0.1	1
3918	A Case of Pathologic Complete Response with Neoadjuvant Biweekly-DCF Therapy and following Laparoscopic Transhiatal Extended Total Gastrectomy for Advanced Esophagogastric Junction Adenocarcinoma. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2019, 80, 707-713.	0.0	1
3919	Radiation therapy in the postoperative management of esophageal cancer. Journal of Gastrointestinal Oncology, 2010, 1, 102-11.	0.6	21
3920	Gastric cancer: Classification, histology and application of molecular pathology. Journal of Gastrointestinal Oncology, 2012, 3, 251-61.	0.6	368
3921	Surgical management of gastric cancer: the East vs. West perspective. Journal of Gastrointestinal Oncology, 2015, 6, 79-88.	0.6	38
3922	Increased risk of death due to heart disease after radiotherapy for esophageal cancer. Journal of Gastrointestinal Oncology, 2015, 6, 516-23.	0.6	25
3923	Neoadjuvant therapy for gastric cancer: current evidence and future directions. Journal of Gastrointestinal Oncology, 2015, 6, 534-43.	0.6	58
3924	AKT expression is associated with degree of pathologic response in adenocarcinoma of the esophagus treated with neoadjuvant therapy. Journal of Gastrointestinal Oncology, 2016, 7, 158-65.	0.6	10
3925	Preoperative chemotherapy for locally advanced resectable colon cancer - a new treatment paradigm in colon cancer?. Annals of Translational Medicine, 2013, 1, 11.	0.7	15
3926	A case of esophageal adenocarcinoma arising from the ectopic gastric mucosa in the thoracic esophagus. Rare Tumors, 2010, 2, 12-15.	0.3	17
3927	Adjuvant chemo-radiotherapy in patients with gastric cancer. Indian Journal of Cancer, 2006, 43, 174.	0.2	5
3928	Emerging role of S-1 in gastric cancer. Indian Journal of Medical and Paediatric Oncology, 2015, 36, 219-228.	0.1	5

#	Article	IF	Citations
3929	Intensity modulated radiation therapy (IMRT) is not superior to three-dimensional conformal radiation (3DCRT) for adjuvant gastric radiation: A matched pair analysis. Journal of Cancer Research and Therapeutics, 2015, 11, 623.	0.3	13
3930	Adjuvant chemotherapy for gastric cancer in elderly patients has same benefits as in younger patients. Journal of Cancer Research and Therapeutics, 2018, 14, 593.	0.3	7
3931	Gastric cancer review. Journal of Carcinogenesis, 2014, 13, 14.	2.5	181
3932	Current strategies in the diagnosis and management of resectable gastric adenocarcinoma. Astrocyte, 2014, 1, 41.	0.0	1
3933	Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature. Indian Journal of Cancer, 2017, 54, 646.	0.2	11
3934	Radical gastrectomy for gastric cancer at Tata Memorial Hospital. Indian Journal of Cancer, 2017, 54, 605.	0.2	7
3935	The incidence of free peritoneal tumor cells before and after neoadjuvant chemotherapy in gastroesophageal junction cancer. Journal of Cytology, 2020, 37, 40.	0.2	3
3936	The Effect of Adjuvant Chemotherapy on Stage IV (T4N1-3M0 and T1-3N3M0) Gastric Cancer. Cancer Research and Treatment, 2009, 41, 19.	1.3	2
3937	Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Research and Treatment, 2018, 50, 518-529.	1.3	10
3938	Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer. Cancer Research and Treatment, 2020, 52, 1178-1187.	1.3	12
3939	Gastric Cancer: Environmental Risk Factors, Treatment and Prevention. Journal of Carcinogenesis & Mutagenesis, 2013, S14, .	0.3	9
3940	Quantitative and Sensitive Detection of Cancer Genome Amplifications from Formalin Fixed Paraffin Embedded Tumors with Droplet Digital PCR. Translational Medicine (Sunnyvale, Calif), 2012, 02, .	0.4	33
3941	Jejunostomy Feeding Tube Placement in Gastrectomy Procedures: A Systematic Review. Open Journal of Gastroenterology, 2017, 07, 52-64.	0.1	1
3942	Preoperative chemotherapy with a trastuzumab-containing regimen for a patient with gastric cancer and hepatic metastases. Genetics and Molecular Research, 2014, 13, 10952-10957.	0.3	5
3943	Incidence of anastomotic stricture after Ivor-Lewis oesophagectomy using a circular stapling device. World Journal of Gastrointestinal Surgery, 2019, 11, 407-413.	0.8	3
3944	Neoadjuvant chemotherapy for locally advanced gastric cancer: With or without radiation. World Journal of Gastrointestinal Surgery, 2012, 4, 27.	0.8	7
3945	A decade in gastric cancer curative surgery: Evidence of progress (1999-2009). World Journal of Gastrointestinal Surgery, 2012, 4, 45.	0.8	8
3946	Sixth and seventh tumor-node-metastasis staging system compared in gastric cancer patients. World Journal of Gastrointestinal Surgery, 2013, 5, 287.	0.8	12

#	Article	IF	Citations
3947	Timing of chemotherapy and survival in patients with resectable gastric adenocarcinoma. World Journal of Gastrointestinal Surgery, 2013, 5, 321.	0.8	15
3948	Multimodal treatment of gastric cancer. World Journal of Gastrointestinal Surgery, 2014, 6, 55.	0.8	31
3949	Pathological factors affecting gastric adenocarcinoma survival in a Caribbean population from 2000-2010. World Journal of Gastrointestinal Surgery, 2014, 6, 94.	0.8	6
3950	Accuracy of computed tomography in nodal staging of colon cancer patients. World Journal of Gastrointestinal Surgery, 2015, 7, 116.	0.8	18
3951	Conversion surgery for gastric cancer patients: A review. World Journal of Gastrointestinal Oncology, 2018, 10, 398-409.	0.8	30
3952	Precision medicine in gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 804-829.	0.8	56
3953	Safety and efficacy of a docetaxel-5FU-oxaliplatin regimen with or without trastuzumab in neoadjuvant treatment of localized gastric or gastroesophageal junction cancer: A retrospective study. World Journal of Gastrointestinal Oncology, 2019, 11, 634-641.	0.8	2
3954	Advancements and challenges in treating advanced gastric cancer in the West. World Journal of Gastrointestinal Oncology, 2019, 11, 652-664.	0.8	25
3955	Current status of adjuvant chemotherapy for gastric cancer. World Journal of Gastrointestinal Oncology, 2019, 11, 679-687.	0.8	20
3956	Interpretation of the development of neoadjuvant therapy for gastric cancer based on the vicissitudes of the NCCN guidelines. World Journal of Gastrointestinal Oncology, 2020, 12, 37-53.	0.8	40
3957	Complete response to preoperative chemoradiotherapy in highly advanced gastric adenocarcinoma. World Journal of Gastrointestinal Oncology, 2010, 2, 282.	0.8	4
3958	Recent advances in chemotherapy for advanced gastric cancer. World Journal of Gastrointestinal Oncology, 2010, 2, 287.	0.8	5
3959	Gastric cancer: Where is the place for the surgeon, the oncologist and the endoscopist today?. World Journal of Gastrointestinal Oncology, 2011, 3, 10.	0.8	12
3960	Evidence based radiation therapy for locally advanced resectable and unresectable gastric cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 131.	0.8	5
3961	Multimodality management of resectable gastric cancer: A review. World Journal of Gastrointestinal Oncology, 2014, 6, 393.	0.8	18
3962	Operable gastro-oesophageal junctional adenocarcinoma: Where to next?. World Journal of Gastrointestinal Oncology, 2014, 6, 145.	0.8	2
3963	Esophageal cancer management controversies: Radiation oncology point of view. World Journal of Gastrointestinal Oncology, 2014, 6, 263.	0.8	16
3964	Gastric cancer: The times they are a-changinâ€™. World Journal of Gastrointestinal Oncology, 2015, 7, 303.	0.8	16

#	Article	IF	Citations
3965	Neo-adjuvant chemo(radio)therapy in gastric cancer: Current status and future perspectives. World Journal of Gastrointestinal Oncology, 2015, 7, 389.	0.8	32
3966	Robot-assisted surgery for gastric cancer. World Journal of Gastrointestinal Oncology, 2016, 8, 8.	0.8	9
3967	Current adjuvant treatment modalities for gastric cancer: From history to the future. World Journal of Gastrointestinal Oncology, 2016, 8, 439.	0.8	20
3968	Questionnaire survey regarding the current status of super-extended lymph node dissection in Japan. World Journal of Gastrointestinal Oncology, 2016, 8, 707.	0.8	3
3969	Macroscopic appearance of Type IV and giant Type III is a high risk for a poor prognosis in pathological stage II/III advanced gastric cancer with postoperative adjuvant chemotherapy. World Journal of Gastrointestinal Oncology, 2017, 9, 166.	0.8	9
3970	Endoscopic ultrasound fine needle aspiration: Technique and applications in clinical practice. World Journal of Gastrointestinal Endoscopy, 2012, 4, 532.	0.4	23
3971	Changing Trends in Gastric Cancer Surgery. Balkan Medical Journal, 2017, 34, 10-20.	0.3	12
3972	Large lymph node size harvested as prognostic factor in gastric cancer?. Revista Espanola De Enfermedades Digestivas, 2010, 102, 169-75.	0.1	4
3973	Usefulness of endoscopic ultrasonography in preoperative gastric cancer staging: diagnostic yield and therapeutic impact. Revista Espanola De Enfermedades Digestivas, 2010, 102, 413-20.	0.1	11
3974	Survival predictors for second-line chemotherapy in Caucasian patients with metastatic gastric cancer. Swiss Medical Weekly, 2011, 141, w13249.	0.8	6
3975	The relation between postoperative surgical complications and colorectal cancer survival. Annals of Cancer Research and Therapy, 2016, 24, 54-55.	0.1	1
3976	Identification of clinical biomarkers for adjuvant chemotherapy in gastric cancer after D2 dissection by pooled analysis of individual patient data from three large randomized clinical trials. Annals of Cancer Research and Therapy, 2018, 26, 43-45.	0.1	1
3977	Dealing with the gray zones in the management of gastric cancer: The consensus statement of the Istanbul Group. Turkish Journal of Gastroenterology, 2019, 30, 584-598.	0.4	4
3978	Survival outcomes after D1 and D2 lymphadenectomy with R0 resection in stage IIâ€“III gastric cancer: Longitudinal follow-up in a single center. Turkish Journal of Surgery, 2018, 34, 125-130.	0.1	7
3979	The clinicopathologic characteristics and prognostic factors of gastroesophageal junction tumors according to Siewert classification. Turkish Journal of Surgery, 2017, 33, 18-24.	0.1	7
3980	Targeting the Phosphatidylinositol-3-kinase Pathway in Gastric Cancer: Can Omics Improve Outcomes?. International Neurourology Journal, 2016, 20, S131-140.	0.5	20
3981	Postoperative Radiotherapy Improves Survival in Gastric Signet-Ring Cell Carcinoma: a SEER Database Analysis. Journal of Gastric Cancer, 2019, 19, 393.	0.9	14
3982	Novel Biomarkers for Prediction of Response to Preoperative Systemic Therapies in Gastric Cancer. Journal of Gastric Cancer, 2019, 19, 375.	0.9	11

#	Article	IF	Citations
3983	Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. Journal of Gastric Cancer, 2020, 20, 313.	0.9	4
3984	Is there a role for treatment-oriented surgery in liver metastases from gastric cancer?. World Journal of Clinical Oncology, 2020, 11, 477-494.	0.9	8
3985	Neoadjuvant therapy for gastroesophageal adenocarcinoma. World Journal of Clinical Oncology, 2016, 7, 284.	0.9	9
3986	The value of ¹⁸F-FDG PET/CT in assessment of metabolic response in esophageal cancer for prediction of histopathological response and survival after preoperative chemoradiotherapy. Biomedical Papers of the Medical Faculty of the University Palacký, Olomouc, Czechoslovakia, 2012, 156, 171-179.	0.2	14
3987	Esophageal cancer: diagnosis and management. Chinese Journal of Cancer, 2010, 29, 843-854.	4.9	24
3988	The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy. Chinese Journal of Cancer, 2012, 31, 399-408.	4.9	11
3990	Barrett Esophagus: When to Endoscope. Clinical Endoscopy, 2014, 47, 40.	0.6	6
3991	Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 855-883.	2.3	672
3992	Emerging Multimodality Approaches to Treat Localized Esophageal Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 1009-1014.	2.3	79
3993	Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 297-303.	2.3	8
3994	Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 556-563.	2.3	26
3995	siRNA Interference with a Proliferation-Inducing Ligand Gene in the Sgr-7901 Gastric Carcinoma Cell Line. Asian Pacific Journal of Cancer Prevention, 2012, 13, 1511-1514.	0.5	4
3996	Impact of Adjuvant Chemotherapy Cycles on Prognosis of Resectable Stomach Cancer: A Retrospective Analysis. Asian Pacific Journal of Cancer Prevention, 2013, 14, 381-386.	0.5	6
3997	Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis. Asian Pacific Journal of Cancer Prevention, 2013, 14, 5735-5740.	0.5	44
3998	Autophagy Inhibition Sensitizes Cisplatin Cytotoxicity in Human Gastric Cancer Cell Line Sgc7901. Asian Pacific Journal of Cancer Prevention, 2013, 14, 4685-4688.	0.5	30
3999	Establishment and Partial Characterization of an Epirubicin-Resistant Gastric Cancer Cell Line with Upregulated ABCB1. Asian Pacific Journal of Cancer Prevention, 2014, 15, 6849-6853.	0.5	6
4000	Adjuvant Radiotherapy for Gastric Carcinoma: 10 years Follow-up of 244 cases from a Single Institution. Asian Pacific Journal of Cancer Prevention, 2014, 15, 8871-8876.	0.5	4
4001	Esophageal Cancer, Gastric Cancer and the use of Pesticides in the Southwestern of Turkey. Asian Pacific Journal of Cancer Prevention, 2014, 15, 2821-2823.	0.5	14

#	Article	IF	Citations
4002	Mortality and Morbidity and Disease Free Survival after D1 and D2 Gastrectomy for Stomach Adenocarcinomas. Asian Pacific Journal of Cancer Prevention, 2015, 16, 5253-5256.	0.5	3
4003	Change of SPARC expression after chemotherapy in gastric cancer. Cancer Biology and Medicine, 2015, 12, 33-40.	1.4	7
4004	Systemic therapy of non-colorectal gastrointestinal malignancies in the elderly. Cancer Biology and Medicine, 2015, 12, 284-91.	1.4	5
4005	Clinical application of nano-carbon to improve the accuracy of lymph node staging in patients with advanced gastric cancer receiving neoadjuvant chemotherapy: a prospective randomized controlled trial. Journal of Gastrointestinal Oncology, 2021, 12, 2052-2060.	0.6	4
4006	Neoadjuvant therapy versus direct to surgery for T4 colonÂcancer: meta-analysis. British Journal of Surgery, 2021, 109, 30-36.	0.1	15
4007	Gastric Cancer: Synopsis of Treatment Indications. Updates in Surgery Series, 2022, , 191-201.	0.0	0
4008	Gastric Cancer: Locoregional Disease. UNIPA Springer Series, 2021, , 559-585.	0.1	0
4009	Locally Advanced Gastric Cancer: Neoadjuvant Treatment. Updates in Surgery Series, 2022, , 93-98.	0.0	0
4011	Research Progress of Neoadjuvant Chemotherapy for Gastric Cancer. Advances in Clinical Medicine, 2021, 11, 4648-4652.	0.0	1
4012	Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Where we Stand; An Italian Single Center Perspective. In Vivo, 2021, 35, 3459-3466.	0.6	4
4013	Survival analysis of stage II gastric cancer patients after D2 gastrectomy: a Chinese people-based research. BMC Gastroenterology, 2021, 21, 363.	0.8	3
4014	Clinico-epidemiological profile and treatment outcomes in patients with squamous cell carcinoma of the esophagus following docetaxel-based neoadjuvant chemotherapy: experience from a cancer care center in Northeast India. Journal of the Egyptian National Cancer Institute, 2021, 33, 35.	0.6	0
4015	Adjuvant Chemotherapy for Stage I Pancreatic Ductal Adenocarcinomaâ€”Is It Based on Evidence or Clinical Wisdom?. JAMA Oncology, 2021, 7, 1759.	3.4	6
4016	Prognostic factors of minimally invasive surgery for gastric cancer: Does robotic gastrectomy bring oncological benefit?. World Journal of Gastroenterology, 2021, 27, 6659-6672.	1.4	12
4017	Results of the observational prospective RealFLOT study. BMC Cancer, 2021, 21, 1086.	1.1	17
4018	Patterns of care and outcomes for gastric and gastroâ€oesophageal junction cancer in an Australian population. ANZ Journal of Surgery, 2021, , .	0.3	2
4019	Lymph Node Evaluation after Neoadjuvant Chemotherapy for Patients with Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 1242-1253.	0.7	10
4020	Knockdown of Serum- and Glucocorticoid-Regulated Kinase 1 Enhances Cisplatin Sensitivity of Gastric Cancer Through Suppressing the Nuclear Factor Kappa-B Signaling Pathway. , 2021, 38, 331-340.		2

#	Article	IF	Citations
4021	Oesophageal adenocarcinoma: In the era of extended lymphadenectomy, is the value of neoadjuvant therapy being attenuated?. World Journal of Gastrointestinal Surgery, 2021, 13, 1235-1244.	0.8	0
4022	Assessment on the Prognostic Validity of Dissected and Positive Lymph Node Counts and Lymph Node Ratio in Patients with Gastric Cancer: A Multi-central Cohort Study. International Journal of Cancer Management, 2021, 14, .	0.2	1
4023	Advances in the curative management of oesophageal cancer. British Journal of Cancer, 2022, 126, 706-717.	2.9	40
4025	Perioperative Chemotherapy with FLOT Scheme in Resectable Gastric Adenocarcinoma: A Preliminary Correlation between TRG and Radiomics. Applied Sciences (Switzerland), 2021, 11, 9211.	1.3	0
4027	Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma. Acta OncolÃ³gica, 2021, 60, 1629-1636.	0.8	2
4028	Value of Neoadjuvant Radiation Therapy in the Management of Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2021, 39, 3773-3777.	0.8	17
4029	Impact of Type of Postoperative Complications on Long-Term Survival of Gastric Cancer Patients: Results From a High-Volume Institution in China. Frontiers in Oncology, 2021, 11, 587309.	1.3	10
4031	Malignome des Gastrointestinaltrakts. , 2007, , 573-690.		0
4032	Neoplasms of the Stomach and Small Intestine. , 2007, , 249-265.		0
4033	Surgical Treatment of Esophageal Carcinoma. , 2007, , 33-42.		0
4034	Screen-detected breast cancer. , 2007, , 129-136.		0
4035	Neoadjuvant Chemotherapy in Gastric Cancer. Korean Journal of Clinical Oncology, 2008, 4, 26-29.	0.1	0
4036	Adjuvant Chemotherapy for Gastric Cancer. Korean Journal of Clinical Oncology, 2008, 4, 37-41.	0.1	0
4038	Erkrankungen des Gastrointestinalsystems. , 2009, , 841-1057.		0
4039	A CASE OF GASTRIC CANCER DEMONSTRATING DIFFERENT RESPONSES TO NEO-ADJUVANT CHEMOTHERAPY BETWEEN ADENOCARCINOMA AND AFP-PRODUCING COMPONENT. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2009, 70, 1992-1996.	0.0	1
4041	The Medical Oncologistâ€™s Point of View. , 2009, , 37-47.		0
4042	Histopathologic Classification of Adenocarcinoma of the Esophagogastric Junction. Recent Results in Cancer Research, 2009, 182, 29-38.	1.8	2
4043	Combining Platinums in Gastric Cancer. , 2009, , 251-270.		0

#	Article	IF	Citations
4044	EvaluaciÃ³n de la morbimortalidad precoz de la quimiorradioterapia adyuvante en una serie de pacientes tratados por cÃ¡ncer gÃ¡strico. Cuadernos De CirugÃa, 2009, 23, 19-23.	0.0	0
4045	MULTIMODAL APPROACH TO ADVANCED GASTRIC CANCER: NEOADJUVANT CHEMOTHERAPY BASED ON FDG-PET, SURGERY AND HIPEC. BioInfoBank Library Acta, 0, , 1283.	0.0	0
4046	MULTIMODAL APPROACH TO ADVANCED GASTRIC CANCER: NEOADJUVANT CHEMOTHERAPY BASED ON FDG-PET, SURGERY AND HIPEC. BioInfoBank Library Acta, 0, , 1283.	0.0	0
4047	Quimiorradioterapia adyuvante en el cÃ¡ncer gÃ¡strico resecado con intenciÃ³n curativa: AnÃ¡lisis de supervivencia y toxicidad de pacientes tratados entre 1995 y 2003 en el Instituto Nacional del CÃ¡ncer, Chile. Revista Medica De Chile, 2009, 137, .	0.1	3
4048	SURGERY FOR GASTRIC CANCER IN HIGH-RISK AREA: A RETROSPECTIVE STUDY. BioInfoBank Library Acta, 0, , 1891.	0.0	0
4050	Epirubicin, Cisplatin, and Fluorouracil (ECF) Regimen. Hospital Pharmacy, 2009, 44, 1072-1081.	0.4	0
4052	Cancer of the Stomach. , 2010, , 788-800.		0
4053	Upper Gastrointestinal Surgery: Current Trends and Recent Innovations. , 2010, , 793-814.		0
4054	Signet-Ring Cell Carcinoma of the Ampulla of Vater: A Case Report. Japanese Journal of Gastroenterological Surgery, 2010, 43, 391-397.	0.0	1
4055	The Results of Intraoperative Radiotherapy for Stomach Cancer. The Journal of the Korean Society for Therapeutic Radiology and Oncology, 2010, 28, 79.	0.1	0
4057	Resection A Surgery: An Exclusion Criterion of Adjuvant Treatment for Gastric Cancer. [Chapchi] Journal Taehan Oekwa Hakhoe, 2010, 79, 196.	1.1	0
4058	Cancer of the Gastrointestinal Tract and Neuroendocrine Tumors. , 2010, , 169-232.		0
4059	Trends in incidence, management, and survival of gastric and cardia carcinomas in the area of Finistere (France) between 1984 and 2003. European Journal of Gastroenterology and Hepatology, 2010, 22, 1.	0.8	8
4060	Combined Modality Therapy in Cancer Management. , 2011, , 483-517.		0
4062	Gastric Cancer in the Elderly. , 2011, , 781-792.		0
4063	Magenchirurgie. , 2011, , 77-90.		0
4064	Maagcarcinoom. , 2011, , 355-359.		0
4065	Esophageal Surgery for Malignant Disease in the Elderly. , 2011, , 535-551.		0

#	Article	IF	Citations
4066	Erkrankungen von Mund, SpeiserÃ¶hre und Magen. , 2011, , 273-357.		0
4067	Esophageal Cancer in the Elderly. , 2011, , 747-761.		0
4068	Complete Pathologic Response in Advanced Primary Gastric Signet-Ring Cell Carcinoma: A Case Report. Journal of Cancer Science & Therapy, 2011, 03, .	1.7	0
4070	Topoisomerase II Inhibitors: Current Use and Prospects. Cancer Drug Discovery and Development, 2012, , 279-307.	0.2	1
4071	Multimodal Treatment of Resectable Gastric Cancer with Intensive Neoadjuvant Radiation Therapy: Obninsk Radiological Center Experience. Open Surgical Oncology Journal (Online), 2011, 3, 1-6.	1.7	0
4072	CONTEMPORARY APPROACHES TO THE TREATMENT OF ESOPHAGEALCANCER. Clinical Anatomy and Operative Surgery, 2011, 10, 87-94.	0.2	0
4075	Multimodal Therapies for Upper Gastrointestinal Cancers â€“ Past, Now, and Future. , 0, , .		0
4076	Literaturhinweise und Internetadressen. , 2012, , e1-e61.		0
4078	Treatment of Adenocarcinoma of the Esophagogastric Junction. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2012, 12, 151.	0.1	0
4079	Malignome des Gastrointestinaltrakts. , 2012, , 557-665.		0
4080	Neoadjuvant Treatment for Resectable Locally Advanced Gastric Cancer: European Ongoing Trials. , 2012, , 167-173.		0
4082	Neoadjuvant Chemotherapy of Resectable Advanced Gastric Cancer. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of Surgeons), 2012, 37, 197-204.	0.0	0
4083	Strategies of Targeting Tumors and Cancers. Journal of Cancer Research Updates, 2022, 1, .	0.3	2
4084	Evaluation of Pre-operative Clinical Prognosticator in Gastric Cancer-from the Viewpoint of Neoadjuvant Chemotherapy (NAC)-. Nihon Gekakei Rengo Gakkaishi (Journal of Japanese College of) Tj ETQq1 1 0.784314 rgBT /Over	0.0	0
4086	Thoracoscopic Esophagectomy. , 2012, , 65-75.		0
4087	Modern surgical treatment of gastric cancer. Materia Medica, 2012, 28, 432-444.	0.0	0
4088	Adjuvant Treatment After Surgical Resection. , 2012, , 187-194.		0
4089	Treatment of Resectable Advanced Gastric Cancer. , 2012, , 89-94.		0

#	Article	IF	Citations
4091	Current Therapy for Esophageal Adenocarcinoma. , 0, , .		0
4092	Adjuvant Treatments for Localized Advanced Gastric Cancer: Differences among Geographic Regions. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e31-e34.	1.8	0
4093	Will Disease Heterogeneity Help Define Treatment Paradigms for Gastroesophageal Adenocarcinoma? A Global Perspective. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 256-259.	1.8	0
4094	Surrogate Markers: The Role of Positron Emission Tomography Scanning. , 2013, , 275-296.		0
4095	Cancer recurrence, peri-operative interventions and anaesthesia: Review of current evidence. Sri Lankan Journal of Anaesthesiology, 2012, 20, 68.	0.2	0
4096	Curative treatment in a patient with gastric cancer stage IV: a case report. F1000Research, 2012, 1, 34.	0.8	0
4098	Genetics of Esophageal Cancer. , 2013, , 382-394.		0
4099	A Multidisciplinary Approach to the Treatment of Gastric Cancer: What Is the Role of the Surgeon?. Journal of Cancer Therapy, 2013, 04, 16-26.	0.1	0
4100	Using Genomic Biomarkers to Predict Patient Prognosis and Treatment Response in Gastric Cancer. , 2013, , 105-136.		1
4101	OPRT Is a Potential Predictive Factor for the Response to S-1 in Gastric Cancer. Journal of Cancer Therapy, 2013, 04, 104-111.	0.1	0
4102	Multimodality Treatment for Potentially Resectable Esophageal Cancer. , 2013, , 451-461.		0
4103	Gastro-Oesophageal Cancer. , 2013, 03, .		0
4105	Surgical Management of Advanced Gastric Cancer. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2013, 13, 138.	0.1	1
4106	Magenkarzinom. , 2013, , 619-627.		0
4107	Neoadjuvant Chemotherapy for Esophageal Squamous Cell Carcinoma. Japanese Journal of Gastroenterological Surgery, 2013, 46, 877-884.	0.0	0
4108	Ã–sophaguskarzinom und Karzinom des gastroÃ¶sophagealen Ãœberganges. , 2013, , 593-618.		0
4111	New treatments for gastric cancer: are they changing clinical practice?. Clinical Practice (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	0.1	2
4113	Upper GI Surgery. , 2013, , 319-334.		0

#	Article	IF	Citations
4114	Maagcarcinoom. , 2014, , 219-230.		0
4115	Polymorphisms in Genes of Drug Targets and Metabolism. Cancer Drug Discovery and Development, 2014, , 289-332.	0.2	0
4117	Experiences of multidisciplinary gastric cancer treatment at the National Cancer Center, Korea. Korean Journal of Clinical Oncology, 2013, 9, 71-75.	0.1	1
4118	Three Cases of Advanced Gastric Cancer Confirmed as pathological Complete Response following Neoadjuvant Chemotherapy and Gastric Resection. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	1
4119	Cancer of the Esophagus. , 2014, , 1207-1239.e7.		0
4121	Neoadjuvant chemotherapy in the combined treatment of gastric cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2014, 3, 13.	0.0	3
4122	Cancer of the Stomach and Gastroesophageal Junction. , 2014, , 1240-1270.e7.		1
4123	Esophageal Cancer: Neoadjuvant and Adjuvant Therapy. , 2014, , 227-240.		0
4124	Preoperative Chemo Versus Chemoradiotherapy for Regionally Advanced Esophageal Adenocarcinoma. Difficult Decisions in Surgery: an Evidence-based Approach, 2014, , 287-299.	0.0	0
4125	Current Status of Immunotherapy in Gastroesophageal Cancer. , 2014, , 179-191.		0
4127	Medical Practice Variations in Cancer Surgery. , 2014, , 1-21.		0
4128	Neoadjuvant chemotherapy in localized resectable stomach cancer. Korean Journal of Clinical Oncology, 2014, 10, 1-5.	0.1	0
4131	Standards for Surgical Therapy of Gastric Cancer. , 2015, , 73-91.		0
4132	Multimodality Therapy in Gastric Cancer. , 2015, , 105-117.		0
4134	Oesophageal Cancer. , 2015, , 219-252.		0
4135	Targeted Therapy and Novel Agents for the Treatment of Gastric Cancer: A View Toward the Future. , 2015, , 317-330.		0
4137	Comparison of Different Methods of Multislice Spiral Computed Tomography for the Preoperative Gastric Cancer Staging. Surgical Science, 2015, 06, 427-435.	0.1	3
4138	Current approaches to treating locally advanced and resectable gastric cancer. Onkologiya Zhurnal Imeni P A Gertsena, 2015, 4, 52.	0.0	1

#	Article	IF	Citations
4139	Gastric Cancer: Molecular Mechanisms, Diagnosis, and Treatment. , 2015, , 229-261.		0
4140	The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. , 2015, , 203-220.		0
4141	Intravenous Fluorouracil versus Oral Capecitabine: Postoperative Chemoradiation for Gastric Cancer. Journal of Cancer Therapy, 2015, 06, 954-962.	0.1	0
4143	Perioperative Chemotherapie: Magen- und Ã–sophaguskarzinom. , 2015, , 1-3.		0
4144	BÃ¶sartige Ã–sophagustumoren â€“ internistische Therapie. , 2015, , 1-7.		0
4145	Evidence-Based Treatment for 1 Case with Advanced Gastric Cancer Patients. Asian Case Reports in Oncology, 2015, 04, 20-25.	0.0	0
4146	Analysis of surgically treated gastric cancers: a tertiary hospital experience in Turkey. Ä°stanbul Kuzey Klinikleri, 2015, 2, 101-106.	0.1	1
4147	E28 Literaturhinweise und Internetadressen. , 2015, , e1-e79.		0
4148	Malignome des Gastrointestinaltrakts. , 2015, , 579-693.		0
4149	Karzinome des Magens und Ã¶sophagogastralen Ãœbergangs. , 2015, , 1-11.		0
4150	Gastric cancer and complications of relapsed disease. , 2015, , 89-98.		0
4151	Oesophageal cancer and dysphagia. , 2015, , 77-88.		0
4152	Correlation between CD34 Marker and Clinico-Pathologic Characteristics of Gastric Cancer. International Journal of Cancer Research, 2015, 11, 136-142.	0.2	0
4153	Surgical management of gastric cancer: Single center experience from a developing country. South Asian Journal of Cancer, 2015, 04, 127-129.	0.2	0
4154	Multimodality Management of Esophageal Malignancies beyond Endoscopy. , 2015, , 199-240.		0
4158	Original Article: Prognostic Factors of Recurrence Pattern, Survival and Toxicity in Patients with Gastric Cancer Treated According to Protocol INT-0116 with 3D-Conformal Radiotherapy. SOJ Surgery, 2015, 2, 1-6.	0.0	0
4159	Peritoneal Dissemination of Gastrointestinal Tumors. , 2016, , 1-41.		1
4161	A Case of Adenocarcinoma of the Esophagogastric Junction with Esophageal Intramural Metastases Effectively Treated with Preoperative Chemotherapy. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan) Tj ETQq1 1 0.784314 rgBT /Ov		

#	Article	IF	Citations
4162	Gastric and Small Bowel Tumors. Cancer Treatment and Research, 2016, 168, 1-16.	0.2	2
4163	Gastric Cancer Among Asian Americans. , 2016, , 249-269.		1
4164	â€œMagicâ€•of our gastric cancer results on perioperative chemotherapy. World Journal of Gastrointestinal Pathophysiology, 2016, 7, 283.	0.5	0
4165	Gastric Adenocarcinoma. , 2016, , 137-148.		0
4166	Chirurgie des Magenkarzinoms bei alten Patienten. , 2016, , 145-154.		0
4167	Phase II study of docetaxel, cisplatin and capecitabine as preoperative chemotherapy in resectable gastric cancer. World Journal of Gastrointestinal Surgery, 2016, 8, 706.	0.8	2
4168	Diagnostik und Therapie des Magenkarzinoms. , 2016, , 43-53.		0
4169	Gastroesophageal Cancer: Prognostic Factors and Treatment Results. Journal of Cancer Science and Clinical Oncology, 2016, 3, .	0.0	0
4170	Ã–sophagus, Magen und Duodenum. , 2017, , 1-23.		0
4171	Focused update on Gastrointestinal (GI) Oncology from ASCO 2016. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 314-318.	0.1	0
4172	The Influence of Neoadjuvant Chemotherapy with Docetaxel, Nedaplatin and 5-Fluorouracil After Esophagectomy. Anticancer Research, 2016, 36, 6165-6172.	0.5	0
4173	Pathologic Complete Response After Preoperative Chemotherapy With a Regimen Containing Trastuzumab in Esophagogastric Junction Adenocarcinoma: A Case Report. International Surgery, 2021, 105, 152-156.	0.0	0
4174	Distal Gastrectomy (Open). Journal of Medical Insight, 0, , .	1.0	0
4175	Minimally Invasive Esophageal Resection. , 2017, , 53-58.		0
4176	Perioperative radioonkologische Verfahren des Magen- und Kardiakarzinoms. , 2017, , 85-90.		0
4177	Signet Ring Carcinoma in EGJ: What Is It?. , 2017, , 163-169.		0
4178	Gastric Cancer: Background and Clinical Evidence. , 2017, , 53-58.		0
4179	Neoadjuvant Treatment of Gastric Cancer. , 2017, , 149-157.		0

#	Article	IF	Citations
4180	Molecular Markers in the Prediction of Response to Neoadjuvant Treatments in Esophagogastric Junction Adenocarcinoma. , 2017, , 85-94.		0
4181	How to Treat EGJ Cancer: Indications and Treatment Strategy. , 2017, , 117-137.		0
4182	Gastric Adenocarcinoma Treatment in Africa: Surgery Alone or Perioperative Chemotherapy?. Journal of Cancer Therapy, 2017, 08, 653-662.	0.1	0
4183	Perioperative Systemtherapie bei Magen- und Kardiakarzinom. , 2017, , 79-84.		0
4184	Resektionsverfahren bei Magenkarzinom und AEG. , 2017, , 91-100.		0
4185	The staged treatment of locally advanced stomach cancer complicated by relapsing hemorrhage under conditions of the multi-speciality hospital. Russian Journal of Evidence-Based Gastroenterology, 2017, 6, 78.	0.3	0
4186	Histopathologie des Magen- und Kardiakarzinoms. , 2017, , 11-20.		0
4187	Maagcarcinoom. , 2017, , 333-342.		0
4188	Customized Chemotherapy in Advanced Gastric Cancer. , 2017, , 45-59.		0
4189	The relation between postoperative surgical complications and gastric cancer survival. Annals of Cancer Research and Therapy, 2017, 25, 88-89.	0.1	0
4190	Short Term Outcomes of Laparoscopic versus Open Distal Gastrectomy with D2 Lymph Nodes Dissection for Gastric Cancer: A Prospective Study. Surgical Science, 2017, 08, 334-347.	0.1	0
4191	Open or Minimally Invasive Esophagectomy After Neoadjuvant Therapy. , 2017, , 49-57.		0
4193	Gastric Cancer in the Elderly. , 2017, , 1-26.		0
4194	Esophageal Cancer: Background and Clinical Evidence. , 2017, , 23-38.		0
4195	Magenkarzinom beim alten und geriatrischen Patienten. , 2017, , 1-8.		0
4196	Neoadjuvant Treatment of Esophageal and Gastro-Esophageal Cancer. , 2017, , 33-42.		0
4197	Chemotherapy in Oesophagogastric Junctional Cancer. , 2017, , 139-148.		0
4199	Body composition indices and tissue loss in patients with resectable gastric adenocarcinoma. JCSM Clinical Reports, 2017, 2, .	0.5	0

#	Article	IF	Citations
4200	Neoadjuvant Chemoradiotherapy for Stage II or III Esophageal Squamous Cell Carcinoma. Anticancer Research, 2017, 37, 3301-3306.	0.5	1
4201	Phase I Study of Neoadjuvant Chemotherapy with Capecitabine and Oxaliplatin for Locally Advanced Gastric Cancer. Anticancer Research, 2017, 37, 3703-3710.	0.5	3
4205	Polish Consensus on Treatment of Gastric Cancer; update 2017. Polski Przeglad Chirurgiczny, 2017, 89, 59-73.	0.2	2
4206	The challenges of delivering care to a non-English speaking patient, with a rare sarcomatoid gastric cancer. Cancer Nursing Practice, 2017, 16, 31-36.	0.2	0
4207	Esophageal Cancer in the Elderly. , 2018, , 1-11.		0
4208	Gastric cancer with high risk of intraperitoneal progression: clinical course and current treatments. Current Issues in Pharmacy and Medical Sciences, 2017, 30, 190-194.	0.1	0
4210	Perioperative Treatment in Gastric Cancerâ€"Developments in Patient Selection. Journal of Cancer Therapy, 2018, 09, 101-105.	0.1	1
4211	Neoadjuvant and Adjuvant Therapy. , 2018, , 55-63.		0
4212	Indikation von CRS und HIPEC beim peritoneal metastasierten Magenkarzinom. , 2018, , 195-207.		0
4213	Induktive prÃoperative Chemotherapie bei peritonealen Metastasen von Tumoren des oberen GI-Trakts. , 2018, , 63-71.		0
4214	Improved Survival after Implementation of Multidisciplinary Team Meetings, Perioperative Chemotherapy, Extended Lymphnode Dissection and Laparoscopic Surgery in the Treatment of Advanced Gastric Cancer. Journal of Cancer Therapy, 2018, 09, 106-117.	0.1	0
4215	Magentumoren. , 2018, , 215-253.		0
4216	BÃ¶sartige Ã–sophagustumoren â€“ internistische Therapie. , 2018, , 285-290.		0
4217	Total Gastrectomy. , 2018, , 209-218.		0
4218	Magenkarzinom beim alten und geriatrischen Patienten. , 2018, , 325-332.		0
4219	Preoperative Conformal Radiotherapy Concurrently with Paclitaxel/Carboplatin in Gastric Cancer. Journal of Cancer Therapy, 2018, 09, 503-515.	0.1	1
4220	Chemotherapy versus chemoradiotherapy following surgery and neoadjuvant chemotherapy for resectable gastric cancer (CRITICS): an editorial. Digestive Medicine Research, 0, 1, 12-12.	0.2	1
4221	The Role of Radiation Therapy. , 2018, , 57-64.		0

#	Article	IF	Citations
4222	Ã–sophaguskarzinom inkl. Karzinome des gastroÃ¶sophagealen Ãœbergangs. Evidenzbasierte Chirurgie, 2018, , 35-63.	0.0	0
4223	The Role of Chemotherapy. , 2018, , 65-75.		0
4224	Estimation of Risk of Normal-tissue Toxicity Following Gastric Cancer Radiotherapy with Photon- or Scanned Proton-beams. Anticancer Research, 2018, 38, 2619-2625.	0.5	7
4225	CHEMOTHERAPY IN ELDERLY PATIENTS WITH STOMACH CANCER. Malignant Tumours, 2018, 8, 64-75.	0.1	2
4226	Human epidermal growth factor 2 status in gastric adenocarcinoma. Egyptian Journal of Pathology, 2018, 38, 126-130.	0.0	0
4227	ANALYSIS OF HEMATOLOGIC, HEPATIC AND PANCREATIC TOXICITY DURING NEOADJUVANT CHEMORADIOTHERAPY IN PATIENTS WITH LOCALLY ADVANCED GASTRIC CANCER. Siberian Journal of Oncology, 2018, 17, 20-27.	0.1	2
4228	PrÃ©habilitationâ€“rÃ©habilitation : pour qui ? comment ?. Colon and Rectum, 2018, 12, 145-152.	0.0	0
4229	Are all centers able to offer an adequate carcinological treatment for gastric carcinoma?. International Clinical Pathology Journal, 2018, 6, .	0.1	0
4230	Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy?. World Journal of Gastrointestinal Oncology, 2018, 10, 271-281.	0.8	2
4231	Oesophagogastric Surgery. , 2018, , .		0
4232	EBV Positive Gastric Carcinomas and Their Clinicopathological Characteristics. Open Access Macedonian Journal of Medical Sciences, 2018, 6, 1829-1832.	0.1	1
4233	Supervivencia y complicaciones en pacientes con cÃ¡ncer gÃ¡strico y de la uniÃ³n gastroesofÃ¡gica tratados con quimioterapia perioperatoria mÃ¡s cirugÃa comparada con cirugÃa mÃ¡s terapia adyuvante: estudio multicÃ©ntrico, BogotÃ¡ D.C., 2010-2017. Revista Colombiana De Cirugia, 2018, 33, 353-361.	0.2	2
4235	Improving Clinical Trial Design in Gastrointestinal Oncology. , 2019, , 493-507.		0
4236	Literatur zu Giordano/Wenz: Strahlentherapie kompakt, 3. Auflage. , 2019, , e.1-e.39.		0
4237	Advances in Radiation Therapy for Gastrointestinal Cancers. , 2019, , 421-443.		0
4238	Esophageal and Gastroesophageal Junction Tumors. , 2019, , 55-71.		1
4240	Ã–sophaguskarzinom. , 2019, , 69-76.		0
4242	Gastrointestinal System Cancers. , 2019, , 197-268.		0

#	Article	IF	Citations
4243	NEOADJUVANT TREATMENT OF THE LOCALLY ADVANCED COLON CANCER (REVIEW). Voprosy Onkologii, 2019, 65, 63-68.	0.1	0
4244	The Prognostic Role of Pre-operative Positron Emission Tomography-Computed Tomography and Endoscopic Ultrasound Parameters in Oesophageal Adenocarcinoma. Chirurgia (Romania), 2019, 114, 443.	0.2	1
4245	Clinical Aspect: Chemo- and/or Radiation Therapy and Micrometastasis. , 2019, , 237-248.		0
4246	Preoperative treatment of locally advanced gastrointenstinal cancer. , 2019, 10, 71-82.	0.0	0
4247	Magenkarzinom. , 2019, , 77-80.		0
4248	Multimodality Therapy in the Management of Locally Advanced Esophageal Cancer. , 2019, , 391-404.		0
4249	Treatment in resectable non-metastatic adenocarcinoma of stomach: Changing paradigms. Indian Journal of Cancer, 2019, 56, 74.	0.2	2
4250	The Relationship between Pulmonary Function Testing Including Cardiopulmonary Exercise Testing (CPET) and Outcomes in Patients with Oesophagogastric Cancer Undergoing Neo-adjuvant Chemotherapy. Annals of the College of Medicine Mosul, 2019, 41, 43-51.	0.0	0
4251	Kolon Kanserlerinde BilgisayarlÄ± Tomografinin Lenf Nodu Tespitindeki RolÃ¼. Bozok TÄ±p Dergisi, 0, , .	0.0	1
4253	Fever of Undetermined Origin During Neoadjuvant Chemoradiotherapy of Gastroesophageal Junction Adenocarcinoma Due to Radiation-induced Liver Disease. Cureus, 2019, 11, e5803.	0.2	0
4254	Single nucleotide polymorphisms as the new predictors of therapy decisions in gastroesophageal junction and gastric adenocarcinoma?. Translational Cancer Research, 2019, 8, 1656-1658.	0.4	0
4255	Magnetic-resonance imaging in diagnostics of esophageal cancer (literature review). Medical Visualization, 2019, , 28-43.	0.1	1
4256	Role of Perioperative Chemotherapy in Lymph Node-negative Esophageal Cancer After Resection. American Journal of Clinical Oncology: Cancer Clinical Trials, 2019, 42, 924-931.	0.6	4
4259	Principles of Radiation Therapy. , 2020, , 199-220.		0
4260	FLOaTing toward new standards in locally advanced resectable gastroesophageal cancer. Journal of Thoracic Disease, 2019, 11, 5694-5700.	0.6	1
4261	MICROSATELLITE INSTABILITY AND GASTRIC CARCINOMA. REVIEW OF THELITERATURE. , 2019, 18, 17-24.	0.3	1
4262	The Multidisciplinary Management of Early Distal Esophageal and Gastroesophageal Junction Cancer. , 2020, , 251-273.		0
4263	T-Staging and Target Volume Definition by Imaging in GI Tumors. Medical Radiology, 2020, , 203-220.	0.0	0

#	Article	IF	Citations
4264	Gastric Adenocarcinoma. , 2020, , 199-223.		0
4265	Impact of interval timing to surgery on tumor response after neoadjuvant treatment for gastric cancer. Revista Espanola De Enfermedades Digestivas, 2020, 112, 598-604.	0.1	12
4268	Gastric Cardia Adenocarcinoma with Metastasis to the Scalp: A Case Report. Cureus, 2020, 12, e6781.	0.2	2
4269	Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience, 2020, 14, 1020.	0.6	4
4270	A retrospective study comparing D1 limited lymph node dissection and D2 extended lymph node dissection for N3 gastric cancer. Translational Cancer Research, 2020, 9, 2259-2266.	0.4	1
4271	Contrast-enhanced swallow study sensitivity for detecting esophagojejunostomy leakage. Revista De GastroenterologÃa De MÃ©xico (English Edition), 2020, 85, 118-122.	0.1	0
4273	Nomogram for predicting pathological complete response to neoadjuvant chemotherapy in patients with advanced gastric cancer. World Journal of Gastroenterology, 2020, 26, 2426-2438.	1.4	0
4274	Perioperative chemotherapy for advanced gastric cancer - results from a tertiary-care hospital in Germany. World Journal of Gastrointestinal Oncology, 2020, 12, 559-568.	0.8	3
4276	Meta-analysis of prognostic factors of overall survival in patients undergoing oesophagectomy for oesophageal cancer. Ecological Management and Restoration, 2020, 33, .	0.2	9
4277	Positive lymph node ratio as a novel indicator of prognosis in gastric signet ring cell carcinoma: a population-based retrospective study. Translational Cancer Research, 2020, 9, 3658-3668.	0.4	3
4278	Nasojejunal Feeding Is Safe and Effective Alternative to Feeding Jejunostomy for Postoperative Enteral Nutrition in Gastric Cancer Patients. South Asian Journal of Cancer, 2020, 9, 070-073.	0.2	2
4281	Advanced Gastric Carcinoma in Southern Odisha- A Prospective Study. Journal of Evidence Based Medicine and Healthcare, 2020, 7, 1154-1157.	0.0	0
4282	Robot-assisted minimally invasive esophagectomy: systematic review on surgical and oncological outcomes. Mini-invasive Surgery, 0, , .	0.2	1
4283	A multinational review: Oesophageal cancer in low to middleâ€'income countries (Review). Oncology Letters, 2020, 20, 42.	0.8	9
4284	Gastroesophageal Junction Cancer. , 0, , .		0
4285	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. American Journal of Surgery, 2022, 223, 1055-1062.	0.9	5
4286	Adjuvant SOX chemotherapy versus concurrent chemoradiotherapy after D2 radical resection of locally advanced esophagogastric junction (EGJ) adenocarcinoma: study protocol for a randomized phase III trial (ARTEG). Trials, 2021, 22, 753.	0.7	1
4287	Comparison of efficacy and safety between pembrolizumab combined with chemotherapy and simple chemotherapy in neoadjuvant therapy for esophageal squamous cell carcinoma. Journal of Gastrointestinal Oncology, 2021, 12, 2013-2021.	0.6	23

#	Article	IF	Citations
4288	Lymph node ratio-based the ypTNrM staging system for gastric cancer after neoadjuvant therapy: a large population-based study. Surgery Today, 2022, 52, 783-794.	0.7	4
4289	Multimodal Prehabilitation During Neoadjuvant Therapy Prior to Esophagogastric Cancer Resection: Effect on Cardiopulmonary Exercise Test Performance, Muscle Mass and Quality of Lifeâ€"A Pilot Randomized Clinical Trial. Annals of Surgical Oncology, 2022, 29, 1839-1850.	0.7	40
4290	Enhanced Recovery After Surgery: Recommendations for Esophagectomy. , 2020, , 385-394.		2
4291	The Efficacy Analysis in the Treatment of Advanced Gastric Cancer with Neoadjuvant Chemotherapy. Advances in Clinical Medicine, 2020, 10, 1376-1382.	0.0	0
4292	Transcriptomic biomarkers for predicting response to neoadjuvant treatment in oesophageal cancer. Gastroenterology Report, 2020, 8, 411-424.	0.6	4
4293	Peritoneal Lavage Cytology Following Neoadjuvant Chemotherapy for Gastric Adenocarcinoma: Low Yield in Detecting Peritoneal Metastases. American Surgeon, 2020, , 000313482098486.	0.4	1
4294	The modern management of Barrettâ€™s oesophagus and related neoplasia: role of pathology. Histopathology, 2021, 78, 18-38.	1.6	4
4295	Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Annals of Translational Medicine, 2020, 8, 1684-1684.	0.7	8
4296	Radiotherapy Combined with Chemotherapy for Regional Lymph Node Recurrence in Gastric Cancer. Cancer Management and Research, 2020, Volume 12, 13339-13346.	0.9	1
4297	ypT0 gastric carcinoma after preoperative chemotherapy: a unique status according to AJCC 8th edition cancer staging system. Translational Cancer Research, 2020, 9, 7384-7393.	0.4	1
4298	Impact of surgical resection rate on survival in gastric cancer: nationwide study. BJS Open, 2021, 5, .	0.7	3
4299	Does age affect oesophagectomy survival: a cohort study. ANZ Journal of Surgery, 2021, 91, E14-E19.	0.3	3
4300	ERKRANKUNGEN DER VERDAUUNGSORGANE. , 2020, , pA-1-pA7.8-14.		0
4302	Phase II Study of Preoperative Intra-Arterial Epirubicin, Etoposide, and Oxaliplatin Combined with Oral S-1 Chemotherapy for the Treatment of Borrmann Type 4 Gastric Cancer. Journal of Gastric Cancer, 2020, 20, 395.	0.9	5
4303	Gastric Cancer in the Elderly. , 2020, , 931-956.		0
4306	Esophageal Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2020, 1296, 103-116.	0.8	2
4307	Neoadjuvant chemotherapy-induced severe neutropenia is associated with histopathological response and survival in locally advanced gastric cancer. Translational Cancer Research, 2020, 9, 280-293.	0.4	0
4308	Esophageal Cancer in the Elderly. , 2020, , 957-966.		0

#	Article	IF	Citations
4309	CONVERSION SURGERY FOR STAGE IV GASTRIC CANCER. LITERATURE REVIEW AND OWN EXPERIENCE. Voprosy Onkologii, 2020, 66, 50-57.	0.1	1
4310	Management of Gastric Outlet Obstruction in a Patient With Gastric Cancer. Journal of the Advanced Practitioner in Oncology, 2020, 11, 111-112.	0.2	0
4311	Systemic Treatment of Gastroesophageal Cancer during SARS-CoV2. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 141-143.	0.1	0
4312	Survival Benefit of Neoadjuvant Chemotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction. Cancer Diagnosis & Prognosis, 2021, 1, 185-191.	0.3	0
4313	Factors Associated with Worse Outcome in Early Stage Gastric Cancer Using the Surveillance, Epidemiology, and End Results (SEER) Database. Cureus, 2020, 12, e7360.	0.2	0
4314	Bidirectional chemotherapy combining intraperitoneal docetaxel with intravenous 5-fluorouracil and oxaliplatin for patients with unresectable peritoneal metastasis from gastric cancer: the first study in Western countries. Pleura and Peritoneum, 2020, 5, 20190035.	0.5	1
4315	Navigating Nodal Metrics for Node-Positive Gastric Cancer in the United States: An NCDB-Based Study and Validation of AJCC Guidelines. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 86-97.	2.3	7
4316	State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer. Biologics: Targets and Therapy, 2021, Volume 15, 451-462.	3.0	2
4317	American Society of Clinical Oncology 2021 Annual Meeting Highlights for Radiation Oncologists. Advances in Radiation Oncology, 2022, 7, 100779.	0.6	1
4318	Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis. EClinicalMedicine, 2021, 42, 101183.	3.2	17
4320	Biomarker analysis to predict the pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer: An exploratory biomarker study of COMPASS, a randomized phase II trial. Oncotarget, 2020, 11, 2906-2918.	0.8	4
4321	The efficacy and adverse reactions of DCF and FOLFOXs regimens for patients with advanced gastric cancer in China: a meta-analysis. Translational Cancer Research, 2020, 9, 4279-4289.	0.4	0
4322	Molecular Targets in Gastric Cancer and Apoptosis. , 2009, , 157-192.		2
4323	Magenkarzinom. , 0, , 679-691.		0
4324	Medical Oncology. , 2008, , 528-780.		0
4326	Diagnosis of Barrettâ€™s Carcinoma: Role of Diagnostic Imaging. , 2021, , 135-150.		0
4328	Outcome of Locally Advanced Esophageal Cancer Patients Treated With Perioperative Chemotherapy and Chemoradiotherapy Followed by Surgery. American Journal of Clinical Oncology: Cancer Clinical Trials, 2021, 44, 10-17.	0.6	3
4329	Comparative effectiveness of treatment modalities in non-metastatic gastric adenocarcinoma: a propensity score matching analysis of the National Cancer Database. BMJ Open Gastroenterology, 2020, 7, e000483.	1.1	1

#	Article	IF	Citations
4330	Prognostic factors for survival among gastric cancer patients receiving neoadjuvant chemotherapy: A cross sectional study from Turkey. Journal of Surgery and Medicine, 2020, 4, 1073-1076.	0.0	0
4331	SURGICAL MANAGEMENT OF ADENOCARCINOMA OF ESOPHAGOGASTRIC JUNCTION - A TERTIARY CARE CENTRE EXPERIENCE IN SOUTH INDIA. , 2020, , 1-4.		0
4332	Perioperative treatment for locally advanced gastric cancer. Onkologie (Czech Republic), 2020, 14, 240-245.	0.0	0
4333	â€œMÄ°DE KANSERÄ°NDE ADJUVAN KEMORADYOTERAPÄ°: TEK MERKEZ DENEYÄ°MÄ°. NamÄ±k Kemal TÄ±p Dergisi, 2020, , .	0.0	0
4334	Does Neoadjuvant Chemotherapy Increase the Survival in Patients with Locally Advanced Gastric Cancer Patients? â€“ A Realâ€World Evidence. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 832-840.	0.1	0
4335	Management of Locally Advanced Esophageal Cancer. Surgical Oncology Clinics of North America, 2020, 29, 631-646.	0.6	3
4336	Siewert III Adenocarcinoma. Surgical Oncology Clinics of North America, 2020, 29, 647-653.	0.6	0
4337	Intra-tumoral heterogeneity and immune responses predicts prognosis of gastric cancer. Aging, 2020, 12, 24333-24344.	1.4	7
4338	EUS of the Stomach and Duodenum. , 0, , 83-97.		2
4339	Neoadjuvant chemo-radiotherapy for locally advanced esophageal cancer: a monocentric study. Tumori, 2012, 98, 451-7.	0.6	6
4340	Unanswered Questions in the Management of Gastroesophageal Junction Adenocarcinoma: An Overview from the Medical Oncologist's Perspective. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, e155-e159.	1.8	1
4341	Usefulness of combined PET/CT to assess regional lymph node involvement in gastric cancer. Tumori, 2014, 100, 201-6.	0.6	17
4342	Latest developments and emerging treatment options in the management of stomach cancer. Cancer Management and Research, 2011, 3, 257.	0.9	15
4343	Reflections on adjuvant treatment of gastric cancer. Therapeutics and Clinical Risk Management, 2007, 3, 563-7.	0.9	2
4344	A cost-effectiveness analysis of adjuvant chemoradiotherapy for resected gastric cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, 57-63.	0.8	10
4345	Esophageal cancer chemotherapy: recent advances. Gastrointestinal Cancer Research: GCR, 2008, 2, 85-92.	0.8	58
4346	The Quality of Quality-of-Life and Cost-Effectiveness Analyses. Gastrointestinal Cancer Research: GCR, 2008, 2, 94-5.	0.8	0
4347	Adjuvant and preoperative therapy for localized gastric cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 139-45.	0.8	2

#	Article	IF	Citations
4348	We have entered a new era of adjuvant/neoadjuvant therapy for gastric cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 156-7.	0.8	2
4349	Outcomes after surgery for esophageal cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, 188-96.	0.8	34
4350	Treatment of esophageal cancer: does surgery make the cut?. Gastrointestinal Cancer Research: GCR, 2007, 1, 207-8.	0.8	0
4351	At the crossroads in the management of gastroesophageal junction carcinomas-where do we go from here?. Gastrointestinal Cancer Research: GCR, 2008, 2, 253-5.	0.8	3
4352	Crossroads in the combined-modality management of gastroesophageal junction carcinomas. Gastrointestinal Cancer Research: GCR, 2008, 2, 235-43.	0.8	4
4353	Biological imaging in the assessment of neoadjuvant treatment response in esophageal cancer: a new era?. Gastrointestinal Cancer Research: GCR, 2008, 2, 296-7.	0.8	0
4354	The Value of PET Imaging in Patients with Localized Gastroesophageal Cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, 287-94.	0.8	16
4355	Thromboembolism in gastrointestinal cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, 267-72.	0.8	6
4356	Global perspectives on chemotherapy for patients with gastric carcinoma: a roundtable discussion. Gastrointestinal Cancer Research: GCR, 2007, 1, 107-14.	0.8	0
4357	Current status and future of chemotherapy and biochemotherapy in gastroesophageal cancers. Gastrointestinal Cancer Research: GCR, 2008, 2, 187-97.	0.8	7
4358	Section II: Current Approaches to Treating Localized Gastrointestinal Cancers. Gastrointestinal Cancer Research: GCR, 2007, 1, S4-7.	0.8	1
4359	Section IV: Significance of Recent Study Results and Future Research Directions in Gastrointestinal Oncology. Gastrointestinal Cancer Research: GCR, 2007, 1, S13-6.	0.8	0
4360	The role of adjuvant radiation therapy in nonmetastatic gastric cancer: an evolving paradigm. Gastrointestinal Cancer Research: GCR, 2009, 3, 33-5.	0.8	2
4361	Preoperative therapy for potentially resectable localized gastric cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, 36-7.	0.8	0
4362	Gastric cancer in Turkey-a bridge between west and East. Gastrointestinal Cancer Research: GCR, 2009, 3, 29-32.	0.8	13
4363	Is radiation therapy needed in the treatment of gastroesophageal junction adenocarcinoma?. Gastrointestinal Cancer Research: GCR, 2008, 2, S2-5.	0.8	4
4364	Diverse eastern and Western approaches to the management of gastric cancer. Gastrointestinal Cancer Research: GCR, 2007, 1, S10-5.	0.8	7
4365	Evolution of preoperative and postoperative therapies in the management of localized gastroesophageal cancers. Gastrointestinal Cancer Research: GCR, 2007, 1, S4-9.	0.8	0

#	Article	IF	Citations
4366	Gastroesophageal cancer: understanding the disease process and advancing therapy. Gastrointestinal Cancer Research: GCR, 2007, 1, S1-3.	0.8	0
4367	Accomplishments in 2007 in the management of localized gastric cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S42-6.	0.8	1
4368	Particle radiation therapy for gastrointestinal malignancies. Gastrointestinal Cancer Research: GCR, 2007, 1, S50-9.	0.8	1
4369	In pursuit of progress: multimodality strategies will form the cornerstone of cure for esophageal cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, 74-6.	0.8	0
4370	Localized gastric or gastroesophageal cancer - chemoradiation is a pertinent component of adjuvant treatment for patients at high risk of relapse. Gastrointestinal Cancer Research: GCR, 2009, 3, S26-32.	0.8	2
4371	Localized gastric cancer: chemoradiation is not always needed. Gastrointestinal Cancer Research: GCR, 2009, 3, S22-5.	0.8	3
4372	Accomplishments in 2008 in the management of localized gastric cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S48-52.	0.8	1
4373	Accomplishments in 2008 in the management of esophageal cancer. Gastrointestinal Cancer Research: GCR, 2009, 3, S53-7.	0.8	3
4374	Stomach cancer. Clinical Evidence, 2008, 2008, .	0.2	0
4375	A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?. Gastrointestinal Cancer Research: GCR, 2009, 3, 233-8.	0.8	4
4376	Stomach cancer. Clinical Evidence, 2011, 2011, .	0.2	0
4377	The role of taxanes in the management of gastroesphageal cancer. Journal of Gastrointestinal Oncology, 2011, 2, 240-9.	0.6	19
4378	Adjuvant therapy in esophagogastric adenocarcinoma: controversies and consensus. Gastrointestinal Cancer Research: GCR, 2012, 5, 85-92.	0.8	5
4379	Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296). Gastrointestinal Cancer Research: GCR, 2012, 5, 191-7.	0.8	2
4380	Adjuvant and neoadjuvant therapy for gastric cancer: taking stock of the options. Gastrointestinal Cancer Research: GCR, 2012, 5, 203-4.	0.8	1
4381	Comparing Efficacy of Preoperative neo-Adjuvant Chemotherapy and Surgery versus Surgery Alone in Patients with Resectable Gastroesophageal Cancer. International Journal of Hematology-Oncology and Stem Cell Research, 2013, 7, 24-8.	0.3	5
4382	The outcomes of esophageal and gastric cancer treatments in a retrospective study, single center experience. International Journal of Hematology-Oncology and Stem Cell Research, 2014, 8, 9-13.	0.3	3
4383	Gastric cancer: toward a cisplatin-free disease?. Journal of Gastrointestinal Oncology, 2014, 5, 318-22.	0.6	2

#	Article	IF	Citations
4384	The Phase 2 Study of "(TOX) Preoperative Chemotherapy" Response Rate and Side Effects in [Locally Advanced Operable Gastric Adenocarcinoma] Patients With Docetaxel, Oxaliplatin and Capcitabine. Iranian Journal of Cancer Prevention, 2013, 6, 133-40.	0.7	1
4385	Benefit of Adjuvant Chemoradiotherapy for Gastric Adenocarcinoma: A SEER Population Analysis. Gastrointestinal Cancer Research: GCR, 2014, 7, 82-90.	0.8	18
4386	Saudi Oncology Society clinical management guideline series. Gastric cancer 2014. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1529-33.	0.5	2
4387	Saudi Oncology Society clinical management guideline series. Esophageal cancer 2014. Journal of King Abdulaziz University, Islamic Economics, 2014, 35, 1545-9.	0.5	0
4388	Radiotherapy patterns of care in gastric adenocarcinoma: a single institution experience. Journal of Gastrointestinal Oncology, 2015, 6, 247-53.	0.6	2
4389	Management of primary gastric small cell carcinoma in China. International Journal of Clinical and Experimental Medicine, 2015, 8, 1589-97.	1.3	8
4390	Vascular invasion as an independent predictor of poor prognosis in nonmetastatic gastric cancer after curative resection. International Journal of Clinical and Experimental Pathology, 2015, 8, 3910-8.	0.5	17
4391	A clinical exploration of neoadjuvant chemotherapy with tegafur, gimeracil, and oteracil potassium capsules combined with oxaliplatin for advanced gastric cancer. International Journal of Clinical and Experimental Medicine, 2015, 8, 19030-6.	1.3	3
4392	Single centre outcomes from definitive chemo-radiotherapy and single modality radiotherapy for locally advanced oesophageal cancer. Journal of Gastrointestinal Oncology, 2016, 7, 166-72.	0.6	1
4393	The relationship between pathologic nodal disease and residual tumor viability after induction chemotherapy in patients with locally advanced esophageal adenocarcinoma receiving a tri-modality regimen. Journal of Gastrointestinal Oncology, 2016, 7, 196-205.	0.6	4
4394	HER2 Expression Status and Prognostic, Diagnostic, and Demographic Properties of Patients with Gastric Cancer: a Single Center Cohort Study from Iran. Asian Pacific Journal of Cancer Prevention, 2018, 19, 1721-1725.	0.5	3
4395	Clinical, Histological and Prognosis Correlations in Diagnosis and Treatment of Gastric Cancer. Current Health Sciences Journal, 2016, 42, 238-256.	0.2	0
4396	Comparison the Incidence and Severity of Side Effects Profile Of FOLFOX and DCF Regimens in Gastric Cancer Patients. Iranian Journal of Pharmaceutical Research, 2019, 18, 1032-1039.	0.3	5
4397	Survival of gastric cancer patients based on pathologic and demographic characteristics in Mazandaran between 2007 and 2013. Gastroenterology and Hepatology From Bed To Bench, 2019, 12, 315-321.	0.6	0
4398	Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study. BMJ Open, 2020, 10, e039574.	0.8	1
4399	Impact of the 8th edition of the AJCC TNM classification on gastric cancer prognosis-study of a western cohort. Ecancermedicalscience, 2020, 14, 1124.	0.6	1
4400	Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
4401	Variability in multimodality treatment influences survival in non-metastatic gastric cancer patients. Journal of Gastrointestinal Oncology, 2020, 11, 952-963.	0.6	0

#	Article	IF	Citations
4402	Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. Ecancermedicalscience, 2020, 14, 1137.	0.6	0
4403	The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2723-2731.	0.5	0
4404	Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer. American Journal of Translational Research (discontinued), 2021, 13, 1568-1579.	0.0	0
4405	Efficacy and safety of neoadjuvant chemoradiotherapy plus apatinib for patients with locally advanced, HER2-negative, Siewert's type II-III adenocarcinoma of esophagogastric junction: a single-arm, open-label, phase II trial. American Journal of Translational Research (discontinued), 2021, 13, 9015-9023.	0.0	0
4406	Magenkarzinom. , 2022, , 259-267.		0
4407	Ã–sophaguskarzinom. , 2022, , 252-258.		0
4408	Costunolide-Induced Apoptosis via Promoting the Reactive Oxygen Species and Inhibiting AKT/GSK3Î² Pathway and Activating Autophagy in Gastric Cancer. Frontiers in Cell and Developmental Biology, 2021, 9, 722734.	1.8	8
4409	Elevated expression of NFE2L3 promotes the development of gastric cancer through epithelial-mesenchymal transformation. Bioengineered, 2021, 12, 12204-12214.	1.4	6
4410	Influence of correction of nutritive deficiency on the effectiveness of neoadjuvant chemotherapy in patients with locally advanced gastric cancer. Journal of Modern Oncology, 2021, 23, 519-524.	0.1	4
4411	Neoadjuvant/Perioperative Treatment Affects Spatial Distribution and Densities of Tumor Associated Neutrophils and CD8+ Lymphocytes in Gastric Cancer. Journal of Personalized Medicine, 2021, 11, 1184.	1.1	4
4412	Association of Preoperative Chemosensitivity With Postoperative Survival in Patients With Resected Gastric Adenocarcinoma. JAMA Network Open, 2021, 4, e2135340.	2.8	8
4414	Comparison of Eastâ€Asia and Westâ€Europe cohorts explains disparities in survival outcomes and highlights predictive biomarkers of early gastric cancer aggressiveness. International Journal of Cancer, 2022, 150, 868-880.	2.3	6
4415	Diagnostic Performance of Artificial Intelligence-Centred Systems in the Diagnosis and Postoperative Surveillance of Upper Gastrointestinal Malignancies Using Computed Tomography Imaging: A Systematic Review and Meta-Analysis of Diagnostic Accuracy. Annals of Surgical Oncology, 2022, 29, 1977-1990.	0.7	14
4416	Characterization of Total RNA, CD44, FASN, and PTEN mRNAs from Extracellular Vesicles as Biomarkers in Gastric Cancer Patients. Cancers, 2021, 13, 5975.	1.7	6
4417	Trends in Distal Esophageal and Gastroesophageal Junction Cancer Care. Annals of Surgery, 2023, 277, 619-628.	2.1	5
4418	Distinct Differences in Gastroesophageal Junction and Gastric Adenocarcinoma in 2194 Patients. Annals of Surgery, 2023, 277, 629-636.	2.1	4
4419	Impact of chemotherapy and radiotherapy on the survival of elderly esophageal cancer patients undergoing surgery: a SEER database analysis. BMC Gastroenterology, 2021, 21, 430.	0.8	4
4420	International variation in oesophageal and gastric cancer survival 2012â€“2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study). Gut, 2021, , gutjnl-2021-325266.	6.1	10

#	Article	IF	Citations
4421	Health-Related Quality of Life in Locally Advanced Gastric Cancer: A Systematic Review. Cancers, 2021, 13, 5934.	1.7	9
4422	Symptomatic Recurrence and Survival Outcomes After Curative Treatment of Gastric Cancer: Does Intensive Follow-up Evaluation Improve Survival?. Annals of Surgical Oncology, 2022, 29, 274-284.	0.7	7
4423	Predictive and Prognostic Value of an MicroRNA Signature for Gastric Carcinoma Undergoing Adjuvant Chemotherapy. DNA and Cell Biology, 2021, 40, 1428-1444.	0.9	1
4424	LncRNA NR038975, A Serum-Based Biomarker, Promotes Gastric Tumorigenesis by Interacting With NF90/NF45 Complex. Frontiers in Oncology, 2021, 11, 721604.	1.3	8
4425	miR-4295 Promotes the Malignant Progression of Gastric Cancer via Targeting PTEN. Combinatorial Chemistry and High Throughput Screening, 2022, 25, 1897-1906.	0.6	2
4426	Novel Biomarkers of Gastric Adenocarcinoma: Current Research and Future Perspectives. Cancers, 2021, 13, 5660.	1.7	16
4427	Application of Gross Tissue Response System in Gastric Cancer After Neoadjuvant Chemotherapy: A Primary Report of a Prospective Cohort Study. Frontiers in Oncology, 2021, 11, 585006.	1.3	3
4428	Comparison of 4 lymph node staging systems for the prognostic prediction of esophagogastric junction adenocarcinoma with â‰¥15 retrieved lymph nodes. European Journal of Surgical Oncology, 2021, , .	0.5	3
4429	Radiomics signature based on computed tomography images for the preoperative prediction of lymph node metastasis at individual stations in gastric cancer: A multicenter study. Radiotherapy and Oncology, 2021, 165, 179-190.	0.3	9
4431	Magenkarzinom: Neue molekulare Konzepte. , 0, , .		3
4432	A case of successful extended combined gastrectomy for locally advanced gastric cancer after a failed attempt of laparoscopic surgery. Onkologiya Zhurnal Imeni P A Gertsena, 2021, 10, 83.	0.0	0
4433	Economic costâ€“utility analysis of stage-directed gastric cancer treatment. BJS Open, 2021, 5, .	0.7	0
4434	Treatment Options for T1 Stage Adenocarcinoma of Esophagogastric Junction: A Real-World Retrospective Cohort Study. Cancer Control, 2021, 28, 107327482110639.	0.7	0
4435	PET/CT-tailored treatment of locally advanced oesophago-gastric junction adenocarcinoma: a report on the feasibility of the multicenter GastroPET study. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110651.	1.4	4
4436	Research Progress on the Effect of Body Composition Changes on Neoadjuvant Chemotherapy for Gastric Cancer. Advances in Clinical Medicine, 2021, 11, 5299-5303.	0.0	0
4437	Signaling pathways and their potential therapeutic utility in esophageal squamous cell carcinoma. Clinical and Translational Oncology, 2022, 24, 1014-1032.	1.2	8
4438	Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma. Oncologist, 2022, 27, e18-e28.	1.9	41
4439	Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives. World Journal of Gastrointestinal Oncology, 2022, 14, 181-202.	0.8	4

#	Article	IF	Citations
4440	Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer. Journal of Oncology, 2022, 2022, 1-9.	0.6	5
4441	Incidence and risk factors for postoperative pancreatic fistula in 2089 patients treated by radical gastrectomy: A prospective multicenter cohort study in China. International Journal of Surgery, 2022, 98, 106219.	1.1	6
4442	Oesophageal carcinoma: The prevalence of DNA tumour viruses and therapy. Tumour Virus Research, 2022, 13, 200231.	1.5	6
4443	Ã–sophaguskarzinom: Therapie ist hoch diversifiziert. , 0, , .		0
4444	Efficacy of conversion surgery on stage IV gastric cancer and its prognosis analysis. Panminerva Medica, 2020, , .	0.2	0
4445	The Effect of Obesity on Response to Neoadjuvant Therapy in Locally Advanced Gastric Cancer. Asian Pacific Journal of Cancer Prevention, 2020, 21, 2723-2731.	0.5	2
4446	Variability in multimodality treatment influences survival in non- metastatic gastric cancer patients. Journal of Gastrointestinal Oncology, 2020, 11, 952-963.	0.6	0
4447	Impact of the 8th edition of the AJCC TNM classification on gastric cancer prognosisâ€”study of a western cohort. Ecancermedicalscience, 2020, 14, 1124.	0.6	7
4448	Brazilian Group of Gastrointestinal Tumoursâ€™ consensus guidelines for the management of gastric cancer. Ecancermedicalscience, 2020, 14, 1126.	0.6	3
4449	Cohort profile: gastric cancer in the population-based, Finnish National Esophago-Gastric Cancer Cohort (FINEGO) Study. BMJ Open, 2020, 10, e039574.	0.8	6
4450	The Complexity of Defining Postoperative Pneumonia following Esophageal Cancer Surgery. Annals of Surgery, 2020, Publish Ahead of Print, .	2.1	5
4451	Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. Ecancermedicalscience, 2020, 14, 1137.	0.6	0
4452	Immunotherapy of Gastric Cancer: Focus on Perioperative Strategies. , 2021, , 59-73.		0
4453	Ã–sophaguskarzinom: Hybridtechnik verbessert die Prognose. , 0, , .		0
4454	A Novel Technique of 4K Laparoscopic Suprapancreatic Lymph Node Dissection After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer With Right Lateral Approach. SSRN Electronic Journal, 0, , .	0.4	0
4455	A Prognostic Nomogram and Heat Map to Predict Survival in Stage II/III Gastric Cancer Patients After Curative Gastrectomy Followed by Adjuvant Chemotherapy. Cancer Management and Research, 2022, Volume 14, 287-301.	0.9	4
4456	Optimising Multimodality Treatment of Resectable Oesophago-Gastric Adenocarcinoma. Cancers, 2022, 14, 586.	1.7	2
4457	Effect of perioperative FLOT versus ECF/ECX on short-term outcomes after surgery for resectable oesophagogastric adenocarcinoma: propensity score-matched study. BJS Open, 2022, 6, .	0.7	3

#	Article	IF	Citations
4458	Anatomic Subsites and Prognosis of Gastric Signet Ring Cell Carcinoma: A SEER Population-Based 1â€‰:â€‰1 Propensity-Matched Study. BioMed Research International, 2022, 2022, 1-18.	0.9	4
4459	Postoperative and Pathological Outcomes of CROSS and FLOT as Neoadjuvant Therapy for Esophageal and Junctional Adenocarcinoma. Annals of Surgery, 2023, 277, e1026-e1034.	2.1	15
4460	Significance of Lymph Node Metastasis in the Treatment of Gastric Cancer and Current Challenges in Determining the Extent of Metastasis. Frontiers in Oncology, 2021, 11, 806162.	1.3	19
4461	OUP accepted manuscript. Oncologist, 2022, 27, 251-e304.	1.9	1
4462	A Practical Nomogram for Predicting the Prognosis of Elderly Patients with Gastric Adenocarcinoma After Gastrectomy. International Journal of General Medicine, 2022, Volume 15, 473-488.	0.8	1
4463	Pathological complete response after neoadjuvant chemotherapy with FOLFOX for locally advanced sigmoid colon cancer with diverticulitis: A case report. International Journal of Surgery Case Reports, 2022, 90, 106685.	0.2	0
4464	Pharmaceutical advances in the treatment of gastric adenocarcinoma. Expert Opinion on Pharmacotherapy, 2022, , 1-11.	0.9	0
4465	Black race is independently associated with underutilization of preoperative chemotherapy in clinical stage T2 or higher gastric adenocarcinoma. Surgery, 2022, 171, 1562-1569.	1.0	1
4466	Diagnostic Value of Endoscopic Ultrasound after Neoadjuvant Chemotherapy for Gastric Cancer Restaging: A Meta-Analysis of Diagnostic Test. Diagnostics, 2022, 12, 100.	1.3	0
4467	Visceral obesity with and without metabolic syndrome: incidence and clinical impact in esophageal adenocarcinoma treated with curative intent. Ecological Management and Restoration, 2022, , .	0.2	4
4468	Superiority of Laparoscopic Gastrojejunostomy Combined With Multimodality Therapy for Gastric Outlet Obstruction Caused by Advanced Gastric Cancer. Frontiers in Oncology, 2022, 12, 814283.	1.3	2
4469	Risk Assessment and Preventive Treatment for Peritoneal Recurrence Following Radical Resection for Gastric Cancer. Frontiers in Oncology, 2021, 11, 778152.	1.3	2
4470	Gastric cancer cell death analyzed by live cell imaging of spheroids. Scientific Reports, 2022, 12, 1488.	1.6	15
4471	Modern Management of Esophageal Cancer: Radio-Oncology in Neoadjuvancy, Adjuvancy and Palliation. Cancers, 2022, 14, 431.	1.7	7
4472	Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial. British Journal of Sports Medicine, 2022, 56, 402-409.	3.1	25
4473	Adjuvant Chemotherapy Might Be Recommended to Patients With Positive Margin After Gastrectomy: A 20-Year Retrospective Analysis in a Single Center. Frontiers in Oncology, 2021, 11, 794032.	1.3	1
4474	Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?. Critical Reviews in Oncology/Hematology, 2022, 170, 103597.	2.0	19
4475	Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma â€“ A comparison of the FLOT and â€˜MAGICâ€™ regimens. European Journal of Cancer, 2022, 163, 180-188.	1.3	8

#	Article	IF	Citations
4476	Effect of perioperative probiotic supplements on postoperative short-term outcomes in gastric cancer patients receiving neoadjuvant chemotherapy: A double-blind, randomized controlled trial. Nutrition, 2022, 96, 111574.	1.1	9
4478	Esophageal cancer: emerging therapeutics. Expert Opinion on Therapeutic Targets, 2022, 26, 107-117.	1.5	51
4479	Multimodal treatment in oligometastatic gastric cancer. World Journal of Gastrointestinal Oncology, 2022, 14, 434-449.	0.8	8
4480	Response to neoadjuvant chemotherapy and survival in molecular subtypes of resectable gastric cancer: a post hoc analysis of the D1/D2 and CRITICS trials. Gastric Cancer, 2022, 25, 640-651.	2.7	10
4481	Neoadjuvant chemotherapy with liposomal paclitaxel plus platinum for locally advanced esophageal squamous cell cancer: Results from a retrospective study. Thoracic Cancer, 2022, , .	0.8	6
4482	The effect of preoperative body mass index on short-term outcome after esophagectomy for cancer: A nationwide propensity scoreâ€“matched analysis. Surgery, 2022, 172, 137-144.	1.0	5
4483	Multicenter randomised trial of two versus three courses of preoperative cisplatin and fluorouracil plus docetaxel for locally advanced oesophageal squamous cell carcinoma. British Journal of Cancer, 2022, 126, 1555-1562.	2.9	13
4484	Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 193-202.	2.3	4
4485	Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis. BMC Cancer, 2021, 21, 1328.	1.1	6
4488	Gastric adenocarcinoma peritoneal carcinomatosis: a narrative review. Digestive Medicine Research, 0, .	0.2	2
4489	The treatment of resectable gastric cancer: a literature review of an evolving landscape. Journal of Gastrointestinal Oncology, 2022, 13, 871-884.	0.6	3
4491	A Comprehensive and Comparative Review of Global Gastric Cancer Treatment Guidelines. Journal of Gastric Cancer, 2022, 22, 3.	0.9	34
4492	Magen â€“ Duodenum. , 2022, , 161-192.		0
4493	Does the Computed Tomography Hounsfield Units Change Predict Response to Perioperative Chemotherapy in Patients with Gastric Adenocarcinoma. Journal of Cancer, 2022, 13, 1449-1455.	1.2	1
4494	Indication of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer (Gastripec, Gastrichip). Visceral Medicine, 2022, 38, 81-89.	0.5	4
4496	Nutritional Status Indicators Affecting the Tolerability of Postoperative Chemotherapy After Total Gastrectomy in Patients With Gastric Cancer. Journal of Gastric Cancer, 2022, 22, 56.	0.9	2
4497	Neurological complications of GI cancers. , 2022, , 365-386.		0
4499	Predicting Response to Neoadjuvant Therapy in Oesophageal Adenocarcinoma. Cancers, 2022, 14, 996.	1.7	3

#	Article	IF	Citations
4500	Effect of Shengbai Decoction on Chemotherapy-Induced Myelosuppression and Survival of Gastric Cancer Patients After Radical Resection: A Retrospective Study. Medical Science Monitor, 2022, 28, e935936.	0.5	0
4501	(Neo)Adjuvant Treatment of Locally Advanced Esophageal and Gastroesophageal Adenocarcinoma: Special Focus on Sex Differences. Cancers, 2022, 14, 1088.	1.7	4
4502	ASO Perspectives: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer: Never Stop Questioning. Annals of Surgical Oncology, 2022, 29, 2735-2738.	0.7	2
4503	Laparoscopic vs open total gastrectomy for advanced gastric cancer following neoadjuvant therapy: A propensity score matching analysis. World Journal of Gastrointestinal Surgery, 2022, 14, 161-173.	0.8	4
4504	The Use of miRNAs in Predicting Response to Neoadjuvant Therapy in Oesophageal Cancer. Cancers, 2022, 14, 1171.	1.7	3
4505	â€œImpact of neoadjuvant therapy followed by laparoscopic radical gastrectomy with D2 lymph node dissection in Western population: A multiâ€institutional propensity score matched studyâ€â€”Authors' reply. Journal of Surgical Oncology, 2022, 125, 1338-1339.	0.8	0
4506	Effect of S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Plus Oxaliplatin as Perioperative Chemotherapy for Locally Advanced, Resectable Gastric Cancer. JAMA Network Open, 2022, 5, e220426.	2.8	11
4507	Completion of FLOT Therapy, Regardless of Tumor Regression, Significantly Improves Overall Survival in Patients with Esophageal Adenocarcinoma. Cancers, 2022, 14, 1084.	1.7	3
4508	Prophylactic hyperthermic intraperitoneal chemotherapy may benefit the long-term survival of patients after radical gastric cancer surgery. Scientific Reports, 2022, 12, 2583.	1.6	9
4509	CT-Based Radiomics Showing Generalization to Predict Tumor Regression Grade for Advanced Gastric Cancer Treated With Neoadjuvant Chemotherapy. Frontiers in Oncology, 2022, 12, 758863.	1.3	7
4510	Mismatch repair deficiency, chemotherapy and survival for resectable gastric cancer: an observational study from the German staR cohort and a meta-analysis. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1007-1017.	1.2	6
4512	Medical Oncology or Surgical Oncology: Which Branch Should Be Started in Esophageal Cancer Diagnostic Evaluation?. Cureus, 2022, 14, e22286.	0.2	1
4513	Clinical significance of molecular subtypes of gastrointestinal tract adenocarcinoma. World Journal of Gastrointestinal Oncology, 2022, 14, 628-645.	0.8	6
4514	Neoadjuvant therapy combined with surgery is superior to chemoradiotherapy in esophageal squamous cell cancer patients with resectable supraclavicular lymph node metastasis: a propensity score-matched analysis. Annals of Translational Medicine, 2022, 10, 349-349.	0.7	0
4515	Efficacy of immunonutritional supplement after neoadjuvant chemotherapy in patients with esophageal cancer. Journal of Cardiothoracic Surgery, 2022, 17, 41.	0.4	1
4516	Expression of Neighbor of Punc E11 (NOPE) in early stage esophageal adenocarcinoma is associated with reduced survival. Scientific Reports, 2022, 12, 3584.	1.6	0
4517	Quality performance indicators for the surgical treatment of gastric adenocarcinoma: a systematic review. ANZ Journal of Surgery, 2022, 92, 1995-2002.	0.3	2
4518	A population-based study on treatment and outcomes in patients with gastric adenocarcinoma diagnosed with distant interval metastases. European Journal of Surgical Oncology, 2022, 48, 1964-1971.	0.5	3

#	Article	IF	Citations
4519	Quality of Life Is Associated With Survival in Patients With Gastric Cancer: Results From the Randomized CRITICS Trial. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 261-267.	2.3	7
4520	Current treatments and outlook in adenocarcinoma of the esophagogastric junction: a narrative review. Annals of Translational Medicine, 2022, 10, 377-377.	0.7	6
4521	Systemic therapy for gastric cancer: Perioperative strategies and beyond. Journal of Surgical Oncology, 2022, 125, 1151-1160.	0.8	10
4522	Neoadjuvant Treatment Strategies for Resectable Proximal Gastric, Gastroesophageal Junction and Distal Esophageal Cancer. Cancers, 2022, 14, 1755.	1.7	2
4523	Localized stomach cancer: Perioperative or postoperative approach? A metaâ€analysis of phase III studies. JGH Open, 2022, 6, 236-240.	0.7	0
4524	Short-term efficacy and toxicity of total neoadjuvant chemotherapy in patients with resectable gastric cancer. Siberian Journal of Oncology, 2022, 21, 11-19.	0.1	4
4525	Surgical and perioperative treatment strategy for resectable esophagogastric junction cancer. Japanese Journal of Clinical Oncology, 2022, 52, 417-424.	0.6	6
4526	Gastric and gastroesophageal junction cancer: Risk factors and prophylactic treatments for prevention of peritoneal recurrence after curative intent surgery. Annals of Gastroenterological Surgery, 0, , .	1.2	1
4527	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. Gastric Cancer, 2022, 25, 619-628.	2.7	18
4528	Surgical Management of Gastric Cancer. JAMA Surgery, 2022, 157, 446.	2.2	73
4529	Surgical Efficacy and Safety of Patients with Locally Advanced Gastric Cancer following Neoadjuvant Concurrent Chemoradiotherapy and Chemotherapy. Journal of Oncology, 2022, 2022, 1-6.	0.6	4
4530	Accuracy of preoperative staging of gastric stump cancer. Japanese Journal of Clinical Oncology, 2022, , .	0.6	0
4531	The iGreenGO Study: The Clinical Role of Indocyanine Green Imaging Fluorescence in Modifying the Surgeonâ€™s Conduct During the Surgical Treatment of Advanced Gastric Cancerâ€”Study Protocol for an International Multicenter Prospective Study. Frontiers in Oncology, 2022, 12, 854754.	1.3	4
4532	Interspatial Distribution of Tumor and Immune Cells in Correlation with PD-L1 in Molecular Subtypes of Gastric Cancers. Cancers, 2022, 14, 1736.	1.7	4
4533	Evolution of treatment in gastric cancer- a systematic review. Journal of the Egyptian National Cancer Institute, 2022, 34, 12.	0.6	5
4534	An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian Journal of Cancer, 0, , .	0.2	1
4535	Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study. , 2022, 10, e003635.		42
4536	SEOM-GEMCAD-TTD Clinical Guideline for the diagnosis and treatment of esophageal cancer (2021). Clinical and Translational Oncology, 2022, 24, 658-669.	1.2	8

#	Article	IF	Citations
4537	Considerations and Challenges in the Management of the Older Patients with Gastric Cancer. Cancers, 2022, 14, 1587.	1.7	6
4538	Impact of Postoperative Chemotherapy in Patients with Gastric/Gastroesophageal Adenocarcinoma Treated with Perioperative Chemotherapy. Current Oncology, 2022, 29, 1983-1996.	0.9	0
4539	Assessment of the short-term outcomes of laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: A prospective single-armed clinical trial. Surgery, 2022, , .	1.0	1
4540	Transhiatal esophagectomy as a treatment for locally advanced adenocarcinoma of the gastroesophageal junction: postoperative and oncologic results of a single-center cohort. World Journal of Surgical Oncology, 2022, 20, 70.	0.8	2
4541	Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies. Journal of Cancer Research and Clinical Oncology, 2022, , 1.	1.2	2
4542	Effects of H2O2 Treatment Combined With PI3K Inhibitor and MEK Inhibitor in AGS Cells: Oxidative Stress Outcomes in a Model of Gastric Cancer. Frontiers in Oncology, 2022, 12, 860760.	1.3	3
4543	Laparoscopic vs. Open Gastrectomy for Locally Advanced Gastric Cancer: A Propensity Score-Matched Retrospective Case-Control Study. Current Oncology, 2022, 29, 1840-1865.	0.9	13
4544	Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study. EBioMedicine, 2022, 78, 103971.	2.7	8
4546	Evaluation of Event-Free Survival Surrogating Overall Survival as the Endpoint in Neoadjuvant Clinical Trials of Gastroesophageal Adenocarcinoma. Frontiers in Oncology, 2022, 12, 835389.	1.3	2
4547	Undifferentiated-predominant mixed-type early gastric cancer is more aggressive than pure undifferentiated type: a systematic review and meta-analysis. BMJ Open, 2022, 12, e054473.	0.8	4
4549	Supportive oncology care at home interventions: protocols for clinical trials to shift the paradigm of care for patients with cancer. BMC Cancer, 2022, 22, 383.	1.1	10
4550	Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. JAMA Network Open, 2022, 5, e225557.	2.8	15
4551	Role of Neoadjuvant Chemotherapy in Locally Advanced Carcinoma Stomach: An Analysis of the Short-Term Outcomes. Cureus, 2022, 14, e23936.	0.2	0
4552	Neoadjuvant Therapy for Locally Advanced Esophageal Cancers. Frontiers in Oncology, 2022, 12, 734581.	1.3	6
4553	International Tumor Budding Consensus Conference criteria determine the prognosis of oesophageal adenocarcinoma with poor response to neoadjuvant treatment. Pathology Research and Practice, 2022, 232, 153844.	1.0	2
4554	Metastasectomy or Stereotactic Body Radiation Therapy With or Without Systemic Therapy for Oligometastatic Esophagogastric Cancer. Annals of Surgical Oncology, 2022, 29, 4848-4857.	0.7	7
4555	Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial. BMC Medicine, 2022, 20, 107.	2.3	15
4556	Significance of neoadjuvant downstaging in gastric adenocarcinoma. Surgery, 2022, 172, 593-601.	1.0	7

#	Article	IF	Citations
4557	Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study. Frontiers in Oncology, 2022, 12, 853337.	1.3	1
4558	Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism. Free Radical Biology and Medicine, 2022, 184, 53-65.	1.3	17
4559	PD-1 and PD-L1 expression predict regression and prognosis following neoadjuvant radiochemotherapy of oesophageal adenocarcinoma. Clinical and Translational Radiation Oncology, 2022, 34, 90-98.	0.9	3
4560	The impact of performing gastric cancer surgery during holiday periods. A population-based study using Dutch upper gastrointestinal cancer audit (DUCA) data. Current Problems in Cancer, 2022, 46, 100850.	1.0	2
4561	Impact of postoperative chemotherapy on survival for oesophagogastric adenocarcinoma after preoperative chemotherapy and surgery. British Journal of Surgery, 2022, 109, 227-236.	0.1	9
4562	Transthoracic esophagectomy compared to transhiatal extended gastrectomy for adenocarcinoma of the esophagogastric junction: a multicenter retrospective cohort study. Ecological Management and Restoration, 2021, , .	0.2	5
4564	The jury is still out on peri-operative vs. adjuvant chemotherapy for distal gastric cancer. American Journal of Surgery, 2021, , .	0.9	1
4565	A novel robust nomogram based on preoperative hemoglobin and albumin levels and lymphocyte and platelet counts (HALP) for predicting lymph node metastasis of gastric cancer. Journal of Gastrointestinal Oncology, 2021, 12, 2706-2718.	0.6	10
4567	Gastric cancer: Russian clinical guidelines. Journal of Modern Oncology, 2021, 23, 541-571.	0.1	2
4568	A Comparison of Clinicopathologic Outcomes Across Neoadjuvant and Adjuvant Treatment Modalities in Resectable Gastric Cancer. JAMA Network Open, 2021, 4, e2138432.	2.8	8
4569	Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer. Seminars in Cancer Biology, 2022, 86, 566-582.	4.3	33
4570	Role sharing between minimally invasive oesophagectomy and organ preservation approach for surgically resectable advanced oesophageal cancer. Japanese Journal of Clinical Oncology, 2022, 52, 108-113.	0.6	2
4571	Surgical treatment of gastric adenocarcinoma: Are we achieving textbook oncologic outcomes for our patients?. Journal of Surgical Oncology, 2022, 125, 621-630.	0.8	9
4572	Impact of neoadjuvant chemotherapy on nodal regression and survival in oesophageal adenocarcinoma. European Journal of Surgical Oncology, 2022, 48, 1001-1010.	0.5	4
4573	Peripheral Cytokine Levels as a Prognostic Indicator in Gastric Cancer: A Review of Existing Literature. Biomedicines, 2021, 9, 1916.	1.4	6
4574	Perioperative FOLFOX in Patients With Locally Advanced Oesogastric Adenocarcinoma. Anticancer Research, 2022, 42, 185-193.	0.5	2
4575	Microsatellite instability in Chinese gastric cancer and its correlation with clinical characteristics. Journal of Gastrointestinal Oncology, 2021, 12, 2719-2727.	0.6	0
4576	Comparison of tumor regression grading systems for locally advanced gastric adenocarcinoma after neoadjuvant chemotherapy. World Journal of Gastrointestinal Oncology, 2021, 13, 2161-2179.	0.8	7

#	Article	IF	Citations
4577	Correlative Analysis Between Adverse Events of Preoperative Chemotherapy and Postoperative Complications of Gastric Cancer. Frontiers in Surgery, 2021, 8, 768243.	0.6	1
4579	Leptomeningeal carcinomatosis in gastric cancer: a case report of a rare yet aggressive entity. Archive of Clinical Cases, 2022, 9, 6-11.	0.1	2
4580	Efficacy of Different Number of XELOX or SOX Chemotherapy Cycles After D2 Resection for Stage III Gastric Cancer. Journal of Gastric Cancer, 2022, 22, 107.	0.9	3
4581	Evidence-based approach to the treatment of esophagogastric junction tumors. World Journal of Clinical Oncology, 2022, 13, 159-167.	0.9	2
4582	Outcome and prognostic factors in patients undergoing salvage therapy for recurrent esophagogastric cancer after multimodal treatment. Journal of Cancer Research and Clinical Oncology, 2023, 149, 1373-1382.	1.2	4
4584	Progress in neoadjuvant therapy for gastric cancer (Review). Oncology Letters, 2022, 23, 172.	0.8	2
4585	Can Clinical Response Predict Pathologic Response Following Neoadjuvant Chemoradiation for Esophageal Cancer?. Journal of Gastrointestinal Surgery, 2022, 26, 1345-1351.	0.9	2
4586	Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications. Current Cancer Drug Targets, 2022, 22, .	0.8	3
4587	Concurrent Chemoradiotherapy-Driven Cell Plasticity by miR-200 Family Implicates the Therapeutic Response of Esophageal Squamous Cell Carcinoma. International Journal of Molecular Sciences, 2022, 23, 4367.	1.8	2
4588	The role of chemotherapy in patients with stage IB gastric adenocarcinoma: a real-world competing risk analysis. World Journal of Surgical Oncology, 2022, 20, 123.	0.8	3
4589	Successful robotic proximal gastrectomy with side overlap esophagogastrostomy following preoperative chemotherapy: A case report. International Journal of Surgery Case Reports, 2022, 94, 107040.	0.2	0
4590	Early Return to Intended Oncologic Therapy after implementation of an Enhanced Recovery After Surgery pathway for gastric cancer surgery. Langenbeck's Archives of Surgery, 2022, 407, 2293-2300.	0.8	1
4591	The stomach. , 0, , 1853-1924.		0
4619	Cancer of the Oesophagus and Stomach. , 0, , 254-268.		0
4620	Adjuvant therapy following oesophagectomy for adenocarcinoma in patients with a positive resection margin. British Journal of Surgery, 2020, 107, 1801-1810.	0.1	3
4621	Adherence to guidelines at the patientâ€•and hospitalâ€levels is associated with improved overall survival in patients with gastric cancer. Journal of Surgical Oncology, 2022, 126, 479-489.	0.8	9
4623	Total neoadjuvant chemotherapy: a silver lining during the COVID pandemic for a patient with locally advanced diffuse distal gastric adenocarcinoma. Annals of the Royal College of Surgeons of England, 2022, 104, e197-e201.	0.3	0
4624	The impact of age on long-term survival following gastrectomy for gastric cancer. Annals of the Royal College of Surgeons of England, 2023, 105, 269-277.	0.3	1

#	Article	IF	Citations
4625	Is there still a place for conventional histopathology in the age of molecular medicine? LaurÃ©n classification, inflammatory infiltration and other current topics in gastric cancer diagnosis and prognosis. Histology and Histopathology, 2021, 36, 587-613.	0.5	8
4626	A sebÃ©szeti elvek vÃ¡ltozÃ¡sa a modern, hatÃ©kony, perioperatÃv onkolÃ³giai kezelÃ©sek kÃ¶vetkezmÃ©nyekÃ©nt. Orvosi Hetilap, 2022, 163, 544-550.	0.1	2
4627	Propensity-score-matching-based analysis of laparoscopic gastrectomy with neoadjuvant chemotherapy for gastric carcinoma.. , 2021, 7, 50-53.		1
4634	CROSS and beyond: a clinical perspective on the results of the randomized ChemoRadiotherapy for Oesophageal cancer followed by Surgery Study. Chinese Clinical Oncology, 2016, 5, 13.	0.4	4
4635	Endoscopic submucosal dissection for early esophagogastric junction adenocarcinomas: a systematic review. Annals of Gastroenterology, 2022, , .	0.4	0
4636	Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study. Diseases of the Colon and Rectum, 2023, 66, e996-e1005.	0.7	8
4637	Predictors of Metastatic Lymph Nodes at Preoperative Staging CT in Gastric Adenocarcinoma. Tomography, 2022, 8, 1196-1207.	0.8	1
4638	Tumor Microenvironment Characterization for Assessment of Recurrence and Survival Outcome in Gastric Cancer to Predict Chemotherapy and Immunotherapy Response. Frontiers in Immunology, 2022, 13, 890922.	2.2	6
4639	Usefulness of Surgical Staging of Gastric Cancer in Neoadjuvant Chemotherapy Candidates: A Single-center Retrospective Study. Anticancer Research, 2022, 42, 2719-2725.	0.5	0
4640	Exosomal Functional Cargoes from Liquid Biopsy of Gastric Cancer: A Systematic Review of Studies With Potential Clinical Relevance. Anticancer Research, 2022, 42, 2249-2259.	0.5	3
4641	Gastric Cancer: A review of risk factors and new insights into treatment. Current Cancer Therapy Reviews, 2022, 18, .	0.2	1
4642	Impact of Examined Lymph Node Count on Precise Staging and Long-term Survival After Neoadjuvant Therapy for Carcinoma of the Esophagus: A SEER Database Analysis. Frontiers in Surgery, 2022, 9, 864593.	0.6	0
4643	Improving the quality of gastric cancer surgery: factors associated with positive resection margins for gastrectomy. , 2022, 1, 1.		0
4644	Preoperative Concurrent Chemoradiotherapy Versus Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: Phase II Randomized Study. Frontiers in Oncology, 2022, 12, 870741.	1.3	4
4645	Neoadjuvant docetaxel, oxaliplatin and Sâ€‘1 (DOS) combination chemotherapy for patients with resectable adenocarcinoma of esophagogastric junction. Gastric Cancer, 2022, 25, 966-972.	2.7	9
4647	Body Composition Is a Predictor for Postoperative Complications After Gastrectomy for Gastric Cancer: a Prospective Side Study of the LOGICA Trial. Journal of Gastrointestinal Surgery, 2022, 26, 1373-1387.	0.9	7
4648	Patterns of Multimodality Management of Gastric Cancerâ€”Single Institutional Experience of 372 Cases From a Tertiary Care Center in North India. Frontiers in Oncology, 2022, 12, 877493.	1.3	1
4649	High Infiltration of CD68⁺/CD163^{â^'} Macrophages Is an Adverse Prognostic Factor after Neoadjuvant Chemotherapy in Esophageal and Gastric Adenocarcinoma. Journal of Innate Immunity, 2022, 14, 615-628.	1.8	8

#	Article	IF	Citations
4650	Analysis of Opioid Use in Patients Undergoing Open Versus Robotic Gastrectomy. Annals of Surgical Oncology, 2022, 29, 5861-5870.	0.7	5
4651	Intra-tumoral FGFR2 Expression Predicts Prognosis and Chemotherapy Response in Advanced HER2-positive Gastric Cancer Patients. Cancer Diagnosis & Prognosis, 2022, 2, 293-299.	0.3	1
4652	Salvage Surgery for Recurrent Disease after Definitive Chemoradiotherapy for Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2022, 29, 5657-5665.	0.7	1
4653	Approach to Resectable Gastric Cancer: Evolving Paradigm of Neoadjuvant and Adjuvant Treatment. Current Treatment Options in Oncology, 2022, 23, 1044-1058.	1.3	4
4654	Perioperative treatment in resectable gastric cancer with spartalizumab in combination with fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a phase II study (GASPAR). BMC Cancer, 2022, 22, 537.	1.1	14
4655	Comparison of neoadjuvant regimens for resectable gastroesophageal junction cancer: a systematic review of randomized clinical trials across three decades. Journal of Gastrointestinal Oncology, 2022, 13, 1454-1466.	0.6	3
4656	Modern surgical therapy for gastric cancerâ€"Robotics and beyond. Journal of Surgical Oncology, 2022, 125, 1142-1150.	0.8	0
4657	Current and future imaging modalities in gastric cancer. Journal of Surgical Oncology, 2022, 125, 1123-1134.	0.8	1
4659	Research Status of Neoadjuvant Therapy for Locally Advanced Gastric Cancer. Advances in Clinical Medicine, 2022, 12, 4028-4032.	0.0	0
4660	Outcomes of surgical treatment of non-metastatic gastric cancer in patients aged 70 and older: A systematic review and meta-analysis. European Journal of Surgical Oncology, 2022, 48, 1882-1894.	0.5	3
4661	Adverse impact of postoperative intra-abdominal infectious complications on cancer recurrence-related survival after curative gastric cancer surgery. American Journal of Surgery, 2022, , .	0.9	0
4662	Efficacy and Safety of Totally Laparoscopic Gastrectomy Compared with Laparoscopic-Assisted Gastrectomy in Gastric Cancer: A Propensity Score-Weighting Analysis. Frontiers in Surgery, 2022, 9, .	0.6	6
4663	The effect of histologic grade on neoadjuvant treatment outcomes in esophageal cancer. Journal of Surgical Oncology, 2022, , .	0.8	0
4664	Reciprocity between lymphadenectomy quality and adjuvant chemotherapy compliance in gastric cancer: post hoc analysis of two randomized controlled trials. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 8774-8783.	1.3	2
4665	Real life experience of patients with locally advanced gastric and gastroesophageal junction adenocarcinoma treated with neoadjuvant chemotherapy: a Turkish oncology group study. Journal of Chemotherapy, 2022, , 1-8.	0.7	0
4666	Impact of tumor-related factors and inter-institutional heterogeneity on preoperative T staging for gastric cancer. Future Oncology, 2022, 18, 2511-2519.	1.1	3
4667	Microsatellite instability and chemosensitivity in solid tumours. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210993.	1.4	8
4668	Short and long-term outcomes between laparoscopic and open total gastrectomy for advanced gastric cancer after neoadjuvant chemotherapy. World Journal of Gastrointestinal Surgery, 2022, 14, 452-469.	0.8	7

#	Article	IF	Citations
4669	A phase Ib feasibility trial of response adapted neoadjuvant therapy in gastric cancer (RANT-GC). Future Oncology, 0, , .	1.1	0
4670	Recent advances in treatment of breast cancers. Current Trends in Pharmacy and Pharmaceutical Chemistry, 2022, 4, 67-74.	0.1	0
4671	The quality of life in neoadjuvant versus adjuvant therapy of esophageal cancer treatment trial () Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6	0.8	2
4672	Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multi-Center Observational. SSRN Electronic Journal, 0, , .	0.4	0
4673	Todayâ€™s Mistakes and Tomorrowâ€™s Wisdom in the Surgical Treatment of Barrettâ€™s Adenocarcinoma. Visceral Medicine, 2022, 38, 203-211.	0.5	0
4674	Comparison of Four Lymph Node Staging Systems in Gastric Adenocarcinoma after Neoadjuvant Therapy â€“ A Population-Based Study. Frontiers in Surgery, 2022, 9, .	0.6	0
4675	Experience of Surgery for Advanced Gastric Cancer Performed after COVID-19 Infection. Japanese Journal of Gastroenterological Surgery, 2022, 55, 317-323.	0.0	1
4676	Tislelizumab combined with chemotherapy as neoadjuvant therapy for surgically resectable esophageal cancer: A prospective, single-arm, phase II study (TD-NICE). International Journal of Surgery, 2022, 103, 106680.	1.1	62
4677	Non-bacterial Thrombotic Endocarditis as a Rare Manifestation of Early Stage Gastric Cancer. Cureus, 2022, , .	0.2	1
4678	The Safety and Feasibility of Laparoscopic Gastrectomy after Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Journal of Oncology, 2022, 2022, 1-9.	0.6	2
4679	Safe drug therapy in clinical practice: experience of using microinfusion single-use mechanical systems in treatment of patients with malignant diseases of hematopoietic tissue and solid tumors. , 2022, 2, 51-62.		1
4680	Integration of Genomic Biology Into Therapeutic Strategies of Gastric Cancer Peritoneal Metastasis. Journal of Clinical Oncology, 2022, 40, 2830.	0.8	23
4681	Identification of hub pathways and drug candidates in gastric cancer through systems biology. Scientific Reports, 2022, 12, .	1.6	9
4682	Esophageal and gastric cancer. , 2023, , 349-357.		0
4683	Gastrointestinal Surgery. , 2022, , 97-135.		0
4684	Prognostic value and clinicopathological correlation of the tumor regression grade in neoadjuvant chemotherapy for gastric adenocarcinoma: a retrospective cohort study. Journal of Gastrointestinal Oncology, 2022, 13, 1046-1057.	0.6	6
4685	Treatment Model of Locally Advanced Esophageal Cancer. World Journal of Cancer Research, 2022, 12, 107-110.	0.1	0
4687	Central Line Associated Bloodstream Infection in Adult Intensive Care Unit Populationâ€”Changes in Epidemiology, Diagnosis, Prevention, and Addition of New Technologies. Advances in Infectious Diseases, 2022, 12, 252-280.	0.0	0

#	Article	IF	Citations
4688	Adjuvant Chemotherapy in Node-Negative Advanced Gastric Cancer Patients. Journal of Oncology, 2022, 2022, 1-7.	0.6	1
4689	Survival benefit of adjuvant chemotherapy following neoadjuvant therapy and oesophagectomy in oesophageal adenocarcinoma. European Journal of Surgical Oncology, 2022, , .	0.5	0
4690	Efficacy and Safety of Sintilimab in Combination with Concurrent Chemoradiotherapy for Locally Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (SHARED): Study Protocol of a Prospective, Multi-Center, Single-Arm Phase 2 Trial. Cancer Management and Research, 0, Volume 14, 2007-2015.	0.9	6
4691	Metastasis Related Epithelial-Mesenchymal Transition Signature Predicts Prognosis and Response to Immunotherapy in Gastric Cancer. Frontiers in Immunology, 0, 13, .	2.2	2
4692	Neoadjuvant Chemoradiotherapy for Locally Advanced Gastric Cancer: Where Are We at?. Cancers, 2022, 14, 3026.	1.7	8
4693	Effect of Chemoradiotherapy on the Survival of Resectable Gastric Cancer Patients: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 0, , .	0.7	1
4694	Postâ€neoadjuvant assessment of tumour budding according to <scp>ITBCC</scp> subgroups delivers stageâ€and <scp>regressionâ€grade</scp> independent prognostic information in intestinalâ€type gastric adenocarcinoma. Journal of Pathology: Clinical Research, 0, , .	1.3	4
4695	ASO Author Reflections: Chemoradiotherapy Versus Chemotherapy, Which One Is Better for Resectable Gastric Cancer Patients?. Annals of Surgical Oncology, 0, , .	0.7	0
4696	Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer. Annals of Surgical Oncology, 2022, 29, 5422-5431.	0.7	8
4697	The safety and efficacy of laparoscopic gastrectomy for patients with locally advanced gastric cancer following neoadjuvant chemotherapy. Scientific Reports, 2022, 12, .	1.6	3
4698	Nomograms for Predicting Disease-Free Survival in Patients With Siewert Type II/III Adenocarcinoma of the Esophagogastric Junction Receiving Neoadjuvant Therapy and Radical Surgery. Frontiers in Oncology, 0, 12, .	1.3	1
4699	Effects of Laparoscopic versus Open Surgery for Advanced Gastric Cancer after Neoadjuvant Chemotherapy: A Meta-Analysis. Journal of Healthcare Engineering, 2022, 2022, 1-10.	1.1	1
4700	Toripalimab combined with targeted therapy and chemotherapy achieves pathologic complete response in gastric carcinoma: A case report. World Journal of Clinical Cases, 2022, 10, 6184-6191.	0.3	1
4701	Triplet Chemotherapy with Cisplatin versus Oxaliplatin in the CRITICS Trial: Treatment Compliance, Toxicity, Outcomes and Quality of Life in Patients with Resectable Gastric Cancer. Cancers, 2022, 14, 2963.	1.7	0
4702	A neoadjuvans FLOT-terÃ¡pia hatÃ¡sa az elÅ‘rehaladott gyomor-cardia tumorok rÃ¶vid tÃ¡vÃº onkolÃ³giai Ã©s sebÃ©szi kezelÃ©s eredmÃ©nyeire. Magyar SebÃ©szet, 2022, 75, 142-150.	0.0	0
4703	Contrast-Enhanced Computed Tomographyâ€“Based Radiogenomics Analysis for Predicting Prognosis in Gastric Cancer. Frontiers in Oncology, 0, 12, .	1.3	4
4704	Survival trends of patients with nonâ€metastatic gastric adenocarcinoma in the US and European countries: the impact of decreasing resection rates. Cancer Communications, 2022, 42, 648-662.	3.7	7
4705	Lymph node metastases rate of locoregional and non-locoregional lymph node stations in gastric cancer. Journal of Gastrointestinal Oncology, 2022, 13, 1605-1615.	0.6	3

#	Article	IF	Citations
4706	Validation of the Memorial Sloan Kettering Gastric Cancer Post-Resection Survival Nomogram: Does It Stand the Test of Time?. Journal of the American College of Surgeons, 2022, 235, 294-304.	0.2	5
4707	Invited Commentary: Assessing Gastric and Gastroesophageal Junction Cancer Patient Prognosis in the Neoadjuvant Therapy Era. Journal of the American College of Surgeons, 2022, 235, 304-305.	0.2	0
4708	Survival of Locally Advanced MSI-high Gastric Cancer Patients Treated With Perioperative Chemotherapy. Annals of Surgery, 2023, 277, 798-805.	2.1	8
4709	Total hip arthroplasty for an intracapsular femoral neck fracture of high-femoral amputee. Archive of Clinical Cases, 2022, 9, 50-55.	0.1	0
4710	Efficacy and tolerability of fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in unselected patients with advanced gastric and gastroesophageal cancer: does age really matter?. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	2
4711	Prediction of Gastric Cancer-Related Genes Based on the Graph Transformer Network. Frontiers in Oncology, 0, 12, .	1.3	1
4712	Impact of mismatch repair deficiency on tumour regression grade after neoadjuvant chemotherapy in localized gastroesophageal adenocarcinoma. Digestive and Liver Disease, 2023, 55, 276-282.	0.4	1
4713	Learning Curve of Laparoscopic Gastrectomy: A Multicenter Study. Annals of Surgery, 2023, 277, e808-e816.	2.1	6
4714	Survival benefits from neoadjuvant treatment in gastric cancer: a systematic review and meta-analysis. Systematic Reviews, 2022, 11, .	2.5	2
4715	Identification of plasma proteins associated with oesophageal cancer chemotherapeutic treatment outcomes using SWATH-MS. Journal of Proteomics, 2022, 266, 104684.	1.2	1
4716	Role of prophylactic HIPEC in non-metastatic, serosa-invasive gastric cancer: a literature review. Pleura and Peritoneum, 2022, 7, 103-115.	0.5	2
4717	The Key Clinical Questions of Neoadjuvant Chemoradiotherapy for Resectable Esophageal Cancerâ€"A Review. Frontiers in Oncology, 0, 12, .	1.3	3
4718	Gastric hydrodistension CT versus CT without gastric distension in preoperative TN staging of gastric carcinoma: analysis of single-center cancer registry. Scientific Reports, 2022, 12, .	1.6	1
4719	Preoperative prediction of the pathological stage of advanced gastric cancer by 18F-fluoro-2-deoxyglucose positron emission tomography. Scientific Reports, 2022, 12, .	1.6	0
4720	Postoperative Nutrition Status of Patients With Esophago-gastric Junction Cancer With Gastric Tube or Esophago-gastric Reconstruction. Anticancer Research, 2022, 42, 3645-3652.	0.5	0
4721	The 8th Wonder of the Cancer World: Esophageal Cancer and Inflammation. Diseases (Basel,) Tj ETQq1 1 0.784314 rgBT /Overlock 10	1.6	6
4722	Treatment Response Predictors of Neoadjuvant Therapy for Locally Advanced Gastric Cancer: Current Status and Future Perspectives. Biomedicines, 2022, 10, 1614.	1.4	5
4723	Understanding the association between clinical staging accuracy, treatment response, and survival among gastric cancer patients through Bayesian analysis. Journal of Surgical Oncology, 0, , .	0.8	0

#	Article	IF	Citations
4724	Efficacy and safety of camrelizumab in combination with neoadjuvant chemotherapy for ESCC and its impact on esophagectomy. Frontiers in Immunology, 0, 13, .	2.2	15
4725	Preoperative Chemoradiation versus Chemotherapy in Locally Advanced Resectable Esophageal Cancer: A Retrospective Study. Asian Journal of Oncology, 0, , .	0.2	0
4726	Bombyx mori Cecropin D could trigger cancer cell apoptosis by interacting with mitochondrial cardiolipin. Biochimica Et Biophysica Acta - Biomembranes, 2022, 1864, 184003.	1.4	7
4727	Clinical Understaging, Treatment Response, and Survival Among Esophageal Adenocarcinoma Patients. Journal of Surgical Research, 2022, 279, 256-264.	0.8	0
4728	Role of Neoadjuvant therapy in the treatment of patients with colorectal liver metastases. , 2023, , 81-99.		0
4729	Gastric Carcinoma. , 2023, , 234-249.		0
4730	Gastric cancer: Environmental risk factors, treatment, and prevention. Ibnosina Journal of Medicine and Biomedical Sciences, 2020, 12, 162-168.	0.2	0
4731	Partial omentectomy maybe practicable for <scp>T3</scp> or shallower gastric cancer patients. Cancer Medicine, 0, , .	1.3	1
4732	Total neoadjuvant therapy for locally advanced gastric cancer and esophagogastric junction adenocarcinoma: study protocol for a prospective, multicenter, single-arm, phase II clinical trial. BMC Gastroenterology, 2022, 22, .	0.8	4
4733	CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma. Annals of Surgery, 2022, 276, 792-798.	2.1	15
4734	Recurrent Disease After Esophageal Cancer Surgery. Annals of Surgery, 2022, 276, 806-813.	2.1	8
4735	Immunotherapy in MSI/dMMR tumors in the perioperative setting: The IMHOTEP trial. Digestive and Liver Disease, 2022, 54, 1335-1341.	0.4	12
4736	New Approaches to Neoadjuvant Treatment for Locally Advanced Esophageal Cancer. Foregut, 2022, 2, 143-153.	0.3	0
4737	Identification of Src as a Therapeutic Target in Oesophageal Adenocarcinoma through Functional Genomic and High-Throughput Drug Screening Approaches. Cancers, 2022, 14, 3726.	1.7	1
4738	Oesophageal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 992-1004.	0.6	145
4739	Protein-bound polysaccharide K prolonged overall survival in gastric cancer patients from a non-Japanese Asian country who received gastrectomy and adjuvant chemotherapy. Medicine (United) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	2
4740	An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. Annals of Surgery, 2022, 276, 799-805.	2.1	15
4741	Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Annals of Oncology, 2022, 33, 1005-1020.	0.6	313

#	Article	IF	Citations
4742	Utility of PET Scans in the Diagnosis and Management of Gastrointestinal Tumors. Digestive Diseases and Sciences, 2022, 67, 4633-4653.	1.1	4
4743	Neoadjuvant treatment in gastric cancer. Memo - Magazine of European Medical Oncology, 0, , .	0.3	1
4744	Dynamic contrast-enhanced and diffusion-weighted MR imaging in early prediction of pathologic response to neoadjuvant chemotherapy in locally advanced gastric cancer. Abdominal Radiology, 2022, 47, 3394-3405.	1.0	6
4745	Efficacy of S-1 or Capecitabine Plus Oxaliplatin Adjuvant Chemotherapy for Stage II or III Gastric Cancer after Curative Gastrectomy: A Systematic Review and Meta-Analysis. Cancers, 2022, 14, 3940.	1.7	5
4746	Poorly cohesive cells gastric carcinoma including signet-ring cell cancer: Updated review of definition, classification and therapeutic management. World Journal of Gastrointestinal Oncology, 2022, 14, 1406-1428.	0.8	8
4747	American Radium Society (ARS) Appropriate Use Criteria (AUC) for Locoregional Gastric Adenocarcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 0, Publish Ahead of Print, .	0.6	0
4748	Neoadjuvant Nivolumab Plus Ipilimumab and Adjuvant Nivolumab in Localized Deficient Mismatch Repair/Microsatellite Instabilityâ€“High Gastric or Esophagogastric Junction Adenocarcinoma: The GERCOR NEONIPIGA Phase II Study. Journal of Clinical Oncology, 2023, 41, 255-265.	0.8	98
4750	A nomogram to predict survival probability of gastric cancer patients undergoing radical surgery and adjuvant chemotherapy. Frontiers in Oncology, 0, 12, .	1.3	4
4751	Enhanced CT-based radiomics predicts pathological complete response after neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction: a two-center study. Insights Into Imaging, 2022, 13, .	1.6	6
4752	Neoadjuvant chemoradiotherapy for resectable gastric cancer: A meta-analysis. Frontiers in Oncology, 0, 12, .	1.3	4
4753	Clinicopathological Features and Prognostic-Related Risk Factors of Gastric Signet Ring Cell Carcinoma: A Meta-Analysis. Computational and Mathematical Methods in Medicine, 2022, 2022, 1-11.	0.7	4
4754	Editorial: Surgical interventions in gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	0
4755	Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study. Gastric Cancer, 2022, 25, 1039-1049.	2.7	4
4756	Influence of postoperative complications following esophagectomy for cancer on quality of life: A European multicenter study. European Journal of Surgical Oncology, 2023, 49, 97-105.	0.5	4
4757	Absence of a weekday effect on short- and long-term oncologic outcomes of gastrectomy for gastric cancer: a propensity score matching analysis. BMC Surgery, 2022, 22, .	0.6	1
4758	Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instabilityâ€“High Gastric Cancer: A Case Series. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 857-865.	2.3	1
4759	Surgeonâ€™s Neoadjuvan Therapy Approach in Gastric Cancer. BezmiÃ¢lem Science, 2022, 10, 398-401.	0.1	0
4760	FLOT and CROSS chemotherapy regimens alter the frequency of CD27+ and CD69+ T cells in oesophagogastric adenocarcinomas: implications for combination with immunotherapy. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0

#	Article	IF	Citations
4761	Neoadjuvant and Adjuvant Therapy Approaches to Gastric Cancer. Current Treatment Options in Oncology, 2022, 23, 1247-1268.	1.3	19
4762	Efficacy and safety of sintilimab plus XELOX as a neoadjuvant regimen in patients with locally advanced gastric cancer: A single-arm, open-label, phase II trial. Frontiers in Oncology, 0, 12, .	1.3	13
4763	The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. Ca-A Cancer Journal for Clinicians, 2023, 73, 49-71.	157.7	23
4764	Lymph node ratio is a prospective prognostic indicator for locally advanced gastric cancer patients after neoadjuvant chemotherapy. World Journal of Surgical Oncology, 2022, 20, .	0.8	5
4765	Implementation of Multimodality Therapy and Minimally Invasive Surgery: Short- and Long-term Outcomes of Gastric Cancer Surgery in Medium-Volume Center. Journal of Gastrointestinal Surgery, 2022, 26, 2061-2069.	0.9	3
4766	Prognostic role of iodine values for gastric cancer after neoadjuvant chemotherapy: a strong independent prognostic factor. Diagnostic and Interventional Radiology, 2022, 28, 388-395.	0.7	2
4767	Apoptosis and autophagy markers predict survival in neoadjuvant treated oesophageal adenocarcinoma patients. BMC Cancer, 2022, 22, .	1.1	1
4768	Feature Review Papers on Gastroesophageal Junction and Gastric Cancers. Cancers, 2022, 14, 3979.	1.7	0
4769	A national advanced training program for laparoscopic radical gastrectomy has a positive impact on surgical trainees: A before and after study (ATP-LRG-1). International Journal of Surgery, 2022, 104, 106781.	1.1	0
4770	A feasibility trial of prehabilitation before oesophagogastric cancer surgery using a multi-component home-based exercise programme: the ChemoFit study. Pilot and Feasibility Studies, 2022, 8, .	0.5	4
4771	POF (paclitaxel/oxaliplatin/5-fluorouracil/leucovorin) vs. SOX/CAPOX/FOLFOX as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer: Study protocol for a randomized controlled trial, FNF-014 trial. Frontiers in Medicine, 0, 9, .	1.2	1
4772	Development and validation of a deep learning model to predict survival of patients with esophageal cancer. Frontiers in Oncology, 0, 12, .	1.3	8
4773	Nodal downstaging to ypN0 after neoadjuvant chemotherapy positively impacts on survival of cT4N+ GC/GEJ patients. Journal of Surgical Oncology, 2022, 126, 1403-1412.	0.8	4
4774	Cardiovascular disease related death among patients with esophagus cancer: A population-based competing risk analysis. Frontiers in Oncology, 0, 12, .	1.3	2
4775	Common strategies for effective immunotherapy of gastroesophageal cancers using immune checkpoint inhibitors. Pathology Research and Practice, 2022, 238, 154110.	1.0	1
4776	Short- and long-term outcomes of laparoscopic gastrectomy for locally advanced gastric cancer after preoperative chemotherapy: a single-center experience. Foregut Surgery, 2022, 2, 62.	0.0	0
4777	Viszeralchirurgie. , 2022, , 223-437.		0
4778	Gastric Cancer Invading the Pancreas: A Review of the Role of Pancreatectomy. In Vivo, 2022, 36, 2014-2019.	0.6	0

#	Article	IF	Citations
4779	Gastric Signet Ring Cell Carcinoma: An Overview. Journal of Medical & Radiation Oncology, 2022, 2, 8-16.	0.0	0
4780	The safety of neoadjuvant chemotherapy combined with non-tube nofasting fast-track surgery for esophageal carcinoma. Frontiers in Oncology, 0, 12, .	1.3	1
4781	Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?. Journal of Gastrointestinal Surgery, 2022, 26, 2050-2060.	0.9	3
4782	Fifty years of progress in gastric cancer. Journal of Surgical Oncology, 2022, 126, 865-871.	0.8	0
4783	Meta-Analysis of the Effects of Three-Dimensional Visualized Medical Techniques Hepatectomy for Liver Cancer with and without the Treatment of Sorafenib. Evidence-based Complementary and Alternative Medicine, 2022, 2022, 1-8.	0.5	0
4784	Real-time Tracking and Classification of Tumor and Nontumor Tissue in Upper Gastrointestinal Cancers Using Diffuse Reflectance Spectroscopy for Resection Margin Assessment. JAMA Surgery, 2022, 157, e223899.	2.2	9
4785	Optimizing the Choice for Adjuvant Chemotherapy in Gastric Cancer. Cancers, 2022, 14, 4670.	1.7	4
4786	ELEVATE â€“ evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: study protocol for a single arm phase II trial. BMC Cancer, 2022, 22, .	1.1	1
4787	Exploring factors influencing uptake and adherence to a home-based prehabilitation physical activity and exercise intervention for patients undergoing chemotherapy before major surgery (ChemoFit): a qualitative study. BMJ Open, 2022, 12, e062526.	0.8	7
4788	Versican enrichment predicts poor prognosis and response to adjuvant therapy and immunotherapy in gastric cancer. Frontiers in Immunology, 0, 13, .	2.2	4
4789	Clinicopathological and prognostic significance of SOX9 expression in gastric cancer patients: A meta-analysis. Medicine (United States), 2022, 101, e30533.	0.4	0
4790	Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study. BMC Cancer, 2022, 22, .	1.1	3
4791	Systemic Therapy Is Associated with Improved Oncologic Outcomes in Resectable Stage II/III Intrahepatic Cholangiocarcinoma: An Examination of the National Cancer Database over the Past Decade. Cancers, 2022, 14, 4320.	1.7	1
4792	Single-center experience in implementation of endoscopic surveillance protocol after esophagectomy. Ecological Management and Restoration, 0, , .	0.2	0
4793	Evaluation of tumor regression by neoadjuvant chemotherapy regimens for esophageal adenocarcinoma: a systematic review and meta-analysis. Ecological Management and Restoration, 0, , .	0.2	1
4794	Accuracy of preoperative clinical staging for locally advanced gastric cancer in KLASS-02 randomized clinical trial. Frontiers in Surgery, 0, 9, .	0.6	4
4795	Regional Patterns of Hospital-Level Guideline Adherence in Gastric Cancer: An Analysis of the National Cancer Database. Annals of Surgical Oncology, 2023, 30, 300-308.	0.7	4
4796	No survival benefit could be obtained from adjuvant radiotherapy in esophageal cancer treated with neoadjuvant chemotherapy followed by surgery: A SEER-based analysis. Frontiers in Oncology, 0, 12, .	1.3	0

#	Article	IF	Citations
4797	Impact of Preoperative Chemotherapy Features on Patient Outcomes after Hepatectomy for Initially Unresectable Colorectal Cancer Liver Metastases: A LiverMetSurvey Analysis. Cancers, 2022, 14, 4340.	1.7	1
4798	The value of CT-based radiomics nomogram in differential diagnosis of different histological types of gastric cancer. Physical and Engineering Sciences in Medicine, 0, , .	1.3	4
4799	Early-stage gastric and gastroesophageal junction cancer: Is there a survival benefit to neoadjuvant therapy?. Surgery, 2022, 172, 1753-1758.	1.0	1
4800	Esophageal Cancer: Whether and What Before or After Surgery?. Indian Journal of Surgical Oncology, 0, , .	0.3	0
4801	Intraoperative frozen section analysis of margin status as a quality indicator in gastric cancer surgery. Journal of Surgical Oncology, 2023, 127, 66-72.	0.8	2
4802	Pattern of lymph node metastases in gastric cancer: a side-study of the multicenter LOGICA-trial. Gastric Cancer, 2022, 25, 1060-1072.	2.7	8
4803	Proteomic characterization of gastric cancer response to chemotherapy and targeted therapy reveals potential therapeutic strategies. Nature Communications, 2022, 13, .	5.8	18
4804	Neoadjuvant immune checkpoint inhibitor in combination with chemotherapy or chemoradiotherapy in resectable esophageal cancer: A systematic review and meta-analysis. Frontiers in Immunology, 0, 13, .	2.2	8
4805	Risk Factors and Prognostic Impact of Postoperative Complications in Patients with Advanced Gastric Cancer Receiving Neoadjuvant Chemotherapy. Current Oncology, 2022, 29, 6496-6507.	0.9	5
4806	Recurrent Hepatocellular Carcinoma: Patterns, Detection, Staging and Treatment. Journal of Hepatocellular Carcinoma, 0, Volume 9, 947-957.	1.8	12
4807	Gastrectomy with or without Complete Omentectomy for Advanced Gastric Cancer: A Meta-Analysis. Medicina (Lithuania), 2022, 58, 1241.	0.8	2
4808	Lymph node response to neoadjuvant chemotherapy as an independent prognostic factor in gastric cancer. Oncology Letters, 2022, 24, .	0.8	3
4810	Molecular mechanisms underlying the action of carcinogens in gastric cancer with a glimpse into targeted therapy. Cellular Oncology (Dordrecht), 2022, 45, 1073-1117.	2.1	10
4812	Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)â€”a randomized phase II trial of the AIO pancreatic cancer group. Annals of Oncology, 2023, 34, 91-100.	0.6	37
4813	The order of surgery and chemotherapy matters: Multimodality therapy and stageâ€specific differences in survival in gastric cancer. Journal of Surgical Oncology, 2023, 127, 56-65.	0.8	3
4814	Esophageal cancer in China: Practice and research in the new era. International Journal of Cancer, 2023, 152, 1741-1751.	2.3	21
4815	Pancreatic Cancer: A Review of Current Treatment and Novel Therapies. Journal of Investigative Surgery, 2023, 36, .	0.6	54
4816	Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer. BMC Cancer, 2022, 22, .	1.1	3

#	Article	IF	Citations
4817	The impact of baseline ¹⁸F-FDG PET-CT on the management and outcome of patients with gastric cancer: a systematic review. British Journal of Radiology, 2022, 95, .	1.0	4
4819	Means for Target Volume Delineation and Stabilisation: Fiducial Markers, Balloons and Others. , 2022, , 221-247.		0
4821	Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east. Research in Pharmaceutical Sciences, 2022, 17, 621.	0.6	1
4822	Short-term outcomes of laparoscopicâ€‰/â€‰robotic gastrectomy compared with open gastrectomy for advanced gastric cancer following chemotherapy. Journal of Medical Investigation, 2022, 69, 261-265.	0.2	0
4823	Leveraging the Multidisciplinary Tumor Board for Dissemination of Evidence-Based Recommendations on the Staging and Treatment of Gastric Cancer: A Pilot Study. Annals of Surgical Oncology, 2023, 30, 1120-1129.	0.7	1
4824	Value of the Preoperative D-Dimer to Albumin Ratio for Survival and Recurrence Patterns in Gastric Cancer. Annals of Surgical Oncology, 2023, 30, 1132-1144.	0.7	3
4825	Evaluation of systemic inflammatory and nutritional indexes in locally advanced gastric cancer treated with adjuvant chemoradiotherapy after D2 dissection. Frontiers in Oncology, 0, 12, .	1.3	6
4826	Perspectives on the Management of Oligometastatic Disease in Esophago-Gastric Cancer. Cancers, 2022, 14, 5200.	1.7	4
4828	Developing and validating nomograms for predicting the survival in patients with clinical local-advanced gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	1
4829	Health-related quality of life following neoadjuvant chemoradiotherapy versus perioperative chemotherapy and esophagectomy for esophageal cancer: a European multicenter study. Ecological Management and Restoration, 0, , .	0.2	0
4830	Signaling pathways and therapeutic interventions in gastric cancer. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	54
4831	Protocol digest of a phase III trial to evaluate the efficacy of preoperative chemotherapy with S-1 plus oxaliplatin followed by D2 gastrectomy with postoperative S-1 in locally advanced gastric cancer: Japan Clinical Oncology Group study JCOG1509 (NAGISA Trial). Japanese Journal of Clinical Oncology, 0,	0.6	2
4832	Borrmann Type Predicts Response to Preoperative Therapy in Advanced Gastric Cancer. Journal of Gastrointestinal Cancer, 0, , .	0.6	2
4835	Cardiopulmonary Exercise Testing as a Predictor of Postoperative Outcome in Patients Undergoing Oesophageal Cancer Surgery Following Neoadjuvant Chemotherapy. , 2022, 50, 358-365.		1
4836	Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis. Medicina (Lithuania), 2022, 58, 1505.	0.8	3
4837	Neoadjuvant PD-1 blockade plus chemotherapy induces a high pathological complete response rate and anti-tumor immune subsets in clinical stage III gastric cancer. OncoImmunology, 2022, 11, .	2.1	17
4838	Identification of potential hub genes of gastric cancer. Medicine (United States), 2022, 101, e30741.	0.4	1
4839	Perioperative Modified FLOT Versus EOX in Locally Advanced Resectable Gastric and Gastro-Oesophageal Junction Adenocarcinoma: Results of a Matched-Pair Analysis. Journal of Gastrointestinal Cancer, 0, , .	0.6	0

#	Article	IF	Citations
4840	Incidence and Impact of Nonâ€alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. World Journal of Surgery, 2023, 47, 227-235.	0.8	0
4841	Prognostic Value of [18F]-FDG PET/CT Radiomics Combined with Sarcopenia Status among Patients with Advanced Gastroesophageal Cancer. Cancers, 2022, 14, 5314.	1.7	3
4842	Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma. Annals of Surgical Oncology, 2023, 30, 861-870.	0.7	3
4843	Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go?. Expert Opinion on Pharmacotherapy, 0, , 1-10.	0.9	0
4844	Neoadjuvant Therapy in Esophageal Cancer. Thoracic Surgery Clinics, 2022, 32, 447-456.	0.4	4
4845	Adjuvant Therapies for Esophageal Cancer. Thoracic Surgery Clinics, 2022, 32, 457-465.	0.4	2
4846	Pathological complete remission of a locally advanced gastric cancer by neoadjuvant therapy â€œsandwichâ€•regimen as SOXAP+ fluorescence laparoscopic surgery +SOXAP: Case report. Frontiers in Pharmacology, 0, 13, .	1.6	2
4847	Ongoing Controversies in Esophageal Cancer II. Thoracic Surgery Clinics, 2022, 32, 553-563.	0.4	2
4848	Interdisciplinary tumour boards in Switzerland: quo vadis?. Swiss Medical Weekly, 0, , .	0.8	0
4849	Perspectives of laparoscopic surgery for gastric cancer. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2022, 34, 533-538.	0.7	4
4850	The Role of Surgery in the Management of Gastric Cancer: State of the Art. Cancers, 2022, 14, 5542.	1.7	6
4851	Prognostic and predictive value of a pathomics signature in gastric cancer. Nature Communications, 2022, 13, .	5.8	31
4852	Perioperative treatment and biomarker analysis of <scp>LP002</scp>, an <scp>antiâ€PDâ€L1</scp> antibody, plus chemotherapy in resectable gastric and gastroesophageal junction cancer. Cancer Medicine, 2023, 12, 5639-5648.	1.3	3
4853	Intratumoral heterogeneity affects tumor regression and Ki67 proliferation index in perioperatively treated gastric carcinoma. British Journal of Cancer, 2023, 128, 375-386.	2.9	3
4854	McKeown Esophagectomy. , 2023, , 243-250.		0
4856	The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis. European Journal of Medical Research, 2022, 27, .	0.9	2
4857	Tumor Depth Prediction of Gastric Cancer With a T4 Score. Cancer Diagnosis & Prognosis, 2022, 2, 641-647.	0.3	0
4858	Economic evaluation of FLOT and ECF/ECX perioperative chemotherapy in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. BMJ Open, 2022, 12, e060983.	0.8	0

#	Article	IF	Citations
4859	Laparoscopic versus Open Total Gastrectomy for Locally Advanced Gastric Cancer: Short and Long-Term Results. Current Oncology, 2022, 29, 8442-8455.	0.9	3
4860	Current developments in gastric cancer: from molecular profiling to treatment strategy. Nature Reviews Gastroenterology and Hepatology, 2023, 20, 155-170.	8.2	61
4861	The role of adjuvant chemotherapy after neoadjuvant chemotherapy or chemoradiotherapy plus esophagectomy in patients with esophageal cancer: a retrospective cohort study. Journal of Gastrointestinal Oncology, 2022, .	0.6	0
4862	A Nomogram for Predicting the Cancer-Specific Survival of Patients with Initially Diagnosed Metastatic Gastric Cancer. Clinical Medicine Insights: Oncology, 2022, 16, 117955492211420.	0.6	0
4863	Comprehensive evaluation of biopolymer immune implants for peritoneal metastasis carcinoma therapy. Journal of Controlled Release, 2023, 353, 289-302.	4.8	8
4864	Perioperative Chemotherapy: Review of Randomized Trials and Recommended Approach. , 2022, , 197-209.		0
4866	Treatments for resectable esophageal cancer: from traditional systemic therapy to immunotherapy. Chinese Medical Journal, 2022, 135, 2143-2156.	0.9	8
4867	The validity of neoadjuvant chemotherapy with paclitaxel plus S-1 is not inferior to that of SOX regimen for locally advanced gastric cancer: an observational study. BMC Cancer, 2022, 22, .	1.1	1
4868	Trimodality Versus Surgery as Needed: Is Delayed or Salvage Esophagectomy Justified?. Foregut, 0, , 263451612211375.	0.3	1
4869	Impact of perioperative chemotherapy in the treatment of patients with gastric cancer. Porto Biomedical Journal, 2022, 7, e180.	0.4	0
4870	Systematic review and meta-analysis comparing proximal gastrectomy with double-tract-reconstruction and total gastrectomy in gastric and gastroesophageal junction cancer patients: Still no sufficient evidence for clinical decision-making. Surgery, 2023, 173, 957-967.	1.0	1
4871	Gastrectomy for Cancer: A 15-Year Analysis of Real-World Data from the University of Athens. Medicina (Lithuania), 2022, 58, 1792.	0.8	0
4872	Does postoperative chemotherapy improve overall survival of patients with ypT1-2N0 cancer?. World Journal of Surgical Oncology, 2022, 20, .	0.8	2
4873	EBV and MSI Status in Gastric Cancer: Does It Matter?. Cancers, 2023, 15, 74.	1.7	6
4874	Prostate-Specific Membrane Antigen Targeted Pet/CT Imaging in Patients with Colon, Gastric and Pancreatic Cancer. Cancers, 2022, 14, 6209.	1.7	4
4875	Safety and short-term outcomes of gastrectomy after preoperative chemotherapy plus immunotherapy versus preoperative chemotherapy: a retrospective cohort study. BMC Cancer, 2022, 22, .	1.1	1
4876	UICC Staging after Neoadjuvant/Perioperative Chemotherapy Reveals No Significant Survival Differences Compared to Primary Surgery for Locally Advanced Gastric Cancer. Cancers, 2022, 14, 6169.	1.7	0
4877	Comparison of <scp>MRI</scp> and <scp>CT</scp>â€Based Radiomics and Their Combination for Early Identification of Pathological Response to Neoadjuvant Chemotherapy in Locally Advanced Gastric Cancer. Journal of Magnetic Resonance Imaging, 2023, 58, 907-923.	1.9	4

#	Article	IF	Citations
4878	Development and Validation of a Predictive Model of Therapeutic Effect in Patients with Esophageal Squamous Cell Carcinoma Who Received Neoadjuvant Treatment: A Nationwide Retrospective Study in Japan. Annals of Surgical Oncology, 2023, 30, 2176-2185.	0.7	4
4879	Incidental nodal irradiation in patients with esophageal cancer undergoing (chemo)radiation with 3D-CRT or VMAT. Scientific Reports, 2022, 12, .	1.6	0
4880	A molecular classification of gastric cancer associated with distinct clinical outcomes and validated by an XGBoost-based prediction model. Molecular Therapy - Nucleic Acids, 2023, 31, 224-240.	2.3	6
4881	SOX chemotherapy with anti-PD-1 and iNKT cell immunotherapies for stage IV gastric adenocarcinoma with liver metastases: A case report. Frontiers in Immunology, 0, 13, .	2.2	0
4882	Multiparametric MRI-based radiomics nomogram for early prediction of pathological response to neoadjuvant chemotherapy in locally advanced gastric cancer. European Radiology, 2023, 33, 2746-2756.	2.3	5
4883	Reconstruction of the gastric cancer microenvironment after neoadjuvant chemotherapy by longitudinal single-cell sequencing. Journal of Translational Medicine, 2022, 20, .	1.8	8
4884	Adjuvant Chemotherapy for Patients with Adenocarcinoma of the Esophagogastric Junction: A Retrospective, Multicenter, Observational Study. Annals of Surgical Oncology, 0, , .	0.7	2
4885	Perioperative chemotherapy with FLOT regimen in patients with resectable gastric or gastroesophageal junction adenocarcinoma (SIEWERT type Iâ€“III). Experience of the N.â€ŠN. Blokhin russian cancer research center. Malignant Tumours, 2022, 12, 5-13.	0.1	0
4886	The significance of time interval between perioperative SOX/XELOX chemotherapy and clinical decision model in gastric cancer. Frontiers in Oncology, 0, 12, .	1.3	0
4887	Interval time between neoadjuvant chemotherapy and surgery in advanced gastric cancer doesn't affect outcome: A meta analysis. Frontiers in Surgery, 0, 9, .	0.6	2
4888	A phase II study of perioperative treatment in gastric cancer with No.16a2/b1 lymph node metastasis: DRAGON-06 trial. Future Oncology, 0, , .	1.1	0
4889	Neoadjuvant therapy with immune checkpoint blockade, antiangiogenesis, and chemotherapy for locally advanced gastric cancer. Nature Communications, 2023, 14, .	5.8	52
4890	Extended Lymphadenectomy for Gastric Cancer in the Neoadjuvant Era: Current Status, Clinical Implications and Contentious Issues. Current Oncology, 2023, 30, 875-896.	0.9	8
4891	Patient-Derived Organoids from Locally Advanced Gastric Adenocarcinomas Can Predict Resistance to Neoadjuvant Chemotherapy. Journal of Gastrointestinal Surgery, 2023, 27, 666-676.	0.9	1
4892	Survival Outcomes of Hepatectomy in Gastric Cancer Liver Metastasis: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2023, 12, 704.	1.0	2
4893	A standardized pathology report for gastric cancer: 2nd edition. Journal of Pathology and Translational Medicine, 2023, 57, 1-27.	0.4	4
4894	Gastric cancer in 2022: Is there still a role for endoscopic ultrasound?. World Journal of Gastrointestinal Endoscopy, 0, 15, 1-9.	0.4	0
4895	Advances in conduits and anastomotic techniques employed in esophageal cancer resections: A review. Journal of Surgical Oncology, 2023, 127, 228-232.	0.8	1

#	Article	IF	Citations
4897	Is there still a place for radiotherapy in gastric cancer?. Current Opinion in Pharmacology, 2023, 68, 102325.	1.7	2
4898	Preoperative hiatal hernia in esophageal adenocarcinoma; does it have an impact on patient outcomes?. Surgical Oncology, 2023, 46, 101904.	0.8	0
4899	The evolution of treatment for resectable gastric cancer. , 2023, 2, 100008.		0
4900	Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study. Radiation Oncology, 2022, 17, .	1.2	3
4901	Repurposed Drugs in Gastric Cancer. Molecules, 2023, 28, 319.	1.7	1
4902	Optimal extent of lymph node dissection in gastric cancer. Frontiers in Surgery, 0, 9, .	0.6	0
4903	Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial. Journal of Gastrointestinal Oncology, 2022, 13, 3300-3313.	0.6	2
4904	PrÃoperative Konditionierung bei ZweihÃ¶hleneingriffen. , 2022, , 269-280.		0
4905	The Oesophageal Cancer Multidisciplinary Team: Can Machine Learning Assist Decision-Making?. Journal of Gastrointestinal Surgery, 2023, 27, 807-822.	0.9	1
4906	Significant Tumor Regression after Neoadjuvant Chemotherapy in Gastric Cancer, but Poor Survival of the Patient? Role of MHC Class I Alterations. Cancers, 2023, 15, 771.	1.7	1
4907	Personalized Prehabilitation Improves Tolerance to Chemotherapy in Patients with Oesophageal Cancer. Current Oncology, 2023, 30, 1538-1545.	0.9	1
4908	Korean Practice Guidelines for Gastric Cancer 2022: An Evidence-based, Multidisciplinary Approach. Journal of Gastric Cancer, 2023, 23, 3.	0.9	66
4909	Combining neoadjuvant chemotherapy with PD-1/PD-L1 inhibitors for locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: A systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	3
4910	Efficacy and safety of neoadjuvant immunotherapy combined with chemoradiotherapy or chemotherapy in esophageal cancer: A systematic review and meta-analysis. Frontiers in Immunology, 0, 14, .	2.2	4
4911	Preoperative Chemotherapy for Operable Colon Cancer: Mature Results of an International Randomized Controlled Trial. Journal of Clinical Oncology, 2023, 41, 1541-1552.	0.8	94
4912	Critical Analysis of the Klass-02 Randomized Clinical Trial. JAMA Surgery, 0, , .	2.2	0
4913	A Standardized Pathology Report for Gastric Cancer: 2nd Edition. Journal of Gastric Cancer, 2023, 23, 107.	0.9	4
4914	Event-Free Survival as a Surrogate for Overall Survival in Gastric and Gastroesophageal Junction Adenocarcinoma: A Meta-analysis in the Neoadjuvant Â± Adjuvant Setting. Clinical Cancer Research, 2023, 29, 1360-1367.	3.2	1

#	Article	IF	Citations
4915	Multiplex immune profiling reveals the role of serum immune proteomics in predicting response to preoperative chemotherapy of gastric cancer. Cell Reports Medicine, 2023, 4, 100931.	3.3	3
4916	Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer. Journal of Gastric Cancer, 2023, 23, 182.	0.9	1
4917	Clinical outcomes and toxicities of locally advanced esophageal squamous cell carcinoma patients treated with early thoracic radiation therapy after induction chemotherapy. International Journal of Clinical Oncology, 0, , .	1.0	0
4918	Neoadjuvant Chemotherapy Compared with Surgery for Oesophageal Carcinoma: A Retrospective Study and Missing Evidence. Journal of Cancer, 2023, 14, 434-445.	1.2	0
4919	Paraconduit hernia after minimally invasive esophagectomy â€“ incidence and risk factors. Scandinavian Journal of Gastroenterology, 2023, 58, 764-770.	0.6	1
4920	Surgical management of cancer of the stomach and gastroesophageal junction after neoadjuvant therapy: the experience of the MRRC and literature review. Siberian Journal of Oncology, 2023, 22, 101-109.	0.1	0
4921	ASO Author Reflections: Toward a Universal Definition of Tumor Regression Grade in Gastric Cancer. Annals of Surgical Oncology, 0, , .	0.7	0
4922	Systemische Therapie des Ã–sophagus- und Magenkarzinoms: Innovative Optionen auch im ambulanten Setting. , 0, , .		0
4923	Perioperative therapy with FLOT4 significantly increases survival in patients with gastroesophageal and gastric cancer in a large realâ€world cohort. International Journal of Cancer, 2023, 153, 609-622.	2.3	2
4924	Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy. Frontiers in Surgery, 0, 10, .	0.6	0
4925	Neoadjuvant Management of Adenocarcinoma of the Esophagus and Esophagogastric Junction: Review of Randomized Evidence and Definition of Optimum Treatment Algorithm. Oncology, 2023, 101, 553-564.	0.9	0
4926	Understanding Factors Leading to Surgical Attrition for â€œResectableâ€•Gastric Cancer. Annals of Surgical Oncology, 2023, 30, 4207-4216.	0.7	3
4927	Efficacy and safety of PD-1/PD-L1 inhibitor combined with chemotherapy versus chemotherapy alone in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma: a systematic review and meta-analysis. Frontiers in Oncology, 0, 13, .	1.3	0
4928	Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study. Value in Health Regional Issues, 2023, 35, 13-18.	0.5	0
4929	Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study. Translational Oncology, 2023, 31, 101657.	1.7	2
4930	The definition of â€œR1â€•lymph node dissection status in patients undergoing curative-aim gastrectomy for gastric carcinoma: A proof of concept study. Surgical Oncology, 2023, 48, 101908.	0.8	0
4931	Response Evaluation after Neoadjuvant Chemotherapy for Resectable Gastric Cancer. Cancers, 2023, 15, 2318.	1.7	2
4932	PDâ€L1 expression in gastric and gastroesophageal junction cancer patients treated with perioperative chemotherapy. Journal of Surgical Oncology, 2022, 126, 150-160.	0.8	2

#	Article	IF	Citations
4933	Preoperative chemotherapy is a better strategy than upfront surgery in cT4 gastric cancer. Journal of Surgical Oncology, 2022, 126, 132-138.	0.8	1
4934	Gastric cancer with microsatellite instability displays increased thymidylate synthase expression. Journal of Surgical Oncology, 2022, 126, 116-124.	0.8	1
4935	Retrospective analysis of risk factors for distant metastasis of early-onset gastric cancer during the perioperative period. Frontiers in Oncology, 0, 13, .	1.3	2
4936	Overview of Chemotherapy for Gastric Cancer. Journal of Clinical Medicine, 2023, 12, 1336.	1.0	10
4937	Perioperative chemotherapy with 5-FU, leucovorin, oxaliplatin, and docetaxel (FLOT) for esophagogastric adenocarcinoma: ten years real-life experience from a surgical perspective. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	1
4938	Tumor Regression Grade and Overall Survival following Gastrectomy with Preoperative Therapy for Gastric Cancer. Annals of Surgical Oncology, 2023, 30, 3580-3589.	0.7	5
4939	Prognostic value of claudin 18.2 expression in gastric adenocarcinoma. World Journal of Gastrointestinal Oncology, 0, 15, 343-351.	0.8	5
4940	Increased CD4/CD8 Lymphocyte ratio predicts favourable neoadjuvant treatment response in gastric cancer: A prospective pilot study. World Journal of Gastrointestinal Oncology, 0, 15, 303-317.	0.8	4
4941	Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR. FASEB Journal, 2023, 37, .	0.2	6
4942	Relation between mismatch repair status, chemoresponse, survival and anatomic location in gastroesophageal adenocarcinoma. Canadian Journal of Surgery, 2023, 66, E79-E87.	0.5	1
4943	Neoadjuvant Therapy with Immune Checkpoint Inhibitors in Gastric Cancer: A Systematic Review and Meta-Analysis. Annals of Surgical Oncology, 2023, 30, 3594-3602.	0.7	3
4944	Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer: S PyrhÃ¶nen, T Kuitunen, P Nyandoto & M Kouri. British Journal of Cancer, 2023, 128, 439-440.	2.9	0
4945	Characterization of glycometabolism and tumor immune microenvironment for predicting clinical outcomes in gastric cancer. IScience, 2023, 26, 106214.	1.9	5
4946	Pattern of recurrence and overall survival in esophagogastric cancer after perioperative FLOT and clinical outcomes in MSI-H population: the PROSECCO Study. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	4
4947	Recent advances in the management of gastric adenocarcinoma patients. Faculty Reviews, 0, 12, .	1.7	1
4948	Improved survival after laparoscopic compared to open gastrectomy for advanced gastric cancer: a Swedish population-based cohort study. Gastric Cancer, 2023, 26, 467-477.	2.7	4
4949	Spectral CT-based nomogram for preoperative prediction of perineural invasion in locally advanced gastric cancer: a prospective study. European Radiology, 2023, 33, 5172-5183.	2.3	4
4950	How organoids can improve personalized treatment in patients with gastro-esophageal tumors. Current Opinion in Pharmacology, 2023, 69, 102348.	1.7	6

#	Article	IF	Citations
4951	Quality performance indicator compliance for the treatment of gastric adenocarcinoma. ANZ Journal of Surgery, 2023, 93, 1294-1299.	0.3	0
4952	Gastric adenocarcinoma: A review of the TNM classification system and ways of spreading. Radiologia, 2023, 65, 66-80.	0.3	1
4953	Conditional relative survival in nonmetastatic esophagogastric cancer between 2006 and 2020: A populationâ€based study. International Journal of Cancer, 2023, 152, 2503-2511.	2.3	2
4954	Xiaotan Sanjie decoction normalizes tumor permissive microenvironment in gastric cancer (Review). Oncology Reports, 2023, 49, .	1.2	2
4955	Trends in bestâ€case, typical and worstâ€case survival scenarios of patients with nonâ€metastatic esophagogastric cancer between 2006 and 2020: A populationâ€based study. International Journal of Cancer, 2023, 153, 33-43.	2.3	1
4957	Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment. , 2023, , 305-325.		0
4958	Lymph node metastatic patterns and the development of multidisciplinary treatment for esophageal cancer. Ecological Management and Restoration, 2023, 36, .	0.2	6
4960	Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. International Journal of Molecular Sciences, 2023, 24, 4877.	1.8	5
4961	Predicting peritoneal recurrence in gastric cancer with serosal invasion using a pathomics nomogram. IScience, 2023, 26, 106246.	1.9	2
4962	Feasibility and Safety of Laparoscopic D2 Gastrectomy in Combination with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) in Patients with Gastric Cancer at High Risk of Recurrenceâ€"The PIPAC-OPC4 Study. Annals of Surgical Oncology, 2023, 30, 4433-4441.	0.7	3
4963	A Paradigm Shifts: Neoadjuvant Therapy for Clearly Resectable Pancreatic Cancer. Annals of Surgical Oncology, 2023, 30, 3427-3436.	0.7	5
4964	A novel nomogram for identifying candidates for adjuvant chemotherapy in patients with stage IB gastric adenocarcinoma. BMC Gastroenterology, 2023, 23, .	0.8	0
4965	Development and validation of survival prediction model for gastric adenocarcinoma patients using deep learning: A SEER-based study. Frontiers in Oncology, 0, 13, .	1.3	4
4966	Gastric adenocarcinoma burden, trends and survival in Cali, Colombia: A retrospective cohort study. Frontiers in Oncology, 0, 13, .	1.3	0
4967	A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma. Cancers, 2023, 15, 1628.	1.7	2
4968	Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment. Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research, 2023, 35, 44-57.	0.7	1
4970	The inaccuracies of gastric adenocarcinoma clinical staging and its predictive factors. Journal of Surgical Oncology, 2023, 127, 1116-1124.	0.8	2
4971	Nodal Yield <15 Is Associated With Reduced Survival in Esophagectomy and Is a Quality Metric. Annals of Thoracic Surgery, 2023, , .	0.7	1

#	Article	IF	Citations
4972	Impact of the Interval between Neoadjuvant Chemotherapy and Gastrectomy on Pathological Response and Survival Outcomes for Patients with Locally Advanced Gastric Cancer: A Meta-analysis. Euroasian Journal of Hepato-gastroenterology, 2023, 12, 81-91.	0.1	0
4973	Short-Term and Textbook Surgical Outcomes During the Implementation of a Robotic Gastrectomy Program. Journal of Gastrointestinal Surgery, 2023, 27, 1089-1097.	0.9	4
4974	Effect of neoadjuvant chemotherapy combined with arterial chemoembolization on short-term clinical outcome of locally advanced gastric cancer. BMC Cancer, 2023, 23, .	1.1	0
4975	Aspartate Î²-Hydroxylase Serves as a Prognostic Biomarker for Neoadjuvant Chemotherapy in Gastric Cancer. International Journal of Molecular Sciences, 2023, 24, 5482.	1.8	2
4976	Gastric Cancer with Peritoneal Metastases: Current Status and Prospects for Treatment. Cancers, 2023, 15, 1777.	1.7	4
4977	Time to surgery does not affect oncologic outcomes in locally advanced gastric cancer after neoadjuvant chemotherapy: a meta-analysis. Future Oncology, 0, , .	1.1	0
4978	Examined lymph node count for gastric cancer patients after curative surgery. World Journal of Clinical Cases, 0, 11, 1930-1938.	0.3	3
4979	Effect of multimodal chemotherapy on survival of gastric cancer with liver metastasis â€“ a population based analysis. Frontiers in Oncology, 0, 13, .	1.3	1
4980	Neoadjuvant therapy for pancreatic cancer. Nature Reviews Clinical Oncology, 2023, 20, 318-337.	12.5	61
4981	Identification of LSM family members as potential chemoresistance predictive and therapeutic biomarkers for gastric cancer. Frontiers in Oncology, 0, 13, .	1.3	1
4982	Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1. Esophagus, 2023, 20, 343-372.	1.0	36
4983	Impact of Programmed Death-Ligand 1 Expression on Mismatch Repair Deficiency and Epsteinâ€“Barr Virus Status on Survival Outcomes in Patients with Stage II/III Gastric Cancer After Surgery. Annals of Surgical Oncology, 2023, 30, 5227-5236.	0.7	2
4984	Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. Journal of Personalized Medicine, 2023, 13, 553.	1.1	3
4985	Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis. Advances in Medical Sciences, 2023, 68, 138-146.	0.9	1
4986	An Association Between Comorbidities and Postsurgical Complications in Adults Who Underwent Esophagectomy. Cureus, 2023, , .	0.2	0
4987	Neoadjuvant radiochemotherapy and perioperative chemotherapy do not represent a standard at the same priority level for esophageal adenocarcinomas (with regard to â€˜Oesophageal cancer: ESMO) Tj ETQq1 1 0.784314 rgBT /Overlo 553-554.	0.6	0
4988	Supervivencia a dos aÃ±os en pacientes con cÃ¡ncer gÃ¡strico localmente avanzado en una instituciÃ³n de PopayÃ¡n entre 2018 y 2020. Revista Colombiana De Cirugia, 0, , .	0.2	1
4989	Pathological regression of primary tumour and metastatic lymph nodes following chemotherapy in resectable OG cancer: pooled analysis of two trials. British Journal of Cancer, 2023, 128, 2036-2043.	2.9	3

#	Article	IF	Citations
4990	Current trends in perioperative treatment of resectable gastric cancer. World Journal of Gastrointestinal Surgery, 0, 15, 323-337.	0.8	0
4991	Effect of COP1 in Promoting the Tumorigenesis of Gastric Cancer by Down-Regulation of CDH18 via PI3K/AKT Signal Pathway. Analytical Cellular Pathology, 2023, 2023, 1-20.	0.7	0
4992	Current Status and Research Progress of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer. Journal of Biosciences and Medicines, 2023, 11, 156-170.	0.1	0
4993	Facing adenocarcinoma of distal esophagus and esophagogastric junction: a CROSS versus FLOT propensity score-matched analysis of oncological outcomes in a high-volume institution. Updates in Surgery, 2023, 75, 921-930.	0.9	4
4994	Post-operative weight loss affects 3-year survival in patients with gastric adenocarcinoma after gastrectomy and hyperthermic intraperitoneal chemotherapy. European Journal of Surgical Oncology, 2023, , .	0.5	0
4995	Microsatellite instability and sex-specific differences of survival in gastric cancer after neoadjuvant chemotherapy without and with taxane: An observational study in real world patients. Journal of Cancer Research and Clinical Oncology, 0, , .	1.2	0
4996	Clinical Impact of Metastatic Lymph Node Size on Therapeutic Effect and Prognosis in Patients with Esophageal Squamous Cell Carcinoma Who Underwent Preoperative Chemotherapy Followed by Esophagectomy. Annals of Surgical Oncology, 0, , .	0.7	1
4997	Gastric Cancer: Correlation of Histologic Type with Commonly Used Prognostic Variables. International Journal of Cancer Management, 2023, 16, .	0.2	0
4998	Two decades of gastric and gastroesophageal junction cancer surgery. Journal of Cancer Research and Clinical Oncology, 2023, 149, 7679-7688.	1.2	1
4999	Systematic review and meta-analysis of the outcomes following neoadjuvant therapy in upfront resectable gastric cancers compared to surgery alone in phase III randomised controlled trials. Journal of Gastrointestinal Surgery, 2023, 27, 1261-1276.	0.9	0
5000	Perioperative Cetuximab with Cisplatin and 5-Fluorouracil in Esogastric Adenocarcinoma: A Phase II Study. Cancers, 2023, 15, 2188.	1.7	1
5001	Does nonâ€metastatic gastric cancer of the cardia warrant a different treatment strategy?. Journal of Surgical Oncology, 2023, 128, 231-241.	0.8	2
5002	A propensity scoreâ€“matched analysis of neoadjuvant chemoimmunotherapy versus surgery alone for locally advanced esophageal squamous cell carcinoma. Journal of Surgical Oncology, 0, , .	0.8	2
5003	Lymph node ratio precisely predicts the benefit of postoperative radiotherapy in esophageal cancer: A retrospective cohort study. Asian Journal of Surgery, 2023, 46, 3680-3686.	0.2	0
5004	Treatment Status and Progress of Advanced Gastric Cancer. Advances in Clinical Medicine, 2023, 13, 5419-5426.	0.0	0
5006	A Novel ypTLM Staging System Based on LODDS for Gastric Cancer After Neoadjuvant Therapy: Multicenter and Largeâ€Sample Retrospective Study. World Journal of Surgery, 2023, 47, 1762-1771.	0.8	0
5007	Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis. Surgical Endoscopy and Other Interventional Techniques, 0, , .	1.3	2
5008	Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors. Cancer Control, 2023, 30, .	0.7	1

#	Article	IF	Citations
5009	Gastric Extent of Tumor Predicts Peritoneal Metastasis in Siewert II Adenocarcinoma. Annals of Thoracic Surgery, 2024, 117, 320-326.	0.7	1
5010	Characterizing treatment burden during neoadjuvant therapy for patients with gastrointestinal cancer: A mixed methods analysis. Journal of Surgical Oncology, 2023, 128, 393-401.	0.8	2
5011	Preliminary report on the short-term efficacy and safety of SAPO-S1 therapy for locally advanced gastric cancer with a deep learning perspective. Biotechnology and Genetic Engineering Reviews, 0, , 1-16.	2.4	0
5012	Improving outcomes in patients with oesophageal cancer. Nature Reviews Clinical Oncology, 2023, 20, 390-407.	12.5	13
5013	Role of microsatellite instability and HER2 positivity in locally advanced esophago-gastric cancer patients treated with peri-operative chemotherapy. Clinical and Translational Oncology, 0, , .	1.2	0
5014	Gut microbiome can predict chemoradiotherapy efficacy in patients with esophageal squamous cell carcinoma. Esophagus, 2023, 20, 691-703.	1.0	1
5015	Skeletal muscle mass and quality before preoperative chemotherapy influence postoperative long-term outcomes in esophageal squamous cell carcinoma patients. World Journal of Gastrointestinal Surgery, 0, 15, 621-633.	0.8	1
5023	A systematic review of minimal length of lroximal margin in gastric adenocarcinoma resection. Langenbeck's Archives of Surgery, 2023, 408, .	0.8	1
5039	Obesity and Cancer: Two Sides of the Same Coin. Obesity Surgery, 2023, 33, 2253-2254.	1.1	0
5079	Early stage gastric adenocarcinoma: clinical and molecular landscapes. Nature Reviews Clinical Oncology, 2023, 20, 453-469.	12.5	7
5098	Surgical Resection and Perioperative Chemotherapy. , 2023, , 113-119.		0
5100	Palliative Chemotherapy in Advanced or Metastatic Gastric Cancer. IX-1. Overview and Cytotoxic Agents. , 2023, , 57-61.		0
5102	Adjuvant Chemotherapy. , 2023, , 51-55.		0
5105	Progress of Porphyrin-based Nanoassemblies for Cancer Theranostics. Chemical Research in Chinese Universities, 2023, 39, 612-623.	1.3	2
5118	Current neoadjuvant therapy for operable locally advanced esophageal cancer. , 2023, 40, .		1
5122	Perioperative immune checkpoint inhibitor therapy for gastric and gastroesophageal junction cancers: a review of current approaches and future perspectives. International Journal of Clinical Oncology, 0, , .	1.0	0
5165	Magenkarzinom. Springer Reference Medizin, 2023, , 1-49.	0.0	0
5189	Imaging advances in efficacy assessment of gastric cancer neoadjuvant chemotherapy. Abdominal Radiology, 2023, 48, 3661-3676.	1.0	1

#	Article	IF	Citations
5214	Total neoadjuvant therapy in oesophageal and gastro-oesophageal junctional adenocarcinoma. British Journal of Cancer, 0, , .	2.9	0
5223	Radiologic Evaluation of Esophageal Cancer. , 2023, , 47-59.		0
5224	Multimodal Therapy for Locally Advanced Esophageal Cancer. , 2023, , 81-92.		0
5257	Immunotherapy in Esophagogastric Cancer: Treatment Landscape, Challenges, and New Directions. Journal of Gastrointestinal Cancer, 0, , .	0.6	0
5259	Management of Microsatellite Instability High (MSI-H) Gastroesophageal Adenocarcinoma. Journal of Gastrointestinal Cancer, 0, , .	0.6	0
5279	Clinical Management of Gastric Cancer Treatment Regimens. Current Topics in Microbiology and Immunology, 2023, , 279-304.	0.7	0
5281	Identification of subtype-specific master regulatory long non-coding RNAs of gastric cancer through a network-based approach. , 2023, , .		0
5308	Role of Preoperative Radiation Therapy for Resectable Gastric Cancer. Journal of Gastrointestinal Cancer, 0, , .	0.6	0
5310	Malignome des Gastrointestinaltrakts. , 2024, , 675-799.		0
5311	Neoplastic obstructions. , 2024, , 155-181.		0
5318	Biomarkers of minimal residual disease and treatment. Advances in Clinical Chemistry, 2024, , 33-70.	1.8	0